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Abstract  
 
The regulation of skeletal muscle mass and function by nutrition and exercise is of fundamental interest in 
both athletic performance and healthy aging paradigms. The amino acid leucine has received much interest in 
recent years due its potential anabolic properties in athletes, and has been described as a pharmaconutrient 
for the preservation of skeletal muscle health in older adults. While it is well accepted that elevating plasma 
leucinemia is a potent stimulator of muscle protein synthesis (MPS), less is understood about how 
supplementation and dietary strategies can be manipulated to create a plasma aminoacidemia most optimal 
for MPS. Furthermore, the role of leucine-rich interventions on recovery from exercise induced muscle damage 
in young athletes, and longer term changes in muscle mass and function when administered over time in 
older adults, is inconclusive to date, and warrants further investigation. Consequently, the aim of this thesis is 
to contribute to our current understanding of these areas.  
 
Chapter 4 describes the habitual protein intake, distribution and dietary patterns in young and older adults in 
Ireland. Chapters 5 and 6 describe the plasma leucine kinetics after ingestion of microencapsulated leucine 
and free leucine, alone and in combination with a low leucine-containing meal in young, healthy males. 
Chapter 7 demonstrates that leucine supplementation in the 14 hour recovery period after intense resistance 
exercise exhibits no beneficial effect on markers of muscle damage and recovery of muscle function. Chapter 8 
describes a dietary intervention targeting three leucine-rich meals per day can increase protein intake and 
improve protein distribution in older adults. Finally, chapter 9 establishes that the same dietary intervention in 
combination with concurrent aerobic and resistance exercise training is an effective strategy to augment 
increases in lean body mass and lower limb strength in older adults over 12 weeks compared to training 
alone.  
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Chapter 1 
1.0 Introduction  
 
  2 
1.1 The Regulation of Skeletal Muscle Mass 
Skeletal muscle, which constitutes approximately 40% of the body’s total weight, is vital for locomotion, 
physical exertion and metabolic health (Brook et al., 2016; Petersen et al., 2007). In healthy, active adults, 
skeletal muscle protein turnover occurs at an average rate of 1.2% per day, and the potential maintenance, 
growth or loss of muscle mass occurs in response to the dynamic balance between muscle protein synthesis 
(MPS) and muscle protein breakdown (MPB) (Atherton and Smith, 2012). After an overnight fast, MPB is 
elevated above MPS, resulting in an overall negative net protein balance, termed a catabolic state. Once 
adequate energy and amino acids (AAs) are consumed, MPB decreases and MPS increases, resulting in an 
overall positive net protein balance, termed an anabolic state (Kreider and Campbell, 2009). When positive net 
protein balance is achieved over a prolonged period (i.e. several weeks) this results in muscle accretion over 
time ( McGlory and Phillips, 2014; Churchward-Venne, Burd and Phillips, 2012).  
1.2 Dietary Protein as an Anabolic Stimulus  
Ingestion of dietary protein and AAs act as an anabolic stimulus, increasing rates of MPS above resting values, 
in a dose-dependent manner in the several hours post-ingestion (Witard et al., 2014; Moore et al., 2009). This 
characteristic has led to huge interest in the optimisation of protein intake across populations; in particular, for 
its application in recovery from exercise and support of muscle hypertrophy in athletes, and for mitigating the 
age-related decline in skeletal muscle mass in older adults.  The branched chain amino acid (BCAA), leucine, 
has been identified as unique in its ability to stimulate the activation of intracellular pathways that mediate 
MPS and protein translation (Atherton et al., 2010a). Hyperleucinemia, the increase of plasma leucine 
concentration, after the ingestion of exogenous protein/AAs, is considered a key driver of MPS (Atherton, et al., 
2010b; Pasiakos, 2012). As a consequence, leucine is a nutrient that has generated much interest in recent 
years. In athletic populations, leucine has received attention for its role in the accretion of skeletal muscle, and 
its potential use in recovery from exercise (Mobley et al., 2017; Stock et al., 2010).  Leucine also has 
application in healthy ageing, and has been described as a pharmaconutrient in the preservation of skeletal 
muscle health in older adults (Leenders and van Loon, 2011). The role of plasma leucine kinetics in the muscle 
protein synthetic response remains unclear, with some studies challenge the hypothesis that the kinetics of 
plasma leucine modulated MPS (Van Vliet et al., 2017; Gorissen et al., 2016; Burd et al., 2015), suggesting 
that the regulation of MPS by protein ingestion is more complex than solely leucine plasma kinetics. 
Nonetheless, few studies have investigated the plasma leucine kinetics after the ingestion of leucine in its free 
form and after varying temporal feeding strategies of leucine. 
  3 
 The ingestion of animal-based proteins has been shown to elicit a robust muscle protein synthetic response 
when compared to a plant-based protein (Gorissen et al., 2016; Wilkinson et al., 2007; Yang et al., 2012a; 
2012b; Tang et al., 2009). However, this does not imply a blanket recommendation for the reliance on animal-
based foods for promoting muscle growth and/or maintenance and meeting nutritional needs. The 
consumption of some processed animal-based foods has been associated with an increased risk of heart 
disease, stroke, diabetes mellitus and cancers (Chan et al., 2011; Micha, Wallace and Mozaffarian, 2010). 
Furthermore, an overreliance on animal-based foods poses a threat to environmental sustainability (de Vries 
and de Boer, 2010). These are some of the reasons that a shift towards plant-based foods in the diet is 
apparent (Leitzmann, 2014). Plant-based proteins are inherently low in leucine and other essential amino 
acids (EAAs) and have been shown to exhibit an inferior postprandial muscle protein synthetic response when 
compared to animal-based proteins. This makes plant-based proteins an appropriate candidate for leucine-
enrichment to potentially increase the postprandial muscle protein synthetic response (Gorissen and Witard, 
2018; van Vliet, Burd and van Loon, 2015). Despite the ever-growing research interest of enrichment of plant-
based foods with leucine, the plasma AA kinetics after the ingestion of plant-based food in combination with 
leucine has not been investigated. 
1.3 Amino Acids in the Recovery from Exercise Induced Muscle Damage   
Intense exercise can result in dull aching pain, tenderness and stiffness and strength loss in the days following 
an exercise bout. This is often termed delayed-onset muscle soreness (DOMS) and is in large part a 
consequence of exercise-induced muscle damage (EIMD) (Cheung, Hume and Maxwell, 2003; Connolly, 
Sayers and Mchugh, 2003) . A nutritional strategy that is efficacious in ameliorating the deleterious effect of 
EIMD may be advantageous in minimising the compromised quality of exercise sessions in the subsequent 
days following this muscle-damaging exercise bout. The use of protein and essential amino acids (EAAs) 
supplemented in the post-exercise window is emerging as one such potential strategy (Howatson et al., 2012; 
Cockburn et al., 2008; Greer et al., 2007; Matsumoto et al., 2007). The exact mechanism that underpins this 
enhancement in recovery with AA ingestion is not fully understood. It has been suggested that an increase in 
post-exercise MPS after protein feeding elicits an increase in muscle recovery. However, since the remodelling 
of myofibrillar proteins is a lengthy process, it is unlikely that this remodelling process would result in 
significant benefits on recovery in the several days following exercise. Nonetheless, protein, and in particular, 
BCAAs have been shown to elicit a benefit on recovery from EIMD (Howatson et al., 2012; Cockburn et al., 
2008; Greer et al., 2007; Matsumoto et al., 2007). The efficacy of supplementary leucine alone, or the 
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enrichment of meals, in ameliorating the negative effects on an intense exercise bout, is underexplored, and 
warrants further investigation.  
1.4 Adjunct Nutrition Strategies for Maximising Muscle Protein Synthesis  
While current recommendations on protein intake are given on a gram per body mass (g/kg) per day basis, 
there is an increased emphasis on the importance of per meal protein recommendations (Layman et al., 2015). 
The cumulative magnitude and duration of postprandial MPS after the ingestion of each protein meal dictates 
the time spent in a positive net protein balance over the course of a day (Layman et al., 2015; Areta et al., 
2013; Paddon-Jones, 2004). For that reason, it is accepted that maximising the MPS response to each meal 
results in a greater cumulative daytime stimulation of MPS, and therefore more time spent in a positive net 
protein balance, which is favourable for muscle accretion. A minimum of 20-30g per meal, or 0.24g/kg per 
meal in young, and 0.4g/kg in old, has been shown to maximise MPS after a single meal (Witard et al., 2014; 
Moore et al., 2015; 2009; Symons et al., 2009). This has led to the hypothesis of distributing daily protein 
evenly over ~4 meals, ensuring each meal reaches this purported meal threshold, is optimal for supporting 
recovery and adaptation to athletic training, and the preservation of muscle health with advancing age 
(Morton, McGlory and Phillips, 2015; Breen and Phillips, 2011). Indeed, a more ‘even’ distribution of protein 
(e.g. 4 x 20g) throughout the day can result in a greater cumulative anabolic response compared to smaller 
and frequent meals, or larger and less-frequent protein meals in young (Areta et al., 2013; Moore et al., 2012). 
The habitual ‘skewed’ distribution of protein intake in which breakfast and lunch often fall under this meal 
threshold, while dinner significantly surpasses it (Cardon-Thomas et al., 2017; Tieland et al., 2015) is therefore 
seen as suboptimal for maximising MPS (Paddon-Jones et al., 2015; Mamerow et al., 2014). Moreover, while 
protein dose plays an important role in stimulating postprandial MPS response, the source of that protein also 
plays a role in the magnitude and duration of that response. Indeed, it is well supported that animal protein, 
which is inherently higher in leucine and other EAAs, stimulates a robust MPS response when compared to and 
equivalent dose of plant-based protein (Gorissen et al., 2016; Wilkinson et al., 2007; Yang et al., 2012a; 
2012b; Tang et al., 2009). Along with total daily protein intake, the protein dose per meal, protein distribution 
throughout the day and protein source are additional factors that need to be considered when aiming to refine 
protein recommendations to optimise athletic performance and manage the age-related decline of muscle 
mass in elderly.  
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1.5 Minimum is Not the Same as Optimum  
The regulation of muscle mass by nutrition is a fundamental consideration in both athletic performance and 
healthy aging paradigms (Burd, Gorissen and Van Loon, 2013). Nutrition interventions that maximise MPS, 
thereby facilitating this shift into a positive net protein balance, have potential application in recovery and 
athletic performance and in the preservation of muscle mass and function in elderly populations (Kreider and 
Campbell, 2009; Paddon-Jones and Rasmussen, 2009). Protein recommendations in public health terms are 
currently given on ‘one size fits all’ basis, with young adults, older adults and athletes considered to have the 
same protein requirements (European Food Safety Authority, 2012). However, there is a wealth of research, 
particularly from acute metabolic studies, to suggest that these recommendations are insufficient, for both 
athletes and older adults (Thomas, Erdman and Burke, 2016; Bauer et al., 2013). When we consider the 
population reference intake (PRI) of protein, we should be cognisant that these are minimum requirements, 
and ‘minimum’ is not the same as ‘optimum’ in many circumstances. This is particularly relevant for athletes, 
whose primary goals are optimal adaptation to training and ultimately, maximal athletic performance; and 
also older adults whose aim is to age well (i.e. by attenuating the decline in functional capacity).  
1.6 Age-Related Decline in Muscle Mass 
The age-related decline in skeletal muscle mass and function in older adults is a fundamental threat to ageing 
well and maintaining independence and quality of life throughout the lifespan ( Fielding et al., 2011; Janssen, 
Heymsfield and Ross, 2002). However, the regulation of muscle mass is a process which is modifiable, 
particularly through exercise and nutrition strategies (Norton et al., 2016; Daly et al., 2014; Liu and Latham, 
2010; Onambélé-Pearson, Breen and Stewart, 2010). Therefore, appropriately-designed recommendations 
around physical activity and diet show promise in ameliorating the loss in muscle mass and function 
associated with advancing age. While resistance exercise is well-accepted as a means to increase lean body 
mass (LBM) and strength in older adults (Onambélé-Pearson, Breen and Stewart, 2010), the optimal nutrition 
strategy for the growth and/or preservation of skeletal muscle in older adults remains to be established. There 
is a wealth of research, particularly from acute metabolic studies, which suggests the current protein 
recommendations are insufficient for older adults (Traylor, Gorissen and Phillips, 2018; Bauer et al., 2013), 
particularly because they exhibit a dampened muscle protein synthetic response to the ingestion of EAAs, also 
termed ‘anabolic resistance’ (Wall et al., 2015; Katsanos et al., 2006; Katsanos et al., 2005; Cuthbertson, 2004; 
Volpi et al., 2000). Nutrition strategies to overcome this anabolic resistance include an increase in per meal 
protein intake, to optimising daily protein distribution, favouring higher leucine animal-based food over plant-
based foods, and the enrichment of lower leucine meals with supplementary leucine to increase the anabolic 
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potential of that meal (Gorissen and Witard, 2018; van Vliet, Burd and van Loon, 2015). Despite these efforts, 
an appropriate nutrition strategy in ameliorating the age-related decline in muscle mass, particularly one that 
is pragmatic for older adults in a real-world setting, remain unclear. Moreover, intervention studies, 
investigating the effect of supplementary protein on changes in LBM and physical function, have traditionally 
focused on powdered supplements, as opposed to whole food. There is evidence to suggest that protein its 
whole-form may exhibit superior anabolic properties; such is the case in young, for whole egg vs. egg whites 
(Van Vliet et al., 2017), and whole-milk vs. skimmed-milk (Elliot et al., 2006). A whole food-based intervention 
may therefore show promise in augmenting exercise-mediated changes in LBM and physical function in older 
adults, but this approach remains underexplored to date.  
 
In summary, while it is well-accepted that leucine plays a key role in the regulation of MPS in the hours after 
ingestion, its effect on postprandial plasma AA kinetics, recovery from EIMD in young athletes, and longer term 
changes in muscle mass and function when administered over time in older adults, is underdeveloped, and 
these gaps in knowledge warrant further investigation.  
1.7 Thesis Overview  
The central theme of this thesis is supplementation with the branched chain amino acid leucine, as well as 
dietary protein distribution strategies, and their applications in recovery from exercise, and supporting 
adaptations to exercise training in older adults. The main research questions of this thesis are: (1) What is the 
current habitual dietary protein intake and protein distribution in Irish adults? (2) How do different leucine 
supplementation strategies affect postprandial plasma leucinemia? (3) What is the application of these 
strategies in recovery from intense resistance exercise in young healthy males? (5) Can a high protein diet, 
targeting leucine-rich meals, augment exercise-mediated effect on LBM and function over a 12-week period in 
older adults?   
1.7.1 Chapter 4: Habitual protein intake, protein distribution patterns and protein source across the 
lifespan in Irish adults between 2008 and 2010 
 
Aim: The aim of this current study was to determine age and gender patterns for overall protein intakes, 
protein distribution and protein sources across the lifespan in Irish adults. Overview: The National Adult 
Nutrition Survey (NANS) investigated habitual food and beverage consumption in 1500 adults aged 18-90 
years, in the Republic of Ireland, between 2008 and 2010. This current study was secondary analysis of the 
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NANS database. Using SPSS statistical software package, patterns for total, body mass relative and per meal 
protein intake, between genders and across age categories were determined. Protein distribution was 
assessed, in which the number of meals reaching ≥20g and ≥30g protein per day; and ≥0.24, ≥0.3 and 
≥0.4g/kg body mass protein per day was calculated. The source of protein intake across 16 food groups, and 
between animal- and plant-based proteins were also determined.  
1.7.2 Chapter 5: The plasma leucine kinetics after an oral load using micro-encapsulated leucine in 
young, healthy males 
 
Aim: The aim of this study was to investigate the plasma kinetics of leucine in response to consuming leucine 
in either its free form or in a novel microencapsulated form, in comparison to that of a maltodextrin control. 
Overview: This study was a randomised control trial with a cross-over design, with five experimental 
conditions; A bolus of 3g free leucine (BOLUS), a bolus of 1.5g free leucine, and a bolus of 1.5g free leucine 
consumed 2 hours later (PULSE), 1.5g microencapsulated targeted-release leucine + 1.5g free leucine with 
(ME LEU+LEU), 3g microencapsulated, targeted-release leucine (ME LEU), 3g maltodextrin (CONTROL). Ten 
healthy active males, (aged 26.4±4.1 years) visited the laboratory on five separate occasions, consuming one 
of each condition. Blood samples were taken at 15, 30, 45 and 60 min, and every 30 min thereafter for the 
subsequent 3 hours. Blood samples were later analysed for plasma AA concentrations using high performance 
liquid chromatography.    
1.7.3 Chapter 6: The plasma leucine kinetics after oral loading using leucine-enrichment of a low-
leucine mixed meal, in young, healthy males  
 
Aim: The aim of this study was to investigate the plasma kinetics of leucine in response to consuming a low-
leucine mixed meal enriched with free leucine. Overview: This study was a single-blind placebo control trial, 
with a cross-over design, with three experimental conditions; Bolus-fed free leucine (BOLUS), Pulse-fed free 
leucine (PULSE) and Placebo - Maltodextrin (CON); with a low leucine meal. Five healthy active males, (age 
25.6 years ± 2.4 years), visited the laboratory on three separate occasions, in which they were randomly 
assigned to one of three conditions. Blood samples were taken at 15, 30, 45 and 60 min, and every 30 min 
thereafter for the subsequent 3 hours. Blood samples were later analysed for plasma AA concentrations using 
high performance liquid chromatography.    
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1.7.4 Chapter 7: The effect of leucine supplementation on delayed onset muscle soreness and 
recovery of muscle function after intense exercise 
 
Aim: The aim of this study was to determine whether recovery from resistance exercise in young resistance 
trained males can be enhanced by either intermittent or bolus feedings of leucine during recovery. Overview: 
This study was a double-blind placebo-controlled cross-over design, including three different experimental 
conditions; Bolus feeding (BOLUS) - 3g free leucine every 4 hours for 14 hours, pulse feeding (PULSE) - 1.5g 
free leucine fed every 2 hours for 14 hours, a control group (CON) - 3g maltodextrin fed every 2 hours for 14 
hours. Thirteen healthy, active males (age 25.5 years ± 5.2 years) performed 10 sets of 10 repetitions of a leg 
press at 60% 1RM. Participants were given one of the three supplementation strategies to follow during the 
14-hour post-exercise period in addition to a low-leucine meal plan. Plasma concentrations of creatine kinase 
and lactate dehydrogenase; ratings of perceived soreness and recovery; and performance measures using a 
counter-movement jump; were assessed immediately before, after, 24 hours after and 48 hours after the 
exercise bout. 
 
1.7.5 Chapter 8: The effect of a nutrition intervention targeting leucine-rich meals on changes in 
calorie, macronutrient and micronutrient intake, and protein distribution in older adults  
 
Aim: The aim of the present study was to determine if instruction on a nutrition intervention, prescribing the 
equivalent of 3g of leucine per meal, can augment protein intake and protein distribution in older adults. 
Overview: This study was a randomised control trial with three groups: Exercise and Nutrition group 
(EX+NUTR), Nutrition only group (NUTR ONLY), Exercise only group (EX ONLY). Fifty-six community-dwelling 
older males and females (m/f, 28/28; age, 69.3±4.0 years) were randomly assigned to one of three groups for 
12 weeks. NUTR+EX and NUTR were instructed to follow a leucine-rich dietary strategy, in which meals 
equating to 3g of leucine were translated to user-friendly portion sizes. EX were asked not to change their diet 
for the duration of the study. All participants completed a 3-day portion estimate food diary before (week 0), 
during (week 6) and after (week 12) the 12-week intervention, which were later analysed (using Nutritics 
Nutrition Analysis Software) to determine energy, macronutrient and micronutrient intake. Protein distribution 
was assessed, in which the number of meals reaching ≥20g and ≥30g protein per day; and ≥0.4g/kg body 
mass protein per day was calculated. 
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1.7.6 Chapter 9: The effect of concurrent exercise training and/or a high protein diet intervention 
targeting leucine-rich meals on body composition and physical function in older adults 
 
Aim: The aim of this study was to determine if the nutrition intervention prescribed in chapter 8 augmented 
exercise training-mediated effects on LBM and physical function in older adults. Overview: This study was 
performed in combination with the analysis in chapter 8. Participants in NUTR+EX and EX performed exercise 
training, which consisted of 24 min of combined resistance and aerobic exercise per session, three times per 
week for 12 weeks. Body composition and physical function were assessed before (week 0), during (week 6) 
and after (week 12) the 12-week intervention.  
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Chapter 2 
2.0 Review of Literature   
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2.1 Introduction  
The aim of this chapter is to (1) Summarise the current understanding of the role of dietary essential amino 
acids (EAAs), in particular leucine, in muscle protein synthesis (MPS); (2) Discuss the potential ways in which 
this understanding can be used to maximise the anabolic response to a meal, namely protein quality, protein 
quantity, protein distribution and leucine-enrichment; (3) Discuss the potential of these strategies to delay the 
age-related decline in muscle mass and contribute to the preservation of muscle mass and muscle function in 
older adults; (4) Identify the potential of these strategies to ameliorate the deleterious effects of exercise 
induced muscle damage (EIMD) and  thereby enhance recovery from an intense training bout in athletic 
populations.  
 
2.2 Muscle Protein Turnover   
2.2.1 Muscle Protein Synthesis and Muscle Protein Breakdown  
Muscle protein remains in a state of constant remodelling through the dynamic processes of the formation of 
new proteins and the degradation of existing proteins. This state, termed muscle protein balance, is regulated 
by MPS and muscle protein breakdown (MPB), that both fluctuate over the course of a typical day (McGlory and 
Phillips, 2014; Norton and Layman, 2006). When the magnitude of MPS outweighs that of MPB, a positive 
protein balance is achieved, which is conducive to muscle accretion over time. In contrast, when MPB 
outweighs that of MPS, a negative protein balance ensues, which over time can result in muscle loss (Damas et 
al., 2015; Koopman et al., 2007). These processes are sensitive to external stimuli, in particular, the intake of 
dietary protein (Atherton and Smith, 2012). During periods of fasting (between meals or after an overnight 
fast) MPB is elevated above MPS. When a protein meal is eaten, MPS is elevated above MPB, as per figure 
2.1.  
The importance of dietary protein in the regulation of skeletal muscle mass is based on the principle that the 
amino acids (AAs) within the matrix of dietary protein are used to synthesise new muscle protein, which are 
incorporation into the skeletal muscle cell (Kreider and Campbell, 2009). The way in which dietary protein 
ultimately signals the synthesis of new proteins will be discussed in detail in section 2.4. Much of the 
research to date has focused predominantly on MPS as opposed to MPB, as a proxy for measuring muscle 
protein turnover, mainly because MPS is more sensitive to the external stimuli such as nutrient and exercise, in 
some instances, 4-5 fold more responsive than MPB to the same stimulus (Damas et al., 2015; McGlory and 
  12 
Phillips, 2014). Furthermore, MPB is technically challenging to measure compared to MPS. MPB can be 
determined by assessing the dilution of amino acid tracer across the limb, in conjunction with blood flow. 
However, blood flow can be difficult to measure and the calculation of MPB involves the use of complex 
mathematical modelling (McGlory and Phillips, 2014; Atherton and Smith, 2012). Quantifying MPS is 
therefore widely used as a means of determining the efficacy of nutrition and training strategies in skeletal 
muscle remodelling and the potential for muscle accretion over time. 
 
 
Figure 2.1: Graphic representation of the daily fluctuations of muscle protein synthesis (black dotted line) 
and muscle protein breakdown (red dotted line), which affect net protein balance. Fasting acts as a stimulus 
for muscle protein breakdown, while dietary protein acts as a stimulus for muscle protein synthesis. 
 
2.2.2 Quantifying Muscle Protein Synthesis  
The use of stable isotopes is now most widely used as a measure of MPS. Isotope tracer method involves the 
use of non-radioactive stable isotopes, which are identical to exogenous AAs, but can be differentiated based 
on their mass. Through muscle biopsy, the incorporation of isotopically labelled AAs, such as [1,2-13C2] leucine 
and [13C6] phenylalanine, into the skeletal muscle can be identified, therefore quantifying MPS (McGlory and 
Phillips, 2014; Atherton and Smith, 2012). Fractional synthetic rate (FSR) is most frequently used to quantify 
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the rate of synthesis of new proteins (% per h) in the muscle compartments. Using this technique, 
incorporation of the labelled tracer can be identified in the sub fractions of muscle, such as the contractile 
myofibrillar proteins (e.g. actin, myosin and troponin) and the non-contractile myofibrillar proteins (e.g. 
sarcoplasmic and mitochondria)(Witard et al., 2016). However, this measurement is carried out in a controlled 
lab environment over several hours, and often requires several muscle biopsies, and is therefore not 
representative of a free-living environment. A new method of assessing MPS, involves the use of deuterated 
water (D20) and has the ability to assess MPS over several weeks to months, outside of a lab setting (McGlory 
and Phillips, 2014; Atherton and Smith, 2012). This method involves the ingestion of D20, and the 
measurement of the incorporation of deuterium into skeletal muscle. While this technique enables the 
collection of data in a free-living setting; nutrition, exercise and other lifestyle factors are therefore difficult to 
control.	 
2.3 Current Protein Recommendations  
2.3.1 Current Protein Recommendations  
Nitrogen balance studies have traditionally been used as method for quantifying protein requirements (Rand, 
Pellett and Young, 2003) and have informed the current population reference intake (PRI) for dietary protein, 
which now stands at 0.83 grams per kilogram body mass per day (g/kg/d) (European Food Safety Authority, 
2012). The premise of using nitrogen balance studies for quantifying protein requirements is that protein is 
the only nitrogen-containing macromolecule in the body. Through monitoring nitrogen intake and nitrogen 
excretion, nitrogen balance, and therefore an individual’s minimum protein requirement can be determined 
(Rand, Pellett and Young, 2003). A major limitation of this technique is accounting for the various routes of 
nitrogen intake and loss from the body (Bauer et al., 2013). Furthermore, the studies which inform protein 
recommendations use predominantly young adults in good health and in energy balance, therefore not 
accounting for populations, particularly, athletes and older adults (Traylor, Gorissen and Phillips, 2018; Witard 
et al., 2016). With the recent advances in techniques for assessing skeletal muscle metabolism, our 
understanding of protein requirements across populations has changed. In particular, the indicator amino acid 
oxidation (IAAO) method is emerging as an adjunct technique in assessing protein requirements. This is a 
technique in which a labelled tracer amino acid is infused and its rate of oxidation is observed and correlated 
to protein requirements (Humayun et al., 2007). When protein intake is insufficient, the rate of incorporation 
of the tracer AA into the cell for MPS will be limited, and the tracer AA will remain in the free AA pool and be 
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oxidised. As protein intake increases and approaches sufficiency, the rate of oxidation of the tracer AA will 
decrease, eventually reaching a plateau when the sufficient protein is reached.  
 
The IAAO method has determined that protein requirements in young adults are indeed higher than the 
current population reference intake (PRI), at 0.93g/kg (Humayun et al., 2007). While the current 
recommendations inform protein requirements to prevent deficiencies across the entire population, minimum 
requirement is not the same as optimal requirement, and the current recommendations potentially fail to 
address what is optimal and enables an individual to thrive. This is particularly relevant for athletes, whose 
primary goals are optimal adaptation to training and ultimately, maximal athletic performance (Phillips and 
van Loon, 2011). Furthermore, there are additional factors which may call for even higher protein needs in 
athletes, such as, their chosen sport, energy intake, physique characteristics, performance goals, training 
volume, intensity, frequency, phase and goals (Egan, 2016; Thomas, Erdman and Burke, 2016; Tipton and 
Wolfe, 2004). As a consequence, there is an emerging recognition that 1.2g to 2g/kg/d of dietary protein 
represents a more appropriate recommendation for athletic populations (Egan, 2016; Kato et al., 2016; 
Thomas, Erdman and Burke, 2016; Morton, McGlory and Phillips, 2015). Resistance trained athletes may 
require more protein than their endurance trained counterpart, and protein intake at the highest range may 
offer benefit in minimising skeletal muscle loss during periods of a caloric deficit (Phillips and van Loon, 
2011). 
 
A further limitation of the current recommendations is that it does not account for older adults who exhibit a 
blunted muscle protein synthetic response to ingestion of exogenous protein, when compared to their 
younger counterpart, a phenomenon termed ‘anabolic resistance’ (Wall et al., 2015; Katsanos et al., 2006; 
2005; Cuthbertson, 2004; Volpi et al., 2000). The IAAO method has estimated that protein requirements are 
0.94-1.24g/kg in older males and 0.96-1.29g/kg in older women (Traylor, Gorissen and Phillips, 2018; Rafii et 
al., 2016; 2015). As a result of these acute metabolic studies, it is well accepted that older adults have higher 
protein requirements than the current PRI, closer to 1.2g/kg/d (Bauer et al., 2013), which will be discussed 
further in a later section.  
 
In summary, protein requirements vary largely, and need to be individualised based on the nature of the 
training stimulus and goals in athletic populations. Meanwhile, older adults possess a higher protein 
requirement, predominantly due to the presentation of anabolic resistance. These unique requirements are 
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not reflected in current ‘one size fits all’ recommendations, which, based on ample evidence, necessitate 
revision.  
 
2.4 The Role of Nutrition and Exercise in Muscle Protein Synthesis    
2.4.1 Dietary Protein and Muscle Protein Synthesis   
Dietary protein is a potent anabolic stimulus that results in an increase in MPS in the postprandial (post-meal) 
period (Witard et al., 2014; Moore et al., 2009). Essential amino acids (EAAs) in particular are responsible for 
eliciting this postprandial anabolic response, whilst non-essential amino acids (NEAAs) do not elicit this same 
stimulation in MPS (Smith et al., 1998). Leucine is an essential amino acid that not only acts as a substrate for 
the synthesis of skeletal muscle, but is also involved in the initiation of a signalling cascade which ultimately 
results in an increase in MPS, above postabsorptive (period following absorption of nutrients, i.e. between 
meals) values (Haran, Rivas and Fielding, 2012; Pasiakos, 2012). 
2.4.2 Leucine and mTOR Signalling 
Increased availability of AAs in the plasma and intramuscular compartment triggers MPS. EAAs act as an 
anabolic stimulus, with leucine in particular playing a key role in initiating this anabolic response by the 
activation of proteins that mediate the process of MPS (Pasiakos, 2012; Atherton et al., 2010a). Following AA 
uptake via large neutral amino acid transporter (LAT1), leucine directly binds Sestrin-2 and CASTOR1, 
respectively, relieving their repression of GATOR2. Sestrin-2 is seen as the primary leucine sensor for the 
activation of mTORC1 (Wolfson and Sabitini, 2017). In turn, GATOR2 inhibits GATOR1, which maintains Rag 
GTPases in their respective inactive nucleotide bound configurations. GATOR1 and Rag GTPases are tethered to 
the lysosomal surface by the ragulator and KICSTOR complexes, respectively. Once activated, Rag proteins bind 
Raptor on mechanistic target of rapamycin complex 1 (mTORC1), thus facilitating its translocation to the 
lysosomal surface where it interacts with Rheb, an obligitary activator (Saxton and Sabitini, 2017). mTORC1 
subsequently regulates mRNA translation via the phosphorylation of its downstream effectors; 1. The activation 
of p70 S6 kinase; 2. The activation of the repressor of mRNA translation, eukaryotic initiation factor 4E (eIF4E) 
binding protein (4E-BP1). mTORC1 phosphorylates and activates S6K1, which enhances translation initiation. 
In addition, mTORC1 also phosphorylates and inactivates 4E-BP1, a protein that binds to eIF4E, thereby 
blocking the formation of eIF4E-eIF4G, a complex involved in upregulating translation initiation. However, 
when phosphorylation of 4E-BP1 occurs, eIF4E is released, binding to eIF4G and forming eIF4E-eIF4G. This 
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complex upregulates mRNA binding to the 40S ribosomal subunit, resulting in increased translation initiation, 
and therefore MPS (Laplante and Sabatini, 2012). Both of these signalling cascades ultimately result in the 
initiation of protein translation in the overall process of MPS, and thus, increased formation of new proteins.  
Leucine is unique in its ability to stimulate the signalling cascade associated with MPS. Leucine increases the 
phosphorylation of mTOR and 4E-BP1, 1.7-fold and 2.5-fold, respectively, with other AAs exhibiting no effect 
on change in phosphorylation of these signalling proteins (Atherton et al., 2010a). Leucine also exhibited a 6-
fold greater increase in signalling through p70 S6 kinase, compared to 1.6-2-fold for other EAAs (Atherton et 
al., 2010a). Due to the anabolic potential of leucine, it remains a nutrient that has received much interest in 
recent years, both in athletic populations and in ameliorating age-related atrophy in older adults.  
 
2.4.3 The Role of Insulin in MPS   
Leucine stimulates MPS via an insulin-dependent and insulin-independent pathway (Haran, Rivas and 
Fielding, 2012), but insulin is unlikely to be the primary mediator of MPS after AA ingestion. Leucine is seen to 
stimulate MPS when insulin is kept constant (Atherton et al., 2010b). Hyperaminoacidemia (an increase in 
plasma amino acid concentration above baseline) shows a dose dependent relationship to MPS, without any 
increase in plasma insulin (Cuthbertson et al. 2005). Hyperinsulinemia promotes MPS only when there is an 
increase of muscle blood flow, AA delivery and availability (Fujita et al., 2006). Insulin is therefore suggested to 
be permissive of MPS as oppose to modulatory (Haran, Rivas and Fielding, 2012). Insulin may instead be more 
effective in preventing MPB, and it has been shown that MPB is inhibited with an increase in plasma insulin, 
and in the absence of AA availability (Abdulla et al., 2016). In conclusion, insulin is seen as permissive to MPS, 
as opposed to its concentration exhibiting a direct influence on MPS.  
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Figure 2.2: Mixed muscle fractional synthetics rate (FSR) after the ingestion of 0g, 5, 10g, 20g and 40g 
egg protein, in young healthy males, after exercise. Adapted from Moore et al., (2009). MPS, muscle protein 
synthesis.  
 
2.4.4 The Leucine Threshold Hypothesis and The Upper Limit of Muscle Protein Synthesis  
It is well established that the ingestion of exogenous EAAs stimulates the mTOR pathway and acutely elevates 
MPS above postabsorptive values (Dreyer et al., 2008; Fujita et al., 2007). Hyperaminoacidemia has been 
shown to directly modulate MPS rates in a dose-dependent manner (Witard et al., 2014; Moore et al., 2009; 
Cuthbertson, 2004). When EAAs are ingested, thereby causing a sufficient increase in plasma aminoacidemia 
and leucinemia (plasma leucine concentration), MPS increases above postabsorptive values. The point at which 
mTOR signalling and MPS is significantly elevated above postabsorptive values is termed the ‘leucine 
threshold’ (Breen and Phillips, 2011). This threshold is not absolute, and has been shown to differ between 
young and old. While the leucine threshold is purported to be ~1g in young, older adults exhibiting a 
decreased sensitivity to increases plasma leucinemia, and therefore a higher leucine threshold of >2g, the 
quantity found in 20g high quality protein (Phillips, 2015). As a result of the key role played by leucine in the 
muscle protein synthetic response to a meal, the use of crystalline leucine as a supplement, and in particular, 
the enrichment of lower leucine foods, has received much interest in recent years (Murphy et al., 2016; Trabal 
et al., 2015; Casperson et al., 2012; Verhoeven et al., 2009).  Adding leucine to a lower leucine meal may 
‘rescue’ the inferior anabolic response of that lower leucine meals. Indeed, a 3g EAA beverage rich in leucine 
(1.2g), has been shown to cause a postprandial stimulation in MPS, similar to that of 20g whey protein 
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(Bukhari et al., 2015). Similarly, 6g EAA, containing 2.4g leucine, stimulates MPS to the same extent as 40g 
whey protein in older adults (Wilkinson et al., 2017). This is particularly relevant in the case of plant-based 
protein, which are inherently lower in leucine, and therefore result in an inferior muscle protein synthetic 
response when compared to the ingestion of isonitrogenous animal-based proteins (Burd et al., 2012; Yang et 
al., 2012a; 2012b; Tang et al., 2009). Leucine-enrichment, as a nutrition strategy for increasing the anabolic 
potential of a meal, will be discussed further in section 2.6.3.    
 
Witard et al., (2014) sought to determine myofibrillar protein synthesis with graded dose of whey protein. 0g, 
10g, 20g, and 40g, containing 0g, 1.1g, 2.2g, 4.4g leucine, respectively, was ingested 10 min after resistance 
exercise. 10g of whey protein did not cause an increase in MPS above values apparent after the ingestion 0g 
whey. The ingestion of 20g and 40g whey resulted in a 49% and 56% increase in MPS, respectively, compared 
to 0g whey. There was no statistically significant difference between myofibrillar FSR after the ingestion of 20g 
and 40g whey. Therefore, the equivalent of 20g of a high quality protein source is likely to be sufficient to 
maximise MPS. Similarly, Moore et al. (2009) investigated rates of mixed muscle FSR in response to egg 
protein, containing 0g, 0.42g, 0.84g, 1.68g and 3.36g of leucine, respectively. Plasma leucine concentration 
peaked at 101, 120, 146 and 167µmol/L with the ingestion of 0g, 5g, 10g, 20g and 40g at 45 min, after the 
ingestion of 5g, 10g, 20g and 40g protein, respectively. Mixed muscle FSR increased by ~37%, ~56%, ~93% 
and ~93% after the ingestion of 5g, 10g, 20g and 40g egg protein, above fasted values, as per figure 2.2. In 
accordance with finding by Witard et al. (2014), MPS reached a plateau after the ingestion of 20g protein, and 
there was a marked increase in leucine oxidation after the ingestion of 40g protein. This suggests that when 
dietary protein is ingested in excess of the rate needed for incorporation into skeletal muscle, irreversible 
oxidation occurs. This 20g dose of whey protein equates to approximately 10g EAAs, which is consistent with 
studies demonstrating that 10g EAAs maximally stimulates MPS (Glynn et al., 2010; Moore et al., 2009; 
Cuthbertson, 2004). Glynn et al. (2010) compared the ingestion of 10g EAA enriched with 1.7g leucine with 
10g EAA enriched with an additional 2.8g leucine. There was no difference in area under the curve (AUC) of 
mixed muscle FSR or net protein balance between groups. In this study, 1.8g leucine in an AA mixture was 
sufficient to elicit maximal MPS, such that further increase in leucine content (3.5g in total) did not have an 
additive effect on MPS or net protein balance. In summary, MPS is stimulated in a dose dependent manner to 
graded increases in dietary protein. However, MPS has an upper limit of activation in response to a given 
quantity of leucine, meaning above a certain ingested dose or resultant plasma concentration of leucine, MPS 
is not further stimulated.  
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2.4.5 The Refractory Period and The Muscle Full Hypothesis     
Not only does MPS possess an upper limit of activation, but muscle can also exhibit a ‘refractory period’ during 
this upper limit, in which MPS cannot be further stimulated despite plasma leucine concentration remaining 
elevated (Glynn et al., 2010; Moore et al., 2009; Cuthbertson, 2004). This concept was well demonstrated by 
Bohé et al. (2001). During a constant AA infusion over 6 h, MPS responded after 30-60 min and peaked with a 
2.8-fold increase for 1.5 h. Plasma AA concentrations remained elevated during the 6 h infusion, but rates of 
MPS returned to baseline 4 h after the infusion had commenced. In short, MPS increases transiently, but after 
a time, muscle exhibits a ‘refractory’ response to sustained elevation in plasma leucine concentration. 
Thereafter, MPS returns to baseline and cannot be further stimulated (Atherton, et al., 2010a; Bohé et al., 
2001). Atherton et al. (2010a) demonstrated myofibrillar FSR rate in response to ingestion of 48g whey protein 
in a single bolus. Similar to findings by Bohé et al. (2001), MPS increased 3-fold at 45-90 min but returned to 
baseline by 120 min despite plasma AA concentrations remaining elevated. Interestingly, mTORC1 signalling 
and S6K and IF4eF phosphorylation remained elevated despite the decline in MPS, mimicking the rise and 
decline of plasma AA concentrations, and returning to baseline after >180 min. This suggests that discordance 
exists between signalling and MPS, which has been reported elsewhere (Glynn et al., 2010; Norton et al., 
2009) and a drop in intracellular signalling regulating MPS does not explain the refractory response of muscle 
to sustained hyperaminoacidemia (Atherton et al., 2010b). Despite elevated plasma and intramuscular 
leucine, MPS declined, which suggests that the muscle possesses a mechanism that monitors its capacity to 
synthesise new proteins, and terminates the process when a limit is reached. The phenomenon is termed the 
‘muscle full’ hypothesis (Atherton et al., 2010b). This hypothesis is based on the ‘bag full’ theory first coined by 
Millward, (1995). Millward akined the endomysium which surrounds each muscle fibre to a bag. Due to the 
minimal elasticity of the endomysium,  the ‘bag’ has a fixed volume, which limits the production of muscle 
proteins after a certain capacity has been reached. This refractory characteristic of muscle in response to a 
sustained concentration of plasma EAA, has led to the hypothesis that pulse fed AAs is more appropriate than a 
continuous supply of AAs, in maximising MPS. In this instance, pulse-fed refers to the ingestion of intermittent 
boluses of AAs, separated by a time period, while bolus-fed tends to be greater doses on AAs, separated by 
greater time periods. Bolus-fed is most often similar to a normal diet, in which meals are separated by several 
hours.   
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Figure 2.3: Graphic representation of the leucine threshold* and the discordance between sustained 
elevation of plasma amino acids* and muscle protein synthesis*, termed the muscle full response*. 
Despite plasma aminoacidemia and anabolic signalling* remaining elevated after the ingestion of 
exogenous amino acids, MPS returns to baseline after 90 min. MPS, muscle protein synthesis; *, arbitrary 
figures.  
 
2.4.6 Protein Timing and Meal Distribution  
The refractory characteristic of muscle to a sustained concentration of plasma EAA, has led to the hypothesis 
that feeding sufficient amounts of AAs in one bolus, is more appropriate than a continuous supply of AAs, in 
maximising MPS. West et al. (2011) compared a single 25g whey protein bolus (BOLUS), to 2.5g whey fed 
every 20 min (PULSE) on rates of MPS in the post-exercise period after reistsance exercise. 60 min after 
exercise, plasma AA concentration peaked in BOLUS at 290μmol/L, while PULSE was ~120 μmol/L at the same 
time-point. However, PULSE, due to the continous feeding nature of the condition, maintained a sustained 
aminoacidemia, which was higher than of BOLUS 180-220 min after exercise. While the AUC for plasma EAA 
concentration did not differ between conditions, myofibrillar FSR was elevated by 92% and 42% above basline 
in BOLUS and PULSE respectively, between 1-3 h post-exercise. At 3-5 h post-exercise, FSR was elevated by 
193% and 121% above baseline, in BOLUS and PULSE respectively. This shows that a rapid and pronounced 
rise in amniacidemia in the post-exersise period stimulates MPS to a greater extent than a gradual and 
sustained rise in aminoacidemia. Indeed, consumption of 2-3 meals containing 20-30g of high quality protein 
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has been shown to cause greater rate of MPS over 24 h, when compared to one large protein meal, or several 
small protein meals (Areta et al., 2013). Areta et al., (2013) compared the effects of three different feeding 
strategies of 80g of whey protein on post-exercise MPS rates over 12 h– PULSE, 10g protein every 1.5 h; 
INTERMEDIATE, 20g protein every 3 h; BOLUS, 40g every 6 h. Myofibrillar FSR increased above baseline in all 
conditions. Cumulative myofibrillar FSR of INTERMEDIATE condition was 32% and 49% greater than BOLUS 
and PULSE condition. Therefore, 20g protein in the INTERMEDIATE condition was sufficient to stimulate a 
robust anabolic response, which is consistent with the dose that maximises MPS as reported elsewhere (Witard 
et al., 2014; Moore et al., 2009). Furthermore, the 3 h gap between 20g feeds seems to be sufficient in 
duration for recovery of the refractory response of muscle, enabling repeated MPS stimulation over 12 h. Taken 
further, this implies a more ‘even’, as opposed to ‘skewed’, distribution of daily protein intake is therefore 
considered optimal for maximising diurnal MPS rates. Strategic dosing and distribution of AAs with sufficient 
protein boluses, fed ≥3 h apart, is therefore likely to overcome this refractory response by modulating relative 
changes in plasma AA concentration. This is a fundamental consideration for the appropriate design of 
nutrition interventions to maximise muscle accretion, since it is clear evidence that total protein intake is not 
the only factor modulating to MPS. However, extrapolating acute rates of MPS to positive changes in muscle 
accretion over-time should be interpreted with caution. Long duration intervention studies, which assess lean 
body mass (LBM) and strength, are more representative of chronic adaptations to changes in protein 
distribution. The current literature available in this area, specifically using an older cohort, will be explored 
further in section 2.8.4. 
2.4.7 The Role of Exercise in Muscle Protein Synthesis  
The refractory response of MPS to sustained hyperaminoacidemia may be minimised by exercise. Similar to 
increased plasma concentrations of EAAs, exercise is a potent stimulator of MPS. Intramuscular mechanical 
strain created during the contractile forces elicited during exercise, ultimately results in the stimulation of 
intracellular anabolic signalling pathways that regulate MPS, a phenomenon known as mechanotransduction 
(Pasiakos, 2012). Akin to EAA, and leucine in particular, the upregulation of the master regulator of protein 
synthesis, mTORC1, is responsible for the increased rate of MPS seen in the post-exercise period. Of note, 
resistance exercise (8 sets of 8 repetitions at 80% 1RM) has been shown to increase positive net protein 
balance for 2 days after exercise cessation (Phillips et al., 1997). This exercise bout also resulted a 112%, 65% 
and 34% increase in muscle FSR, 3 h, 24 h and 48 h after exercise, respectively. The anabolic effects of AA 
alone are greater than that of exercise alone, as per figure 2.4 (Phillips, 2012b). However, the combination of 
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both exogenous EAA and exercise elicits a robust effect on MPS, greater than of AA or exercise alone. Exercise 
may enhance the sensitivity of skeletal muscle to the anabolic potential of AA, since mechanical loading has 
been reported to increase the muscle intracellular permeability to extracellular AAs (Pasiakos, 2012). 
Furthermore, blood flow, which increases with exercise, enhances the delivery of AAs to the muscle cell (Biolo 
et al., 1997). Indeed, increased stimulation of intracellular signalling regulating MPS and greater rates of 
myofibrillar FSR are apparent when AA are ingested in the exercised state, compared to at rest, in both young 
(Witard et al., 2014; Burd et al., 2012; Churchward-Venne et al., 2012; Moore et al., 2011) and old (Yang et al., 
2012a). In young, myofibrillar FSR was 44% higher at 3-5 h post ingestion, in the resistance exercised leg, 
compared to the rested leg, after the ingestion of 25g whey (Churchward-Venne et al., 2012). In older adults, 
Yang et al. (2012a) demonstrated that while 40g of whey conferred no additional increase in FSR compared to 
20g of whey at rest, after resistance exercise, 40g of whey elicited a 32% greater increase in FSR compared to 
20g whey. These results demonstrate that in an acute setting, exercise results in a greater increase in 
postprandial MPS, when compared to ingesting protein in a rested state, in both young and older adults. The 
potential effects of exogenous EAA in combination with resistance training on changes in LBM and strength 
over time in older adults will be discussed in section 2.8.4.  
 
 
Figure 2.4: Muscle protein synthesis*, muscle protein breakdown* and the resulting net protein balance* 
at rest, after the ingestion of amino acids, after exercise, and after a combination of amino acids and 
exercise. Adapted from Phillips (2012b). MPS, muscle protein synthesis; MPB, muscle protein breakdown; NPB, net 
protein balance; AA, amino acids; REX, resistance exercise; *, arbitrary units.  
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2.5 Postprandial Aminoacidemia and Muscle Protein Synthesis  
2.5.1 Digestion and Absorption Kinetics of Leucine  
After ingestion of a protein-containing food source, whole proteins are denatured by acid in the stomach, and 
broken down into smaller peptides. These proteins and peptides then pass into the small intestine, where 
peptide bonds are further broken down by proteolytic enzymes, into single AAs. These AAs are transported into 
the mucosal cell by AA specific carriers (Gropper and Smith, 2012; Kreider and Campbell, 2009). Leucine, 
being a neutral AA, crosses the gut wall by active transport (Adibi and Gray, 1967). AAs with the greatest 
transport affinity compete more effectively for carrier membranes, consequently impeding the transport of low 
affinity AAs, particularly at higher concentrations (Webb, 1990). Indeed, leucine, isoleucine, valine and 
methionine show greater absorption rates than threonine when presented to the intestinal mucosa in 
equimolar mixtures (Adibi and Gray, 1967). AAs are subsequently absorbed in to the portal blood system, 
while some are metabolised within the mucosal cell. Absorbed AAs pass into the liver, where some are 
metabolised, and the remainder are released into circulation and delivered to peripheral tissues. The 
metabolic fates of the AAs include the formation of function protein such as enzymes, signalling proteins such 
as hormones, and structural proteins such as the skeletal muscle (Gropper and Smith, 2012; Kreider and 
Campbell, 2009).  
 
A rise in plasma aminoacidemia, and in particular leucinemia, is a potent stimulator of MPS. Consequently, 
factors that influence the plasma kinetics of AAs are of interest in the present review. Both protein/AA dose, 
protein/AA source and co-ingestion of other macronutrients influence the postprandial plasma AA kinetics. 
Matsumoto et al. (2014) compared the plasma kinetics of leucine after the ingestion of graded doses (10, 20, 
30, 45, 60, 75, 90mg/kg) of crystalline leucine diluted/partially diluted in water. Plasma concentrations of 
leucine peaked at 15-30 min for all conditions. Peak leucinemia was achieved at a dose of 45mg/kg, or ~3g 
leucine, at ~800	 μmol/L, with no further increase in peak leucinemia apparent after the ingestion of 60, 75 
and 90mg/kg (~4g, 5g and 6g leucine). This suggests that the absorption rate of leucine is maximised at ~3g 
leucine in crystalline form. This may be explained by the poor solubility of leucine, which did not completely 
dissolve in water at doses ≥60mg/kg. After the ingestion of 10-30mg/kg leucine, plasma leucine 
concentrations had returned to baseline at 240 min, while plasma leucine remained elevated at 240 min after 
the ingestion of 45-90mg/kg (~3-6g leucine). Peak leucinemia is apparent after the ingestion of ~3g leucine, 
however, the ingestion of ~4, 5 and 6g leucine results in a sustained elevation of plasma leucinemia for up 4 
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h after ingestion. The source of dietary protein has also been shown to influence postprandial plasma kinetics 
of AA. Burke et al. (2012) demonstrated that 20g protein from various food exhibit marked differences on 
plasma leucinemia, with liquid-form protein achieving peak aminoacidemia twice as fast, compared to the 
ingestion of  protein in solid form.  Indeed, free form AAs results in a faster and greater peak leucinemia when 
compared the AAs given in a mixed meal, with a decrease circulation of EAAs apparent in the meal condition 
(Rondanelli et al., 2017). This may be explained by the presence of carbohydrates and fat in the mixed meal, 
which slows down gastric emptying, and therefore intestinal absorption of AAs (Have et al., 2007). As 
mentioned previously, leucine-enrichment is a promising strategy for enhancing the anabolic response to a 
low leucine meal. However, the plasma kinetics of AAs after the ingestion of a leucine-enriched mixed meal 
remains unexplored, and warrants further investigation.  
2.5.2 Enhanced Food Ingredient Delivery by Microencapsulation Technology   
With our present understanding of the modulatory effects of plasma aminoacidemia on MPS, it is within 
scientific reason that optimising the plasma kinetics of leucine to favour MPS, shows promise for enhancing 
the anabolic potential of a meal. However, the ideal postprandial plasma kinetics of leucine required to 
maximise MPS remains unclear. West et al. (2011) demonstrated that rapid postprandial aminoacidemia 
enhances anabolic signalling and myofibrillar MPS to a greater extent than an identical amount of whey 
protein that has a slower digestion kinetics, concluding that a more pronounced peak in aminoacidemia is 
optimal for enhanced MPS in young after exercise. However, while not entirely conclusive, several studies have 
pointed to the notion that a prolonged low amplitude elevation in postprandial leucinemia may instead 
facilitate an extended MPS response after meal ingestion (Gorissen et al., 2016; Mitchell et al., 2015a; Areta et 
al., 2013). Maintaining a low amplitude leucinemia after a single meal may offer a means of overcoming the 
refractory response to a sustained high elevation in leucinemia, by preventing the muscle full response. 
Interestingly, microencapsulation is an emerging technology that has shown potential for the optimal delivery 
of drugs and nutrients (Dias, Ferreira, & Barreiro, 2015; Singh, Hemant, Ram, & Shivakumar, 2010; 
Champagne & Fustier, 2007). This technology is based on the immobilization of a core ingredient in a 
miniature-sealed capsule that maintains structural integrity until degradation and release of the ingredient at 
an appropriate time or site in the body (Dias, Ferreira, & Barreiro, 2015). Furthermore, through appropriate 
design, the degradation and release of the ingredient can be manipulated to potentially create the desired 
plasma kinetics. A microencapsulation technology has been recently developed by Anabio Technologies, who 
part-funded the work undertaken in this PhD thesis, which can be used to encapsulate leucine and claims 
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enhanced bioavailability and a sustained-release design (Brodkorb and Doherty, 2015). This patent relates to a 
process for producing microcapsules, whereby the core ingredient (leucine) is encapsulated within a protein 
matrix (whey protein). This protein matrix, acting as carrier system for the core ingredient, is purported to have 
the optimal pH to minimise degradation of the core ingredient by gastric acids, enabling enhanced 
bioavailability and timely release and absorption in the intestine. Furthermore, the use of microencapsulated 
leucine may also enhance the palatability of leucine-containing protein supplements, as masking the bitter 
taste properties of free leucine proves difficult (Kato, Rhue, and Nishimura 1989). Microencapsulated leucine 
may also show promise in leucine-enrichment of plant-based proteins. The addition of microencapsulated 
leucine to a plant-based protein supplement may achieve the desired sustained low amplitude plasma 
leucinemia, with the potential to stimulate MPS to a greater magnitude compared to a plant-based protein 
alone.  
2.5.3 Protein Quality and Postprandial Aminoacidemia  
A high quality protein is defined as a protein that provides sufficient EAAs, that is easily digested and can 
readily be used for the synthesis of new proteins (Food and Nutrition Board, 2005). Animal-based protein, such 
as meat, dairy and eggs are inherently high in protein, EAAs and leucine, per 100g, as per table 2.1. 
Meanwhile, plant-based proteins, such as cereals and legumes, provide a lower proportion of protein, EAAs 
and leucine (USDA National Nutrient Database for Standard Reference, 2009). Postprandial 
hyperaminoacidemia is a potent stimulator of MPS. Consequently, foods that are higher in EAAs and leucine, 
and elicit greater and faster digestion and absorption kinetics, have been shown to elicit a superior muscle 
protein synthetic  response. When 21-22g of whey protein hydrolysate, isolate soy protein and micellar casein 
were ingested, the resultant rise in aminoacidemia was more pronounced for whey, compared to soy and 
casein (Tang et al., 2009). While matched for total EAA content, the whey, soy and casein beverage contained 
2.3g, 1.8g and 1.8g leucine, respectively.  
 
When compared to soy, the AUC for leucine after whey ingestion was ~73% greater. Despite whey and soy 
both being classed as ‘fast’ digesting proteins, whey resulted in a steeper and greater overall increase in 
plasma EAA, BCAA and leucine concentration compared to soy. The difference in digestion and absorption 
kinetics between whey and soy can be attributed to greater splanchnic uptake and subsequent lower uptake by 
the peripheral tissues (i.e. skeletal muscle) compared to milk protein. The ingestion of soy is associated with 
greater gut protein synthesis and an increase in ureagenesis, meaning a greater uptake of AAs by the portal 
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vein to the hepatic tissue, which ultimately leads to less AAs being available for release into the plasma and 
use by peripheral tissue (Bos et al., 2005, 2003; Fouillet. et al., 2002). The reason for a greater AA splanchnic 
tissue extraction following the ingestion of soy protein is not fully understood, but it is suggested to be 
attributed the lower EAA content of the protein. In support, Engelen et al. (2007) demonstrated that splanchnic 
extraction can be reduced with the addition of BCAA to a soy protein meal. However, as discussed, beverages 
were matched for EAA content (Tang et al., 2009), therefore the reason for increased gut sequestration and 
uptake by hepatic tissue in soy protein, is not fully understood. Meanwhile, the more modest increase in 
aminoacidemia after the ingestion of micellar casein, classed as a ‘slow’ protein, is attributed to the slower rate 
of gastric emptying, due the coagulant nature of micellar casein (Hall et al., 2003). In any case, Tang et al. 
(2009) observed mixed muscle MPS was ~18% and ~31% greater after the ingestion of whey, compared to 
soy, at rest and after exercise, respectively. The superiority of whole milk over soy protein in stimulating net 
protein balance and FSR is also reported elsewhere in young adults (Wilkinson et al., 2007). However, in 
contrast to findings by Tang et al. (2009), authors reported a more modest and sustained elevation of plasma 
total amino acids (TAAs) in the milk condition compared to soy, albeit EAA and leucine plasma kinetics were not 
measured by Wilkinson et al. (2007). Nonetheless, Tang et al. (2009) concluded that differences in net balance 
and FSR were due to differences in aminoacidemia and attributed this to increase splanchnic uptake of AAs in 
the case of the soy condition. Similar to Tang et al. (2009), Wilkinson et al. (2007) attributed soy’s anabolic 
inferiroirty to increased splanchnic uptake of EAAs. When compared to casein, the AUC for leucine after whey 
ingestion was ~200% greater. MPS was also ~93% and ~122% greater after the ingestion of whey, compared 
to casein, at rest and after exercise, respectively (Tang et al., 2009). This is consistent with findings in older 
adults (Burd et al., 2012). The divergent MPS response between whey and casein is attributed to the blunted 
aminoacidemia peak and smaller AUC following the ingestion of casein. These results underline the potential 
importance of achieving optimal aminoacidemia, when stimulating post meal anabolism. However, several 
studies have contested the modulatory effects of postprandial plasma leucinemia on the muscle protein 
synthetic response (Van Vliet et al., 2017; Gorissen et al., 2016; Burd et al., 2015). Burd et al. (2015) compared 
the postrandial plasma leucine kinetics and resultant muscle protein synthetic response after the ingestion of a 
portion of beef protein and an isonitrogenous portion of milk protein. Authors concluded that the ingestion of 
beef protein resulted in a more accelerated and greater increase in postprandial leucinemia but had an inferior 
anabolic response when compared to milk in the early (0-2 hours) postprandial period. This suggests that an 
increase in plasma leucine kinetics is not the sole determinant of MPS in the postprandial period. Gorissen et 
al.  (2016) compared the plasma leucie kinetics and the postprandial muscle protein synthetic response to 35g 
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whey protein, 35g hydolysed wheat protein and 35g casein. The ingestion of whey protein resulted in the 
greatest increase and area under the curve for plasma leucine in the four hour postprandial period, with wheat 
and casein ingestion exhibiting similar leucine plasma kinetics. However, while the ingestion of casein 
resulted in a 48±16% increase in FSR, the ingestion of whey and wheat protein did not result in a significant 
change in FSR above basal values (4±17%  and 33±24%, respectively). This study refutes the hypothesis that 
the magnitude of postprandial plasma leucinemia dictates MPS and instead suggests that other factors, 
potentially the mileu of other AAs ingested, have an influence on postprandial MPS; a hypothesis which has 
been supported elsehwhere (Churchward-Venne et al., 2012). Finally, Van Vliet et al., (2017) demonstated that 
despite a similar response in postpradial plasma leucine kinetics, a portion of whole egg protein results in a 
greater increase in FSR compared to an isonitogenous portion of egg white protein. This suggests that there 
are other factors which modulate postprandial MPS, such as the co-ingestion of macronutrients and/or 
micronutrients, since whole eggs have a higher fat content, as well as vitamins and minerals, which may 
exhibit an anabolic effect. In summary, while studies have shown that postprandial plasma leucine kinetics has 
an infleunce on MPS, it is not the only factor than influences postprandial MPS, and its importance has been 
challenged recently. Other factors such as the accompanying AAs and the co-ingestion of macronutrients and 
micronutrients are important considerations when discussing the muscle protein synthetic response to the 
ingestion of dietary protein.  
 
Changes in MPS in an acute setting may not necessary represent muscle accretion and changes in strength 
over time, and longer interventions are a more accurate representation of the potential for longitudinal muscle 
accretion and strength gains. Long term intervention studies suggest that animal protein exhibits no added 
benefit on changes in LBM when compared to plant-based proteins.  Joy et al. (2013) investigated the effect of 
whey protein compared to rice protein isolate administered post workout on changes in LBM and strength. 
After 8 weeks resistance exercise training (RET), both the group consuming rice protein and whey protein 
experience an increase in LBM (+2.5kg and +3.2kg, respectively), strength and power and a decrease in fat 
mass. However, there was no difference between treatment groups. Babault et al. (2015) investigated the 
effect of 25g whey protein vs. 25g pea protein, administered twice daily, on changes in muscle thickness. After 
12 weeks RET, rice protein was equally as effective as whey protein in increasing biceps brachii thickness. 
Brown et al. (2004) demonstrated that soy and whey protein bars, administered three times per day, results in 
similar increases in LBM after 9 weeks RET. In contrast, Hartman et al. (2007) compared the effect of 17.5g 
skimmed milk protein, isonitrogenic soy protein and an isoenergetic maltodextrin beverage, ingested 
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immediately post training and again 1 h post training, 5 days per week, on changes in LBM and strength, in 
novice weightlifters. After 12 weeks resistance exercise training (RET), fat and bone free mass (FBFM) increased 
to a similar extent in the control and soy protein group, 3.7% and 4.4% change from week 1, respectively. 
Participants consuming the skimmed milk showed the greatest increase in FBFM, a 6.2% change from week 1, 
and also a greater loss in fat mass, -5.5% from week 1, compared to control and soy group. While all treatment 
groups experienced an increase in strength from baseline, there were no differences between groups.  Cross 
sectional area (CSA) of type I fibres was greater in the milk and soy group, compared to control, while the 
increase is CSA of type II fibres was greatest in milk group. Both groups showed a greater protein intake at 
week 6 and week 12 (1.6-1.8g/kg/d,) compared to week 1 (1.2-1.4g/kg/d), with no differences between 
groups. Despite the superiority of milk protein over soy protein in the study, there was no difference apparent 
in plasma kinetics of leucine, BCAA, EAAs or total AAs after the ingestion of a single bolus of each beverage. 
This would suggest that the differences in LBM and muscle fibre CSA over 12 weeks cannot be explained by 
differences in digestion and absorption kinetics between milk and soy.   
 
In summary, the superiority of beef, whey and milk protein over plant-based protein in stimulating MPS in an 
acute setting is well reported and is attributed predominantly to the relative leucine content of respective 
proteins and the difference in postprandial digestion and absorption kinetics, with beef and whey protein 
resulting in a greater hyperleucinemia and hyperaminoacidemia when compared to soy protein. In longer 
intervention studies in combination with RET, the difference between animal-based and plant-based proteins, 
when daily protein intake is matched, in eliciting differential changes in LBM is less clear. However, the 
development of strategies to enhance the anabolic properties of plant-based proteins remains an important 
consideration, and has particular potential in ameliorating age-related decline of muscle mass. 
 
2.6 Strategies to Enhance the Anabolic Potential of a Meal  
2.6.1 Increasing Quantity of Plant-Based Protein Dose    
Strategies to enhance the anabolic potential of a meal and plant-based proteins have received increased 
interest in recent years. These approaches include ingestion of higher amounts of plant-based proteins, 
combining two or more plant-based proteins to yield a more optimal EAA profile, and leucine-enrichment of 
meals. However, research supporting these strategies in increasing MPS in an acute setting and increase LBM 
and strength over a prolonged period is scarce.  As discussed, the postprandial plasma aminoacidemia, in 
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particular, leucinemia, is an independent driver of the MPS response to a meal.  Hence, it is intuitive that 
consuming a greater quantity of plant-based foods with the aim of achieving a similar plasma kinetics to that 
achieved with beef or whey ingestion, may ‘rescue’ the inferior anabolic properties of plant-based protein (van 
Vliet, Burd and van Loon, 2015). Furthermore, when plant-based proteins are more refined and processed, in 
which anti-nutritional factors that impede protein digestion and absorption are removed, it may be possible to 
render greater postprandial plasma aminoacidemia, similar to that of animal-based proteins (Food and 
Agriculture Organization of The United Nations, 2011). While research documenting the anabolic effect of 
plant-based whole foods is limited, there are several studies in older adults, which investigate graded 
quantities of plant-derived protein powders on MPS, at rest and following exercise (Gorissen et al., 2016; Yang 
et al., 2012a; 2012b). Firstly in terms of animal protein, 20g of whey was sufficient to elevate FSR above 
postabsorptive values in older adults at rest (~66% increase) and following exercise (~33% increase) in older 
males (Yang et al., 2012a). While the ingestion of 20g or 40g of soy protein was unable to stimulate 
myofibrillar FSR above postabsorptive values at rest, 40g soy protein after exercise was sufficient to stimulate 
MPS above baseline, to a magnitude similar to that of 20g whey protein at rest (Yang et al., 2012a; 2012b). 
This suggests that the inferiority of soy protein in stimulating postprandial anabolism can be ‘rescued’ by 
ingesting a sufficient amount of protein, and administered following exercise when the anabolic sensitivity of 
skeletal muscle is likely to be enhanced (Yang et al., 2012b). Gorissen et al. (2016) compared the plasma AA 
kinetics and myofibrillar protein synthesis in older males after the ingestion of 35g and 60g wheat protein 
hydrolysate and 35g micellar casein, providing 2.5g, 4.4g and 3.2g leucine, respectively. Leucinemia peaked 
at ~290 μmol/L at ~75min for both 25g wheat and casein conditions, however, ingestion of casein resulted in 
a more prolonged hyperaminoacidemia compared to wheat protein. Postprandial myofibrillar FSR increased 
48% above postabsorptive values after casein ingestion over 4 h, while there was no change in MPS after 35g 
wheat protein ingestion. Of interest, both casein and wheat ingestion results in a similar peak leucinemia, and 
at the same time, but resulted in a marked difference in rates of MPS. This would suggest that the 
accompanying milieu of other AAs from a given protein source, and/or the kinetics of plasma leucine, and not 
simply the magnitude and time to reach peak concentration of plasma leucine has an effect on postprandial 
rates of MPS. In support of the latter, the ingestion of 60g wheat protein had a similar peak leucinemia to 35g 
casein, but a more prolonged elevation in plasma leucine. Postprandial myofibrillar FSR increased ~77% 
above postabsorptive values between 2-4 h after the ingestion of 60g wheat protein. This suggests a plant-
based protein can stimulate MPS to a similar extent to casein when a greater amount plant-based protein is 
ingested in older men. However, the ingesting of these large quantities of plant-based protein sources may 
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not be feasible in a real world setting, particularly in older adults, who experience a deterioration in appetite 
with advancing age (Morley, 2001), termed ‘anorexia of ageing’. Often a higher calorie intake needs to be 
ingested to enable a plant-based protein to reach a plasma and/or intramuscular leucine threshold, which 
older adults may struggle with. Table 2.1 gives an insight into the approximate calorie content required to 
attain 3g leucine from a food item. Although promising for the efficacy of plant-based proteins, these results 
signify a need for other adjunct strategies to maximise the effectiveness of post-meal anabolic effect of plant-
based proteins.  
 
Food 
Leucine (g)  
Per 100g 
3g Leucine 
(g food item) 
3g Leucine 
 (kcal) 
Cereals and Legumes 
   Cereals, corn grits, yellow, regular and quick, enriched, dry 1.1 278.8 1026.8 
Chickpeas, canned, drained solids 0.5 593.9 826.3 
Kidney beans, canned, drained solids 0.7 443.1 549.7 
Oats, dry 1.0 291.4 1126.4 
Peanuts 1.7 179.4 1019.0 
Potatoes, flesh and skin, raw 0.1 3040.5 2351.4 
Quinoa, uncooked 0.8 357.1 1315.1 
Rice, white, long-grain, parboiled, unenriched, dry 0.7 457.2 1710.0 
Seeds, hemp seed, hulled 2.2 138.7 767.3 
Meat, Poultry and Fish  
   Bacon, raw 1.7 180.1 199.2 
Beef, loin, boneless, separable lean only, all grades, raw 2.1 145.4 201.8 
Chicken, breast, skinless, boneless, meat only, raw 1.9 161.2 193.4 
Fish, cod, Atlantic, raw 1.4 207.3 170.7 
Fish, salmon, Atlantic, wild, raw 1.6 186.0 264.8 
Eggs and Dairy 
   Cottage cheese 1.1 268.8 264.1 
Egg, whole, raw 1.1 276.2 397.8 
Milk, whole, 3.25% milkfat 0.3 1002.7 612.3 
Mozzarella cheese, whole milk 1.8 164.3 492.9 
Soymilk, original and vanilla, unfortified 0.2 1612.8 869.5 
Yogurt, Greek, plain, low-fat 0.5 567.1 414.0 
Table 2.1: The quantity of leucine in 100g of each food item, the quantity (g) and calories (kcal) of each 
food item which would provide 3g of leucine. g, grams; kcal, calories, adapted from USDA National Nutrient 
Database for Standard Reference (2009).  
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2.6.2 Combining Amino Acid Profile  
Animal-based proteins, such as meat, fish, dairy and eggs, are termed ‘complete protein’, due to the presence 
of all 9 EAAs (Food and Nutrition Board, 2005). Most plant-based proteins, such as cereal, grains and legumes, 
which are lacking in one or more EAAs, are termed ‘incomplete proteins’ (Trumbo et al., 2002). While soy and 
quinoa contain 9 EAAs, and are thus termed complete proteins, their EAA content is relatively low in 
comparison to animal-based proteins (Young and Pellett, 1994). Since postprandial plasma EAA is a driver of 
MPS, it is rational that the combination of one or more plant-based proteins may yield a more complete AA 
profile, thereby increasing its anabolic potential. The premise of combining plant-based protein is that one 
protein source will be high in the most limiting AA of the other protein. An example of this is the combination 
of soy, which is inherently low in methionine and high in lysine, with a cereal protein, which are inherently 
high in cysteine and methionine, and low in lysine, resulting in a synergistic effect and a better overall EAA 
content. (Gorissen and Witard, 2018; van Vliet, Burd and van Loon, 2015). However, it remains to be 
investigated if these plant-based protein blends can elicit an MPS response similar to that of an animal protein.  
2.6.3 Leucine-Enrichment   
Table 2.1 offers insight into the quantity and energy (kcal) of a food item, both plant and animal derived, 
which would provide 3g leucine, the quantity of leucine previously shown to maximise MPS in older adults 
(Koopman et al., 2006). However, this table does not infer optimal plasma aminoacidemia or maximal MPS 
rates, as studies on whole food source in this regard have not been done. Nonetheless, it highlights the 
problem of relying solely on plant-based foods to attain 3g leucine, since high quantities of food, and therefore 
high energy intake is often required to reach the purported leucine threshold to stimulate MPS. Leucine is a 
key driver in of MPS, indeed as discussed above, Wilkinson et al. (2013) demonstrated that the ingestion of 
3.42g leucine can elicit a robust increase in postprandial MPS, that is similar to that results in  by 48g whey 
protein (Atherton et al., 2010b). The enrichment of whey protein with leucine has yielded promising results in 
acute studies for changes in MPS (Devries et al., 2018; Kramer et al., 2017; Churchward-Venne et al., 2014),  
and long-term intervention studies in changes of LBM (Bauer et al., 2015). Therefore, the idea of fortifying 
plant-based foods and lower leucine meals appears to be a promising strategy in promoting postprandial 
anabolism. Several studies have investigated the potential of EAA and leucine-enrichment in the context of 
promoting both MPS in an acute setting, and the accretion of skeletal muscle over time.  
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Bukhari et al. (2015) demonstrated that the ingestion of 3g 40% leucine EAA beverage stimulated MPS to a 
similar extent as 20g whey protein (which is most often ~11% leucine), both at rest and post—exercise in older 
women. In a follow up study  within the same cohort profile, Wilkinson et al. (2017) compared the effect of 
1.5g EAA, 6g EAA and 40g whey protein, containing 0.6g, 2.4g and 4g leucine, respectively, on myofibrillar 
PS.  While 1.5g EAA was sufficient to initiate a robust MPS response 0-2h post-ingestion, this increase in MPS 
was not maintained over the 4 h postprandial period. Meanwhile, 6g EAA and 40g whey protein maintained 
MPS throughout the postprandial period, with no difference between each condition. This suggests that a 6g of 
a leucine-rich EAA beverage providing 2.4g  leucine results in an MPS response similar to that of 40g whey 
protein, which has previously been shown to elicit a maximal MPS response in an older cohort (Yang et al., 
2012a). In young adults, Churchward-Venne et al. (2012) compared the effect of three beverages; [25g whey 
protein (WHEY), containing 3g leucine; 6.25g whey with additional leucine (WHEY+LEU), containing 3g 
leucine; and 6.25g whey with additional EAAs without leucine (WHEY-LEU), containing 0.75g leucine], for their 
effect on MPS in exercised and non-exercised state. Results showed that all three beverages increase MPS, but 
there was no difference between groups for the non-exercised muscle. Similarly, no differences were apparent 
in the exercised muscle, in the first 3 h post-exercise. However, 25g whey appeared to show greater MPS rates 
in the 3-5 h period after exercise. The addition of both leucine, and a mixture of EAAs void of leucine, to a 
suboptimal dose of whey are as effective as 25g whey in stimulating MPS in the rested state and in the early 
post-exercise period. In this instance, 0.75g leucine, the amount for leucine provided by 6.25g whey, is 
sufficient to mount a maximal anabolic response, at rest, and 0-3 h after exercise, in young, since additional 
leucine in WHEY and WHEY+LEU did not have any further effect on MPS. Therefore, it is difficult to determine 
the effect of additional leucine, since the MPS response had already been maximised before leucine was 
added. However, despite 25g whey having the same leucine content as WHEY+LEU, 25g whey alone was 
superior than WHEY+LEU and WHEY-LEU in stimulating MPS in the later post-exercise stage (+3 h). This 
suggests that the more sustained and prolonged peak in leucinemia after WHEY ingestion stimulated MPS to a 
greater extent in the 3-5 h after exercise, which has been reported elsewhere (Gorissen et al., 2016; Mitchell et 
al., 2015a; Areta et al., 2013). Another explanantion is that other AAs may have become rate limiting for MPS 
in the later hours of exercise, since WHEY, WHEY+LEU and WHEY-LEU beverages contained 12g, 5g, and 9g of 
EAA and 13g, 3g and 3g non-essential AAs, respectively. This suggests that plasma leucine concentration is not 
the only driver of MPS, and other AAs are required as a substrate to maintain the synthesis of proteins in 
skeletal muscle. The addition of EAAs excluding leucine was as effective as 25g of whey protein at stimulating 
MPS in the early post-exercise stage. In this instance, that additional leucine in WHEY+LEU is not responsible 
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for this equivalent MPS response, since 6.25g of whey in the absence of additional leucine has the same effect 
on MPS. Similar results have been reported elsewhere, in which the addition of leucine to a beverage had no 
further enhancement on MPS in young (Glynn et al., 2010; Tipton et al., 2009; Koopman et al., 2008). 
Nonetheless, in a follow up study Churchward-Venne et al. (2014) determined that the addition of a higher 
dose of leucine to 6.25g whey, totalling 5g leucine, within a mixed meal, results in  an increase in MPS that 
was equivalent magnitude and duration to that of 25g whey in the later post-exercise period. This suggests 
that when a sufficient quantity of leucine is used to enrich a suboptimal protein beverage, MPS in the later 
hours of exercise can be maximised. In the latter studies, the purported suboptimal protein dose may not 
necessarily be suboptimal, particularly in the rested state. The supplementary leucine and EAAs is being added 
to a beverage that possibly has sufficient leucine and EAA content to maximise rates to MPS in young at rest, 
therefore rendering no added benefits. A more appropriate assessment for the potential of leucine-enrichment 
to maximise the anabolic response of a meal, would be to enrich a truly suboptimal leucine/EAA beverage with 
leucine at rest. Engelen et al. (2007) demonstrated that enriching soy protein with BCAA to an amount 
equating that found in casein results in an increase in whole body protein balance compared to soy alone in 
patients with chronic obstructive pulmonary disease. To the best of our knowledge, no studies have observed 
the co-ingestion of leucine with a low leucine/EAA or plant-based protein on direct measurement of MPS. 
 
In older adults, the co-ingestion of 5g of leucine supplement with three main meals enhances 3 day rates of 
MPS, and to a greater extent after exercise (Murphy et al., 2016).  Murphy et al. (2016) demonstrated that 
leucine-enrichment of a diet containing 0.8g/kg/d and 1.2g/kg/d was equally effective at increasing newly 
synthesised myofibrillar proteins, assessed using deuterated water technique in older men. Similarly, 
Casperson et al. (2012) concluded that enrichment of three main meals with 4g leucine, over 2 weeks, results 
in  greater postabsorptive and postprandial mixed muscle FSR in older adults. These data suggest that leucine 
supplementation is a means of acutely improving MPS and chronically improving basal and fed MPS in older 
adults. However, these promising results are not reflected in studies assessing changes in muscle mass and 
function over time (Trabal et al., 2015; Verhoeven et al., 2009). A criticism of these long-term studies is that 
total protein, and not just leucine, plays a key role in the phenotypic changes to AA feeding over time. 
Furthermore, these studies may be too short in duration to detect these changes, particularly with the use of 
dual-energy x-ray absortometry (DXA) which may be insensitive to the detection of subtle changes in lean body 
mass (LBM)(Hind et al., 2018). While leucine-enrichment yields positive results for changes in MPS in the short 
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term (3-14 days), the potential outcome of chronic application of leucine-enrichment on changes in LBM and 
strength remains relatively underexplored.  
 
While its capability is promising, enriching a meal or ingestion crystalline leucine alone has its potential 
drawbacks. The ingestion of leucine has been shown to elicit a reduction in concentrations of other BCAA, both 
in the postprandial state and in the basal fasted state after long-term supplementation (Matsumoto et al., 
2014). Pitkänen et al. (2003) reported a 28% increase in plasma leucine, and a 14% and 25% reduction in 
valine and isoleucine, respectively, after the ingestion of total ~15g leucine ingested 50 min before exercise, 
and during exercise. During 6 months of leucine supplementation (2.5g leucine at three main meals), 
Leenders et al. (2011) reported a 13% increase in basal plasma leucine concentrations after 12 weeks, and a 
23% and 16% reduction in basal plasma valine and isoleucine values, respectively, after 4 weeks, in males with 
type 2 diabetes. These changes in aminoacidemia stayed stable for the duration of the intervention, while no 
change in basal aminoacidemia occurred in the control group. Since these EAA are crucial substrates during 
MPS, their decline may introduce a limitation to MPS and thus, may be counterproductive. Of note, Leenders et 
al. (2011) reported no significant changes in LBM or muscle strength after 3 and 6 months of 
supplementation. Nonetheless, despite this marked drop in BCAA plasma concentration after chronic leucine 
supplementation, the values of valine and isoleucine remained within physiological norms, so it is possible 
that this would exhibit no change in MPS rates.  
 
In summary, enrichment of lower EAA meals with leucine has shown promise in stimulating MPS in older 
adults, in an acute setting. However, positive findings for changes in LBM or strength when leucine is 
supplemented over time are not apparent, but research in the area is scarce. Despite the critical role of plasma 
AA, in particular leucine, on stimulating postprandial MPS, the effect of leucine ingestion, both alone, and with 
a mixed meal, on plasma AA kinetics remains underexplored.   
 
2.7 Muscle Mass and Healthy Ageing   
2.7.1 Age-Related Decline in Muscle Mass & Function  
Muscle mass is well maintained throughout the fifth decade of life, with a modest 10% decrease in muscle 
mass between the mid-20s and 50 years. However, between 50 years and 80 years, muscle mass deteriorates 
more rapidly, and a further 30% loss in muscle mass is apparent, meaning 40% muscle mass is typically lost 
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between the 24th and 80th year of life (Lexell, Taylor and Sjostrom 1988). Sarcopenia, defined as the age-
related decline in muscle mass and function, has been associated with functional impairment, physical 
disability, increased frailty and a decrease in quality of life (Fielding et al. 2011; Doherty, 2003). Age-related 
decline of muscle mass and function has been shown to be directly and independently associated with all-
cause mortality (Ruiz et al., 2008), making it an issue that has significant societal consequences for the 
development of healthcare planning (Fielding et al., 2011; Janssen, Heymsfield and Ross, 2002).  
 
Irrespective of whether an individual has defined sarcopenia or not, the pathophysiology of age-related 
declines in muscle mass and function is complex and is considered to possess a multifaceted aetiology. Non-
modifiable contributors include the ageing process, which results in a reduction in sex hormones and 
mitochondrial dysfunction (Beasley, Shikany and Thomson, 2013). Modifiable contributors include increase in 
fat mass, a decrease in physical activity, inadequate daily calorie and protein intake and a blunted a response 
to anabolic stimuli (Burd, Gorissen and Van Loon, 2013; Malafarina et al., 2013; Thompson, 2007; Latham et 
al., 2004). Systemic inflammation as a result of an increase in fat mass, is associated with the aetiology of 
sarcopenia, more specifically referred to as sarcopenic obesity (Bano et al., 2017).  Furthermore, reduced 
physical activity (PA) has been shown to contribute to the development of sarcopenia, whilst PA shows a 
protective role against sarcopenia development, even reducing the likelihood of progressing to sarcopenia 
later in life (Steffl et al., 2017). Meanwhile, inadequate energy and protein intake (Morley, 2001) combined 
with the manifestation of blunted anabolic response to the ingestion of protein meals  (Katsanos et al., 2006; 
Katsanos et al., 2005; Cuthbertson, 2004), remains one of the most significant and potentially modifiable 
contributors to the age-related decline in muscle mass.  
 
2.7.2 Factors Contributing to Anabolic Resistance in Older Adults  
Age-related decline in muscle mass is attributed to an imbalance between the rate of MPS and MPB, resulting 
in a negative net protein balance, and a decline in muscle mass over time (Burd, Gorissen and Van Loon, 
2013). There remains debate on the potential deterioration of basal MPS and increase in basal MPB with 
advancing age, with some research suggesting there is a difference between basal MPS values between young 
and old (Trappe et al., 2004; Welle, Thornton, Jozefowicz, Statt 1993) and others suggesting that there is no 
difference in MPS between young and old in the basal state (Wall et al., 2015; Katsanos et al., 2006; Katsanos 
et al., 2005; Cuthbertson, 2004). However, research supports the thesis that there is indeed impairment in the 
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MPS response to anabolic stimuli in older adults, which offers an explanation for age-related decline in 
muscle. Figure 2.5 represents the discordance apparent between MPS stimulation in young and elderly, in 
response to an anabolic stimulus, for example, exogenous protein or EAAs, which is well supported in the 
literature (Wall et al., 2015; Katsanos et al., 2006; Katsanos et al., 2005; Cuthbertson, 2004; Volpi et al., 
2000). Indeed, older adults show a 3-fold smaller capability to elevate MPS above postabsorptive values when 
compared to younger adults, after the ingestion of 20g of casein (Wall et al., 2015).  
 
Figure 2.5: Muscle protein synthesis and muscle protein breakdown in response to a protein meal or EAAs 
in young vs. old. Older adults exhibited a blunted anabolic response (dotted line) to the same protein dose, when 
compared to young (solid line).  Adapted from Breen and Phillips (2011).  
 
As mentioned previously, this blunted response to anabolic stimuli in older adults is termed anabolic 
resistance. Potential contributing factors to anabolic resistance after the ingestion of protein-containing meal 
include; compromised digestion and absorption kinetics, increased splanchnic AA sequestration, 
inflammation, decreased satellite cell content and microvascularity (i.e. capillary density and therefore blood 
flow to the muscle) (Morton et al., 2018).  
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Figure 2.6: Graphic representation of the potential factors which contribute to anabolic resistance in older 
adults, in response to a protein meal or EAAs. Adapted from Burd, Gorissen and van Loon, (2013).   
 
Considering the critical role of plasma aminoacidemia in the regulation of rates of MPS (Dreyer et al., 2008; 
Fujita et al., 2007; Bohé et al., 2001), compromised digestion and absorption kinetics of plasma EAAs after the 
ingestion of a protein meal might explain anabolic resistance seen in older adults. Indeed, after the ingestion 
of 8g EAA mixture, Rondanelli et al. (2017) reported a greater increase in aminoacidemia, in terms of 
difference between each time-point and baseline, in old compared to young, but the rate of this increase was 
slower in old compared to young, represented by a marked shift to the right in the dose response curve for 
EAAs and BCAA. Peak aminoacidemia (1822 μmol/L) was achieved at 30 min in young and disappearance from 
plasma occurred at 150 min. Meanwhile, peak aminoacidemia (4298μmol/L) was reached 90 min after 
ingestion in elderly and disappearance from the plasma occurred at 270 min. This slower rate of appearance in 
elderly could be related to increased first pass splanchnic extraction of dietary AAs; indeed phenylalanine 
extraction by the gut and liver is reported to be higher in old compared to young, 29% in young and 47% in 
old (Volpi et al., 1999). Similarly, splanchnic extraction of leucine was 23% in young and 50% in old after the 
ingestion of mixed liquid meal (Boirie, Gachon and Beaufrère 1997). Furthermore, the slower clearance of AAs 
is considered related to reduced uptake by other extra-intestinal organs and tissues, namely skeletal muscle.  
In contrast, Koopman et al. (2009) reported the ingestion of a 35g casein, results in a 71%, 51%, 38%, 37% 
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and 57%, greater increase in plasma phenylalanine, tyrosine, leucine, valine and isoleucine concentrations, 
respectively, in older adults, compared to young adults. Similar findings have been reported elsewhere after 
the ingestion of 20g protein (Pennings et al., 2011a). Therefore, there are discrepancies in the literature. 
Nonetheless, the differences in aminoacidemia between young and old may reflect the difficulty of skeletal 
muscle to uptake and use AAs (i.e a reduced rate of peripheral disappearance rather than increased rate of 
appearance), therefore compromising the anabolic response.  
 
Although difficult to distinguish from co-morbidities such as cardiovascular disease, obesity, arthritis and 
insulin resistance, chronic low-grade inflammation is apparent in older adults, a term known as 
‘inflammaging’ (Franceschi et al., 2007; Roubenoff, 2003). Ageing is associated with increased circulation of 
interleukin 6 (IL-6), tumour necrosis factor (TNF-a) and nuclear factor kappa-light-chain-enhancer of activated B-
cells (NF-kB) (Colbert et al., 2004; Visser et al., 2002). This inflammation is associated with a marked decrease 
in MPS sensitivity to the presence of hyperaminaocimia from exogenous AAs. Indeed, Cuthberston et al. 
(2004) demonstrated that NF-kB, an atrophy mediating signalling protein, associated with inflammation, and 
activated by TNF-a, was 4-fold higher in elderly. In addition, the concentration and degree of activation of AA 
sensing/signalling anabolic pathways were 30-50% less in elderly after the ingestion of exogenous EAA, when 
compared to young adults (Cuthberston et al., 2004). Moreover, anti-inflammatory agents such as fish 
oils/omega 3 fatty acids, non-steroidal anti-inflammatory drugs, Cox-2 inhibitors and anti-cytokine therapy are 
gaining increased interest in the preservation of muscle mass with advancing age (Dalle, Rossmeislova and 
Koppo, 2017; Jensen, 2008). 
 
Skeletal muscle satellite cells, stems cells which are critical in the regulation of muscle fibre repair and growth, 
experience a decline with advancing age (Snijders et al., 2015). In addition, decreased muscle fibre vascularity 
with advancing age is seen as a factor that contributes to impaired regulation of satellite cells in older adults 
(Snijders and Parise, 2017). Indeed, Timmerman et al. (2010) demonstrated that increased muscle perfusion, 
using exogenous vasodilators, resulted in an increase in postabsorptive or postprandial MPS. In summary, the 
underlying mechanisms of anabolic resistance are not fully understood, and are likely a combination of several 
aforementioned contributors.           
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2.8 Ameliorating The Age-related Decline in Muscle Mass - The Role of 
Protein and Exercise  
2.8.1 Overcoming Anabolic Resistance in Older Adults with Protein/EAA Feeding    
Despite factors previously outlined, this blunted anabolic response associated with aging can be overcome by 
ingesting a greater quantity of exogenous EAAs. This is well supported when comparing acute MPS rates in 
elderly, to that of young adults. Katsanos et al. (2006) compared the ingestion of 6.7g EAAs containing either 
1.7g or 2.8g leucine, in both young and elderly. In young participants, FSR showed an increase after ingestion 
of 1.7g leucine, but no further enhancement occurred at 2.8g leucine. However, in elderly participants, there 
was no significant increase in FSR above baseline after ingestion of 1.7g leucine, while 2.8g leucine did cause 
an increase in FSR that was not different from young values. This demonstrates that MPS is not different 
between young and old when a substantial amount of leucine is consumed and underscores the importance of 
providing adequate EAA and leucine content in a meal when aiming to recover the difference in postprandial 
anabolism between young and old. Moreover, the ingestion of 35g whey protein is sufficient to increase 
postprandial MPS above postabsorptive values, with 10g and 20g causing no substantial increase above 
postabsorptive values in older adults (Pennings et al., 2012). Meanwhile in young, 20g of quality protein 
renders maximal MPS stimulation, with 40g having no further benefit (Moore et al. 2009). This decreased 
sensitivity of elderly to the anabolic stimulus of hyperaminoacidemia may be overcome by increased leucine 
ingestion. This suggests that elderly may have a higher ‘leucine threshold’ that young, meaning a greater 
plasma leucine concentration is required to elevate MPS rates above postabsorptive values (Figure 2.7). 
Indeed, Paddon-Jones et al. (2003) demonstrate that the ingestion of 15g EAA, containing 2.8g of leucine, 
produced similar increases in mixed-muscle FSR in elderly (0.103%/h) and young individuals (0.088%/h).  
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Figure 2.7: Graphic representation of the rightward shift in the ‘leucine threshold’ with advancing age. 
Adapted from  Breen and Phillips (2011).  
 
 
Furthermore, physical activity in combination with casein and whey ingestion has been shown to cause an 
additive anabolic response, when compared to a meal alone in the post-exercise recovery period (Pennings et 
al., 2011b; Yang et al., 2012a). Pennings et al. (2011b) achieved a 30% increase in mixed muscle FSR during, 
and 26% increase after, 30 min of moderate intensity cycling and resistance type exercises, when compared to 
non-exercise values. Similarly, Yang et al. (2012a), demonstrated that exercise results in an enhancement in 
myofibrillar FSR at 10g, 20g, 40g whey protein ingestion, when compared to non-exercised values. Of interest, 
while 40g of whey conferred no additional increase in FSR compared to 20g of whey in the absence of exercise, 
after resistance exercise, 40g of whey elicited a 32% greater increase in FSR compared to 20g whey. This is in 
contrast with data from young, in which 20g of protein is sufficient to maximise the MPS response whether 
prior exercise has been performed or not (Witard et al., 2014; Moore et al., 2009). Optimising the meal-
induced anabolic response in older adults should be a main focus in the preservation of skeletal muscle mass 
with advancing age. Exercise should therefore form an integral part of this effort, due to the combined 
synergistic effect of exercise and protein feeding on MPS.  
2.8.2 Habitual Protein Intake in Older Adults  
With the present understanding of the potential importance of protein in healthy ageing, and the diurnal MPS 
and MPB fluctuations in response to meal ingestion, there has a been an increased interest in habitual intake 
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and pattern of protein distribution in older adults in recent years. The general pattern of protein intake in older 
adults is ‘skewed’, in which the majority of protein is eaten at one meal (usually lunch or dinner) with other 
meals representing a suboptimal per meal intake of protein (Cardon-Thomas et al., 2017; Tieland et al., 2015; 
Almoosawi et al., 2013; Bollwein et al., 2013; Ruiz Valenzuela et al., 2013). Habitual dietary intake in the 
Dutch community determined daily protein intake averaged of 71g, 71g and 58g/day in community dwelling, 
frail and institutionalized older adults, accounting for 16%, 16% and 17% of their energy intake, respectively 
(Tieland et al., 2015). Breakfast, lunch and dinner accounted for over 80% of daily protein intake, at 10-12g, 
15-23g and 24-31g, respectively, with dinner accounting for 38%-44% of total daily protein intake.  
Meanwhile, other countries show a trend towards a higher protein lunchtime meal, compared to breakfast and 
dinner (Bollwein et al., 2013; Ruiz Valenzuela et al., 2013).  
 
In addition to total and per meal protein intake, the habitual sources of protein intake in older adults has also 
been explored. In the Dutch community, ≥60% of dietary protein consumed originated from animal sources, 
with meat and dairy as dominant sources. 40% of protein intake in community dwelling, 37% in frail and 29% 
in institutionalised elderly, respectively, is derived from plant-based sources, with bread being the primary 
source (Tieland et al., 2015). Similarly, Cardon-Thomas et al., (2017) reported that the contribution of meat, 
other animal sources and plants to total protein consumption was 42%, 21% and 37%, with animal protein 
accounting for 73% of total protein intake. At dinner, >70% of the protein intake originated from animal 
protein, whilst at breakfast and lunch, a large proportion of protein is derived from plant-based protein sources 
(Tieland et al., 2015). Of note, contributors to inadequate intake of energy and protein include, the cost of 
these more nutrient dense foods, difficulty chewing fibrous foods, diminishing as we age, perceived food 
intolerances and fear of eating too much fat and cholesterol in foods (Bauer et al., 2013; Malafarina et al., 
2013; Chernoff, 2004), which are also factors to consider. To date, neither the protein distribution pattern nor 
sources of protein have been examined in Irish adults. 
 
2.8.3 Rationale for Advocating Protein Intake on a Per Meal Basis in Older Adults  
Daily protein requirements are currently provided relative to body mass, with the PRI currently standing at 
0.83g/kg/d. However, there is a growing acceptance that the recommendations of protein intake for elderly 
populations need reviewing, and increasing the PRI to 1.0-1.5g/kg/d represents a more appropriate strategy 
for ameliorating age-related decline in muscle mass in older adults (Bauer et al., 2013). Furthermore, there is 
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an emerging recognition that per meal protein recommendation, termed ‘meal thresholds’ should be adopted 
in lieu of this broad daily requirement, since it offers an effective strategy in maximising MPS over the course 
of the day (Layman et al., 2015; Areta et al., 2013; Paddon-Jones, 2004). Research suggest that modulating 
daily protein distribution to an even protein intake at each meal, for example ≥30g high quality protein, or 
0.4g/kg of protein, ingested at three main meals, has the potential to maximise MPS, thereby mitigating this 
decline in skeletal muscle mass over time ( Moore et al., 2015; Paddon-Jones and Leidy, 2014; Symons et al., 
2009). 
 
Indeed, when habitual meal intake of older adults is compared to the 0.4g/kg threshold suggested for 
maximal MPS, the proportion of participants meeting this threshold for eating occasion (EO) 1, 2 and 3 is 3%, 
42% and 68%, respectively (n=38)(Cardon-Thomas et al., 2017). No participant consumed 0.4g/kg threshold 
for all 3 meals. 8% of participants did not meet the threshold for any meals, 71% met the threshold for one 
meal, and 21% met the threshold for two meals. These habitual dietary patterns are therefore representative of 
a suboptimal protein intake at given meals for maximising MPS, while meals that exceed the optimal protein 
intake will not cause an additive anabolic response (Areta et al., 2013; Moore et al., 2009). This has led to the 
hypothesis that spreading daily protein intake evenly throughout the day can result in a greater cumulative 
anabolic response compared to a skewed pattern of protein intake (Areta et al., 2013; Moore et al., 2012). Of 
note, a more evenly distributed pattern of protein intake has been associated with non-frail older adults. This 
relationship was investigated in community dwelling older adults (≥75 years of age) in the region of 
Nürnberg, with frailty being defined as three or more, and pre-frailty being defined as one or two of the 
following criteria: weight loss, exhaustion, low physical activity, low handgrip strength and slow walking 
speed. Median total protein intake was 77.5g, 1.07g/kg/d and 16% of total energy intake across participants. 
While there were no difference between groups (frail, pre-frail and non-frail group) for total protein intake, frail 
participants tended to have a more uneven protein distribution, with a lower intake at breakfast and higher at 
lunch (11.9% and 61.4% of total protein consumed at breakfast and lunch in frail, 17.4% and 55.3% in non-
frail) (Bollwein et al., 2013). Furthermore, using data from NHANES 1999-2001, Loenneke et al. (2016) 
determined that participants who consumed 1 or 2 main meals over the 30g protein per meal threshold is 
associated with greater LBM and strength. Furthermore, there was a positive dose-response relationship 
between protein meal thresholds (15g/meal, 20g/meal, 25g/meal) and leg lean mass and strength, with this 
association plateauing at 30g/meal when two meals met this threshold and plateauing at 45g/meal when one 
meal met this threshold. These cross-sectional and epidemiological data provide evidence that a more evenly 
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distribution protein intake and/or a greater number of meals reaching the purported threshold to elicit MPS is 
associated with decreased frailty and greater LBM and strength in older adults. However, intervention trials are 
required to determine if changing distribution in turn has a positive effect of change in muscle mass and 
function.  
 
In addition to optimising the per meal protein dose and meal frequency in older adults, the source of protein 
intake also bears significant importance, due to the role of hyperaminoacidemia and therefore high quality 
proteins in elevating postprandial MPS (Tang et al., 2009). As discussed previously, animal-based sources of 
protein have been shown to elevate postprandial MPS to a greater extent than plant-based sources in younger 
adults, with a similar response also apparent in older adults (Yang et al., 2012b). Indeed, 20g and 40g of soy 
protein were unable to stimulate myofibrillar FSR above postabsorptive values in older adults at rest. 
Meanwhile 20g of whey was sufficient to elevate FSR above baseline values, with no added elevation when 
40g of whey was consumed at rest (Yang et al., 2012a; 2012b). This is related to faster digestibility rates and 
the greater EAA content of animal-based protein, namely, the amino acid leucine. In older adults, breakfast 
and lunch are most often lacking in adequate EAA content, since a large proportion of protein at these meal 
times is derived from plant-based protein sources (Tieland et al., 2015). These sources contain of a lower EAA 
content (USDA National Nutrient Database for Standard Reference, 2009), in particular leucine and therefore 
representing a missed opportunity to maximise postprandial anabolism for that meal time. Emphasising 
adequate, high quality, leucine-rich protein at meal times, particularly at breakfast and lunch where animal 
protein intake is reported to be lowest, is a necessary consideration when applying the per meal protein targets 
in practice in older populations. 
 
2.8.4 Nutrition and Training Interventions in Older Adults  
Resistance exercise training (RET), in the absence of a change in habitual nutritional intake, has been shown to 
have a positive effect on muscle mass and function in older adults (Onambélé-Pearson, Breen and Stewart, 
2010; Liu and Latham, 2009). Considering the anabolic properties of resistance training and protein/EAA 
ingestion, combining both strategies may lead to a greater improvement in muscle mass and function than 
resistance exercise intervention alone. Indeed, the ingestion of a protein supplement alongside resistance-
type exercise in elderly, increases muscle mass and strength gains in older adults, during prolonged (≥6 
weeks) resistance exercise interventions (Cermak et al., 2012).  However, a limitation of this meta-analysis is 
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the low minimum age criteria for exclusion of participants, with the cut off being as young as 50 years of age. 
While muscle mass and muscle function has been shown to decline with advancing age, there is a significant 
sharp rise in the incidence of sarcopenia after the age of 65 (Bautmans et al., 2007), meaning studies using a 
higher age cut off point for inclusion criteria may be more representative of an ‘elderly’ cohort. Meanwhile 
elsewhere, using a more appropriate age cut-off criteria (70 years of age), it is reported that intervention trials 
using protein/EAA supplementation alongside RET, did not result in an additive effect on muscle size, body 
composition and functionality, in elderly populations (Thomas et al., 2016). Authors concluded that overall 
improvement from pre-intervention levels were apparent for the majority of outcomes, indicating a positive 
effect of RET. However, across the 15 studies, these improvements were not significantly different in groups 
receiving protein/EAA supplements and partaking in RET, when compared with groups partaking in RET alone. 
Discrepancies in findings likely exist due to differences in supplement use (AA content, EAA content, leucine 
content), timing (administered once/twice daily), frequency (administered solely on training days/daily) 
duration of intervention and cut off age of participants, between studies. Table 2.1 focuses on RCTs which use 
sufficient per meal protein (~3g leucine/8g EAAs/20-30g protein/~0.4g/kg), in adults >60 years, which have 
LBM and changes in muscle strength as outcomes, in interventions lasting ≥12 weeks. Table 2.3 represents 
the same study characteristics, but also in combination with RET interventions. These studies are discussed in 
further detail in the next sections. In summary, studies using leucine-enrichment alone did not result in 
changes in LBM and muscle function over time (Trabal et al., 2015; Verhoeven et al., 2009). When EAA/protein 
supplementation were only administered once per day, or only on training days there were no changes in LBM 
or muscle function (Arnarson et al., 2013; Verdijk et al., 2009; Godard, Williamson and Trappe, 2002), while 
supplementing >1 per day everyday shows benefits (Dillon et al., 2009; Solerte et al., 2008). Whole food-
based intervention, while scarce, may offer the most benefit in changes in LBM and muscle function (Daly et 
al., 2014; Tieland et al., 2012a). The use of whole foods in combined with RET represents an obvious gap in the 
literature.  
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Reference Design and Participants Protocol,  Intervention, total 
protein intake   
Outcome Measures 
Associated Changed in 
LBM 
Significant Findings For 
Treatment Compared To 
Placebo/Control  
Conclusions  
Norton et al. (2016) 
 
Parallel, single blinded, RCT  
 
N=60, healthy males and 
females; age, 61(5) years 
24-week intervention  
 
PRO, milk protein-based 
enrichment to achieve >0.4g/kg 
protein at breakfast and lunch, 
daily 
 
PLA, isocaloric non-nitrogenous 
maltodextrin,   
 
1.2g-1.6g/kg/d total daily 
protein, NSD  
LBM Outcomes: DXA 
 
↑LBM  Positive effect: The 
enrichment of breakfast and 
lunch with a whey protein 
supplement resulted in a 
positive change of LBM 
compared to a isocaloric non-
nitrogenous maltodextrin 
control in older adults.  
Dillon et al. (2009) 
 
Parallel, double blinded, 
RCT  
 
N=14, healthy women; age, 
68(2)  years 
3 month intervention 
 
AA, 7.5g EAAs (1.4g leucine) 
twice daily between meals  
 
PLA, lactose capsules  
LBM Outcomes: DXA 
 
Strength Outcomes: 
Upper and lower body 
1RM  
 
Other: Basal FSR, 
postprandial FSR 
↑LBM  
 
↑ Basal FSR  
Positive effect: Prolonged 
EAA supplementation for 3 
months enhances LBM and 
basal FSR in older women.  
Verhoeven et al. (2009) 
 
Parallel, double blinded, 
RCT  
 
N=30, healthy males; age, 
71(4) years 
3 month intervention 
 
LEU, 2.5g leucine three times 
daily with meals  
 
LBM Outcomes: 
quadriceps CT, DXA 
 
Strength Outcomes: 
1RM leg press, leg 
↔ No effect: Prolonged leucine 
supplementation (7.5g/day) 
for 3 months does not 
augment LBM or strength.   
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PLA, wheat flour 
 
1g/kg/d total protein NSD 
extension 
 
Solerte et al. (2008) 
 
Parallel, RCT  
 
N=41, sarcopenic adults; 
age, 66-84 years  
 6-month and 18-month 
intervention  
 
AA, 8g EAA (2.5g leucine) twice 
daily 
 
PLA, isocaloric placebo twice 
daily  
 
~75g total protein daily NSD 
LBM Outcomes:  
DXA 
↑ LBM at 6 and 18 months Positive effect: Long term 
supplementation with AA 
beverage twice per day results 
in a significant increase in 
LBM in sarcopenic adults. 
Participants reached normal  
nonsarcopenic  LBM values at 
16 months. 
Table 2.2: Summary of RCTs using protein/amino acids/leucine supplementations ≥12 weeks, in older adults (≥60 years).  n, participant size; PRO, protein supplement group; LEU, 
leucine supplement group; AA, amino acid supplement group; PLA, placebo group; EAA, essential amino acids; CHO, carbohydrate; RCT, randomised control trial; PRT, progressive resistance 
training; RET, resistance exercise training; PRE, pre exercise; POST, post-exercise; LBM, lean body mass; LTM, lean tissue mass; FM, fat mass; DXA, dual x-ray absorptiometry; CT, computer-
tomography; RM, repetition max; FSR, fractional synthetic rate; NSD, no significant difference for dietary protein intake between groups; ↑, significant positive difference to PLA; ↓, significant 
negative difference to PLA, ↔, no difference to PLA.  
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Reference Design and Participants Protocol,  Intervention, 
total protein intake   
Outcome Measures 
Associated Changed in 
LBM 
Significant Findings For 
Treatment Compared To 
Placebo/Control  
Conclusions  
Trabal et al. (2015) Parallel, double blinded, RCT  
 
n =30, healthy older adults; 
age, >70 years 
PRT three times per week, for 
12 weeks  
 
LEU, 5g, twice daily, 60min 
after lunch and dinner  
 1.3g/kg/d protein 
 
PLA, maltodextrin placebo  
 
1.2-1.4g/kg/d protein, NSD 
LBM Outcomes: mid upper 
arm muscle area, calf 
circumference  
 
Strength Outcomes: Leg 
extension MVC, TUG, standing 
balance, 4m walk, chair stand  
 
↑MVC, ↑TUG  Minor positive effect: The 
combination of exercise with a 
twice daily leucine 
supplement, results in 
moderate improvements in 
muscle strength and markers 
of muscle performance, in 
older adults, compared to a 
maltodextrin placebo.  
Daly et al. (2014) Parallel RCT  
 
n =100, healthy females; 
age, 60-90 years 
PRT twice weekly, for 4 
months 
 
PRO, 80g cooked red meat, 
twice daily, at lunch and 
dinner, 6 days per week 
(Additional 45g protein per 
day); 1.3g/kg/d protein 
 
CON, >1 serving 75g cooked 
pasta/rice; 1.15g/kg/d protein 
(p<0.05) 
LBM Outcomes: quadriceps 
CT, DXA 
 
Strength Outcomes: 1RM 
leg extension, TUG, 30 sec 
STS, FSST 
 
↑LBM, ↑leg LTM, ↓FM, ↑1RM 
leg extension 
Positive effect: Protein 
enrichment with 45g protein 
from red meat, 6 times per 
week, enhances the effect of 
PRT on LBM and muscle 
strength in older adults.    
Arnarson et al. (2013) Parallel, double blinded, RCT  
 
n =161, healthy males and 
females; age, 65-91 years 
RET three times weekly, 12 
weeks  
 
PRO, whey protein (20g 
protein, 20g CHO) POST  
LBM Outcomes: DXA 
 
Strength Outcomes: knee 
extensor MVC,  TUG, 6min 
walk distance  
↔ No effect: The ingestion of 
20g whey protein in the post 
training period, did not lead to 
greater gains in LBM, muscle 
strength and muscle function, 
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PLA, 40g CHO POST 
 
0.9-1g/kg/d total protein, NSD 
after 12 weeks RET in older 
adults    
Chalé et al. (2013) Parallel, double blinded, RCT  
 
n =80, mobility-limited 
adults; age, 70-85 years 
PRT three times per week, for 
6 months  
 
PRO, 20g whey and 
maltodextrin twice daily with 
breakfast and evening meal  
 
PLA, isocaloric maltodextrin    
LBM Outcomes: Thigh CT, 
DXA 
 
Strength Outcomes: 1RM 
and PP leg press and leg 
extension, SPBB 
↑ PP leg extension  No effect: Whey protein 
supplementation offers no 
further benefit to the effects of 
a 6 month PRT intervention in 
older adults 
Tieland et al.(2012a) Parallel, double blinded, RCT  
 
n =62, frail older adults; age, 
78(1) years 
2 sessions per week PRT, 24 
weeks 
 
PRO, 15g milk protein with 
breakfast and lunch  
 
1.3g/kg/d total protein 
 
PLA, flavoured placebo  
 
1g/kg/d total protein  
LBM Outcomes: DXA 
 
Strength Outcomes: 1RM 
leg press and leg extension, 
handgrip, SPPB 
↑ LBM  Positive effect: Protein 
supplementation twice per 
day further augments changes 
in LBM associated with PRT, 
when compared to a placebo  
Verdijk et al. (2009) Parallel, randomised placebo 
control trial 
 
n =26, healthy males; age, 
72(2) years  
12 weeks RET x3 days per 
week  
 
PRO, 10g casein, PRE and 
POST  
 
PLA, flavoured water, PRE and 
LBM Outcomes:  
Quadriceps CT scan, DXA scan, 
number of muscle fibres and 
mean fibre CSA via muscle 
biopsy, 
 
Strength Outcomes:  
↔ No effect: Increases in LBM 
and strength are apparent 
after 12 weeks resistance 
training, however, the 
addition of pre training and 
post training protein has no 
additive effect.   
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POST  
 
1.1g/kg/d protein NSD 
1RM leg press and leg 
extension  
Godard, Williamson and 
Trappe (2002) 
Parallel RCT  
 
N =17, healthy males; age, 
>65 years 
3 sessions per week PRT, 12 
weeks  
 
AA, 12g EAA (2.2g leucine) 
and 72g once daily fructose 
and dextrose 
 
CON, no supplement   
 
Daily total protein, 16% total 
kcal NSD 
LBM Outcomes: Mid-thigh 
CT  
 
Strength Outcomes: 1RM, 
MVC, IPT, work capacity test  
 
 No effect: Daily AA 
supplementation results in  no 
further enhancement in 
muscle size and muscle 
strength and performance 
during 12 weeks PRT in older 
males    
Table 2.3: Summary of RCTs using protein/amino acids/leucine supplementations, in combination with prolonged (≥12 weeks) RET in older adults (≥60 years). n, participant 
size; PRO, protein supplement group; LEU, leucine supplement group; AA, amino acid supplement group; PLA, placebo group; EAA, essential amino acids; CHO, carbohydrate; RCT, randomised 
control trial; PRT, progressive resistance training; RET, resistance exercise training; PRE, pre exercise; POST, post-exercise; T2D, type 2 diabetic;  LBM, lean body mass; LTM, lean tissue mass; FM, 
fat mass; DXA, dual x-ray absorptiometry; CT, computer-tomography; RM, repetition max; MVC, maximal voluntary contraction; IPT, isokinetic peak torque; PP, peak power; TUG, timed up-and-go 
test; FSST, four square step test;  SPBB, short physical performance battery; FSR, fractional synthetic rate; NSD, no significant difference for dietary protein intake between groups; ↑, significant 
positive difference to PLA; ↓, significant negative difference to PLA, ↔, no difference to PLA.  
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2.8.5 Leucine-Enrichment in Maximising MPS and Muscle Accretion in Older Adults 
Despite the potential superiority of higher leucine meals in stimulating MPS and the potential for muscle 
accretion over time, few studies have focused on leucine-enrichment of meals in older adults. Murphy et al. 
(2016) demonstrated that the co-ingestion of 5g of leucine supplement with three main meals enhances 
integrated 3 day rates of MPS in free-living older males using deuterated water to assess newly synthesised 
myofibrillar proteins, compared to a placebo. Authors demonstrated that this strategy was equally as effective 
in older males who consume 0.8g/kg/d (low protein, LP) vs. 1.2g/kg/d (high protein, HP) in increasing rates of 
MPS in rested and exercised conditions. Indeed, myofibrillar protein synthesis was higher in LP compared to 
placebo, in the unexercised leg (1.57%/d and 1.48%/d, respectively) and in the exercised leg (1.87%/d and 
1.71%/d, respectively). This supports the caveat of solely relying on body mass relative recommendation for 
total protein intake in elderly, since protein intake was not different between treatment groups (LP leucine, 
67g and LP placebo, 67g; HP leucine, 98g and HP placebo, 102g). This also reiterates the isolated importance 
of leucine in the MPS process in elderly, and underlines that leucine-rich meals, high quality protein, and the 
distribution of meals may have a significant application. Furthermore, myofibrillar protein synthesis values for 
leucine and placebo were higher in both exercise conditions when compared to rested condition, further 
emphasising the importance of combining exercise with the aforementioned dietary approaches. Casperson et 
al. (2012) investigated the effects of 2 weeks leucine supplementation (4g at each main meal =12g total), on 
basal and postprandial mixed muscle FSR and markers of nutrient signalling (mTOR, 4E-BP1 and p70S6K1) in 
older adults. Both postabsorptive FSR (pre, 0.063%/h; post 0.074%/hr) and postprandial FSR (pre, 0.075%/h; 
post, 0.1%/h) were greater on day 15, compared to day 0 values. Furthermore, these changes in FSR coincided 
with a 19% and 13% increase in phosphorylation of mTOR and 4E-BP1in the postprandial state, respectively, 
and a 23% increase in phosphorylation of p70S6K1 in the postabsorptive state. These data suggests that 
leucine is a means of chronically improving basal and fed MPS in older adults. While these results are 
promising in their potential to inform nutrition strategies for ameliorating age-related declines in muscle 
mass, acute changes in MPS may not necessary represent muscle accretion over prolonged periods of time, 
and longer interventions are a more accurate representation of the potential for longitudinal muscle accretion. 
As per table 2.2, Verhoeven et al. (2009) demonstrated that supplementation of 2.5g leucine at 3 main meals 
did not cause changes in LBM or muscle strength over a 3 month period. In the presence of exercise, 
supplementation of 5g leucine twice daily showed a modest improvement in strength outcomes (Change in 
leg flexion MVC and change in TUG)) however, authors did not assess changes in LBM over the 12-week period 
(Trabal et al., 2015). While leucine supplementation shows promise in acute protein synthesis studies, the 
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potential outcome of combining a leucine supplementation or focusing on leucine enrichemnt from whole 
foods, with a structured RET program in older adults, remains unclear. 
2.8.6 Protein/AA Supplementation in Maximising MPS and Muscle Accretion in Older Adults 
While leucine provides the trigger for the stimulation of MPS above postabsoptive values, additional AA are 
required for the synthesis of skeletal muscle proteins. The supplementation of leucine alongside other AAs 
yields more positive findings and suggests a potenital synergistic effect when AAs are provided together. As 
per table 2.2, Dillon et al. (2009) demonstrated that supplementation of 7.5g EAA, twice daily, results in  a 
1.7kg increase in LBM, compared to a control group who gained 0.3kg, over 3 months. Similarly, in sarcopenic 
men, 8g EAA supplementation, twice daily, results in improvements in LBM, with participants achieving 
normal non-sarcopenic LBM values after 16 months (Solerte et al., 2008).  
 
When similar nutrition strategies are combined with resistance exercise, as per table 2.3, the prevailing 
finding is that protein supplementation results in no further enhancements in LBM and muscle strength 
(Arnarson et al., 2013; Verdijk et al., 2009; Godard, Williamson and Trappe, 2002). A noticeable trend in the 
latter studies are the use of one single bolus supplement (Godard, Williamson and Trappe, 2002), or the 
administration of the supplement only on training days (Arnarson et al., 2013: Verdijk et al., 2009). Therefore, 
a rational explanation for these results is that protein distribution was not optimised, and there were meals 
that fell below the leucine threshold purported to maximise MPS, thereby resulting in minimal muscle 
accretion over time. Since multiple adequate protein meals throughout the day can result in a greater 
cumulative anabolic response compared to a skewed pattern of protein intake (Paddon-Jones et al., 2015; 
Mamerow et al., 2014), using >1 per day supplementations may result in more beneficial outcomes for 
muscle hypertrophy and strength in older adults.  
 
2.8.7 Optimal Per Meal Protein in Maximising MPS and Muscle Accretion in Older Adults 
Protein distribution studies that inherently focus on per meal muscle protein anabolism yield conflicting 
results for changes in acute MPS and long term muscle accretion and strength gains. Kim et al. (2015) 
compared a skewed (SKEWED, 15%, 20% and 65% at EO 1, 2 and 3, respectively) and even (EVEN, 33%, 33% 
and 33% at EO 1, 2 and 3 respectively) daily protein intake for 0.8g/kg/d of protein and 1.5g/kg/d protein, 
which represents approximately twice the recommended daily allowance (RDA) of protein. Whole protein 
kinetics and MPS were assessed on day 4 after 3 days of diet habituation. Net protein balance was 61% greater 
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and MPS was 17% greater in the 1.5g/kg/d protein group compared to the 0.8g/kg/d protein group, however, 
protein intake pattern exhibited no effect on net balance or MPS. A limitation of the present study is that the 
skewed group consisted of just four participants, which means the study may have been underpowered to 
detect significant differences between groups, and the lack of change may therefore represent a type II error. 
However, in the aforementioned studies, these acute changes in MPS do not necessarily inform changes in 
LBM and strength over time. Bouillanne et al. (2013) reported that malnourished hospitalised older adults 
who followed a skewed protein diet (4.5g, 47.8g, 2.3g and 10.9g at EO 1, 2, 3 and 4 respectively), experienced 
a 0.91kg increase in LBM over a 6 week period, compared to a more evenly distributed protein diet (12.2g, 
21g, 13.5g and 21.2g at EO 1, 2, 3 and 4 respectively), in which a loss of 0.41kg was reported.  While these 
results are contradictory to what we have discussed previously, a criticism of the study is the insufficient per 
meal protein quantity in the EVEN group, meaning each meal potentially failed to reach the leucine threshold 
required to stimulate MPS above postabsorptive values. Meanwhile, in SKEWED, 47.8g of protein would be 
sufficient to stimulate a robust anabolic response (Pennings et al., 2012). To further support this thesis, with a 
similar design Arnal et al. (1999) reported a 2-fold enhancement in net protein balance in older women when 
a skewed protein distribution was adopted (7%, 79% and14% for EO1, EO2 and E03) compared to a more 
evenly distributed intake (22%, 31%, 19% and 28% for EO1, EO2, EO3 and E04) over 14 days. However, daily 
protein intake was 1.05g/kg/d, which translates to no more than 13g-20g, 0.19g-0.33g/kg of protein for each 
meal in EVEN, which falls short of the purported intake for increasing MPS above postabsorptive values. 
Meanwhile, SKEWED consumed 56g, 0.83g/kg protein for one meal per day, which is more than sufficient to 
maximise MPS in older adults (Moore et al., 2015; Bauer et al., 2013). Adopting a more evenly distributed 
protein intake may only offer value when total protein intake is sufficient, since the per meal threshold for 
maximising MPS would be met. In support, Norton et al. (2016) reported a positive change in LBM when 
breakfast and lunch were enriched with whey protein, over 24 weeks in older adults, resulting in a daily 
protein intake 1.6g/kg/d. The pertinent focus of the additional protein was to enrich breakfast and lunch, in 
which a protein intake of 0.4g/kg and 0.47g/kg was achieved, which is line with previous ‘meal threshold’ 
recommendations for maximising MPS in elderly (Moore et al., 2015). An increase of 0.6kg in LBM occurred in 
the protein group, compared to an isocaloric maltodextrin control group, who experienced a 0.16kg loss in 
LBM over the 24 week period. Of note, protein intake increased from 83g (1.2g/kg/d) to 106g (1.6g/kg/d) with 
the addition of the protein supplement. Therefore, it is not possible to determine if the positive effect on LBM 
was a result of an increase in overall daily protein or the more even protein distribution. This is an issue for 
many studies in that the treatment groups are often not isonitrogenous.  Nonetheless, this study was well 
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designed and long enough in duration to represent muscle accretion in older adults. However, in summary, 
the effect of strategic feeding of sufficient total protein and EAA/leucine-enrichment of lower protein meals, in 
modulating MPS and changes in LBM over time in older adults, remains relatively underexplored.   
 
2.8.8 Food-Based Interventions for Increasing Protein Intake and Maximising MPS and Muscle 
Accretion in Older Adults 
The consumption of whole food meals, as opposed to the consumption of supplements via capsules and 
powders, is representative of a normal diet. To date, much of the research aimed at ameliorating age-related 
decline in muscle mass in older adults has focused on the use of protein powders, such as whey and casein 
protein powder, and AA mixtures, which signifies a gap in the literature for the use of a whole food-based 
nutrition intervention in community-dwelling older adults. Furthermore, there is evidence to suggest that 
protein its whole-form may have greater anabolic properties; such is the case in young, for whole egg vs. egg 
whites (Van Vliet et al., 2017), and whole-milk vs. skimmed-milk (Elliot et al., 2006). The few studies which 
have focused on increasing per meal protein intake with whole foods have indeed reported positive results. 
Daly et al. (2014) investigated the effect of 80g red meat consumed at lunch and dinner, 6 days a week, in 
older adults following a 4 month resistance training program. There was 0.5kg greater gain in whole body 
LBM, which was predominantly leg LBM (0.33kg), and an 18% greater increase in 1RM leg extension in the red 
meat group, when compared to a control group. Of note, dietary protein intake was 1.3g/kg/d for the group 
consuming red meat, while the total protein intake of the control group was 1.15g/kg/d. Similarly, 15g protein 
from whole milk, consumed directly after breakfast and lunch, had a greater effect on changes in LBM 
alongside 24 weeks PRT, when compared to a placebo (Tieland et al., 2012a). The authors reported an increase 
of 1.3kg in LBM in the group consuming milk, while the placebo group experience a 0.3kg decline in LBM. 
Similarly, total protein intake increased from 1g/kg/d to 1.3g/kg/d in the milk-consuming group, with no 
change in the control group. These studies concluded that the increasing per meal protein intake using whole 
food protein source (15g-22.5g protein, twice daily) results in changes in LBM and strength when combined 
with PRT. While these whole food-based interventions yield promising results for muscle accretion and 
strength gains in older adults, a diet which solely focused on deriving addition protein from just one food/food 
group (i.e. milk and red meat) may not be representative of a long term, sustainable approach for healthy 
ageing, particularly with our understanding of the factors which influence food choice in elderly (the cost of 
these more nutrient dense foods, difficulty chewing fibrous foods, diminishing appetite as we age, perceived 
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food intolerances and fear of eating too much fat and cholesterol in foods (Bauer et al., 2013; Malafarina et al., 
2013; Chernoff, 2004). To the best of our knowledge, the effect of a whole food-based intervention, containing 
a variety of food options and targeting optimal protein intake at three main meals, on muscle accretion in older 
adults, in combination with exercise training, has yet to be investigated.  
2.9 Protein Feeding and Recovery from Exercise Induced Muscle Damage  
2.9.1 Exercise Induced Muscle Damage and Delayed Onset Muscle Soreness  
Acute, unaccustomed resistance exercise can produce micro-damage as a result of trauma to muscle fibres and 
connective tissue. This muscle damage is characterised by a mechanical disruption of the muscle membrane, 
the infiltration of inflammatory cells and an increase in the production of inflammatory cytokines (Proske and 
Morgan, 2001). Noteworthy, when compared to concentric and isometric training, eccentric training has been 
shown to create the most significant damage (Nosaka, Newton and Sacco, 2002). The pain and discomfort that 
often accompanies exercise-induced muscle damage (EIMD) is referred to as delayed onset muscle soreness 
(DOMS). DOMS is characterised by dull aching pain, tenderness and stiffness and strength loss, which can last 
up to 10 days after exercise cessation (Connolly, Sayers and Mchugh, 2003; Cheung, Hume and Maxwell, 
2003; Clarkson, Nosaka and Braun, 1992). DOMS is experienced to a greater extent in muscles that are 
untrained (Connolly, Sayers and Mchugh, 2003). Furthermore, athletes who participate in regular resistance 
training often will experience DOMS to a lesser extent during subsequent exercise sessions of similar nature. 
The initial damaging exercise bout results in an adaptive response that acts as a protective mechanism against 
these subsequent bouts of exercise, which can last for several weeks, a phenomenon known as the ‘repeated 
bout effect’ (McHugh, 2003). Nonetheless, the combination of pain, stiffness and this decrement in muscle 
function after unaccustomed exercise can have a detrimental effect on athletic performance (Pearcey et al., 
2015). Thus, a nutritional strategy, aimed at ameliorating the deleterious effects of DOMS, may be 
advantageous by minimally compromising the quality of exercise sessions in the days following a muscle-
damaging exercise bout or during intensified or overreaching training. 
 
The mechanism of the development of DOMS is not fully understood and there is much debate about the role 
of muscle damage in the development of DOMS. Although unaccustomed exercise results in an increase in 
both DOMS and the concentrations in plasma of proteins associated with muscle damage, research suggests 
that they are not closely related, and muscle damage is not entirely causative of DOMS (Nosaka, Newton and 
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Sacco, 2002). Soreness typically peaks 24-48 h post-exercise, returning to pre-exercise values 96 h post-
exercise (Connolly, Sayers and Mchugh, 2003). Closely mirroring the time course of these symptoms, creatine 
kinase (CK) concentrations, widely used as an index of muscle damage, increase 24 to 48 h post-exercise, 
peaking between 3-6 days and returning to baseline values in 7 to 14 days (Lieber and Friden, 2002). 
However, studies demonstrated poor correlation between DOMS and CK values (Nosaka, Newton and Sacco, 
2002; Malm et al., 2000). In support, certain diseases of skeletal muscle, such as Duchenne’s muscular 
dystrophy, which results in disruptions of the myofibrillar and sarcotubular structures, does not cause muscle 
pain (Lieber and Friden, 2002). The current consensus is that one single mechanism is insufficient to explain 
the aetiology of DOMS, and instead a combination of lactic acid accumulation, muscle spasm, connective 
tissue damage, micro trauma, free radical production, nitric oxide, and inflammation best explain its 
pathophysiology (Kim and Lee, 2014; Lewis, Ruby and Bush-Joseph, 2012).  
2.9.2 Role of Exogenous EAAs in Ameliorating Effects of EIMD 
In an effort to reduce the negative symptoms associated with DOMS, several ‘recovery strategies’ have been 
explored which include; cold water immersion, ergogenic aids, antioxidant support, non-steroidal anti-
inflammatories, and nutrition interventions which include caffeine, omega 3 fatty acids and protein 
supplements (Kim and Lee, 2014; Howatson et al., 2012). Of note, the use of omega 3 fatty acids has shown 
promise in minimising the negative effects of EIMD. Tartibian, Maleki and Abbasi, (2009) demonstrated that 
30 days supplementation of 1.8g/d omega-3 fatty acids resulted in a reduction in perceived soreness and thigh 
circumference compared to a placebo, 24-48 h following an intense exercise bout. Furthmore Philpott et al., 
(2018) demonstrated that the addition of 1.1g omega-3 fatty acids to a whey protein, leucine and/or CHO 
beverage, results in a reduction in muscle soreness and plasma CK in the days following an intense exercise 
bout. Therefore, it appears that nutrition plays a role in ameliorating the deleterious effects of EIMD. Of 
particular interest to the present chapter and thesis is the use of AAs, namely branched chain amino acids 
(BCAA), which have shown mixed results in ameliorating symptoms of EIMD (Waldron et al., 2017; Fouré et al., 
2016; Ra et al., 2013; Howatson et al., 2012; Jackman et al., 2010). Research has focused on the ingestion of 
exogenous EAAs prior to and/or after resistance training, seeing this as a critical window to enhance recovery. 
The mechanism behind the beneficial effect of AAs on exercise recovery is not fully understood. It has 
erroneously been suggested that this enhancement in recovery is related to the resultant increase in MPS 
following AA ingestion. Indeed, while the stimulation of MPS following protein ingestion is critical to skeletal 
muscle remodelling over time, this process is long in duration. It is therefore unlikely to be responsible for an 
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enhanced recovery from exercise over a short window of several hours to several days. Studies that have 
investigated the effect of single bolus exogenous EAAs before and after exercise (from an AA mixture, whole 
milk and milk components, such as whey) in ameliorating symptoms of EIMD are summarised in table 2.4.  
Since the recovery period from EIMD typically lasts several days, with soreness, marker of muscle damage and 
performance only peaking +48-72 h after exercise, studies which have investigated these outcomes several 
days after exercise are included. 
2.9.3 The Role of Single Bolus EAAs in Exercise Recovery  
In summary, the present consensus is that a single bolus of exogenous EAAs, ingested prior to or after exercise, 
confers benefits to recovery from EIMD, when compared to a placebo. Indeed, supplementation with an AA 
mixture, milk or whey protein has been shown to ameliorate the deterioration of muscle function and 
increases in blood markers of muscle damage following a bout of muscle damaging exercise. It is within 
scientific reason that supplementing >1 per day or beyond the immediate post-exercise window would confer 
additive benefits for recovery. Studies that have investigated the effect of >1 boluses of exogenous AAs in the 
post-exercise period, in ameliorating the effects of EIMD in the days following exercise, are summarised in 
table 2.5. 
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Reference Design and 
Participants 
Protocol and Intervention  Outcome Measures 
Associated with EIMD 
 
Significant Findings For 
Treatment Compared To 
Placebo/Control* 
Conclusions  
Shimomura et al. 
(2006) 
Crossover design, double 
blinded randomised 
control trial   
 
n =34 untrained males, 
n =16 untrained females  
20 squats x 7 sets  
 
BCAA, 5g (1:2.3:1.2), 1g green tea powder, 1.2g 
aspartame, 15min PRE 
 
PLA, Dextrin, 1g green tea powder, 1.2g 
aspartame 
DOMS: Soreness 
 
Muscle Function: Self-
reported muscle fatigue 
↓Soreness in females (48, 
72, 96, 120 h)  
	↓Muscle fatigue in males 
and females  (96 h) 
Positive Effect: BCAA 
supplementation may 
alleviate symptoms of muscle 
damage after a muscle 
damage bout of exercise, in 
untrained males and females.  
Etheridge, Philp and 
Watt (2008) 
Crossover design, double 
blinded randomised 
control trial   
 
n =9 trained males  
 
30min downhill running at 75% age-predicted HR 
max 
 
MILK, 100g milk protein concentrate (40g EAAs) 
 
PLA, flavoured water  
Immediately POST 
DOMS: Soreness 
 
Muscle Function: MVC 
 
Blood Markers: CK 
 
↑MVC (48 h) Positive Effect: The rate of 
force and power restoration 
following an exercise bout of 
muscle damage, can be 
accelerated by consumption of 
a milk protein mixture 
immediately post-exercise.  
Cockburn et al. 
(2010) 
Single blinded, parallel, 
randomised control trial   
 
n =32, trained males  
 
10 repetitions x 6 sets, knee flexions 
 
PRE, chocolate milk, (33.4g PRO), consumed 3min 
PRE 
 
POST, chocolate milk, (33.4g PRO), consumed 
POST 
 
24 POST, chocolate milk, (33.4g PRO), consumed 
24 h POST 
 
CON, water 
DOMS: Soreness 
 
Muscle Function: PT, 
RSI 
 
Blood Markers: CK 
 
 
↓Soreness, ↑PT, ↑RSI, 
POST and 24 POST, vs. PRE 
and CON 
 
↓CK, PRE, POST and 22 
POST, vs. CON  
Positive Effect: Whether 
supplemented before, 
immediately post or 24 h post-
exercise, a protein and 
carbohydrate drink exhibits a 
positive effect in ameliorating 
the decline in muscle function 
and increase in CK associated 
with EIMD.  
                                                                            
* h denotes the hours post-exercise at which the difference between treatment group and control group for each variable was detected. Differences with h denotation is time-point not specified.  
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Shimomura et al, 
(2010) 
Crossover design, double 
blinded randomised 
control trial   
 
n =12, untrained females  
20 squats x 7 sets  
 
BCAA, 5.5g (1:2.3:1.2), 1g green tea powder, 1.2g 
aspartame, 15min PRE 
 
PLA, Dextrin, 1g green tea powder, 1.2g 
aspartame 
DOMS: Soreness 
 
Muscle Function: MVC,  
 
Blood Markers: CK, Mb 
↓Soreness (24, 48 h), 
↑MVC (72 h), ↓Mb (24-
72 h)	
Positive Effect: BCAA 
supplementation may 
alleviate symptoms of muscle 
damage after a muscle 
damage bout of exercise in 
untrained females.  
Cockburn et al. 
(2012) 
Parallel, randomised 
control trial  
 
n =24, trained males  
 
10 repetitions x 6 sets, knee flexions  
 
1000ml milk, 34g PRO 
 
500ml milk, 17g PRO  
 
CON, 1000ml water  
Immediately POST 
DOMS: Soreness 
 
Muscle Function: PT   
 
Blood Markers: CK, 
Mb, IL-6 
 
↑PT, 1000ml vs. CON  
↓CK, 1000ml vs. CON 
↔ PT, CK, between 
1000ml and 500ml 	
Positive Effect: Decrements 
in isokinetic muscle 
performance and increases in 
CK can be ameliorating with 
the consumption of 500ml 
milk immediately post-
exercise, with 1000ml 
showing no additive benefit.   
Table 2.4: Summary table of studies which use a single bolus of exogenous amino acids before or after exercise induced muscle damage. n, participant size; BCAA, BCCA group; 
PLA, placebo group; CHO, carbohydrate; EIMD, exercise induced muscle damage; PRE, Pre EIMD; POST, Post EIMD; RM, repetition max; MVC, maximal voluntary contraction; MIC, maximal 
isometric contraction; PIT, peak isometric torque; EMG, electromyography;  PO, power output; C, circumference; VJ, vertical jump; CMJ, counter movement jump; CK, creatine kinase, LDH, 
lactate dehydrogenase; Mb, myoglobin; CRP, c-reactive protein; GEL, granulocyte elastase; IL, interleukin; ↑, significant positive difference to PLA; ↓, significant negative difference to PLA, ↔, no 
difference to PLA.  
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Reference Design and Participants Protocol and Intervention  Outcome Measures 
Associated with EIMD 
Significant Findings 
For Treatment 
Compared To PLA* 
Conclusions  
Kraemer et al. (2006) Double blinded, parallel, 
randomised control trial   
 
n =17, trained males    
 
4 week total body, resistance training, designed 
to achieve overreaching  
 
AA, 0.1g/kg between meals  
 
PLA, cellulose 
 
Every day, 4 consecutive weeks  
 
Muscle Function: 1RM 
back squat, 1RM bench 
press  
 
Blood Markers: CK 
 
Others: Total 
testosterone, human 
growth factors,  sex 
hormone binding 
globulin, insulin-like 
growth factor, insulin, 
cortisol, haemoglobin, 
uric acid 
↑1RM back squat, 
↑1RM bench press 
 
Cockburn et al. 
(2008) 
Single blinded, parallel, 
randomised control trial   
n =24, trained males    
 
10 repetitions x 6 sets, knee flexions  
 
CHO+PRO, chocolate milk, (33.4g PRO) 
 
MILK, (34g PRO) 
DOMS: Soreness 
 
Muscle Function: PT,  
  
Blood Markers: CK, Mb 
↑PT in MILK vs. and 
CHO+PRO vs. CON (48 
h) 
 
 
Positive Effect: 
Decrements in isokinetic 
muscle performance and 
increases in CK, Mb can be 
ameliorating with the 
                                                                            
* h denotes the hours post-exercise at which the difference between treatment group and control group for each variable was detected. Differences with h denotation is time-point not specified.  
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CHO, sports drink  
 
CON, water 
 
Immediately POST and 2 h POST  
↓CK in MILK and 
CHO+PRO vs. CHO  
(48 h) 
 
↓Mb in CHO+PRO vs. 
CHO 
consumption of milk 
based protein and carb 
drink, or milk, post-
exercise.   
Betts et al. (2009) Crossover design, single 
blinded, randomised control 
trial   
 
n =17, trained males 
90min intermittent shuttle runs  
 
CHO+PRO, ~21g PRO and ~62g CHO  
 
CHO, ~62g CHO 
 
POST, every 30 min x 8 boluses 
DOMS: Soreness 
 
Muscle Function: PIT 
 
Blood Markers: CK, 
LDH, Mg, IL-1, IL-6, IL-10, 
CRP 
↔ No Effect: The addition of 
protein to a carbohydrate 
drink, in the 4 h following 
exercise, exhibits no 
additive effect on 
ameliorating the negative 
effects of EIMD, when 
compared to carbohydrate 
alone.    
Matsumoto et al.  
(2009) 
Crossover design, double 
blinded, randomised control 
trial   
 
n =12, trained males and 
females  
Uphill and downhill running, for 3 consecutive 
days 
 
BCAA, 8g (4g leucine) x2, between breakfast and 
lunch, between lunch and supper, 4g BCAA (2g 
leucine) x1 after supper, for 3 consecutive days  
 
PLA, dextrin  
DOMS: Soreness, fatigue 
sensation 
 
Blood Markers: CK, 
LDH, GEL 
↓Soreness (24 h), 
↓fatigue sensation (24 
h),  
↓CK (24 h),  
↓LDH (24 h),  
↓GEL (24 h) 
Positive Effect: BCCA 
supplementation during a 
three-day intensive 
training program, reduces 
soreness, fatigue and 
attenuates the increase in 
markers of muscle 
damage, compared to a 
placebo.  
Hoffman et al. (2010) Single blinded, parallel, 
randomised control trial   
10 repetitions x 4 sets, squat, deadlift, lunges 
@80% 1RM, for 3 consecutive days  
DOMS: Soreness 
 
↑Repetitions (24, 48 h) Small Positive Effect: 
Protein supplementation, 
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n =15, trained males    
 
 
PRO, proprietary protein blend (whey, casein, 
BCAA), 42g PRO 
 
PLA, maltodextrin 
 
10min PRE and 15min POST, for 3 consecutive 
days  
Muscle Function: 
Repetitions achieved in 
subsequent days, peak 
PO, mean PO 
 
Blood Markers: CK 
consumed before and after 
exercise, performed for 3 
consecutive days has a 
positive effect on muscle 
function in the days 
following exercise, but 
exhibits no effect on 
markers of muscle 
damage.  
Jackman et al. (2010)  Single blinded, parallel, 
placebo control trial   
 
n =24, untrained males 
10 repetitions x 12 sets eccentric leg extension at 
120% MVC  
 
BCAA, (3.5g leucine, 2.1g isoleucine, 1.7g 
valine) x5 - 30min PRE, 1.5 h POST, before 
breakfast, between lunch and dinner, and 
bedtime.  BCAA x4 consumed between meals for 
subsequent 2 days.  
 
PLA, Artificial sweetener and flavoured water  
DOMS: Soreness 
 
Muscle Function: MIS 
 
Blood Markers: CK, Mb, 
IL-6 
↓Soreness (48, 72 h) Small Positive Effect: 
BCAA supplementation, 
consumed for 3 days post-
exercise, attenuates 
muscle soreness, but has 
no affect no decreased 
muscle function and 
markers of muscle 
damage, following a bout 
of muscle damaging 
exercise.   
Howatson et al. 
(2012) 
Double blinded, parallel, 
randomised control trial   
 
n =12, trained males 
 
 
1 EIMD session, Drop Jump x100 
 
BCAA, 12 days, (7 day loading phase, 4 days 
POST) 10g x2 per day. Additional 20g 1 h PRE, 
and 20g POST.  
 
DOMS: Soreness, Thigh 
C, Calf C 
 
Muscle Function: MVC, 
VJ 
 
↓Soreness (24, 48 h), 
↑MVC , 
↓CK 
Positive Effect: BCCA 
supplementation before 
and after muscle 
damaging exercise 
reduces markers of muscle 
damage and accelerates 
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PLA, artificial sweetener  Blood Markers:  
CK 
recovery.  
Ra et al. (2013) Double blinded, parallel, 
randomised control trial   
n=18, untrained males    
 
5 eccentric repetitions x 6 sets 90% MVC bicep 
curl x 3 consecutive days  
 
BCAA, 3.2g, x3 per day, 2 weeks PRE, 3 days of 
EIMD 
 
PLA, Starch, 2 weeks PRE, 3 days of EIMD  
DOMS: Soreness, Upper 
Arm C 
 
Blood Markers: CK, 
LDH, aldolase, 8-
hydroxydeoxyguanosine  
↔ No Effect: BCAA 
supplementation alone 
three times a day, for 2 
weeks prior and 3 days 
after a muscle damaging 
exercise has no added 
benefits on exercise 
induced DOMS or makers 
of muscle damage, 
compared to control.  
Fouré et al. (2016) Double blinded, parallel, 
randomised control trial   
n=26,untrained males 
Neuromuscular electrostimulation session 
 
BCAA, 100mg/kg (2:1:1) (mean 7g) 30min PRE, 
PRE and POST EIMD, and single dose PRE 4 
subsequent daily testing sessions 
 
PLA, Not specified  
DOMS: Soreness 
 
Muscle Function: MVC 
 
Blood Markers: CK 
 ↔ No Effect: BCAA 
supplementation before 
and after muscle 
damaging exercise did not 
elicit any changes in 
DOMS or markers of 
muscle damage, when 
compared to a placebo. 
Kephart et al. (2016) Double blinded, parallel, 
placebo control trial   
 
n=30, trained males  
5 repetitions x 10 sets back squats at 80% 1RM, 3 
consecutive days 
 
BCAA, leucine (3g), 1g isoleucine, 2g valine, and 
2g CHO/day. POST x3 days 
 
DOMS: Soreness 
 
Muscle Function: 1RM 
back squat, PIT, MIC, 
mean EMG, peak EMG 
 
↓ Monocytes  No Effect: BCAA 
supplementation had no 
enhanced effect on 
markers of performance 
and muscle damage. BCAA 
did attenuate the increase 
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PLA, 42g CHO  Blood Markers: Mg, 
WBC, Neutrophils, 
lymphocytes, monocytes 
of monocytes compared to 
placebo. 
Greer et al. (2007) Crossover design, double 
blinded, randomised control 
trial   
 
n=9, untrained males 
90 minute 55% VO2peak  
 
BCAA, 2.5g (1.22g leucine), 5 min PRE and 60 
min later  
 
PLA x2, Isocaloric CHO beverage, and a non-
caloric beverage with artificial sweetener  
DOMS: Soreness 
 
Muscle Function: MVC  
 
Blood Markers: CK, 
LDH 
↓Soreness (24 h) , 
↓CK (4, 24, 48 h),  
↓LDH (4 h) 
Positive Effect: BCAA 
supplementation 
attenuates muscle 
damage after prolonged 
endurance exercise.  
Waldron et al. (2017) Double blinded, parallel, 
randomised control trial   
n=16, untrained males    
 
20 squats x 7 sets @70% 1RM 
 
BCAA, 0.087g/kg (2:1:1) (mean 8g) and 
dextrose, PRE and POST EIMD and testing at 24, 
48, 72 hr.  
 
PLA, Dextrose  
DOMS: Soreness 
 
Muscle Function: MIC, 
CMJ 
  
Blood Markers: CK 
↓Soreness (24, 48 h), 
↑MIC (24 h), 
↑ CMJ (24 h), 
↑CK (24, 48 h) 
Positive Effect: Acute 
supplementation of BCAA 
before and after muscle 
damaging exercise 
improves performance 
markers and decreases 
perceived DOMS, 24 and 
48 h post-exercise.  
Table 2.5: Summary table of studies which use >1 bolus of exogenous amino acids after exercise induced muscle damage. n, participant size; BCAA, BCCA group; PLA, placebo 
group; CHO, carbohydrate; EIMD, exercise induced muscle damage; PRE, Pre EIMD; POST, Post EIMD; RM, repetition max; MVC, maximal voluntary contraction; MIC, maximal isometric 
contraction; PIT, peak isometric torque; PT, peak torque; EMG, electromyography;  PO, power output; C, circumference; VJ, vertical jump; CMJ, counter movement jump; CK, creatine kinase, 
LDH, lactate dehydrogenase; Mb, myoglobin; CRP, c-reactive protein; GEL, granulocyte elastase; IL, interleukin; ↑, significant positive difference to PLA; ↓, significant negative difference to PLA, 
↔, no difference to PLA.  
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2.9.4 The Role of >1 Boluses Per Day EAAs in Exercise Recovery  
The present literature on the role of AAs, administered >1 time in the post-exercise period, in ameliorating the 
negative effects of EIMD, has yielded conflicting findings. This is likely due to the difference in participants 
recruited, the muscle damaging protocol employed, outcome measures, degree of dietary control, AA dose 
used, AA source used and supplement strategies used; with some studies using AA supplementation only 
before and after exercise, others having a loading phase in the days before exercise and some strategies 
continuing on for days after the exercise session.  
 
Nonetheless, in summary, AA supplementation, namely BCAA, appears to be efficacious in ameliorating the 
outcome of EIMD, with a propensity to elicit greater benefits when the muscle damaging protocol is less 
severe. Indeed, BCAA supplementation yielded little to no benefit in outcomes of EIMD in studies which 
consisted of three consecutive days of muscle damaging exercises (Kephart et al., 2016; Ra et al., 2013; 
Hoffman et al., 2010). However, these severe, consecutive day, repeated muscle damage protocols are not 
reflective of a real world periodised training plan in sports involving resistance training, therefore concluding 
that AA supplementation does indeed confer benefits for recovery from a single muscle damaging exercise 
session. Furthermore, there is a tendency for longer supplementation strategies to confer greater benefits in 
recovery (Kraemer et al., 2006; Howatson et al., 2012; Waldron et al., 2017). With our current understanding 
of the superiority of multiple adequate high leucine/protein meals in maximising cumulative daily MPS 
(Layman et al., 2015; Areta et al., 2013; Moore et al., 2012), it is possible that longer supplementation period 
is required to elicit the benefits of BCAA supplementation. Indeed, this thesis is well supported by RCTs using 
AA mixtures ingested for several days after EIMD. Nosaka, Sacco and Mawatari, (2006) demonstrated that 
extending AAs supplementation several days beyond post-exercise, confers greater benefits in exercise 
recovery, compared to a AAs ingested simply pre and post-exercise. Two boluses of 4.5g AAs (9 essential and 2 
non-essential AAs) ingested 30 min before and immediately after exercise, was compared to a protocol in 
which the same boluses were ingested pre and post-exercise, with an addition 8 boluses ingested over the 4 
days following exercise. CK, myoglobin (Mg) and muscle soreness using visual analogue scale (VAS) were 
significantly lower in the group which supplemented for an extra 4 days, concluding that AAs attenuate DOMS 
and markers of muscle damage when applied in the subsequent days recovery from a muscle damaging 
exercise bout. In support, Kraemer et al. (2006) investigated the effect of daily, evenly distributed AA ingestion 
on markers of recovery in a group of trained males, during 4 weeks of strategic overreaching training. 0.1g/kg 
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AA was ingested separate to meal (1 h before meals and 2 h after meals), four times per day. Based on mean 
body mass of 89.1kg, each dose of AA was approximately 4.5g of BCAA comprised of 2.2g leucine. Participants 
were weighed every 7 days and kept food diaries, in an aim of keep dietary intake isoenergetic for all 
participants, and was represented by a typical American diet, of 55% carbohydrates, 30% fat and 15% protein. 
Muscle strength and marker of muscle damage were assessed at every 7 days. 1 repetition max (RM) squat and 
bench declined in week 2 for placebo group, with no change apparent in AA group.  In week 3, 1RM returned 
to baseline in placebo group, while the AA group experienced a significant increase in 1RM at this time-point. 
While both groups experienced an elevation in CK in week 1, this increase was significantly lower in the AA 
group. While these results support the use of AA supplementation after EIMD, a significant limitation in the 
present study is poor dietary control. While the aim was to keep calorie intake at maintenance levels for 
participants, quantity and source of protein was not controlled, which means it is difficult to attribute these 
benefits solely to the AA supplement. Matsumoto et al. (2009) demonstrated that when nutrition was 
controlled tightly, in which a BCAA and placebo group consumed the same meals in a cross-over design, 
results are still positive for the BCAA group. Following an intense 3 day training program, in which BCAA 
supplements were provide between meal, 2-4g leucine x 3 times per day for 3 days, muscle soreness and 
fatigue sensation were lower, when compared to a placebo group consuming dextrin only. BCAA 
supplementation also attenuated the increase in plasma CK, lactate dehydrogenase (LDH) and granulocyte 
elastase (GEL) following the training program, when compared to placebo group.  The mechanism behind this 
enhancement in recovery following EIMD is not fully understood. It is unclear whether the benefits of AAs are 
related to a decrease in MPB, an increase in muscle protein anabolism, a combination of both mechanisms, or 
a mechanism yet to be identified. Nonetheless, these are promising results that potentially support the use of 
supplementary BCAA and AAs multiple times per day, for a prolonged period (i.e. beyond the immediate post-
exercise period) in recovery from EIMD. 	
2.9.5 The Role of Leucine and Leucine-Enriched Beverage in Exercise Recovery 
Of the three BCAA, leucine is the most evident contributor to postprandial anabolism and anti-catabolism. 
However, few studies have investigated the effect of leucine, in isolation, on recovery from resistance training. 
Positive results have been achieved in animal models, in which leucine-enriched AAs elicit improved rates of 
MPS and ameliorate muscle soreness after eccentric exercise in rats (Kato et al., 2015). However, the role of 
solely leucine, in ameliorating the effects of EIMD in humans, remains underexplored. Thomson, Ali and 
Rowlands (2011) investigated the effects of a leucine-enriched protein and carbohydrate beverage on recovery 
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from subsequent cycling performances and markers of muscle damage. Trained cyclists performed 2-2.5 h of 
interval cycling on three consecutive evenings, and in a cross-over design consumed one of two beverages 
(one containing ~22g leucine, or an isocaloric control) alongside a carbohydrate and protein meal within the 
first 90 min post-exercise. Each morning following the three cycle trials, participants consumed the alternate 
beverage, thereby isolating the post training nutrition effect. Dietary intake was controlled for the duration of 
the trial, with protein intake fixed at 1.6g/kg/d. 39 h following the last exercise bout, the PRO+CHO+LEU 
group showed a 2.5% improvement in mean sprint power in a repeated sprint performance trial, 13% 
reduction in levels of fatigue, CK was 19% lower, with no difference in perceived tiredness and soreness 
between treatment groups. This suggests that a leucine-enriched beverage and meal in the 90 min following 3 
consecutive days of cycle performance, enhances recovery and subsequent high intensity endurance 
performance. In contrast, when leucine is supplemented without the presence of other AAs, the results are 
contradictory; suggesting that supplementation of leucine alongside other AAs or a mixed meal results in a 
synergistic affect and promising results for recovery, as discussed previously in the context of MPS. Indeed, 
Stock et al. (2010) demonstrated that adding leucine to a carbohydrate beverage before and after exercise has 
no additive benefit on recovery from resistance exercise. Participants consumed a 0.35g/kg carbohydrate 
beverage, alongside 22.5mg/kg leucine, 30 min before and immediately after a muscle-damaging bout of 
exercise. Of note, the average leucine content of each beverage was 1.9g, at a mean body mass of 82.7kg, 
equating to a total of 3.7g leucine consumed within 60 min post-exercise. CK concentrations increased after 
exercise (24 h), and peaked at 48 h, returning to baseline at 72 h in both groups, but there were no differences 
between the treatment groups, nor were differences apparent in the lactate dehydrogenase (LDH) time course 
between groups. When asked to quantify their degree of DOMS using a VAS, participants self-reported DOMS 
peaked at 48 h in both groups, but again there was no difference between treatment groups. In addition, Kirby 
et al. (2012) investigated the effect of leucine supplemented 30 min before, immediately post-exercise and 
the morning of each subsequent recovery days following the exercise bout, compared to a placebo. 250mg/kg 
of leucine, represented an average intake of ~19g per bolus, resulted in no attenuation in CK, Mb or perceived 
soreness, assessed using VAS, with the supplement group reporting greater soreness after exercise. However, 
leucine supplementation attenuated the drop in peak force output during an isometric contraction, when 
compared the placebo group.  
 
In summary, studies to date, which have investigated the effect of leucine alone supplementation on 
accelerating recovery from EIMD, have deemed leucine to elicit little to no benefit. A plausible explanation for 
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the insignificant differences in recovery markers between treatment groups in the latter studies, is that leucine 
was only consumed before and after exercise, or once per day in the subsequent days following the muscle 
damaging bout of exercise. A recovery protocol aimed at providing >2 leucine boluses, one or more days after 
training, may facilitate recovery from EIMD. To the best of our knowledge, no studies have investigated the 
effect of leucine supplementation on exercise recovery parameters in this way, or the role of enriching a low-
leucine meal plan, given that this would also provide a range of other AAs to support recovery processes.   
 
2.10 Conclusions 
From the present review of current literature surrounding the role of leucine in the enrichment of meals, its 
role in the treatment and/or preventative for the age-related decline in muscle mass in older adults, and in 
recovery from EIMD, there are some obvious knowledge gaps which warrant further investigation.  
 
With our present understanding of the role of the plasma leucinemia in postprandial MPS, leucine-enrichment 
is emerging as a promising strategy to increase the anabolic properties of a meal. While several studies 
suggest that leucine-enrichment offers an advantage in stimulating postprandial MPS compared to a meal 
alone, few studies to date have investigated the plasma kinetics of leucine ingested alone, and co-ingested 
with a mixed meal. Microencapsulation technology represents a means to alter the plasma kinetics of leucine, 
and through taste-masking, have broader application in enriching food matrices with leucine, but to date 
microencapsulated leucine has not been studied.  
 
The well-established age-related decline in muscle mass with advancing age has a number of contributing 
factors, including a general decline in physical activity with age and a decrease in appetite which often results 
in a reduction in overall energy and protein intake. Modifications in exercise and diet would therefore appear a 
promising strategy in the treatment and/or prevention of loss of muscle mass and function with age. However, 
there still remains ambiguity of the efficacy of a training and nutrition intervention which positively influences 
changes in muscle mass and function in older adults. Furthermore, the manifestation of ‘anabolic resistance’ in 
which older adults have a dampened response to the anabolic characteristics of exercise and dietary protein, 
further exacerbates the issue. Older adults have been shown to possess a higher ‘leucine threshold’ when 
compared to young adults, in that a higher leucine or protein dose is required to elicit a robust postprandial 
anabolic response.  Despite leucine being a key to potentially overcoming the anabolic resistance exhibited by 
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older muscle, few studies have focused on leucine as a nutrient in combatting the age-related decline in 
muscle mass. Furthermore, much of the research surrounding the modification of dietary protein intake in 
older adults, with an aim to positively influence changes in LBM, has focused on the use of powdered proteins 
and oral solutions. Indeed, few studies have focused on the use of whole foods, despite some research that 
suggests that food in its natural state has greater anabolic characteristics when compared to that which is more 
refined. Therefore, the use of a whole food-based intervention targeting leucine-rich foods as a strategy for 
increasing protein intake, and therefore positive influencing exercise-mediated changes on muscle mass and 
function, remains to be investigated.  
 
Unaccustomed exercise can produce micro-damage to skeletal muscle and connective tissue which results in a 
decrease in muscle function and soreness in the days following exercise. These deleterious effects can result in 
a decrease in performance, compromising the quality of subsequent training sessions. Protein and AAs in the 
post-exercise period appears promising in ameliorating the deleterious effects of intense exercise. However, 
the role of leucine in particular, remains underexplored. Furthermore, the role of different temporal feeding 
strategies (i.e. bolus vs. pulse fed) of leucine in the hours following intense exercise, has not yet been 
investigated. The following chapters aim to address these present knowledge gaps and contribute to the 
current literature.  
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Chapter 3 
3.0 Materials and Methods 
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3.1 Microencapsulation Preparation   
The microencapsulation of leucine using a hydrolysed milk protein matrix material was created as per Hone et 
al. (2017) and described by Brodkorb and Doherty (2015). The method comprises the steps of providing a 
suspension of hydrolysed whey protein and an active component in a carboxylic ester, treating the suspension 
to generate droplets of the suspension and immediately curing the droplets by immersion in a basic curing 
solution. The ester in the suspension reacts with the basic curing solution to release a salt that polymerises the 
hydrolysed whey protein encapsulating the active component (Brodkorb and Doherty, 2015). Whey protein 
isolate (WPI) was dissolved in sterile water (9% w/v) for 16 hr at 4°C under slight agitation (180 rpm); the 
solution was adjusted to pH 7 with 100 mM HCl and filtered through Durapore® 0.45- μm HVLP (Millipore 
Ireland BV, Cork, Ireland). The appropriate formulation for a curing medium was investigated using calcium 
chloride, acetate, and citrate buffers systems. Uniform size whey protein micro-particulates were prepared for 
the encapsulation and extrusion of leucine using an extrusion ratio of 95:5 of leucine:WPI. Process 
temperatures were maintained at 35°C to optimize encapsulation efficiency, as per Hone et al. (2017).  
3.2 Cannulation and Blood Handling    
The participant was laid on a bed with their arm in a hyperextended position. A tourniquet was applied 
approximately 4 inches above the antecubital fossa. The puncture site was cleanses using a sterile pre-injection 
wipe. A single-use butterfly needle (or cannula in the event of multiple draws) was inserted in the antecubital 
vein, with the needle bevel upwards. After the puncture, the tourniquet was removed. For cannulation, the 
sample line was kept patent with saline. Blood samples (~4ml) were drawn into vacutainers containing 
lithium heparin (BD Vacutainers, Heparin Tubes). Once the sufficient blood has been collected, the needle was 
removed and disposed, and a swap was immediately placed with pressure on the participant’s antecubital 
fossa until bleeding had ceased. The vacutainer was inverted eight to ten times and placed on ice. The blood 
was centrifuged at 4000 g for 10 min at 4°C and the upper layer of plasma was transferred into three separate 
1.5ml tubes and stored at -80°C until further analysis.  
3.3 High Performance Liquid Chromatography    
The concentration of amino acids in plasma was measured using High Performance Liquid Chromatography 
(HPLC), according to the manufacturer’s instructions (Henderson and Brooks, 2010) with minor adjustments as 
per Power-Grant et al. (2016). The principle of HPLC is a separation technique that involves the injection of the 
liquid sampleinto a column packed with porous particles, in which individual components of the sample are 
transported along the column by a mobile phase. The components of the sample are separated from one 
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another within the column. The separated components are collected at the exit of this column and identified by 
spectrophotometer measured via fluorescence detection. Fluorescence detection is more sensitive than utra 
violet detection and allows measurement of amino acids at an extremely low concentration. 
3.3.2 Preparation of Reagents  
2L of mobile phase A [10mM Na2HPO4, 10mM Na2B4O7, pH 8.2, 5mM NaN3] was prepared, using 2.8 g of 
Na2HPO4 (Sigma), 7.6 g of Na2B4O7  (Sigma), 32 mg of sodium azide (Sigma). Solutes were dissolve in 800 ml 
of HPLC grade water. 2.4 ml of concentrated HCl. 1L of solution was made in a volumetric flask. 1L HPLC grade 
water was added to a pH of 8.2 using concentrated HCl.2 L of mobile phase B [Acetonitrile (Lennox, Romil 
SPS): methanol (Lennox, Romil SPS): water (45:45:10, v: v: v)] was prepared as follows 900ml acetonitrile, 
900ml methanol, 200ml HPLC grade water. Injection diluent was made using 100ml mobile phase A and 
0.4ml concentration of phosphoric acid (H3PO4, Sigma). This was stored at 4°C. 500 ml 0.1 N HCl was prepared 
using 4.2mL of concentrated HCl (VWR, 36 %) and make up to 500ml with HPLC grade water. 50:50 0.1M HCl 
and water was used for preparing amino acid stock solutions and internal standard stock solutions. Store at 
4°C. 0.4M perchloric acid was also prepared.  
 
3.3.3 Perchloric acid extraction and sample preparation  
Once ready for analysis, plasma samples were defrosted at -20°C and then at room temperature. Samples were 
mixed using a 2 sec (speed 7) vortex. Samples were centrifuged at 4°C, 5000 rpm for 3 minutes. 50 µL of 
plasma was added to 15µl 1mM norvaline. 85µL of ice cold, 0.4M perchloric acid was added. All samples were 
gently vortexed for 5 sec (speed 7) and stored on ice. Samples were centrifuged at 4˚C, 8 min 10,000 rpm. 50 
µl of supernatant was added to each well of the autosampler plate. 
3.3.4 Reference Standards and Calibration  
 
1mM Norvaline was used a standard added to each plasma sample. 0.0293 g of norvaline (Sigma) was 
prepared in 25ml of 50:50 water 0.1M HCl. Stored at 4 ˚C. 1ml of 10 mM norvaline added to 9ml of 50:50 
HCl:water. A Sigma stock consisting of 18mM glutamine, 15 mM taurine and 4mM tryptophan was prepared 
using 65.7 mg of glutamine (Sigma), 46.9mg of taurine (Sigma), and 20.4mg of tryptophan (Sigma) weighed 
into a 50 ml tube. 10 ml of 50:50 water 0.1M HCl was added and vortexed to dissolve the powders. This was 
added to a 25 ml volumetric flask and topped up to the mark. This was stored at 4 ˚C. A working stock solution 
was also prepared as a reference standard using a combination of norveline, Sigma stock and 1nM Aligent 
amino acid stock. 3 ml of working stock solution was prepared as by adding 750 µL of agilent stock, 150 µL of 
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Sigma stock, 75 µL of the norvaline standard and 2025 µL of water to a plastic tube. Vortex mix and store at 
4˚C.  
 
A five-point calibration curve was constructed for each AA in concentration range as per table 3.1.  
Calibration Level 
 
Agilent standard  
(µM) 
Glutamine  
(µM) 
Taurine  
(µM) 
Tryptophan 
(µM) 
Norvaline  
(µM) 
1 250 900 750 200 250 
2 125.0 450 375 100 125 
3 62.5 225 187.5 50 62.5 
4 30 108 90 24 30 
5 15.0 54 45 12 15 
Table 3.1: Five-point calibration curve construction. 
 
Calibration standards level 1 to 5 were prepared per table 3.2. 
Calibration level Volume  Working stock (µL) Volume Water (µL) 
1 200 0 
2 100 100 
3 50 150 
4 24 176 
5 12 188 
Table 3.2: Calibration standards. 
 
3.3.5 Online Derivatisation  
 
Chromatography condition were set as per table 3.3 using a Chemstation interface. The elution programme 
used to separate amino acids consisted of a linear gradient 0–0.2min 2% B; 0.2–7.7min 2–43% B; 7.7– 7.8 min 
43–100% B; 7.8–8.3 min 100% B; 8.3–9 min 100–2% B. The pump was operated at a flow rate of 2.0ml/min 
and 1.0ml of each derivatised sample was injected. O-phthalaldehyde derivatives were detected by 
fluorescence at an excitation of 230 and an emission of 450nm.  
Column Agilent ZORBAX Rapid resolution high throughput column 4.6*100 mm, C18 1.8 
µM (Agilent Technology, Germany) 
Guard column Security Guard C18 (ODS; Phenomenex, UK) 
Flow 1.5 ml/min 
Injection volume 1 μl 
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Operating pressure ~350 bar 
Temperature column 40ºC 
Table 3.3: Chromatography conditions.   
 
3.4 Creatine Kinase (CK) and Lactate Dehydrogenase (LDH) Analysis     
Analysis of CK and LDH concentration was performed using a semi-automated analyser (RX Daytona and RX 
Imola; Randox). Before calibration the system; the wash solutions, ultra-pure water and waste containers were 
assessed to ensure appropriate levels. The relevant reagents were loaded into the reagent carousel. CK NAC 
reagent (Randox) was used to assess CK, and Lactate Dehydrogenase NAD (Randox) was used to assess LDH. 
Calibration and control reagents (Randox) were specific to the CK and LDH analysis, as per the manufacturers 
guidelines. Once the calibration and control were satisfactory, plasma samples were defrosted to room 
temperature using mixer. The epindorphs were directly loaded into the carousel of the analyser. The sample 
sequence table was designed, and the analyser was run.  
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Chapter 4  
4.0 Habitual Protein Intake, Protein Distribution Patterns and 
Protein Source Across the Lifespan in Irish Adults between 2008 
and 2010 
 
Background: Habitual dietary protein intake and distribution pattern across a population is an important consideration 
when designing nutrition strategies to combat the age-related decline of muscle mass and function. The National Adult 
Nutrition Survey (NANS) investigated habitual food and beverage consumption, lifestyle and health indicators in 1500 
adults aged 18-90 years in Ireland between 2008 and 2010. 
 
Objective: The aim of the current study was to complete a secondary analysis of the data collected in NANS to determine 
overall protein intake patterns and food sources by age and gender.  
Data Analysis: The final sample size for the analysis was n=1051 (males, n=523; females, n=528), all of whom 
undertook a four-day semi-weighted food diary to include three weekdays and one weekend day. Total, body mass relative 
intake and percentage contribution to total energy of each macronutrient were determined. Protein distribution scores 
(PDS) were calculated to determine the number of eating occasions per day containing over the 20g, 30g, 0.24g/kg, 
0.3g/kg and 0.4g/kg body mass of protein, averaged over the 4 days. 2,048 pre-existing food codes were aggregated into 
16 food groups. The percentage contribution of these food groups to total protein intake (g/d) was determined. These 
foods codes were further aggregated into two broad animal- and plant-based food groups. Food source contribution to 
total and per meal protein intake was determined. A two-way mixed ANOVA (gender x age) was performed. Post-hoc 
analysis multiple comparisons with Bonferroni’s adjustment was used to determine differences between age groups.  
Results: Total protein intake, and protein intake relative to body mass was greatest in those aged 18-35 y (96±3g per 
day, 1.32±0.40g/kg/d), with lower protein intakes with increasing age, and the lowest intakes apparent in adults aged 
≥65 y (82±22g, 1.15±0.34g/kg/d, P<0.001 for all). This difference in protein intake between age groups was more 
pronounced in males compared to females, with females between ages 35-50 y and 51-64 y showing no difference in 
protein intake. The average number of meals per day reaching the purported per meal protein threshold to maximise 
MPS was highest in adults aged 18-35 y, and lower with increasing age (P<0.001). Protein distribution follows a skewed 
pattern across each age group, in which dinner represents the highest per meal protein intake, followed by lunch and 
breakfast (44±17g, 30±15g and 15±10g, respectively) Plant-based protein is the predominant protein source at 
breakfast (57.5±37.1%). Overall protein is derived predominantly from animal sources (63.1±10.8%, animal protein; 
36.9±10.8%, plant protein in total population), with meat and dairy having the largest contribution to total protein intake 
in both sexes across all age groups.   
 
Conclusion: Protein intake and the number of meals reaching the purported threshold for maximising postprandial 
anabolism is greatest in young, and is lower with increasing age. Breakfast was the lowest total protein and animal 
protein-containing main meal across all age categories, and may represent an opportunity for improving overall protein 
intake, and protein distribution, thereby combatting the age-related decline in muscle mass and function. 
  
 
 75 
4.1 Introduction  
Dietary protein acts as an anabolic stimulus by resulting in the stimulation of MPS (Glynn et al., 2010; Moore 
et al., 2009; Paddon-Jones 2004). If each eating occasion is considered as an opportunity to increase MPS, the 
cumulative magnitude and duration of postprandial MPS after the ingestion of each protein-containing meal 
dictates the time spent in a positive net protein balance over the course of a day (Layman et al., 2015; Areta et 
al., 2013; Paddon-Jones, 2004). For that reason, there is an emerging recognition that ‘per meal’ protein 
recommendations offer an effective strategy for increasing positive net protein balance, and favouring muscle 
accretion over time (Areta et al., 2013; Paddon-Jones, 2004). 20-30g protein per meal, or 0.24g/kg and 
0.4g/kg body mass per meal, in young and old respectively, has been shown to maximise MPS after a single 
meal (Moore et al., 2015, 2009; Witard et al., 2014; Symons et al., 2009). Furthermore, modulating protein 
distribution over the day to create an even protein intake at each meal, for example ≥20g high quality protein 
ingested at three main meals (Areta et al., 2013) maximises rates of MPS over 12 hours (Paddon-Jones and 
Leidy, 2014; Moore et al., 2015; Symons et al., 2009).  
Daily protein intake often follows a ‘skewed’ pattern of distribution, in which protein intake is highest at 
dinner, and lower at other meals and snacks (Cardon-Thomas et al., 2017; Tieland et al., 2015; Almoosawi et 
al., 2013; Bollwein et al., 2013; Ruiz Valenzuela et al., 2013). This skewed pattern of distribution potentially 
exceeds the optimal protein dose at dinner, which does not cause an added anabolic response above ~20g 
high quality protein (Witard et al., 2014; Moore et al., 2009). Furthermore, the resultant lower protein intakes 
at breakfast, lunch and snack times are representative of a sub-optimal protein intake for maximising MPS 
(Witard et al., 2014; Areta, 2013; Moore et al., 2009). This has led to the hypothesis that spreading daily 
protein intake evenly throughout the day can result in a greater cumulative anabolic response compared to 
this skewed pattern of protein intake (Layman et al., 2015). Furthermore, an uneven protein distribution has 
been associated with an increase in incidence of frailty (Bollwein et al., 2013), while the daily consumption of 1 
or 2 main meals over the 30g protein per meal threshold is associated with greater lean mass and strength in 
older adults (Loenneke et al., 2016). These data support the thesis that a more evenly-distributed protein 
intake is more favourable for augmenting LBM and strength, and preventing frailty in older adults. The source 
of dietary protein is also of relevance, since animal proteins, which have a higher essential amino acid (EAA) 
content (USDA National Nutrient Database for Standard Reference, 2009), exhibit greater anabolic properties, 
causing a superior postprandial anabolic response when compared to plant-based proteins (Gorissen et al., 
2016; Yang et al., 2012a; 2012b; Tang et al., 2009; Wilkinson et al., 2007).  
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Habitual dietary protein intake and patterns in Irish adults remains underexplored. The National Adult 
Nutrition Survey (NANS) investigated habitual food and beverage consumption, lifestyle and health indicators 
in 1500 adults aged 18-90 years, in the Republic of Ireland, between 2008 and 2010. The series of interrelated 
databases, which has been compiled from the data collected in this survey, provide the most complete and up-
to-date collection of food consumption data available for adults in Ireland, therefore offering valuable 
information about the protein intake, distribution and source across gender and ages. The aim of this current 
study is to complete secondary analysis of the data collected in this survey to determine overall protein intake 
patterns and food sources by age and gender.  
4.2 Methods 
4.2.1 Study Population  
This study is based on secondary analysis of National Adult Survey (NANS), a cross-sectional food consumption 
survey in Irish adults. The surveys were carried out by the Irish Universities Nutrition Alliance (IUNA) in a 
sample of 1500 free-living adults aged 18-90 years (males, n=740; females, n=760), in the Republic of 
Ireland between 2008 and 2010. Respondents were randomly selected from a database of names and address 
from Data Ireland (An Post). Exclusion criteria include pregnancy, lactation and inability to complete the survey 
due to disability. The final survey response rate was 59.6%. The final sample was representative of the Irish 
population with respect to gender, age, location, social class and geographical location, when compared to the 
Irish censuses (IUNA, 2011). Informed consent from respondents was obtained before the survey commenced. 
Ethical approval was granted by University College Cork Clinical Research Ethics Committee of the Cork 
Teaching Hospitals [ECM 3(p) 4 September 2008].  
4.2.2 Primary Anthropometric Measures and Dietary Assessment 
Anthropometric measurements were carried out by the researcher in the respondent’s home. Body mass, 
height and body composition were measured. Body mass (kg), muscle mass (kg), body fat (g) and percentage 
body fat were assessed using a Tanita SC-331S body composition analyzer (Tanita, Tokyo, Japan). Height was 
assessed using a Leicester portable height measure to the nearest 0.1cm. Body Mass Index (BMI) was 
calculated as weight (kg) divided by height (m2). A four-day semi-weighed food diary, at brand level where 
possible, was used to collect food, beverage and supplement intake. Participants were asked to report three 
weekdays and one weekend day. The researchers made three visits to the respondent’s homes during the four 
days: A visit to demonstrate how to use a food weighing scales and log the food diary; a second visit to review 
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the diary 24-36 hours into the recording process; and a final visit 1-2 days after the recording period to review 
the last recording days and collect the diary. Food and beverage consumption was quantified using a food 
weighing scales (46%), a photographic food atlas (16%), a food portion size guide (11%), household 
measurements such as teaspoons, tablespoons, etc. (11%), manufacturers weights (10%), IUNA weight guide 
(4%) and an estimate made by the researcher (2%). Food and beverage intake was assessed using WISP 
version 3.0 (Tinuviel Software, Anglesey, UK). This analysis was based on data from the McCance and 
Widdowson’s, The Composition of Foods, Sixth    and Fifth Editions, as well as nine supplementary volumes. 
Modifications to the food composition database was also performed to include commonly consumed Irish 
foods. The anthropometric and dietary assessment carried out is described in further detail elsewhere 
(O’Donovan et al., 2018; Hopkins et al., 2015; Cashman et al., 2013). The final food database comprised of 
133,068 rows of data, with each row representing each food or beverage item at every eating occasion 
throughout the four days of recording. 
4.2.3 Secondary Data Analysis 
This secondary analysis was carried out using SPSS (IBM SPSS Statistics Version 24). Respondents who 
reported an energy intake BMR <1.1 (McGowan et al., 2001) were determined as under-reporters (n=449) 
and were excluded from the present analysis. The final sample size was n=1051 (males, n=523; females, 
n=528). New variables were computed to determine body mass relative macronutrient intake on a gram per 
kg basis. Protein Distribution Scores (PDS) were calculated for the following: PDS20, PDS30, PDS0.24g/kg, 
PDS0.3g/kg, PDS0.4g/kg. PDS20 and PDS30 represents the number of eating occasions per day containing over 20g 
and 30g of protein, averaged across the 4 days. PDS0.24g/kg, PDS0.3g/kg, PDS0.4g/kg represents the number of eating 
occasions per day containing over the 20g, 30g, 0.24g/kg, 0.3g/kg and 0.4g/kg body mass of protein, 
averaged over the 4 days. PDS is a scoring system adapted from MacKenzie et al., (2015) with these values 
being representative of the recommended per meal protein target to maximise MPS in young (Witard et al., 
2014;  Moore et al., 2009) and old ( Moore et al., 2015; Symons et al., 2009). 2,048 pre-existing food codes 
were aggregated into 16 food groups based on foods of similar type and protein content. The percentage 
contribution of these food groups to total protein intake was determined. These foods codes were further 
aggregated into two broad groupings described as either animal- or plant-based foods based on observation of 
the principal contributing protein source. The total and percentage contribution of animal- and plant-based 
foods to total protein intake, as well as per meal protein intake, was determined.  
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In general, the distribution of the data approximated normality, or was transformed as appropriate to 
approximate normality. Four age groups were created (18-35 y, 36-50 y, 51-64 y and ≥65 y). A two-way 
ANOVA (gender x age) was performed. When interaction or main effects were indicated, post-hoc analysis 
using multiple comparisons with Bonferroni’s adjustment was used to assess the differences between age 
groups. Statistical significance was accepted at P<0.05. 
4.3 Results  
4.3.1 Anthropometric Measures  
Table 4.1 represents anthropometric measures for the total population (aged 18->65 y), each age group 18-
35 y, 36-50 y, 51-64 y and ≥65 y, and males and females. There was a gender x age interaction for body fat, 
body fat percentage and waist to hip ratio (WTHR) (P<0.01 for all), in which there were greater differences 
between ages 18-35 y and 36-50 y in males, compared to females, who had smaller differences. There were 
main effects for gender for all anthropometric measures (P<0.01 for all).  Males tended to have higher 
measures in height, body mass, BMI, WTHR and muscle mass, compared to females, while females tended to 
have higher values than males for body fat percentage and fat mass.  
There were main effects for age for differences in all anthropometric measures (P<0.001 for all). Body mass, 
BMI, WTHR, body fat percentage, fat mass tended to be greater with increasing age. However, there was a 
lower body mass in adults aged ≥65 y, compared to 51-64 y.  Height and muscle mass tended to be lower with 
increasing age. However, for height, fat mass and muscle mass, there was no significant difference between 
adults aged 35-50 y and 51-64 y.  
4.3.2 Energy and Macronutrient Intake  
Table 4.2 represents average total daily energy, protein, carbohydrates and fat; and percentage of total 
energy intake for each macronutrient. Table 4.3 represents energy and macronutrient intake relative to body 
mass, and expressed in gram/kilogram body mass per day. There was a gender x age interaction for total 
energy, protein (g/d) and relative protein intake (g/kg)(P<0.01 for all). Energy intake was greater in males 
between ages 35-50 y compared to 51-64 y, while energy intake in females in these age categories were 
similar. Total and relative protein intake in males was greatest in young, and was lower with increasing age, 
while protein intake was similar between age groups for females. There were main effects of gender for total 
and relative calorie and macronutrient intakes (P<0.001 for all). There was a tendency for males to have higher 
intakes compared to females for all total and relative energy and macronutrient intakes.   
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There were main effects for age for differences in all total and body mass relative calorie and macronutrient 
intakes (P<0.001 for all). Total energy, protein, carbohydrate and fat intake was greatest in young, and had a 
tendency to be lower with increasing age. However, there was no significant difference between intakes for 
total energy and macronutrient intakes in adults aged 35-50 y and 51-64 y. Relative protein, carbohydrate and 
fat intake, were significant greater in adults aged 18-35 y compared to 36-50 y, 51-64 y and ≥65 y. Total 
protein intake in adults aged ≥65 y was 81.6±22.3g/d, which was significantly lower than that of adults aged 
18-35 y (96.1±32.4g/d, P<0.001). Relative protein intake in adults aged ≥65 y was 1.15±0.34g/k/d, which 
was significantly lower than intakes in adults aged 18-35 y (1.32±0.40g/kg/d, P<0.001).  
4.3.3 Protein Distribution Scores  
Table 4.4 represents PDS, which were calculated for the following: PDS20, PDS30, PDS0.24g/kg, PDS0.3g/kg, 
PDS0.4g/kg. These values represent the number of eating occasions per day containing over the 20g, 30g, 
0.24g/kg, 0.3g/kg and 0.4g/kg body mass of protein, averaged over the 4 days. There was a gender x age 
interaction for PDS20, PDS30 and PDS0.3g/kg (P<0.05), in which there were greater differences between age 
groups for males, compared to females. There were main effects for gender for PDS20, PDS30, PDS0.24g/kg 
PDS0.3g/kg and PDS0.4g/kg (P<0.05 for all) in which males had higher scores than females for all PDS scores.  
 
There were main effects for age in PDS20, PDS30, and PDS0.4g/kg and PDS0.3g/kg (P<0.01 for all). This revealed that 
the number of meals reaching these thresholds was lower with increasing age. However, for PDS30, PDS0.3g/kg 
and PDS0.4g/kg there was no difference between ages 51-64 y and ≥65 y.   
 
4.3.4 Contribution of Food Source to Total Calorie and Protein Intake  
Table 4.5 represents the contribution of animal- and plant-based proteins to overall protein and energy 
intake. There was a gender x age interaction for animal protein only (P<0.001) in which there were greater 
difference between age groups for males, compared to females. There were main effects for gender for all 
variables in table 4.5 (P<0.05 for all), in which females tended to have a higher percentage of protein and 
energy from plant-based foods compared to males, while males had a higher percentage of protein from 
animal-based foods compared to females. There were main effects for age for all variables in table 4.5 
(P<0.05 for all), in which total animal- and plant-based protein intake showed lower intakes with increasing 
age. Percentage protein intake from animal-based protein was significantly greater in adults aged ≥65 y 
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compared to all groups, while percentage protein intake from plant-based protein was significantly lower in 
adults aged ≥65 y, compared to all groups. Figure 4.1 represents the average per meal protein intake, across 
each group, and the relative contribution of animal- and plant-based protein to total per meal protein intake. 
Figure 4.2 represents the percentage contribution of 16 food groups to total protein intake across each age 
group. In each age group, meat, dairy and breads were the predominant protein sources, accounting for 
40±15%, 15±9% and 12±6% in the total population, respectively.   
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Table 4.1: Anthropometric measures for all participants, across genders and age groups. Values are expressed as mean ± standard deviation. A two-way ANOVA was performed 
(Gender*Age). When P<0.05, post-hoc analysis with Bonferroni’s adjustment was used to determine where differences existed between age groups. Difference existing between age groups is 
indicated by: a P<0.05 vs. 18-35 years; by b P<0.05 vs. 36-50 years; c P<0.05 vs. 51-64 years; d P<0.05 vs. ≥65 years plus.    
 
      All Ages               18-35 y       36-50 y      51-64 y ≥65 y  P Value  
  mean±SD n mean±SD n mean±SD n mean±SD n mean±SD n Gender Age GxA 
Height (m) All 1.69±0.10 966 1.73±0.10bcd 357 1.68±0.09ad 279 1.68±0.10ad 186 1.65±0.09bc 144 <0.001 <0.001 0.224 
 Male 1.76±0.07 477 1.79±0.07 195 1.75±0.07 128 1.75±0.08 89 1.72±0.07 65    
 Female 1.62±0.07 489 1.65±0.05 162 1.62±0.07 151 1.61±0.06 97 1.59±0.06 79    
Body Mass  All 75.1±14.6 964 73.7±14.1bc 356 76.0±14.6a 279 78.1±16.4ad 185 72.9±12.2c 144 <0.001 <0.001 0.27 
(kg) Male 82.6±12.8 475 80.2±12.8 195 85.1±11.8 128 86.5±14.3 88 79.6±10.6 64    
 Female 67.8±12.2 489 65.9±11.4 161 68.2±12.1 151 70.5±14.4 97 67.6±10.7 80    
BMI (kg/m2) All 26.2±4.3 905 24.5±3.6bcd 341 26.8±4.2ac 270 27.9±5.1ab 170 26.9±3.6a 124 0.002 <0.001 0.273 
 Male 26.6±3.9 441 24.8±3.4 186 27.7±3.6 123 28.4±4.2 78 27.1±3.3 54    
 Female 25.8±4.6 464 24.2±3.8 155 26.0±4.5 147 27.4±5.7 92 26.8±3.9 70    
Waist to Hip  All 0.87±0.08 856 0.84±0.07bcd 321 0.88±0.08ac 258 0.91±0.08ab 163 0.90±0.08a 114 <0.001 <0.001 <0.001 
Ratio Male 0.91±0.08 408 0.86±0.07 168 0.93±0.07 116 0.96±0.07 75 0.95±0.07 49    
 Female 0.84±0.08 448 0.81±0.07 153 0.85±0.08 142 0.86±0.07 88 0.87±0.07 65    
Body Fat  (%) All 27.9±8.9 870 23.3±8.8bcd 339 29.9±7.8ac 269 31.7±7.8ab 163 31.8±6.8a 99 <0.001 <0.001 0.002 
 Male 22.4±7.3 431 17.6±5.8 185 25.0±6.4 123 26.8±6.4 76 27.3±4.7 47    
 Female 33.2±6.9 439 30.0±6.8 154 34.1±6.4 146 36.0±6.3 87 35.9±5.7 52    
Fat Mass (kg) All 21.3±9.4 864 17.2±7.9bcd 336 23.5±9.9a 268 25.1±10.0a 161 23.3±6.3a 99 <0.001 <0.001 0.003 
 Male 19.5±10.0 427 14.6±6.8 183 22.8±11.2 122 24.6±11.1 75 22.5±5.8 47    
 Female 23.1±8.4 437 20.3±7.9 153 24.1±8.6 146 25.6±8.8 86 24.2±6.7 52    
Muscle Mass  All 51.1±10.7 864 53.2±11.1bcd 336 50.3±10.3ad 268 50.1±10.8ad 161 47.4±9.5abc 99 <0.001 <0.001 0.163 
(kg) Male 60.3±7.2 427 61.9±7.2 183 60.0±6.6 122 59.8±7.4 75 56.0±6.0 47    
 Female 42.1±3.7 437 42.9±3.2 153 42.3±3.8 146 41.7±3.9 86 39.7±3.5 52    
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Table 4.2: Average energy intake (kcal) and macronutrient intake (g and % of total energy intake) for all participants, across genders and age groups. Values are expressed as 
mean ± standard deviation. N values, total populations, n =1051 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=377; 308; 204; 162]; males, n=523 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=207; 143; 98; 75]; 
females, n=528 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=170; 165; 106; 87]. A two-way ANOVA was performed (Gender*Age). When P<0.05, post-hoc analysis with Bonferroni’s adjustment was used to 
determine where differences existed between age groups. Difference existing between age groups is indicated by: a P<0.05 vs. 18-35 years; by b P<0.05 vs. 36-50 years; c P<0.05 vs. 51-64 years; d 
P<0.05 vs. ≥65 years plus.    
 
 
 
  All Ages 18-35 y 36-50 y 51-64 y ≥65 y  P Value  
  mean±SD mean±SD mean±SD mean±SD mean±SD Gender Age GxA 
Energy intake (kcal/day) All 2234±623 2457±663bcd 2190±565ad 2157±523ad 1899±555abc <0.001 <0.001 0.006 
 Males 2586±594 2816±556 2552±533 2475±510 2162±625    
 Females 1886±423 2020±501 1876±371 1862±327 1673±359    
Protein (g/day) All 90.5±27.7 96.1±32.4bcd 89.6±26.2ad 88.4±21.4ad 81.6±22.3abc <0.001 <0.001 <0.001 
 Males 105.2±27.4 113.1±30.5 105.0±24.6 99.9±19.9 90.4±24.7    
 Females 75.9±18.8 75.4±20.2 76.3±19.3 77.8±16.9 74.1±16.7    
Protein intake  All 16.4±3.4 15.7±3.6bcd 16.6±3.4ad 16.7±3.0a 17.6±3.2ab 0.953 <0.001 0.08 
(% Energy Intake) Males 16.5±3.5 16.2±4.0 16.7±3.1 16.4±2.7 17.2±3.5    
 Females 16.4±3.3 15.1±3.0 16.5±3.6 16.9±3.2 17.9±2.9    
Carbohydrate (g/day) All 252.9±76.6 272.5±80.5bcd 248.1±73.0ad 249.1±71.2ad 221.1±67.5abc <0.001 <0.001 0.079 
 Males 287.9±79.4 308.3±76.5 283.7±78.7 282.6±75.3 246.6±76.5    
 Females 218.2±54.9 228.9±61.6 217.3±50.6 218.1±50.5 199.2±49.3    
Carbohydrate All 45.6±7.3 44.7±7.3d 45.5±7.4 46±7.0 46.9±7.2a 0.001 0.01 0.963 
(% Energy Intake) Males 44.7±7.9 44.0±7.8 44.5±8.3 46±7.3 46.0±8.0    
 Females 46.4±6.5 45.6±6.5 46.4±6.5 47±6.7 47.7±6.4    
Fat (g) All 84.9±28.5 91.7±28.3bcd 84.0±27.7ad 82.2±26.2ad 74.3±29.3abc <0.001 <0.001 0.739 
 Males 96.6±30.3 102.4±27.9 96.8±30.1 93.4±28.7 84.5±35.1    
 Females 73.3±20.9 78.7±22.9 72.8±19.5 71.9±18.6 65.5±19.5    
Fat  All 34.2±6.3 33.8±6.1 34.4±6.0 34±6.4 34.9±6.9 0.04 0.367 0.291 
(% Energy Intake) Males 33.5±6.4 32.7±6.2 33.8±5.8 34±6.8 34.7±7.3    
 Females 34.9±6.1 35.0±5.7 34.9±6.1 35±6.1 35.1±6.6    
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  All Ages 18-35 y 36-50 y 51-64 y ≥65 y  P Value  
  mean±SD mean±SD mean±SD mean±SD mean±SD Gender Age GxA 
Energy intake (kcal/kg/day) All 30.7±7.6 34.0±8.1bcd 29.8±6.3ad 28.8±6.2a 27.0±7.6ab <0.001 <0.001 0.571 
 Males 32.6±7.6 35.8±7.7 31.4±6.1 30.0±6.2 28.6±7.7    
 Females 28.9±7.3 31.8±8.0 28.3±6.1 27.7±6.1 25.8±7.3    
Protein (g/kg/day) All 1.23±0.35 1.32±0.40bcd 1.21±0.31a 1.18±0.30a 1.15±0.34a <0.001 <0.001 0.01 
 Males 1.31±0.36 1.43±0.42 1.28±0.27 1.20±0.30 1.16±0.32    
 Females 1.16±0.33 1.18±0.33 1.15±0.33 1.15±0.31 1.13±0.35    
Carbohydrate (g/kg/day) All 3.49±0.98 3.78±1.01bcd 3.39±0.92a 3.35±0.92a 3.16±0.94a <0.001 <0.001 0.86 
 Males 3.65±1.03 3.93±1.03 3.53±1.01 3.46±0.93 3.29±1.00    
 Females 3.34±0.91 3.59±0.95 3.27±0.81 3.25±0.91 3.06±0.89    
Fat (g/kg/day) All 1.17±0.37 1.28±0.37bcd 1.14±0.32a 1.09±0.34a 1.06±0.43a 0.001 <0.001 0.944 
 Males 1.22±0.39 1.31±0.38 1.19±0.34 1.13±0.36 1.12±0.47    
 Females 1.13±0.35 1.24±0.37 1.10±0.31 1.06±0.31 1.01±0.39    
Table 4.3: Overview of energy and macronutrient intake relative to body mass (grams per kilogram body mass) for all participants, across genders and age groups.  Values are 
expressed as mean ± standard deviation. n =964 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=356; 279;185;144]; males, n=475 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=195; 128; 88; 64]; females, n=489 
[18-35 y; 36-50 y; 51-64 y; ≥65 y, n=161; 151; 97; 80]. A two-way ANOVA was performed (Gender*Age). When P<0.05, post-hoc analysis with Bonferroni’s adjustment was used to determine where 
differences existed between age groups. Difference existing between age groups is indicated by: a P<0.05 vs. 18-35 years; by b P<0.05 vs. 36-50 years; c P<0.05 vs. 51-64 years; d P<0.05 vs. ≥65 
years plus.   
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  All Ages 18-35 y 36-50 y 51-64 y ≥65 y  P Value  
  mean±SD mean±SD mean±SD mean±SD mean±SD Gender Age GxA 
PDS (20g)* All 1.64±0.57 1.73±0.60cd 1.64±0.57d 1.61±0.51ad 1.45±0.51abc <0.001 <0.001 0.003 
 Males 1.88±0.56 2.01±0.55 1.91±0.54 1.79±0.51 1.62±0.56    
 Females 1.39±0.47 1.40±0.48 1.41±0.49 1.45±0.46 1.30±0.41    
PDS (30g)* All 1.08±0.51 1.21±0.57bcd 1.05±0.51a 0.98±0.43a 0.96±0.42a <0.001 <0.001 0.002 
 Males 1.34±0.49 1.48±0.52 1.35±0.47 1.21±0.38 1.13±0.45    
 Females 0.82±0.39 0.87±0.42 0.79±0.38 0.78±0.37 0.81±0.33    
PDS All 1.81±0.56 1.86±0.55 1.81±0.54 1.76±0.56 1.73±0.60 0.02 0.105 0.057 
(0.24g/kg)** Males 1.89±0.54 1.97±0.55 1.91±0.50 1.75±0.50 1.77±0.59    
 Females 1.73±0.57 1.74±0.53 1.72±0.56 1.78±0.61 1.70±0.61    
PDS All 1.47±0.52 1.55±0.53cd 1.45±0.50 1.42±0.49a 1.39±0.53a <0.001 0.005 0.015 
(0.3g/kg)** Males 1.56±0.51 1.67±0.52 1.55±0.46 1.42±0.44 1.41±0.53    
 Females 1.39±0.51 1.41±0.49 1.37±0.51 1.41±0.53 1.37±0.52    
PDS All 1.07±0.47 1.19±0.51bcd 1.02±0.44a 0.98±0.41a 0.98±0.43a <0.001 <0.001 0.493 
(0.4g/kg)** Males 1.17±0.46 1.28±0.52 1.15±0.40 1.05±0.39 1.05±0.41    
 Females 0.97±0.45 1.07±0.47 0.91±0.45 0.92±0.42 0.93±0.43    
Table 4.4: Protein Distribution Scores (PDS) for all participants, across genders and age groups. Values are expressed as mean ± standard deviation. PDS20 and PDS30 represent the 
number of eating occasions per day containing over 20g and 30g of protein, averaged across the 4 days. PDS0.24g/kg, PDS0.3g/kg, PDS0.4g/kg represent the number of eating occasions per day containing 
over the 0.24g/kg, 0.3g/kg and 0.4g/kg body mass of protein, averaged over the 4 days. *n values, total populations, n =1051 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=377; 308; 204; 162]; males, 
n=523 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=207; 143; 98; 75]; females, n=528 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=170; 165; 106; 87]. **n values, total populations, n =964 [18-35 y; 36-50 y; 
51-64 y; ≥65 y, n=356; 279;185;144]; males, n=475 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=195; 128; 88; 64]; females, n=489 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=161; 151; 97; 80]. A two-way 
ANOVA was performed (Gender*Age). When P<0.05, post-hoc analysis with Bonferroni’s adjustment was used to determine where differences existed between age groups. Difference existing 
between age groups is indicated by: a P<0.05 vs. 18-35 years; by b P<0.05 vs. 36-50 years; c P<0.05 vs. 51-64 years; d P<0.05 vs. ≥65 years plus.    
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Figure 4.1: Total protein intake at each eating occasion in males and females aged 18-35 years (A), 36-50 years (B), 51-64 years (C) and over 65 years (D). Values are expressed as 
mean ± standard deviation. 
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Table 4.5: Percentage (%) and total (g) contribution of animal and plant protein to total protein intake, and percentage contribution (%) of animal and plant foods to total 
energy intake, for all participants, across genders and age groups. Values are expressed as mean ± standard deviation. n =1051 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=377; 308; 204; 162]; 
males, n=523 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=207; 143; 98; 75]; females, n=528 [18-35 y; 36-50 y; 51-64 y; ≥65 y, n=170; 165; 106; 87].  A two-way ANOVA was performed (Gender*Age). 
When P<0.05, post-hoc analysis with Bonferroni’s adjustment was used to determine where differences existed between age groups. Difference existing between age groups is indicated by: a P<0.05 
vs. 18-35 years; by b P<0.05 vs. 36-50 years; c P<0.05 vs. 51-64 years; d P<0.05 vs. ≥65 years plus.    
  All Ages 18-35 y 36-50 y 51-64 y 65 y  P Value  
  mean±SD mean±SD mean±SD mean±SD mean±SD Gender Age GxA 
Percentage Protein  Animal Protein (%)         
Contribution All 63±11 63±11d 63±11d 63±11d 66±9 0.013 0.012 0.303 
 Males 64±10 64±11 65±10 63±10 65±8    
 Females 62±11 61±12 61±12 62±11 66±9    
 Plant Protein (%)         
 All 37±11 37±11d 37±11d 37±11d 34±9 0.013 0.012 0.303 
 Males 36±10 36±11 35±10 37±10 35±8    
 Females 38±11 39±12 39±12 38±11 34±9    
Total Daily Protein  Animal Protein (g)         
Intake All 57.9±23 61.2±27.1cd 57.2±22.2 56.0±18.7a 53.9±17.3a <0.001 0.021 <0.001 
 Males 68.3±24.5 73.2±28.1 68.8±23.2 64.0±18.9 59.5±19.3    
 Females 47.6±15.5 46.5±16.5 47.1±15.4 48.7±15.3 49.1±13.9    
 Plant Protein (g)         
 All 32.6±12.4 34.9±13.7bd 32.4±12.9ad 32.4±10.2d 27.7±9.2abc <0.001 <0.001 0.042 
 Males 36.8±11.9 39.8±12.4 36.2±11.5 36.0±10.9 31.0±10.0    
 Females 28.4±11.4 28.9±12.8 29.2±13.1 29.1±8.2 25.0±7.3    
Percentage Total Energy Animal-Based  Foods (%)         
Contribution All 36±10 33±9bcd 36±10ad 36±10ad 41±10abc 0.008 <0.001 0.313 
 Males 37±10 35±10 37±10 37±10 41±10    
 Females 35±10 32±8 34±10 35±10 42±10    
 Plant-Based Foods (%)         
 All 64±10 67±9bcd 64±10ad 64±10ad 59±10abc 0.008 <0.001 0.313 
 Males 63±10 65±10 63±10 63±10 59±10    
 Females 65±10 68±8 66±10 65±10 58±10    
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Figure 4.2: Percentage contribution of food groups to total protein intake in males and females aged 18-35 years (A), 36-50 years (B), 51-64 years (C) and over ≥65 years (D). 
Values are expressed as mean ± standard deviation. 
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4.4 Discussion  
The age-related decline in muscle mass and function is a fundamental threat to maintaining independence 
and a good quality of life throughout the lifespan (Fielding et al., 2011; Janssen, Heymsfield and Ross, 2002). 
Dietary intake, and in particular protein intake, has been identified as a preventative and potential treatment in 
combatting the age-related decline in muscle mass and function (Norton et al., 2016; Daly et al., 2014; Liu and 
Latham, 2010; Onambélé-Pearson, Breen and Stewart, 2010). The aim of the present study was to identify age 
and gender related patterns in protein intake, distribution, and sources in Irish adults, thereby identifying 
areas where nutrition may improve the outcome of those at risk of declining muscle mass with age. This 
analysis identified that total protein intake, and protein relative to body mass is generally lower with increasing 
age, with males typically consuming more protein than females, and greater difference apparent between age 
groups for males. The average number of meals per day reaching the purported per meal protein threshold to 
maximise MPS is typically lower with increasing age, with males typically achieving a higher PDS score 
compared to females. Protein distribution follows a skewed pattern across each age group, in which dinner 
represents the highest per meal protein intake, followed by lunch and breakfast.  
This analysis identified that total and relative protein intake are lower in older adults, compared to younger 
adults, in which adults aged 18-35 y typically consume 96±3g/1.32±0.40g/kg per day, while adults aged 
≥65 y consume significantly less daily protein (82±22g/1.15±0.34g/kg). Males typically consume more 
protein than females (105±27g/1.31±0.36g/kg vs. 76±19g/1.16±0.33g/kg, respectively), as per table 4.2. 
However, there was no significant difference between intakes for total protein intake in adults aged 35-50 y 
and 51-64 y, suggesting that adults in these age groups tend to eat the same amount of protein. This same 
trend occurred for total energy, carbohydrates and macronutrients, suggesting that adults between the ages of 
35 and 64 y show no obvious difference in overall energy and macronutrient intake. At the age of ≥65 y, there 
is a noticeably lower total energy and macronutrient intake compared to adults aged 35-51 y.  
Of note, there was gender x age interaction effect for total and body mass relative protein intake, in which 
males tend to have consistent differences in protein intake with each increment in age category, while there 
was no difference in protein intake between females aged 35-50 y and 51-64 y. This absence of a difference 
may be related to an increase in dairy intake, which is often promoted by healthcare practitioners as females’ 
approach peri-menopausal age category, as a preventative for osteoporosis (Munger, Cerhan and Chiu, 1999). 
However, dairy intake shows an arguably negligible difference across ages in males (~13% from age 18-35 y 
to 51-64 y), while females aged 51-64 y have ~5% greater dairy intake compared to females aged 18-35 y.  
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The National Health and Nutrition Examination Survey (NHANES) 2003-3004 from the USA reported a greater 
difference in protein intake between young and old, in which total protein intake in young adults aged 19-30 
years was 91±22g/day/1.3g±0.4g/kg (n=874), and 66±17g/day/1.0±0.3g/kg in older adults aged >71 
years (n=818) (Fulgoni, 2008). A survey in Dutch community-dwelling older adults aged 77±5 y (n=739), 
reported habitual dietary intake was 71g/day (Tieland et al., 2015), which is similar to our findings. Similar to 
the present findings, in an Italian national food consumption survey, Sette et al., (2011) reported that males 
aged 18-65 y consumed 93±25 protein per day, and females consumed 76±20 protein per day. From 
interpreting the present analysis, if Irish adults, in particularly males who show greater differences in protein 
intake across ages, could maintain the protein intake at ages 35-50 y and 51-64 y, into the latter years of life, 
they may have a decreased risk of age-related decline in muscle mass, thereby ageing with a better quality of 
life (Bauer et al., 2013). 
There was a significantly higher percentage contribution of protein to total energy intake with increasing age, 
since energy intake was lower with an increase in age, both of which have been reported in Spanish food 
consumption survey (Ruiz et al., 2015). The reasons for this reduction in energy intake in older adults is 
considered related to the decrease in appetite with age (Morley, 2001). Additional contributors to this decrease 
in energy intake in older adults may also be the financial cost of these more nutrient-dense foods, difficulty 
chewing fibrous foods, perceived food intolerances and fear of eating too much fat and cholesterol in foods 
(Bauer et al., 2013; Malafarina et al., 2013; Chernoff, 2004). Of note, Tieland et al., (2015) reported that 
energy intake is positively correlated to protein intake in older adults, and therefore daily energy intake is an 
important factor in determining habitual protein intake.  
The way in which protein is distributed over the course of a typical day dictates the cumulative rates of MPS 
(Layman et al., 2015; Paddon-Jones et al., 2015; Mamerow et al., 2014; Areta et al., 2013). Furthermore, there 
is an increased recognition of importance of per meal protein recommendations, with 20-30g of high quality 
protein, or 0.24-0.4g/kg protein per meal, seen as the amount needed to maximise MPS in young (Witard et 
al., 2014;  Moore et al., 2009) and old (Moore et al., 2015; Symons et al., 2009). The general pattern of protein 
intake across the total population was ‘skewed’, in which the majority of protein was eaten at dinner (15±10g, 
30±15 and 44±17g at breakfast, lunch and dinner, for total population, respectively), as per figure 4.1. This 
skewed pattern of protein intake has been reported elsewhere (Cardon-Thomas et al., 2017; Tieland et al., 
2015; Almoosawi et al., 2013; Bollwein et al., 2013; Ruiz Valenzuela et al., 2013). In particular, in adults aged 
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≥65 y, breakfast, lunch and dinner accounted for 15%, 29% and 37% of average daily protein intake, which is 
similar to finding by Tieland et al., (2015) in a similar aged cohort, in which these meals accounted for 15%–
21%, 26%–32% and 38%–44% of total protein intake respectively. While similar in protein distribution, per 
meal protein intake in the present study is more optimal, as both lunch and dinner potential meet the 20-30g 
meal threshold (15±7g, 29±14g and 37±16g at breakfast, lunch and dinner, respectively), due to a higher 
overall protein intake compared to findings by Tieland et al. (2015). However, inevitably due to the large 
variability in protein intake for lunch and dinner, there are people who still fell below these protein thresholds 
for those meal times. Regardless, breakfast in the present cohort was representative of a suboptimal per meal 
protein intake, which is a worthy consideration when designing strategies to minimise the decline in muscle 
mass with age. Indeed, a nutrition intervention targeting supplemental protein intake at breakfast and lunch 
(0.17g/kg protein/~12g protein per meal) was successful in increasing in LBM over 24 weeks in Irish adults 
aged 50-70 y (Norton et al., 2016).  
 
With 20-30g of protein representing the total protein meal threshold for maximising MPS in young and old 
(Witard et al., 2014;  Moore et al., 2009; Symons et al., 2009), we sought to determine the age and gender 
patterns for the number of meals per day reaching this meal threshold, averaged over 4 days. PDS20 and PDS30 
(the average number of meals per day reaching the 20g or 30g per day) was generally lower with increasing 
age, which was most notable between 51-64 y and ≥65 y for PDS20 (1.61±0.5 vs. 1.45±0.51, respectively) 
and 18-35 y and 35-50 y for PDS30 (1.21±0.6 vs. 1.05±0.5). Adults aged 18-35 y consumed 1.73±0.60 meals 
containing 20g, while adults aged ≥65 y consumed a smaller amount of meals providing ≥20g protein 
(1.45±0.51). Mirroring the trend for daily protein intake, there were greater differences in PDS20, PDS30 and 
PDS0.3g/kg between age groups for males compared to females, who showed smaller differences between age 
groups.  
Per meal protein intake was also determined relative to body mass, in which the number of meals reaching 
0.24g, 0.3g and 0.4g/kg per meal protein was determined. This body mass relative protein intake has been 
reported as the per meal protein requirement to elicit a maximal/near maximal stimulation of MPS (Moore et 
al., 2015).  There was no difference in the number of meals reaching 0.24g/kg protein with age. At the 0.3g/kg 
per meal threshold, older adults consumed less meals at this threshold, compared to young, in which adults 
aged 18-35 y consumed 1.55±0.53 meals per day containing ≥0.3g/kg protein, while in adults aged ≥65 y a 
significantly smaller amount of meals ≥0.3g/kg protein (1.39±0.53). The same age and gender trend 
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occurred for meals reaching 0.4g/kg protein, in which older adults aged ≥65 y, on average, did not consume 
any meals reaching this threshold (0.98±0.43). In contrast to the present findings, Cardon-Thomas et al., 
(2017) reported that older adults meeting the 0.4g/kg protein per meal threshold for eating occasion (EO) 1, 2 
and 3 was 3%, 42% and 68%. Cardon-Thomas et al., (2017), in community dwelling adults aged >70 y in 
United Kingdom, reported that 8% of participants did not meet the threshold for any meals, 71% met the 
threshold for one meal, 21% met the threshold for two meals and no participant consumed ≥0.4g/kg 
threshold for all 3 meals. These are different protein distribution trends to that found in the present analysis, 
however, Cardon-Thomas et al., (2017) assessed a cohort of n=38, while the present analysis of ≥65 y was 
n=144, and was a nationally representative survey, therefore the dietary intakes reported by Cardon-Thomas 
et al., (2017) is less likely to be representative of intakes for the entire older population. The habitual protein 
distribution patterns found in the present study are representative of a suboptimal protein intake at given 
meals for maximising MPS, while meals that exceed the optimal protein intake may not cause an additive 
anabolic response (Moore et al. 2009; Areta. 2013). This has led to the hypothesis that spreading daily protein 
intake evenly throughout the day can result in a greater cumulative anabolic response compared to a skewed 
pattern of protein intake (Layman et al., 2015; Bauer et al., 2013).  
 
The source of protein (animal vs. plant) was a focus in the present study, since animal-based proteins have 
been reported to elicit a greater postprandial increase in MPS Gorissen et al., 2016; Yang et al., 2012a; 2012b; 
Tang et al., 2009; Wilkinson et al., 2007). In the present analysis, protein is derived predominantly from 
animal sources (63.1±10.8%, animal protein; 36.9±10.8%, plant protein in total population) (See table 4.5), 
with meat and dairy having the largest percentage contribution to total protein intake across both sexes and all 
age groups (39.8±14.5% and 15.0±8.5%, respectively, as per figure 4.1). This is similar to finding by Tieland 
et al., (2015) in a Dutch population, in which 60% of dietary protein consumed originated from animal 
sources, with meat and dairy as dominant sources. Similarly, Sahni et al. (2015) reported that ~70% protein 
intake from animal protein and ~30% from plant protein, in adults aged 29-86 y in the USA.  
When assessed on a per meal basis, dinner has the greatest animal protein contribution (72±16% animal 
protein), while lunch is lower (63±19% animal protein) and breakfast is predominantly plant protein 
(43±22% animal protein), as per figure 4.2. This is similar to finding by Tieland et al. (2015), in which >70% 
of the protein intake at dinner originated from animal protein, whilst lunch and breakfast was made up of 
~63% and <50% animal protein, respectively.  Similarly, in Dutch athletes aged 18-65 years, Gillen et al., 
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(2017) reported the contribution of animal-based protein was greatest at dinner (70%), while animal-based 
protein contributed to 50% of protein intake at breakfast and lunch. Since a large proportion of protein at these 
meal times is derived from plant-based protein sources, these meal times, particularly breakfast, are likely to 
contain a lower EAA content (USDA National Nutrient Database for Standard Reference, 2009). These meals 
may therefore signify a missed opportunity to maximise postprandial anabolism for that meal time (Mamerow 
et al., 2014; Areta et al., 2013). Emphasising adequate, high quality protein at meal times, particularly at 
breakfast and lunch where animal protein intake is reported to be lowest, is a necessary consideration when 
applying the per meal protein targets in practice, particularly in older populations who are most at risk of age-
related decline in muscle mass (Gorissen and Witard, 2018; van Vliet, Burd and van Loon, 2015).  However, 
these recommendations should be interpreted with caution and not taken out of a context that may 
compromise the overall health of an individual’s diet. Guidance towards better choices for protein at breakfast 
is imperative, particularly foods that are low in saturated fat, and/or high in polyunsaturated and 
monounsaturated fats should be emphasised. The consumption of highly processed meats, which are 
associated with an increased risk of heart disease, stroke, diabetes mellitus and cancers (Chan et al., 2011; 
Micha, Wallace and Mozaffarian, 2010) should continue to be discouraged. Before recommendations based on 
this analysis could be incorporated into a public health framework, intervention trials investigating the effects 
of increasing animal-based protein and/or protein at breakfast and/or lunch on changes in LBM and health 
markers is required. These interventions would need to be long in duration and place a large emphasis on 
changes in health markers over this time course.   
4.5 Conclusion 
Protein intake and the number of meals reaching the purported threshold for maximising postprandial 
anabolism is highest in young, lower with increasing age, and lowest in adults aged ≥65 y. Breakfast is the 
lowest total protein-containing main meal across all age categories. Furthermore, it is the lowest animal 
protein-containing main meal. Since both protein dose and protein source strongly dictate the postprandial 
anabolic response to a meal, breakfast may represent an opportunity for improving overall protein intake, and 
protein distribution. This is an important consideration for strategies that would target age-associated declines 
in skeletal muscle mass and function. 
  93 
Chapter 5 
5.0 The plasma leucine kinetics after an oral load using free leucine 
and microencapsulated leucine in young, healthy males 
 
Background: Amino acids (AAs) act as an anabolic stimulus, with leucine in particular playing a key role in initiating this 
anabolic response. Postprandial plasma leucine kinetics strongly influence rates of postprandial muscle protein synthesis 
(MPS). Microencapsulation is an emerging technology that has shown potential for the optimal delivery of drugs and 
nutrients, and may be used  for the microencapsulation of leucine to optimise postprandial leucine plasma kinetics.  
 
Objective: The aim of the present study is to investigate the plasma kinetics of leucine in response to the ingestion of 
leucine in its free form or in a novel microencapsulated form, in comparison to that of a maltodextrin control.  
 
Design: Ten healthy active males [age (26.4±4.1y)] visited the laboratory on five separate occasions, and were randomly 
assigned to one of the following five conditions, in a single-blind cross-over design; A bolus of 3g free leucine (BOLUS), 3g 
microencapsulated leucine (ME), 3g maltodextrin (CONTROL), 1.5g free leucine consumed at 0 min and 1.5g consumed 
at 120 min (PULSE), 1.5g microencapsulated leucine + 1.5g free leucine (ME+LEU) combined at 0 min. Blood samples 
were taken every 15 min in the first hour, and every half hour for the subsequent three hours.  
 
Data Analysis: Plasma AA concentrations were measured using high performance liquid chromatography. The 
difference from baseline over time and the difference between conditions, for plasma leucine, branched-chain amino 
acids (BCAAs), total AAs, essential amino acids (EAAs) and non-essential amino acids (NEAAs), was analysed using a two-
way (time x condition) repeated measures analysis of variance (ANOVA). Post-hoc analysis was performed using a repeated 
measures ANOVA and pairwise comparisons with Bonferroni’s adjustment. 
 
Results: BOLUS, plasma leucinemia peaked at 30 min at 542±83μM, which was significantly different from baseline 
(P<0.001), with an AUC of 32±7µM.240min-1, which significantly different from CONTROL (P<0.001). During ME, 
leucinemia peaked at 30 min, 212±38μM, which was significantly different from baseline (P=0.02), with an AUC of 6±3 
µM.240min-1. During PULSE, plasma leucinemia peaked from baseline at 30 min (325±72μM, P=0.001), trended 
towards baseline levels at 120 min (169±23.2μM) and peaked again at 273±81μM 30 min after the second leucine 
ingestion, which was significantly different from baseline (P=0.023). PULSE AUC was 24±7µM.240min-1, which was not 
significantly different from BOLUS AUC 32±7µM.240min-1, P=0.116).  
 
Conclusion: The present form of microencapsulated leucine shows reduced bioavailability when compared to free 
leucine in BOLUS and PULSE conditions. The peak postprandial leucinemia achieved with ingestion of 3g free leucine is 
significantly greater than that of whole protein, such as egg and whey, providing the same dose of leucine, reported in the 
literature. Since plasma leucine concentration is a key regulator of activating MPS, dietary supplementation with free form 
leucine, or the enrichment of lower leucine meals, may show promise as a strategy for optimising the plasma kinetics 
required to maximise MPS.  
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5.1 Introduction 
Skeletal muscle accretion and function is dictated by the dynamic balance between MPS and muscle protein 
breakdown (MPB). After feeding, when MPS exceeds MPB, an overall positive net protein balance is achieved, 
which enables the maintenance and growth of skeletal muscle (Atherton and Smith, 2012). Nutrition 
interventions to maximise this stimulation of MPS throughout the day may have a significant positive effect on 
recovery and adaptation in athletic training, and also slowing the rate of age-related decline of skeletal muscle 
mass in elderly populations. Muscle mass and function, is not only seen as a vital component of athletic 
performance, but its maintenance is fundamental to healthy ageing and correlates with longevity and 
enhanced quality of life (Kreider and Campbell, 2009; Paddon-Jones and Rasmussen, 2009). 
	
Amino acids (AAs) act as an anabolic stimulus, with leucine in particular playing a key role in initiating this 
anabolic response. Protein ingestion results in the activation of signalling cascades that stimulate MPS, and 
the resultant increases in rates of MPS occurs in a dose-dependent manner to the quantity of protein ingested 
(Witard et al., 2014; Moore et al., 2009). However, MPS exhibits an upper limit of activation in response to the 
magnitude and duration of plasma leucine elevation, and after this threshold, MPS is not further stimulated 
(Witard et al., 2014; Glynn et al., 2010; Moore et al., 2009; Cuthbertson, 2004). The magnitude of MPS shows 
a dose-dependent response to the ingestion of 0g, 5g, 10g, 20g and 40g of protein, with fractional synthetic 
rate (FSR) reaching an upper limit in response to 20g protein. At this upper limit, whole body leucine oxidation 
increases markedly, suggesting that the leucine content of 20g protein is sufficient to stimulate MPS 
maximally, and leucine provided in excess of this is simply oxidized (Witard et al., 2014; Moore et al., 2009). 
Furthermore, muscle exhibits a refractory response to sustained elevation of plasma aminoacidemia (Atherton 
et al. 2010a; Bohé et al., 2001). This refractory response was first described when despite AAs remaining 
elevated during a 6 hour infusion and a sustained elevation in plasma leucine concentration, rates of MPS 
returned to baseline 2 hours after the beginning of the infusion (Bohé et al., 2001). Similarly, a large bolus 
meal resulted in an increased magnitude of MPS at 45-90 min, but returned to baseline shortly thereafter, 
despite plasma AA concentrations remaining elevated (Atherton et al. 2010a). This refractory response has 
been termed the ‘muscle full’ phenomenon (Mitchell et al., 2015b).  
 
Several studies have pointed to the notion that a prolonged low amplitude elevation in postprandial 
leucinemia may facilitate an extended MPS response after meal ingestion (Gorissen et al., 2016; Mitchell et al., 
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2015; Areta et al., 2013). Gorissen et al., (2016) demonstrated that both 35g casein and 35g wheat protein 
ingestion resulted in a similar peak leucinemia, and at the same time, but resulted in a marked difference in 
postprandial MPS rates. This would suggest that the kinetics of plasma leucine, and not simply the magnitude 
and time to reach peak concentration of plasma leucine has an effect on postprandial MPS rates. In support, 
the ingestion of 60g wheat protein had a similar peak leucinemia to 35g casein, but a more prolonged 
elevation in plasma leucine, resulting in postprandial MPS rates similar to that of 35g casein (Gorissen et al., 
2016). Therefore, prolonging this lower amplitude postprandial plasma concentration of AAs may offer a 
means of overcoming or minimising the refractory response that muscle exhibits to sustained elevation of AAs. 
The anabolic potential of a meal may therefore be optimised by appropriate manipulation of postprandial AA 
plasma kinetics. These findings provide rationale for the use of a targeted-release form of leucine that would 
be capable of achieving the prolonged low amplitude leucinemia. Interestingly, microencapsulation is an 
emerging technology that has shown potential for the optimal delivery of drugs and nutrients ( Dias, Ferreira 
and Barreiro, 2015; Champagne and Fustier, 2007). This technique is based on the immobilization of a core 
ingredient, in this case leucine, in a miniature-sealed capsule which maintains structural integrity until 
degradation and release of the ingredient at an appropriate time or site in the body (Champagne and Fustier, 
2007). Furthermore, through appropriate design, the degradation and release of the leucine can be 
manipulated to create the desired plasma kinetics. We propose that a targeted-release form of leucine can 
cause an initial rise in leucinemia, with a more prolonged sustained low amplitude leucinemia, compared to 
that of 3g free leucine. Such a technology has recently been developed (Brodkorb and Doherty, 2015) and is 
the subject of investigation in this chapter. The present study will investigate the plasma kinetics of leucine in 
response to consuming leucine in either its free form or in a novel microencapsulated form, in comparison to 
that of a maltodextrin control. 
5.2 Methods 
5.2.1 Participants  
The experimental procedure was approved by University College Dublin (UCD) Research Ethics Committee in 
accordance with the Declaration of Helsinki. All participants gave informed written consent before participating 
in the study. Participants were recruited through information leaflets and social media posts targeted at 
university students, seeking out healthy active males, between 18-35 years of age, participating in physical 
activity ≥3 times per week.  
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5.2.1 Materials  
The microencapsulation of leucine was prepared as per section 3.1.  
5.2.2 Method 
Ten healthy active males, [age (26.4±4.1y), height (1.76±0.06m), body mass (76.7±6.9kg), BMI 
(24.4±1.6kg/m2), body fat percentage (15.4±4.2%), body fat mass (11.2±3.1kg), lean body mass 
(61.8±6.9kg)], visited the laboratory in UCD on five separate occasions, with each visit separated by 7 days. 
Participants were randomly assigned to one of the following five conditions, in a cross-over design (See figure 
5.1); 
 
• A bolus of 3g free leucine (BOLUS) 
• 3g microencapsulated targeted-release leucine (ME) 
• 3g maltodextrin (CONTROL) 
• 1.5g free leucine consumed at 0 hours and 1.5g consumed 2 hours later (PULSE) 
• 1.5g microencapsulated targeted-release leucine + 1.5g free leucine (ME +LEU) 
The rationale for using 3g of leucine in BOLUS and ME conditions is that 3g leucine and the equivalent of 3g 
leucine in a whole protein has been shown to maximise the stimulation of MPS in healthy young males, with 
greater doses showing no increase in the magnitude of stimulation (Witard et al., 2014; Glynn et al., 2010; 
Moore et al., 2009; Cuthbertson, 2004). The rationale for using 1.5g of free leucine followed by the same dose 
2 hours later in PULSE condition is to mimic the desired sustained release plasma kinetics of the ME leucine. 
The rationale for using ME+LEU condition, in which 1.5g microencapsulated targeted-release leucine is 
provided with 1.5g free leucine in one bolus, is to observe the plasma kinetics when both supplements are 
combined, which represents a similar situation as enriching a protein meal/beverage with additional ME 
leucine.  
During each visit, participants arrived at the laboratory after an overnight fast (approximately 8 hours). A 
cannula was inserted in the antecubital vein and the line was kept patent with saline. Blood samples (~4ml) 
were drawn into a vaccutainers containing lithium heparin (BD Vaccutainers, Heparin Tubes), inverted eight to 
ten times and placed on ice. The blood was centrifuged at 4000 g for 10 min at 4°C and the upper layer of 
plasma was transferred into three separate 1.5ml tubes and stored at -80°C until further analysis. Participants 
ingested one of the above conditions, dissolved in a total of 250ml of water. Irrespective of the condition, 
participants consumed two white opaque bottles at 0 min and 120 min, as per figure 1, to maintain the single-
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blind design. Blood samples were taken at rest prior to the first drink (0 min), every 15 min in the first hour, 
and every half hour for the next three hours, as per Figure 5.1.  
 
Figure 5.1: Overview of ingestion protocol of five experimental conditions. Blood samples taken every 15 min 
for the first hour and every 30 min for the subsequent 3 hours.  
 
Participants visited the lab on four subsequent occasions, with the same testing procedure being carried out, 
with only the supplement condition being different between trials.  
 
On the first visit, participants provided a two-day food diary, detailing their dietary habits over the two days 
preceding their first laboratory visit. Participants were provided a copy of this diary and asked to repeat the 
same two-day dietary intake prior to the subsequent four visits to the laboratory.  
5.2.3 Data Analysis  
High Performance Liquid Chromatography (HPLC) was carried as per Section 3.3.  
5.2.4 Statistical Analysis 
Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS)(IBM SPSS Statistics 
Version 23). Plasma leucine, branched chain amino acids (BCAAs), total amino acids (AAs), essential amino 
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acids (EAAs) and non-essential amino acids (NEAAs) are presented as mean±SD. The difference from baseline 
over time and the difference between conditions was analysed using a two-way (time x condition) repeated 
measures ANOVA. When a main effect for time was indicated, post-hoc analysis within each condition was 
performed using one-way repeated measures ANOVA, and pairwise comparisons to 0 min with Dunnett’s 
adjustment. When a main effect for condition was indicated, post-hoc analysis between condition was 
performed using one-way repeated measures ANOVA, and pairwise comparisons with Bonferroni’s adjustment. 
The area under the curve (AUC) above baseline (ΔAUC240) for each variable was calculated by trapezoidal 
integration, and is presented as mean±SD. The difference in AUC between conditions was analysed using a 
one-way repeated measures ANOVA with post-hoc pairwise comparisons using Bonferroni’s adjustment. 
Statistical significance was accepted at P<0.05.  
5.3 Results  
5.3.1 Plasma Leucine   
Table 5.1 and figure 5.2 represents plasma leucine concentrations for each condition over 4 h. For plasma 
leucine there was an interaction effect, and main effect for both condition and time (P<0.001 for all). During 
BOLUS, plasma leucine peaked at 30 min at 542±83µM, which was significantly different from baseline 
(P<0.001). During ME, leucine peaked at 30 min, 212±38µM, which was significantly different from baseline 
(P=0.020). During PULSE, plasma leucinemia peaked from baseline at 30 min (325±72µM, P=0.001), 
trended towards baseline levels at 120 min (169±23.2µM) and peaked again at 273±81µM 30 min after the 
second leucine ingestion, which was significantly different from baseline (P=0.023). Plasma leucine remained 
unchanged during CONTROL, in which the peak value, 118±7µM, did not differ significantly from baseline 
(P>0.99). During ME+LEU (1.5g microencapsulated leucine with 1.5g free leucine), leucinemia peaked at 
363±77µM, which was not significantly different from 1.5g LEU + 1.5g LEU, the condition in which 1.5g of 
leucine was ingested alone at 0 min (P=0.695). At 30 min, plasma leucine BOLUS, ME, PULSE and ME+LEU 
was significantly greater than CONTROL (P<0.001 for all). BOLUS AUC was 32±7µM.240min-1, which 
significantly greater than CONTROL (-1±1µM.240min-1,P<0.001) (See figure 5.3A). PULSE AUC was 
24±7µM.240min-1, which was not significantly different from BOLUS AUC (P=0.116). ME had an AUC of 
6±3µM.240min-1, which was significantly greater than CONTROL AUC (P=0.001). The AUC for ME+LEU was 
24±7µM.240min-1, which was not significantly different to 1.5g LEU + 1.5g LEU (15±7µM.240min-
1
,P=0.06).  
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5.3.2 Plasma BCAA 
Results for BCAA plasma kinetics are reported in table 5.2. For plasma BCAA there was an interaction effect, 
and main effect for both condition and time (P<0.001 for all). For BOLUS, plasma BCAA peaked at 30 min 
(808±94µM), which was significantly different from baseline (P<0.001). For ME, plasma BCAA peaked at 30 
min (523±63µM), which was significantly different from baseline (P=0.001). Plasma BCAA peaked in PULSE 
and ME+LEU at 30 min (592±86µM and 640±101µM, respectively, both of which were significantly greater 
than baseline (P<0.002 for both). At 30 min, plasma BCAA was significantly greater in BOLUS, ME, PULSE and 
ME+LEU compared to CONTROL (P<0.001 for all). BCAA AUC is presented in figure 5.3B. BCAA AUC for 
BOLUS, was 16±3µM.240min-1, which was significantly greater than ME and CONTROL (3±1 and -5±1 
µM.240min-1, P=0.003, P=0.002, respectively). AUC for PULSE was 10±3µM.240min-1, which was 
significantly greater than CONTROL (P=0.02).  
5.3.3 Plasma AA, EAA and NEAA  
Results for plasma AAs, EAAs and NEAAs plasma kinetics are presented in table 5.3, 5.4 and 5.5, 
respectively. For plasma AAs, there was an interaction effect (P<0.001), and main effect for condition 
(P=0.025) and time (P<0.001). For plasma EAAs there was an interaction effect, and main effect for both 
condition and time (P<0.001 for all). For NEAAs there was an interaction effect (P=0.002), a main effect for 
time (P=0.043), but no main effect for condition (P=0.72). However, on further post-hoc analysis, no 
difference over time were apparent for plasma NEAAs.  No significant difference existed between condition, for 
total AAs AUC, EAAs AUC or NEAAs AUC (P>0.05 for all).  
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Figure 5.2: Plasma leucine concentration across each condition, expressed in µM. Values are Mean±SD 
BOLUS, 3g leucine; ME, 3g microencapsulated leucine; CONTROL, 3g maltodextrin; PULSE, 1.5g leucine ingested at 0 
hours and 2 hours; ME+LEU, 1.5g microencapsulated leucine and 1.5g leucine. Significance markers are not included on 
the graph due to the complexity of the comparisons, but are described in detail in the main text. 
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Table 5.1: Plasma leucine concentrations across each condition; expressed in µM. Values are Mean±SD. A two-way repeated measures ANOVA was performed (Condition*Time). When 
P<0.05, post-hoc one-way repeated measures ANOVA were used to determine where differences existed between time-points and between conditions. Difference existing from baseline is indicated by 
a P<0.05 vs. 0 min and differences existing between conditions is indicated by b P<0.05 vs. CONTROL.  
Time (min) BOLUS ME CONTROL PULSE ME + LEU 
0 123 ± 12 124 ± 12 118 ± 12 124 ± 18 129 ± 26 
15 483 ± 150 ab 188 ± 34  ab 118 ± 12 273 ± 89 ab 341 ± 102 b 
30 542 ± 84  ab 212 ± 39 ab 114 ± 15 325 ± 73 ab 363 ± 77 ab 
45 450 ± 111 ab  184 ± 29  ab 107 ± 12 263 ± 49 ab 277 ± 56 ab 
60 335 ± 62  ab 161 ± 27  ab 107 ± 11 221 ± 33 ab 225 ± 42 ab 
90 250 ± 47  ab 150 ± 23  ab 110 ± 13 185 ± 21 ab 186 ± 35 ab 
120 208 ± 39 ab 141 ± 18 b 109 ± 8 169 ± 23 ab 171 ± 33 ab 
150 191 ± 37 ab 134 ± 19 114 ± 17 273 ± 81 ab 149 ± 26 
180 162 ± 34 b 132 ± 17 b 112 ± 7 252 ± 30 ab 145 ± 24 b 
210 155 ± 28 b 130 ± 15 b 112 ± 11 211 ± 34 ab 141 ± 24 b 
240 145 ± 22 b 126 ± 16 114 ± 11 187 ± 30 ab 142 ± 24 b 
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Time (min) BOLUS ME CONTROL PULSE ME + LEU 
0 394 ± 31 400 ± 43 375 ± 43 397 ± 64 412 ± 75 
15 768 ± 150 ab 479 ± 55 ab 375 ± 41 544 ± 111 ab 621 ± 121 b 
30 808 ± 94 ab 522 ± 62 ab 365 ± 49 592 ± 86 ab 640 ± 102 ab 
45 694 ± 154 ab 478 ± 48 ab 343 ± 39 510 ± 74 ab 536 ± 92 ab 
60 557 ± 98 ab 433 ± 62 b 345 ± 36 454 ± 63 b 459 ± 70 b 
90 447 ± 81 b 418 ± 60 354 ± 45 399 ± 54 401 ± 60 
120 388 ± 60 399 ± 51 345 ± 28 377 ± 56 383 ± 65 
150 386 ± 76 382 ± 48 361 ± 64 474 ± 96 345 ± 49 
180 332 ± 75 380 ± 46 348 ± 25 443 ± 49 345 ± 49 
210 326 ± 65 375 ± 36 347 ± 38 387 ± 57 339 ± 45 
240 316 ± 45 365 ± 39 352 ± 37 363 ± 56 346 ± 44 
Table 5.2: Plasma branched-chain amino acid concentrations across each condition; expressed in µM. Values are Mean±SD. A two-way repeated measures ANOVA was performed 
(Condition*Time). When P<0.05, post-hoc one-way repeated measures ANOVA were used to determine where differences existed between time-points and between conditions. Difference existing 
from baseline is indicated by a P<0.05 vs. 0 min and differences existing between conditions is indicated by b P<0.05 vs. CONTROL.   
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Time (min) BOLUS ME CONTROL PULSE ME + LEU 
0 2112 ± 159 2026 ± 156 2014 ± 204 2058 ± 223 2135 ± 312 
15 2573 ± 235 ab  2191 ± 225 b 2047 ± 198 2209 ± 226 a 2346 ± 320 a 
30 2578 ± 253 ab 2343 ± 281 ab 2001 ± 237 2316 ± 241 ab 2408 ± 353 ab 
45 2444 ± 259 b 2263 ± 284 1939 ± 235 2212 ± 220 b 2299 ± 326 b 
60 2285 ± 237 2114 ± 274 1949 ± 211 2158 ± 233 2159 ± 279 
90 2132 ± 245 2111 ± 253 2024 ± 265 2019 ± 177 2060 ± 221 
120 2064 ± 211 2035 ± 120 1975 ± 177 2016 ± 177 2119 ± 368 
150 2145 ± 188 2018 ± 156 2089 ± 267 2108 ± 282 1975 ± 276 
180 1985 ± 261 2054 ± 224 2009 ± 153 2084 ± 205 1998 ± 268 
210 2026 ± 242 2079 ± 234 1991 ± 236 1977 ± 191 2005 ± 267 
240 1994 ± 181 2008 ± 139 2013 ± 200 1995 ± 221 2066 ± 295 
Table 5.3: Plasma total amino acid concentrations across each condition, expressed in µM. Values are Mean±SD. A two-way repeated measures ANOVA was performed (Condition*Time). 
When P<0.05, post-hoc one-way repeated measures ANOVA were used to determine where differences existed between time-points and between conditions. Difference existing from baseline is 
indicated by a P<0.05 vs. 0 min and differences existing between conditions is indicated by b P<0.05 vs. CONTROL.   
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Time (min) BOLUS ME CONTROL PULSE ME + LEU 
0 890 ± 51 866 ± 55 840 ± 75 878 ± 116 919 ± 148 
15 1296 ± 157 ab 979 ± 87 ab 851 ± 89 1026 ± 131 a 1134 ± 168 ab 
30 1322 ± 126 ab 1056 ± 112 ab 830 ± 106 1082 ± 111 ab 1164 ± 167 ab 
45 1196 ± 190 ab 996 ± 90 ab 793 ± 82 995 ± 112 ab 1053 ± 163 ab 
60 1048 ± 145 b 917 ± 114 796 ± 77 935 ± 107 b 952 ± 125 b 
90 923 ± 139 904 ± 116 823 ± 96 859 ± 96 878 ± 102 
120 853 ± 103 865 ± 66 805 ± 67 840 ± 94 875 ± 160 
150 871 ± 128 845 ± 77 843 ± 122 927 ± 128 803 ± 109 
180 789 ± 143 850 ± 85 813 ± 53 900 ± 97 811 ± 108 
210 796 ± 126 852 ± 62 806 ± 91 821 ± 82 804 ± 91 
240 781 ± 86 827 ± 49 817 ± 82 810 ± 84 826 ± 104 
Table 5.4: Plasma total essential amino acid concentrations across each condition, expressed in µM. Values are Mean±SD. A two-way repeated measures ANOVA was performed 
(Condition*Time). When P<0.05, post-hoc one-way repeated measures ANOVA were used to determine where differences existed between time-points and between conditions. Difference existing 
from baseline is indicated by a P<0.05 vs. 0 min and differences existing between conditions is indicated by b P<0.05 vs. CONTROL.   
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Time (min) BOLUS ME CONTROL PULSE ME + LEU 
0 1222 ± 125 1160 ± 121 1174 ± 140 1180 ± 130 1216 ± 169 
15 1278 ± 114 1212 ± 147 1197 ± 126 1183 ± 133 1211 ± 169 
30 1256 ± 138 1287 ± 181 1171 ± 143 1234 ± 144 1244 ± 193 
45 1248 ± 103 1268 ± 201 1147 ± 161 1216 ± 130 1246 ± 177 
60 1237 ± 126 1197 ± 175 1153 ± 145 1223 ± 142 1207 ± 167 
90 1209 ± 122 1207 ± 156 1202 ± 174 1160 ± 110 1182 ± 139 
120 1211 ± 133 1169 ± 111 1170 ± 122 1175 ± 112 1244 ± 214 
150 1274 ± 87 1172 ± 117 1246 ± 150 1181 ± 166 1172 ± 179 
180 1196 ± 133 1203 ± 166 1196 ± 112 1184 ± 130 1187 ± 172 
210 1230 ± 136 1227 ± 185 1186 ± 150 1156 ± 125 1201 ± 186 
240 1213 ± 118 1182 ± 123 1196 ± 131 1185 ± 144 1240 ± 197 
Table 5.5: Plasma total non-essential amino acid concentrations across each condition, expressed in µM. Values are Mean±SD. A two-way repeated measures ANOVA was performed 
(Condition*Time). When P<0.05, post-hoc one-way repeated measures ANOVA were used to determine where differences existed between time-points and between conditions. Difference existing 
from baseline is indicated by a P<0.05 vs. 0 min and differences existing between conditions is indicated by b P<0.05 vs. CONTROL.   
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Figure 5.3: AUC for leucine (A) and branched chain amino acids (B) across each condition, expressed in 
µM.240min-1. BOLUS, 3g leucine; ME, 3g microencapsulated leucine; CONTROL, 3g maltodextrin; PULSE, 1.5g leucine 
ingested at 0 hours and 2 hours; ME+LEU, 1.5g microencapsulated leucine and 1.5g leucine. Values are Mean±SD. A 
one-way repeated measures ANOVA by condition was performed. When P<0.05, post-hoc pairwise comparisons, with 
Bonferroni’s adjustment for multiple comparisons, were used to determine where differences existed between conditions, 
as indicated by *=P<0.05, **=P<0.01, ***=P<0.001. Difference from control is indicated by †=P<0.05, ††=P<0.01, 
†††=P<0.001.  
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5.4 Discussion 
Postprandial plasma kinetics of leucine after the ingestion of a protein-containing meal or supplement is a key 
regulator of MPS, but few studies have described the plasma kinetics of leucine after the ingestion of different 
leucine supplementation forms and timing. The aim of this study was to investigate the plasma kinetics of 
leucine in response to consuming leucine in its free form, in a novel microencapsulated form, in a timed 
pulsed ingestion protocol and in comparison to that of a maltodextrin control. The microencapsulation 
technique showed reduced bioavailability in comparison to leucine ingested in its free form. Leucine in its free 
form causes a greater magnitude of postprandial leucinemia compared to the similar doses of leucine ingested 
in a whole protein matrix reported in the literature (Areta 2013; Churchward-Venne et al. 2012; Moore et al., 
2009).  
 
Despite the peak leucinemia and AUC being significantly different from baseline and CONTROL, the 
microencapsulated leucine technology shows poor bioavailability when compared to free leucine in BOLUS 
and PULSE conditions. Although a smaller peak was anticipated when compared to 3g free leucine condition, 
due to the targeted-release characteristic of the condition, the AUC for ME was significantly lower than that of 
BOLUS, suggesting reduced bioavailability (6±3µM.240min-1, vs to 32±7µM.240min-1 respectively). Plausible 
explanations for this reduced bioavailability are the untimely degradation of the microencapsulation 
technology and/or impaired absorption in the small intestine. Microencapsulation is a process in which small 
films are applied to a solid particle to preserve the active ingredient (Jackson and Lee, 1991). Due to the 
intricate nature of the technology it requires accurate design to ensure the core ingredient’s release occurs at 
the correct site of absorption. Otherwise the lower pH of stomach acid may break it down too quickly, or the 
outer shell may be incompletely broken down at the absorption site. It is plausible that the microencapsulated 
leucine was not degraded at the small intestine, and degradation occurred either too early, later in the large 
intestine, or did not entirely breakdown and passed through the gastrointestinal tract incompletely degraded. 
This would be the result of sub-optimal development of the microencapsulation technique, suggesting it 
needs further review. Reduced bioavailability of ME may also be explained by impaired intestinal absorption, 
resulting in a lower plasma leucinemia. Increased splanchnic utilisation blunts the rise in aminoacidemia after 
ingestion of an AA mixture. The splanchnic tissues are responsible for absorption of the ingested AAs and their 
release to the circulatory system, but if the splanchnic tissues utilise these AAs, less AAs will be available for 
absorption to circulation (Bos et al., 2005, 2003; Fouillet. et al., 2002). However, an increased uptake of AAs by 
enterocytes is predominately the result of a slower rate of gastric emptying (Boirie et al., 1997). Factors 
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responsible for a slower rate of gastric emptying include greater food/liquid volume, the addition of 
carbohydrates, fats, proteins, calories, and/or soluble fibre to the meal (Rondanelli et al., 2017; Holwerda et 
al., 2017; Have et al. 2007; Duranti, 2006; Hunt 1980). While the liquid volume ingested was standardised 
across conditions, and there were no additional carbohydrate, fats or calories in any conditions, the whey 
protein component of the microencapsulation matrix may have caused a slowing in gastric emptying. 
However, it is unlikely that the whey protein matrix is entirely responsible for the reduced bioavailability of 
leucine bound in the microencapsulation. While impaired intestinal absorption may certainly be a contributing 
factor to the reduced bioavailability of ME leucine, the untimely breakdown of the microencapsulation 
technology due to sub optimal formulation, may be a more significant factor in these results.  
 
Despite leucine representing the key AA in initiating signalling cascades that activate MPS, few studies have 
investigated the leucinemia after ingestion of leucine alone, with most focusing on postprandial leucinemia 
after the ingestion of milk proteins, plant proteins, AA mixtures, or protein foods. The ingestion of 3g of leucine 
in its free form produced a steep rise in leucinemia to 540μM, peaking at 30 min after ingestion. This is similar 
to finding by Matsumoto et al., (2014), who compared the plasma kinetics of leucine after the ingestion of 
graded doses of crystalline leucine diluted/partially diluted in water. Matsumoto et al., (2014) reported a peak 
of ~800μM at 30 min after the ingestion of 45mg/kg or ~3g leucine. Similarly, Wilkinson et al., (2013) 
reported a peak leucinemia of ~500μM at 30 min after the ingestion of 3.42g leucine. Notably, the absorption 
kinetics of 3g leucine is different to that contained in whole intact proteins reported in the literature. Despite 
egg and milk protein having the highest Protein Digestibility Corrected Amino Acid Score (PDCAAS), ingestion 
of a similar quantity of leucine in these intact forms results in an attenuated and delayed peak leucinemia, 
when compared to free leucine. The ingestion of 40g egg protein, containing 3.4g leucine resulted in a peak in 
plasma leucinemia of 167µM, 45 min after ingestion (Moore et al., 2009), and the ingestion of 25g whey, 
containing ~3g leucine, causes a peak in plasma leucinemia of approximately 390µM, 90 min after ingestion 
(Churchward-Venne et al. 2012). The attenuated and delayed peaks in plasma leucinemia values may be 
explained by the slower rate of gastric emptying due to the increases energy load associated with whole 
proteins. Indeed, doubling the energy density of food from 0.7 to 1.4 kcal/ml increases gastric emptying from 
116 kcal to 176 kcal/30 min, instead of to 232 kcal/30 min had there been no slowing of gastric emptying 
(Hunt 1980). This 50% reduction in the rate of gastric emptying is because receptors on the duodenum wall 
determine the osmotic properties of a food stuff, and are considered to be responsible for modulating the rate 
of gastric emptying. Furthermore, the plasma leucine kinetics after the ingestion of a beverage containing 
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6.25g whey (containing 0.75g leucine) plus 2.25g of free leucine, which provided a total of 3g of leucine 
causes a peak in leucinemia of 530µM, 1 hour after ingestion (Churchward-Venne el al. 2012), which is similar 
in magnitude, although delayed by 30 min, to the results of this current trial after the ingestion of 3g of free 
leucine. This similarity is potentially due to the low energy and macronutrient contribution of 6.25g of whey 
protein to the ingested beverage. This suggests that since a large proportion of leucine in the mixed beverage 
consists of free form leucine, and a small quantity of whole whey, the rate of gastric emptying is slowed less, 
resulting in a high peak leucinemia when compared to whole form protein such as 40g whey protein (Areta 
2013), 40g of egg protein (Moore et al., 2009) or 25g whey (Churchward-Venne et al. 2012). Furthermore, a 
peak postprandial plasma leucinemia of ~500µM is apparent 90 min after the ingestion of 16.6g of whey with 
an additional 3.4g of free form leucine (Tipton et al. 2009). Despite the leucine representing 5.4g of this mixed 
beverage, it does not result in a greater peak leucinemia when compared to that of 3g leucine in the present 
trial. This may be explained by the whey protein component of the beverage causing a slower digestion 
kinetics, and/or the saturation of the transporter proteins carrying leucine across the intestinal wall, and 
thereby a delayed and decreased peak leucinemia.  
 
Regarding the transport process, the absorption of most AAs from the lumen of the intestine requires an active 
transport process across the enterocytes.  Leucine, being a monoamino-monocarboxylic (neutral) AA, uses the 
system L transporters via a single saturable pH-independent transporter (Fraga, Serrão and Saores-de-Silva, 
2002; Iannoli et al., 1999).  Another possible explanation for this discrepancy therefore may be the protein 
transporter within the membrane of the enterocytes is reaching saturation levels at this concentration of 
leucine in the lumen, meaning the greater leucine concentration in the intestines does not result in a higher 
plasma leucine concentration. In support, Matsumoto et al., (2014) reported no further increase in peak 
leucinemia after the ingestion of ~4g, 5g, and 6g free leucine. PULSE fed leucine,1.5g of leucine, ingested at 
0 min and again at 120 min, resulted in a cyclical oscillation of leucinemia, in which plasma leucinemia 
peaked at 325μM at 30 min, and reached as low as 169μM at 120 min.  However, this low concentration was 
significantly different from baseline values for that condition, suggesting that while leucinemia trends towards 
baseline values, it does not reach baseline values 120 min after ingestion of 1.5g free leucine.  Elsewhere, a 
similar dose of leucine, in the form of 10g whey protein, delivered at 0 min and every 90 min thereafter for 12 
hours, causes an initial peak in plasma leucinemia of ~130µM at 90 and 120 min. This increase in leucinemia 
continues to rise and reaches its greatest peak of 270µM at 6.5 hours. Thereafter, it begins to trend 
downwards, despite further ingestion of 10g whey protein every 90 min (Areta et al., 2013). This sustained 
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hyperaminoacidemia pattern may be related to the slower digestion kinetics of whole protein, and the shorter 
interval between feeding times compared to the present study.  
 
The superiority of animal-based protein over plant-based protein in stimulating MPS is well-reported and is 
attributed to the difference in digestion rates and relative leucine content of respective proteins, with animal-
based proteins resulting in a greater hyperleucinemia and hyperaminoacidemia when compared to plant-
based proteins (Gorissen et al., 2016; Tang et al. 2009; Wilkinson et al., 2007). These present results show the 
potential advantage of using free-form AAs in supplement form, compared to whole proteins such as whey and 
egg, when the objective is to cause a sharp rise in leucinemia. Due to the importance of leucine in anabolic 
stimulation, the enrichment of lower leucine meals/supplements with a free-form leucine may have significant 
impact on anabolism and muscle recovery in those following a plant-based or low animal protein diet, or for 
elderly who may find it difficult to eat optimal levels of per meal leucine and protein (Gorissen and Witard, 
2018; van Vliet, Burd and van Loon, 2015). Indeed, the co-ingestion of 5g of leucine supplement with three 
main meals enhances integrated 3-day rates of MPS in free-living older men, consuming 0.8 and 1.2g 
protein/kg per day (Murphy et al. 2016). Therefore, another application of microencapsulated leucine, 
irrespective of any time-release property, would be in leucine-enrichment of plant-based protein supplements 
and food matrices, which may add efficacy to nutrition strategies targeting an increase in MPS, and by 
extension, lean body mass. By increasing plasma leucinemia, this would thereby stimulate MPS to a greater 
magnitude compared to a plant-based or leucine-poor protein alone, which has been reported elsewhere 
(Engelen et al., 2007). However, to the best of our knowledge, post prandial plasma leucine kinetics after the 
ingestion of a leucine-enriched plant-based protein has not been investigated. Since MPS is stimulated in a 
dose-dependent manner in response to a rise in plasma leucine (Glynn et al., 2010; Moore et al., 2009; 
Cuthbertson, 2004), using free form AAs in supplement form may show promise in recovery from training 
bouts in the athletic populations, and in ameliorating the age-related decline of muscle mass in elderly 
populations. Lastly, the use of microencapsulated leucine may also enhance the palatability of leucine-
containing protein supplements, as masking the bitter taste properties of free leucine proves difficult (Buttery 
et al., 1989). 
5.5 Conclusion 
The microencapsulated leucine technology used in this study, which was designed to achieve a sustained 
increase in leucinemia through targeted-release, did not produce the desired effect, and its formulation needs 
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review. The oral ingestion of 3g of leucine in free form resulted in a steep rise in leucinemia to 540μM, 
peaking at 30 min after ingestion. This peak postprandial leucinemia is notably higher than that of whole 
protein, such as egg and whey reported in the literature, providing the same dose of leucine.  This higher and 
earlier peak leucinemia may be explained by the faster digestion and absorption kinetics of leucine when 
provided in its free-form compared to when provided in whole protein. Since change in plasma leucine 
concentration is a key signal in activating MPS, dietary supplementation with free-form leucine may show 
promise as a strategy for optimising the plasma kinetics required to maximise MPS. Furthermore, the 
enrichment of lower leucine meals, beverages and food matrices with a free-form leucine may have significant 
impact on anabolism in those following a plant-based or low animal protein diet, or elderly populations to 
ameliorate age-related decline in muscle mass. 
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Chapter 6  
6.0 The plasma leucine kinetics after the ingestion of a plant-based 
meal enriched with leucine  
Background: Leucine-enrichment, in which free leucine is added to a suboptimal protein dose, is an emerging nutrition 
strategy for increasing the anabolic properties of a meal. Despite plasma leucinemia being a key modulator in the 
postprandial anabolic response, the plasma kinetics after the ingestion of leucine-enriched meals remain underexplored.  
 
Objective: The aim of the present study was to investigate the plasma kinetics of leucine and amino acids (AAs) in 
response to the ingestion of a plant-based meal low in leucine, but enriched with free leucine.   
 
Design: Five healthy active males [age (25.6±2.4y)] visited the laboratory on three separate occasions, and in a cross-
over design were randomly assigned to one of the following conditions in combination with a mixed meal (845 kcal, 24g 
protein, 117g carbohydrates, 33g fat): A bolus of 3g leucine (BOLUS); 1.5g free leucine consumed at 0 hours and 1.5g 
consumed 2 hours later (PULSE); 3g maltodextrin (CONTROL). Blood samples for plasma analysis were taken every 15 min 
in the first hour, and every half hour for the next three hours. These participants had previously participated in Chapter 5, 
which also allowed for comparison of the effects of meal co-ingestion on leucine kinetics. 
 
Data Analysis: Concentrations of AAs in plasma were measured using high performance liquid chromatography. 
Changes in plasma leucine, branched chain amino acids (BCAAs), total AAs, essential amino acids (EAAs) and non-
essential amino acids (NEAAs), over time and between conditions was evaluated using a two-way repeated measures 
ANOVA. Post-hoc analysis was performed using a repeated measured ANOVA and pairwise comparisons with Bonferroni’s 
adjustment for Cmax between conditions, and Dunnett’s adjustment for within condition effects. 
 
Results: The enrichment of a mixed meal with 3g leucine resulted in Cmax for leucinemia of 350±44µM, which was 
significantly greater than Cmax after a mixed meal ingested alone (152±22µM, P<0.05). There was a dampened increase 
in plasma leucinemia when 3g leucine was ingested with a mixed meal compared to the plasma leucinemia achieved 
after the ingestion of 3g leucine alone in chapter 5 (542±83µM), as well as a smaller AUC (15±5 vs. 32±7 µM.240min-1, 
respectively). When 1.5 g of leucine was ingested at 120 min, the prior ingestion of a meal at 0 min resulted in a smaller 
AUC for leucine (4±4 µM.240min-1) in this experiment, when compared to no meal ingested at 0 min (14±5 
µM.240min-1) in Chapter 5.   
 
Conclusion: The enrichment of a plant-based meal with 3g leucine results in a greater increase in leucinemia when 
compared to a plant-based meal alone. The presence of other macronutrients and fibre in the mixed meals compromises 
postprandial plasma leucinemia. Marked difference in postprandial leucinemia are apparent between 3g leucine 
ingested with and without a mixed meal. When using leucine-enrichment as a strategy for increasing the anabolic 
characteristics of a meal, this is an important consideration as addition leucine may be necessary to reach a threshold 
required to maximise MPS.  
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6.1 Introduction 
Leucine has been identified as the key AA that acts as a trigger for stimulating MPS (Atherton et al., 2010a), 
and the resultant leucinemia likely explains in part the dose-response increase in MPS observed after the 
ingestion of a protein-containing meal (Witard et al., 2014; Moore et al., 2009). Consequently, protein sources 
that are low in leucine, particularly plant-based proteins (USDA National Nutrient Database for Standard 
Reference, 2009), exhibit an inferior stimulation of postprandial MPS, when compared to an equivalent dose 
of animal-based protein (Gorissen et al., 2016; Wilkinson et al., 2007; Yang et al., 2012a; 2012b; Tang et al., 
2009). The reason for this inferior anabolic response is likely due at least in part to a blunted increase in 
postprandial leucinemia, and therefore a decreased availability of leucine for delivery to the skeletal muscle 
(Gorissen et al., 2016; Tang et al., 2009). Indeed, anti-nutritional factors present in plant-based foods, such as 
fibre and the energy content of carbohydrate and fat, may slow gastric emptying and impede protein digestion 
and absorption, and therefore attenuate the expected increase in postprandial leucinemia (Gorissen and 
Witard, 2018).  
Efforts have been made to increase the anabolic potential of plant-based meals, such as combining plant-
based foods to render a meal complete in all nine EAAs, and increasing the dose of protein in plant-based 
meals (Gorissen and Witard, 2018; van Vliet, Burd and van Loon, 2015). These approaches are not without 
their shortcomings, particularly because of the food quantity and therefore energy intake required to attain the 
desired AA profile to maximise MPS in one meal. This presents challenges particularly for athletic populations 
and older adults, both of which have protein requirements greater than the PRI (Egan, 2016; Thomas, Erdman 
and Burke, 2016; Bauer et al., 2013; Phillips, 2012a; Phillips and van Loon, 2011). The energy intake 
therefore required to reach the purported leucine threshold when consuming low leucine foods may be an 
issue for athletes whose sport requires close monitoring of body mass and body composition. Furthermore, 
older adults, who experience a deterioration in appetite with age (Morley, 2001), may find it impractical to eat 
large volumes of food in one sitting.   
Leucine-enrichment, in which free leucine is added to a meal or food matrix, is emerging as a promising 
means of ‘rescuing’ the inferior anabolic response apparent after the ingestion of low leucine/plant-based 
protein sources and meals (Murphy et al., 2016; Bauer et al., 2015; Bukhari et al., 2015; Wilkinson et al., 
2017; Casperson et al., 2012). Indeed, the enrichment of whey protein with leucine has yielded promising 
results in acute studies for changes in MPS (Devries et al., 2018; Kramer et al., 2017; Churchward-Venne et al., 
2014), and long-term intervention studies in changes of LBM (Bauer et al., 2015). Despite this interest, the 
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plasma kinetics after the ingestion of leucine in combination with a mixed meal remain underexplored. In 
chapter 5, we investigated the plasma AA kinetics of different forms and timing of leucine when ingested alone 
in a fasted state. While leucine acts as a trigger stimulating MPS above post-absorptive values, other (both non-
essential and essential) AAs are required as a substrate for the synthesis of new muscle protein (Churchward-
Venne et al., 2012), with the rationale that leucine be ingested with other EAA when the aim is to maximise 
MPS. Therefore, the aim of this present study was to determine the plasma leucine and AA kinetics after the 
ingestion of a plant-based mixed meal inherently low in leucine, with or without enrichment with free leucine.  
6.2 Methods 
6.2.1 Study Design 
The experimental procedure was approved by University College Dublin (UCD) Research Ethics Committee in 
accordance with the Declaration of Helsinki. Five healthy males, who had previously been recruited for the 
chapter 5, agreed to take part in the present study. Participants [age (25.6±2.4y), height (1.78±0.08m), body 
mass (75.3±8.7kg), BMI (23.6±0.9kg/m2), body fat percentage (17.3±2.8%), body fat mass (12.46±1.84kg), 
lean body mass (59.87±7.94kg)], visited the laboratory in UCD on three separate occasions, with each visit 
separated by seven days. Participants were assigned in random to one of the following three conditions for 
each visit in a single blind, cross-over design; 
 
• A bolus of 3g free leucine (BOLUS) 
• 1.5g free leucine consumed at 0 hours and 1.5g consumed 2 hours later (PULSE) 
• 3g maltodextrin (CONTROL) 
Test drinks were prepared identically to BOLUS, PULSE and CONTROL in chapter 5. During each visit, 
participants arrived to the laboratory after an overnight fast (approximately 8 hours). A cannula was inserted in 
the antecubital vein and the line was kept patent with saline. Blood samples (~4ml) were drawn into 
vacutainers containing lithium heparin (BD Vaccutainers, Heparin Tubes), inverted eight to ten times and 
placed on ice. The blood was centrifuged at 4000 g for 10 min at 4°C and the upper layer of plasma was 
transferred into three separate 1.5ml tubes and stored at -80°C until further analysis. Participants ingested a 
mixed meal containing a hemp protein shake (Manitoba Hemp 50), almonds, two cereal bars and an 
electrolyte sports drink (See table 6.1 for nutritional information of the meal). Hemp protein was chosen as it 
is one of the lowest leucine-containing protein powders, and we wanted to minimise the interference of 
leucine from mixed meal with plasma leucine concentrations. Participants ingested the meal, with one of the 
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above test conditions, dissolved in a total of 150ml of water. Irrespective of the condition the condition, 
participants consumed two white opaque bottles at 0 min and 120 min, as per figure 6.1, to maintain the 
single-blind design. Blood samples were taken at rest at rest prior to meal (0 min), every 15 min in the first 
hour, and every half hour for the next three hours. Participants visited the laboratory on two subsequent 
occasions, with the same testing procedure being carried out, and participants consuming one of the other two 
conditions. On the first visit, participants provided a two-day food diary, detailing their dietary habits over the 
two days preceding their first laboratory visit. Participants were provided a copy of this diary and asked to 
repeat the same two-day dietary intake prior to the subsequent two visits to the laboratory. 
 
Figure 6.1: Overview of ingestion protocol of each beverage condition.  
 
  Mixed Meal Free Leucine Meal + Leucine 
Energy (kcal) 854 16 870 
Protein (g) 24 3 27 
Leucine (g) 1.2 3 6.2 
Carbohydrate (g) 117 - 117 
Fat  (g) 33 - 33 
Table 6.1: Nutritional composition of mixed meal, leucine powder and combined (Meal+Leucine). 
g, grams; kcal, calories.  
 
6.2.2 Data Analysis  
High Performance Liquid Chromatography (HPLC) was carried as per Section 3.3.  
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6.2.3 Statistical Analysis 
Statistical analysis was performed using SPSS (IBM SPSS Statistics Version 23). Plasma leucine, branched chain 
amino acids (BCAAs), arginine (the second most abundant AA in hemp protein), total amino acids (AAs), 
essential amino acids (EAAs) and non-essential amino acids (NEAAs) are presented as mean±SD. A two-way 
(condition x time) repeated measures ANOVA was performed to determine differences in plasma concentration 
of AAs over time and between conditions.  The difference in AA concentrations from baseline within each 
condition was analysed using a one-way ANOVA, and post-hoc testing with Dunnett’s adjustment. As PULSE 
consisted of leucine ingested at 0 min and again at 120 min, PULSE1 defined plasma AA concentrations from 0-
120 min, and PULSE2 defined as plasma AA concentrations from 150-240 min. As peak plasma AA 
concentrations were reached at different time-points for participants, maximum concentration (Cmax) of AA was 
determined. The area under the curve (AUC) above baseline (ΔAUC240) for each variable was calculated by 
trapezoidal integration, and is presented as mean±SD. The difference in Cmax and AUC between conditions was 
analysed using a one-way repeated measures ANOVA. Where main effect was found, post-hoc testing consisted 
of pairwise comparison using Bonferroni’s adjustment. Statistical significance for all tests was accepted at 
P<0.05. As the 5 participants used for the present study were also used in chapter 5, rather than compare this 
chapter’s data to the n=10 in chapter 5, additional descriptive statistics were performed on the respective n=5 
for plasma leucine in BOLUS and PULSE from chapter 5. This was done in order to compare the plasma leucine 
Cmax and AUC after leucine was ingested alone compared to leucine ingested with a mixed meal in the present 
study.  
6.3 Results  
6.3.1 Plasma Leucine  
Plasma leucine kinetics are presented in figure 6.2 and table 6.3. The time at which plasma leucine 
reached peak concentration varied between participants. Cmax for BOLUS was 350±44 µM, which was 
significantly greater than Cmax for CONTROL (152±22µM, P=0.006). Cmax for PULSE1 was 217±43µM, which 
was not different to Cmax for CONTROL (P=0.2). Cmax for PULSE2 was 209±48µM, which was not different to Cmax 
for CONTROL (P=0.38). Cmax for PULSE1 and PULSE2 showed no difference (P=0.47). For plasma leucine, there 
was a main effect for time (P<0.001) and condition (P<0.001), and an interaction effect (P<0.001). During 
BOLUS, there was a marked increase in plasma leucinemia at 30, 45, 60, 90 and 120 min after ingestion, 
when compared to baseline (P<0.05). During CONTROL, there was a marked decrease in plasma leucinemia at 
150, 180, 210 and 240 min after ingestion, when compared to baseline (P<0.05). AUC for leucine is 
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presented in figure 6.3. BOLUS AUC was significantly greater than AUC for CONTROL (15±5 vs. -3±1 
µM.240min-1, P=0.001). PULSE AUC was 8±9µM.240min-1, which was not significantly different to CONTROL 
(P=0.13). PULSE1 AUC was 4±4µM.120min-1, and PULSE2 AUC was 4±4µM.120min-1, which were not 
significantly different (P=0.82). 
 
 	 BOLUS PULSE1 PULSE2 CONTROL Leucine 350 ± 44 a 217 ± 43  209  ± 48 152 ± 22 
Arginine 130 ± 28 120 ± 30  106  ± 20 122 ± 43 
BCAA 632 ± 75 491 ± 22 427 ± 35 446 ± 38 
AA 2713 ± 273 2538 ± 134 2330 ± 119 2576 ± 296 
EAA 1187 ± 112 1073 ± 41 920 ± 55 1029 ± 111 
NEAA 1566 ± 141 1509 ± 67 1418 ± 74 1579 ± 174 
Table 6.2: Cmax for amino acids concentrations across each condition, expressed in µM. Values are 
mean±SD. PULSE1 is plasma amino acid concentrations, from 0 to 120 min, after the ingestion of 1.5g leucine with a 
mixed meal at 0 min. PULSE2 is plasma amino acid concentrations, from 150 to 240 min, after the second 1.5g leucine 
ingestion at 120 min. A one-way repeated measures ANOVA, with Bonferroni’s adjustment, was used to determine 
differences between conditions. Differences are indicated by a P<0.05 vs. CONTROL. 
 
 
Time 
(min)                                       BOLUS                                    PULSE                               CONTROL 
0 124 ± 25 132 ± 19 130 ± 3 
15 262 ± 62 180 ± 32 133 ± 5 
30 307 ± 55 a  182 ± 27 143 ± 29 
45 286 ± 54 a 190 ± 49 139 ± 22 
60 266 ± 64 a 175 ± 37 131 ± 17 
90 203 ± 26 a 155 ± 29 122 ± 13 
120 181 ± 13 a 134 ± 16 109 ± 3 a 
150 159 ± 12 205 ± 52 106 ± 6 a 
180 128 ± 8 173 ± 28 99 ± 8 a 
210 121 ± 9 140 ± 16 99 ± 9 a 
240 111 ± 11 138 ± 13 99 ± 9 a 
Table 6.3: Plasma leucine concentrations across each condition, expressed in µM. Values are mean±SD. A 
one-way repeated measures ANOVA, with Dunnett’s adjustment was used to determine differences from baseline. 
Differences are indicated by a P<0.05 vs. 0 min. 
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Figure 6.2: Plasma leucine concentration after the ingestion of mixed meal with BOLUS (A), PULSE (B) and 
CONTROL (C), expressed in µM.  Values expressed as individual participant data. BOLUS, 3g leucine; PULSE, 1.5g 
leucine ingested at 0 hours and 2 hours; CONTROL, 3g maltodextrin. 
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Figure 6.3: Area under the curve for leucine across conditions, expressed in µM.240min-1. Values are 
mean±SD. BOLUS, 3g leucine; PULSE, 1.5g leucine ingested at 0 hours and 2 hours; PULSE1, plasma amino acid 
concentrations, from 0 to 120 min, after the ingestion of 1.5g leucine with a mixed meal at 0 min; PULSE2, plasma amino 
acid concentrations, from 150 to 240 min, after the second 1.5g leucine ingestion at 120 min; CONTROL, 3g 
maltodextrin. A one-way repeated measures ANOVA by condition was performed, with Bonferroni’s adjustment for 
multiple comparisons. Differences are indicated by *P<0.05 vs. CONTROL. 
 
6.3.2 Plasma Arginine  
Arginine Cmax for each condition are presented in table 6.2 and revealed no significant differences between 
conditions (P>0.05). Plasma arginine kinetics are presented in table 6.6. For plasma arginine there was a 
main effect for time (P<0.001). During BOLUS, there was a significant increase in plasma arginine above 
baseline at 30 and 60 min (P<0.05). AUC for arginine was 6±4µM.240min-1, 5±4µM.240min-1and 
6±2µM.240min-1 for BOLUS, PULSE and CONTROL, respectively. No significant difference existed between 
condition, for arginine AUC (P=0.87). 
6.3.3 Plasma BCAAs 
BCAA Cmax for each condition are presented in table 6.2 and revealed no significant differences between 
conditions (P>0.05). Plasma BCAA kinetics are presented in table 6.5. For plasma BCAAs, there was a main 
effect for time (P<0.001) and an interaction effect (P<0.001). During BOLUS, there was a significant increase 
in plasma BCAAs above baseline at 30 min (P<0.05). AUC for BCAAs was 4±22µM.240min-1, -
4±12µM.240min-1and -6±6µM.240min-1 for BOLUS, PULSE and CONTROL, respectively. No significant 
difference existed for BCAAs AUC between condition (P=0.59). 
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Time 
(min)                                       BOLUS                                    PULSE                               CONTROL 
0 83 ± 18 80 ± 13 79 ± 20 
15 105 ± 17 90 ± 15 87 ± 33 
30 123 ± 24 a 105 ± 23 114 ± 49 
45 124 ± 31 116 ± 32 113 ± 39 
60 124 ± 27 a 114 ± 33 115 ± 42 
90 116 ± 27 109 ± 16 114 ± 40  
120 115 ± 24 101 ± 20 104 ± 26 
150 112 ± 21 105 ± 20 105 ± 15 
180 97 ± 20 98 ± 19 100 ± 26  
210 92 ± 16 88 ± 18 101 ± 8 
240 86 ± 22 89 ± 19 101 ± 16 
Table 6.4: Plasma arginine concentrations across each condition, expressed in µM. Values are mean±SD. A 
one-way repeated measures ANOVA, with Dunnett’s adjustment, was used to determine differences from baseline. 
Differences are indicated by a P<0.05 vs. 0 min. 
 
 
Time 
(min)                                       BOLUS                                    PULSE                               CONTROL 
0 343 ± 122  411 ± 75 390 ± 42 
15 498 ± 134  446 ± 55 395 ± 29 
30 597 ± 70 a 463 ± 29 416 ± 47 
45 561 ± 85  472 ± 34 420 ± 55 
60 528 ± 126 438 ± 20 399 ± 17 
90 426 ± 60 406 ± 51 386 ± 9 
120 311 ± 82 364 ± 34 352 ± 21 
150 283 ± 88 424 ± 34 351 ± 37 a 
180 236 ± 80 373 ± 42 334 ± 40 a 
210 229 ± 80  319 ± 42  327 ± 45 a 
240 210 ± 52 319 ± 34 325 ± 44 a 
Table 6.5: Plasma branched chain amino acid concentrations across each condition, expressed in µM. 
Values are mean±SD. A one-way repeated measures ANOVA, with Dunnett’s adjustment, was used to determine 
differences from baseline. Differences are indicated by a P<0.05 vs. 0 min. 
 
6.3.4 Plasma AA, EAA and NEAA 
Total AA Cmax for each condition are presented in table 6.2 and revealed no significant differences between 
conditions (P>0.05). Plasma total AA kinetics are presented in table 6.6. For plasma total AAs, there was a 
main effect for time (P<0.001) and condition (P<0.001), and an interaction effect (P=0.011). During BOLUS, 
there was a significant increase in plasma AAs above baseline at 30 and 45 min (P<0.05). AUC for total AAs 
was 29±47µM.240min-1, 4±26µM.240min-1 and 29±28µM.240min-1 for BOLUS, PULSE and CONTROL, 
respectively. No significant difference existed for total AAs AUC between conditions (P=0.81). 
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EAA Cmax for each condition are presented in table 6.2 and revealed no significant differences between 
conditions (P>0.05). Plasma EAA kinetics are presented in table 6.7. For plasma EAAs there was a main effect 
for time (P<0.001) and an interaction effect (P<0.001). During BOLUS, there was a marked increase in plasma 
EAAs at 30 min, when compared to baseline (P<0.05). During PULSE, there was a marked decrease in plasma 
EAAs at 210 and 240 min after ingestion, when compared to baseline (P<0.05). AUC for EAAs was 
1±29µM.240min-1, -11±15µM.240min-1 and -5±12µM.240min-1 for BOLUS, PULSE and CONTROL, 
respectively. No significant difference existed for EAAs AUC between conditions (P=0.46). 
 
NEAA Cmax for each condition are presented in table 6.2 and revealed no significant differences between 
conditions (P>0.05). Plasma NEAA kinetics are presented in table 6.8. For plasma NEAAs there was a main 
effect for condition (P<0.03). However, on further post-hoc analysis, no differences were detected. No 
significant difference existed between conditions for NEAAs AUC (P=0.063). 
 
 
Time 
(min)                                       BOLUS                                    PULSE                               CONTROL 
0 2129 ± 319 2259 ± 213 2154 ± 47 
15 2412 ± 164 2282 ± 158 2237 ± 109 
30 2642 ± 215 a 2450 ± 148 2316 ± 365 
45 2581 ± 309 a 2480 ± 117 2404 ± 306 
60 2558 ± 395 2411 ± 198 2390 ± 224 
90 2373 ± 246 2371 ± 153 2434 ± 301 
120 2248 ± 155 2264 ± 176 2264 ± 93 
150 2240 ± 84 2328 ± 115 2288 ± 115 
180 2008 ± 118 2176 ± 195 2218 ± 180 
210 1965 ± 117 2045 ± 267 2107 ± 155 
240 1823 ± 158 2070 ± 211 2142 ± 207 
Table 6.6: Plasma total amino acid concentrations across each condition, expressed in µM. Values are 
mean±SD. A one-way repeated measures ANOVA, with Dunnett’s adjustment, was used to determine differences from 
baseline. Differences are indicated by a P<0.05 vs. 0 min.  
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Time 
(min)                                       BOLUS                                    PULSE                               CONTROL 
0 832 ± 185 940 ± 122 889 ± 41 
15 1033 ± 152 974 ± 85 923 ± 39 
30 1160 ± 110 a 1030 ± 68 955 ± 145 
45 1102 ± 149 1034 ± 37 972 ± 125 
60 1057 ± 208 982 ± 63 941 ± 69 
90 918 ± 112 934 ± 85 928 ± 84 
120 788 ± 80 865 ± 83 851 ± 16 
150 754 ± 84 918 ± 52 847 ± 54 
180 659 ± 80 832 ± 98 812 ± 70 
210 644 ± 80 751 ± 109 a 778 ± 68 
240 576 ± 69 755 ± 92 a 780 ± 80 
Table 6.7: Plasma essential amino acid concentrations across each condition, expressed in µM. Values are 
mean±SD. A one-way repeated measures ANOVA, with Dunnett’s adjustment, was used to determine differences from 
baseline. Differences are indicated by a P<0.05 vs. 0 min. 
 
 
Time 
(min)                                       BOLUS                                    PULSE                               CONTROL 
0 1296 ± 173 1319 ± 121 1265 ± 13 
15 1379 ± 105 1309 ± 97 1314 ± 73 
30 1481 ± 134 1421 ± 92 1361 ± 219 
45 1480 ± 173  1446 ± 82 1432 ± 184 
60 1501 ± 209 1429 ± 138 1449 ± 157 
90 1455 ± 156 1437 ± 75 1507 ± 218 
120 1460 ± 141 1399 ± 97 1413 ± 84 
150 1486 ± 100 a 1410 ± 77 1441 ± 73 
180 1349 ± 100 1344 ± 103 1406 ± 116 
210 1321 ± 103 1294 ± 162 1329 ± 88 
240 1247 ± 118 1315 ± 122 1362 ± 130 
Table 6.8: Plasma non-essential amino acid concentrations across each condition, expressed in µM. Values 
are mean±SD. A one-way repeated measures ANOVA, with Dunnett’s adjustment, was used to determine differences from 
baseline. Differences are indicated by a P<0.05 vs. 0 min.  
              
6. 4 Discussion 
Leucine-enrichment, in which free leucine is added to a suboptimal protein dose, is an emerging nutrition 
strategy for increasing the anabolic properties of a meal. This is particularly relevant for plant-based meals and 
food matrices, which are inherently low in EAAs, in particular leucine, the critical EAA for stimulating an 
anabolic response in skeletal muscle. Despite plasma leucinemia being considered a key modulator in the 
postprandial MPS response, to the best of our knowledge, no previous studies have investigated the 
postprandial aminoacidemia after the ingestion of a leucine-enriched plant-based meal. As a follow-up study 
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from previous work in chapter 5, the present study sought to determine the effect of the co-ingestion of free 
leucine with a plant-based mixed meal on plasma aminoacidemia.  
 
In the present study, despite the mixed meal containing ~1.2g leucine, plasma leucine concentration did not 
increase significantly from baseline values in CONTROL condition. The enrichment of a plant-based meal with 
3g leucine results in a greater increase in leucinemia when compared to a plant-based meal alone. The 
enrichment of the meal with 3g leucine resulted in a Cmax for leucine of 350±44µM, which is 2.3-fold greater 
than Cmax (152±22µM) for CONTROL, in which only 3g of maltodextrin was ingested with the mixed meal. 
Since PULSE condition consisted of 1.5g leucine ingested with a mixed meal at 0 min, and another bolus at 
120 min without a meal, the condition was separated into two additional variables; PULSE1 and PULSE2, which 
represents plasma AA concentrations at 0-120 min, and 150-240 min, respectively. PULSE1 Cmax was 
217±43µM, and PULSE1 Cmax was 209±48µM.  Despite these being 42% and 38% higher than CONTROL Cmax, 
these were not statistically significant from CONTROL. While there was a main effect for time in PULSE, and 
from figure 6.2B the data shows observational differences from baseline, and marked difference to CONTROL 
in figure 6.2C, post-hoc analysis revealed no significant differences between time-points. The reason for this 
non-significance is likely due to a low n=5, which is a limitation of the study, as well as a large variation in 
plasma leucinemia between participants when leucine is ingested with a meal. Participant 1 and 3 in particular 
did not show a large response in plasma leucinemia to the PULSE condition (See Figure 6.1), which is 
increasing the variability in results, particularly at 45 and 60 min, and another reason for failing to reaching a 
significance from baseline. During CONTROL, there was a significant main effect for time, in which plasma 
leucinemia is significantly lower at 150, 180, 210 and 240 min, compared to baseline. These results suggest 
that there is a marked clearance in leucine in the latter postprandial hours, which is detectable when additional 
leucine is not ingested at baseline. The leucine AUC for CONTROL was -3±1 µM.240min-1, which supports that 
there is a clearance of leucine from circulation results in concentrations below that of baseline. BOLUS AUC was 
15±5µM.240min-1, which was greater than that of CONTROL AUC. PULSE, PULSE1 and PULSE2 AUC were 8±9, 
4±4 and 4±4 µM.240min-1, respectively, however, these did not reach statistical significance compared to 
CONTROL.  
 
When compared to results from the same n=5 from chapter 5, it is clear that there was a smaller peak in 
plasma leucinemia when 3g of leucine was ingested with a mixed meal (350±44µM), compared to the Cmax 
achieved after the ingestion of 3g leucine ingested alone (558±45µM). There was also a smaller AUC for 
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plasma leucinemia after the ingestion of leucine-enriched meal compared to leucine alone (15±5 vs. 
38±8µM.240min-1, respectively). These results suggest that the co-ingestion of a mixed meal with free leucine 
and has a large impact on the bioavailability of addition leucine, in which less AAs are reaching systemic 
circulation. An explanation for this is the presence of other macronutrients, fibres and anti-nutritional factors in 
food matrices and mixed meals act to slow gastric emptying (Rondanelli et al., 2017; Holwerda et al., 2017; 
Have et al., 2007; Duranti, 2006; Hunt 1980). A greater meal volume, as well as solid meals compared to 
liquid meals, also slows the rate of gastric emptying (Achour, Méance and Briend, 2001; Doran et al., 1998). 
This decrease in the rate of gastric emptying results in a delayed and slowed absorption of AAs, possibly as a 
result of increased splanchnic extraction of AAs, in which AAs are taken up by splanchnic tissue, reducing the 
availability of AAs for release into systemic circulation (Boirie et al., 1997). Therefore, the carbohydrate, fat and 
fibre component of the mixed meal explain the reason for the delayed and attenuated increase in leucinemia 
in the present study, compared to results established in chapter 5. Similarly, Dangin et al. (2001) compared 
the plasma kinetics of 30g AA mixture, with 30g casein, both of which contained 3g leucine. After AA ingestion, 
plasma leucinemia peaked at~400µM, while casein ingestion resulted in a modest increase in plasma 
leucinemia (~180µM). These marked differences in plasma AA appearance can be attributed to slower 
digestion of casein, due its coagulation in the stomach, which has been reported elsewhere (Veldhorst et al., 
2009). 
 
This steep increase in plasma leucinemia after the ingestion of free-form AAs in comparison to its co-ingestion 
with other macronutrients is reported elsewhere (Wilkinson et al., 2017; Churchward-Venne et al., 2012). 
Churchward-Venne et al., (2012) demonstrated that the enrichment of 6.25g whey protein to achieve 3g 
leucine, resulted in a steep increase in leucinemia (~500µM at 60 min). This was greater than peak 
leucinemia achieved after the ingestion of 25g whey, which also contained 3g leucine (~500µM at 90 min). 
Wilkinson et al., (2017) demonstrated that a 6g EAA beverage containing 2.4g leucine, resulted in a greater 
peak leucinemia, when compared to 40g whey, which contained 4g leucine. Of interest, the aforementioned 
study by Churchward-Venne et al., (2012) reported no differences in the magnitude of increase in MPS 
between whey and leucine-enriched beverages, under resting conditions.  
 
Observed differences are also apparent in the plasma leucine kinetics of PULSE in the present study when 
compared to results in chapter 5. In the present study, PULSE AUC was 8±9 µM.240min-1 when 3g was 
ingested with a mixed meal, however, chapter 5 showed an AUC for 25±10 µM.240min-1 for n=5, in which 
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leucine was ingested alone. Interestingly, there are also marked differences between PULSE2 in the present 
study, and PULSE2 in chapter 5, despite leucine being ingested alone at 120 min in both conditions.  PULSE2 
AUC was 4±4 µM.240min-1 in the present study, and appears much greater in n=5 for chapter 5 (14±5 
µM.240min-1). This suggests that the mixed meal ingested at 0 min in the present study, has an impact on the 
digestion and absorption of the second 1.5g bolus ingested at 120 min, despite the boluses being 2 h apart.  
 
Being cognisant of the purported ‘leucine threshold’ (the plasma leucine concentration required to increase 
MPS above postabsorptive values), it appears that postprandial leucine concentrations are strongly 
compromised by the co-ingestion of a mixed meal. These differences should be considered when comparing 
the resultant MPS after the ingestion of free AAs vs. whole-protein vs. a mixed meal in various studies, as the 
present results show that each would produce markedly different postprandial plasma leucinemia. When 
using leucine-enrichment as a strategy for increasing the anabolic characteristics of a meal, this attenuated 
increase in leucinemia when free leucine is ingested with a mixed meal is also an important consideration. 
Indeed, a higher dose of leucine may be required when enriching a mixed meal in order to create the desired 
leucine plasma kinetics associated with maximal postprandial MPS. Contrary to these points, it must be noted 
that whole foods produced greater MPS in their whole form in some instances, compared to an isolated form, 
when matched for leucine content (Van Vliet et al., 2017). Therefore, it is important to consider that plasma 
leucinemia is not the sole driver of the postprandial anabolic response and other factors such as the 
accompanying AAs and the co-ingestion of macronutrients and micronutrients may also exhibit a stimulatory 
effect on MPS. It remains to be determined if the plasma leucine kinetics achieved after a leucine-enriched 
plant-based meal is conducive to positive changes in postprandial MPS, or offer an advantage in recovery from 
exercise, when compared to a plant-based meal alone.   
 
6. 5 Conclusion 
The ingestion of a plant-based mixed meal enriched with 3g leucine results in a greater increase in plasma 
leucinemia when compared to the ingestion of a plant-based mixed meal alone, which supports the utility of 
leucine-enrichment of meals and food matrices inherently low in leucine. However, the presence of other 
macronutrients and fibre in the mixed meals act to slow gastric emptying thereby delaying the absorption of 
leucine into the circulation and likely explain the delayed and attenuated increase in leucinemia in the present 
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study compared to free leucine ingested in chapter 5. This is an important consideration when aiming to 
increase the anabolic potential of a meal through leucine-enrichment. 
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Chapter 7  
7.0 The effect of bolus verus pulse-fed leucine supplementation on 
delayed onset muscle soreness and recovery of muscle function 
after intense exercise  
Background: The use of essential amino acids (EAAs) in the post-exercise window is emerging as a potential strategy for 
minimising the deleterious effect of exercise-induced muscle damage (EIMD). In particular, leucine has been identified as 
the key EAA in increasing postprandial anabolism and timing of leucine ingestion has been seen to also exhibit an 
influence on the muscle protein synthetic response. However, the efficacy of leucine, and the timing of its ingestion in 
recovery from EIMD is less understood.  
 
Objective: The aim of the present study was to investigate the efficacy of 12g leucine, bolus and pulse fed, in the 14 h 
post-exercise period on recovery of muscle function, markers of muscle damage and perceived soreness following an 
intense resistance exercise bout.  
 
Design: Thirteen healthy, active males were recruited to participate in this study. Participants performed ten sets of ten 
repetitions on the leg press at 60% of their estimated 1 repetition maximum. In a double-blind, placebo-controlled, 
randomised cross-over design of three trials, participants followed a low leucine meal plan for the 14 h post-exercise 
period, supplemented with three different recovery protocols: BOLUS, 3g leucine every 4 h; PULSE; 1.5g leucine every 2 
h; CON, 3g maltodextrin fed every 2 h. Blood samples were drawn before (PRE), immediately after (POST), 24 and 48 h 
POST and later assessed for plasma creatine kinase (CK) and lactate dehydrogenase (LDH). Perceived soreness and 
recovery using a visual analogue scale was recorded PRE, POST, 24 and 48 h POST. Participants performed a counter 
movement jump (CMJ) for measurement of jump height and peak power at PRE, POST, 24 and 48 h POST.  
 
Data Analysis: Two-way (condition x time) repeated measures ANOVAs were performed. When main or interaction 
effects were indicated, a repeated measures one-way ANOVA was used to determine differences between time-points 
within each supplement condition using post-hoc pair-wise comparisons to PRE with Dunnet’s adjustment for multiple 
comparisons test. For all analyses, statistical significance was accepted at P<0.05.  
 
Results: There was no change in CK or LDH over time. For perceived soreness and recovery, there was a main effect for 
time, in which soreness was increased above PRE at POST, 24 h and 48 h POST. Perceived recovery score was decreased 
from PRE at POST and 24 h POST. There was a decrement in jump height and peak power immediately POST. There was no 
main effect for condition, or time x condition interaction effect for any outcome measures.  
 
 Conclusion: 12g leucine supplemented in the 14 h post-exercise window, appears to exhibit no beneficial effect on 
recovery of muscle function, markers of muscle damage and perceived soreness following an intense resistance exercise 
bout.  
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7.1 Introduction  
Acute, unaccustomed resistance exercise can produce micro-damage as a result of trauma to muscle fibres and 
connective tissue (Nosaka, Newton and Sacco, 2002). This exercise-induced muscle damage (EIMD) is often 
accompanied with dull pain, tenderness and stiffness, termed delayed onset muscle soreness (DOMS) 
(Cheung, Hume and Maxwell, 2003; Connolly, Sayers and Mchugh, 2003; Clarkson, Nosaka and Braun, 
1992), and a decrement in muscle function, which can have a detrimental effect on athletic performance 
(Pearcey et al., 2015).  
 
A nutritional strategy that is efficacious in minimising the deleterious effect of EIMD may be advantageous in 
minimising the compromised quality of exercise sessions in the subsequent days following this muscle-
damaging exercise bout. The use of protein and/or amino acids (AAs) in the post-exercise window is emerging 
as one such potential strategy. However, the results have been equivocal, with some research suggesting a 
beneficial effect on recovery from EIMD (Howatson et al., 2012; Cockburn et al., 2008; Greer et al., 2007; 
Matsumoto et al., 2007) and other suggesting no beneficial effect on recovery (Fouré et al., 2016; Kephart et 
al., 2016; Ra et al., 2013;  Betts et al., 2009).  
 
There are several studies which support the thesis that a single bolus of exogenous AAs, ingested prior to or 
immediately after exercise, ameliorates the deterioration of muscle function and rise in blood markers of 
muscle damage, when compared to a placebo (Shimomura et al., 2010; Etheridge, Philp and Watt, 2008). Of 
note, there is a tendency for longer, rather than acute, supplementation strategies to confer greater benefits in 
recovery from EIMD (Waldron et al., 2017; Howatson et al., 2012; Matsumoto et al., 2010; Kraemer et al., 
2006). In support, Nosaka, Sacco and Mawatari, (2006) demonstrated that extending AA supplementation 
several days beyond the immediate post-exercise period confers greater benefits in exercise recovery, such as 
an attenuated elevation in CK and a decrease in perceived soreness in the days following intense exercise, 
compared to AAs ingested only at pre and post-exercise.  
 
The exact mechanism which underpins the enhancement in recovery after the ingestion of AAs in the post-
exercise period is not understood. It has been erroneously suggested that accelerated recovery is due to the 
increase in MPS apparent after the ingestion of AAs. However, since the magnitude of myofibril protein 
turnover required to render a physiologically meaningful benefit on recovery is a lengthy process, this likely 
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does not explain the benefit in the short (several days) post-exercise period. Nonetheless, of the three 
branched-chain amino acids (BCAAs), leucine is the most evident contributor to postprandial anabolism and 
anti-catabolism (Atherton et al., 2010a). However, few studies have investigated the effect of leucine, in 
isolation, on recovery from intense resistance training. Those few that have investigated the effect of leucine 
supplementation on accelerating recovery from EIMD have deemed leucine alone to elicit little to no benefit 
when compared to a placebo (Stock et al., 2010). A plausible explanation for the insignificant differences in 
recovery markers or perceived soreness between treatment groups is that leucine was only consumed before 
and after exercise (two doses of ~1.9g), on the day of intense exercise bout. Instead, a recovery protocol aimed 
at providing several boluses of leucine in the hours following the intense exercise bout may accelerate 
recovery. To the best of our knowledge, no studies have investigated the effect of leucine supplementation on 
exercise recovery parameters in this way. The primary aim of the present study is to investigate whether 12g 
leucine, supplemented in the 14 h post-exercise period, exhibits a benefit on recovery of muscle function, 
markers of muscle damage and perceived soreness following an intense resistance exercise bout. Furthermore, 
recent research suggest that the timing of AA ingestion exhibits an effect on postprandial MPS, suggesting that 
BOLUS ingestion, in which large boluses are ingested ~4 h apart, over the course of the day, results in greater 
cumulative daily rate of MPS (Mamerow et al., 2014; Areta et al., 2013; Moore et al., 2012). For that reason, 
the two doses used in chapter 5 and 6, BOLUS and PULSE, and their effect on ameliorating the deleterious 
effects of intense resistance exercise, when applied using two different temporal strategies, are under 
investigation as a secondary aim.  
 
7. 2 Methods 
7. 2. 1 Study Design and Participants  
Participants were recruited through information leaflets and social media posts targeted at university students, 
seeking out healthy active males, between 18-35 years of age, participating in physical activity ≥3 times per 
week, for the last 6 months. All participants gave informed written consent before participating in the study. 
The experimental procedure was approved by University College Dublin (UCD) Research Ethics Committee in 
accordance with the Declaration of Helsinki. This study was a double-blind, placebo-controlled randomised 
cross-over design, comprising three experimental conditions (as per figure 7.1) with each separated by 
approximately 14 days as described in detail in Section 7.2.7. All preparation and recovery strategies and 
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experimental procedures were identical for each trial with the exception of the supplementation strategy 
provided in recovery. 
7. 2. 2 Baseline Testing and Familiarisation  
Thirteen healthy, active males [age (25.5±5.2y), height (1.82±0.07m), body mass (86.4kg ± 13.1kg) and BMI 
(26.1±3.4kg/m2)], participated in baseline testing and a familiarisation trial, one week prior to the first 
experimental trial.  
Baseline tests included body mass (to the nearest 0.2 kg) using a calibrated digital scales (SECA, Germany) and 
height (to the nearest 0.01 m) using a wall-mounted stadiometer (Holtain, UK). Participants were familiarised 
with a visual analogue scale (VAS) as a method of assessing soreness and perceived recovery status (Appendix 
1). Counter-movement jump (CMJ) onto a floor-mounted force plate (AMTI, Waterstown, USA) was performed 
to determine maximum jump height and peak power output. Following a warm-up, participants performed 
three CMJs at a self-selected depth, separated by two-minute rest intervals. Participants were familiarized with 
the leg press machine and proper lifting technique. Following a warm-up, the load was increased in single 
increments until a 3 repetition max (RM) was achieved. A two-minute rest period was allowed between each 
attempt. The maximum weight lifted for 3 reps was subsequently used to estimate their 1RM.  Using 60% of 
this estimated 1RM, 3 sets of 10 repetitions were performed with a two-minute rest period between sets.  
7. 2. 3 Diet and Activity Before Experimental Trial  
Participants recorded their food intake for 24 h prior to the start of the first experimental trial. This food record 
was photocopied and sent to participants in advance of subsequent trials. Participants were instructed to 
replicate this diet 24 h before the start of the second and third trial. Participants were instructed to continue 
their habitual training for the duration of their involvement in the study but to refrain from any type of physical 
exercise for 24 hours before each trial.  
7. 2. 4 Pre-Exercise Assessment  
On day 0, after an overnight fast, participants arrived at the laboratory. A resting blood sample (~4ml) was 
taken from the antecubital vein. Blood was drawn into a vacutainer containing lithium heparin (BD 
Vacutainers, Heparin Tubes), inverted eight to ten times and placed on ice. The blood was centrifuged at 4000 
g for 10 min at 4°C and the upper layer of plasma was transferred into three separate 1.5ml tubes and stored 
at -80°C until further analysis. Participants were asked to rate their perceived muscle soreness on 1-10 Likert 
pain VAS, with 0 being ‘no pain at all’ and 10 being ‘the worst pain imaginable’. Participants also rated their 
perceived recovery status using a 1-10 Likert VAS, with 0 being ‘very poorly recovered/extremely tired’ and 10 
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being very well recovered/highly energetic’ (See appendix 1). To minimise the possibility of anchoring bias, 
participants were not shown any of their previous ratings. Following a four-minute general warm-up on a cycle 
ergometer and a specific warm-up for the CMJ, participants completed three maximal effort CMJ, with two-
minute resting intervals between each jump.  
7. 2. 5 Muscle-Damaging Protocol 
The participants completed an individualized, incremental warm-up on the leg press based on their previously 
estimated 1RM. This protocol involved the completion of ten sets of ten (10x10) on the leg press at 60% of the 
individual’s estimated 1RM at a 4111 tempo, with each set separated by a two-minute rest interval. This 
protocol was based on the method used by Macdonald et al., (2014), which was shown to cause a deterioration 
in jump height performance, maximal voluntary contraction and increase in perceived muscle soreness in the 
24-48 h post-exercise period. The only deviation to their protocol was that we used the leg press exercise in 
place of barbell back squat exercise. To standardise the range of motion of the movement, a goniometer was 
used to mark the point on the leg press machine at which the participants produced a knee flexion angle of 
60°. A metre stick was placed at this point for the duration of the session to provide the subject with a visual 
cue for the depth of their movement (See appendix 2 for diagram). If the participants needed to drop the 
resistance in order to complete the total repetitions and sets, this was recorded and repeated for the 
subsequent trials.  
7. 2. 6 Post-Exercise Assessment  
Within 10-15 minutes of completing the exercise protocol (POST), another blood sample was taken. CMJs were 
repeated, in which three maximal effort CMJs, with two-minute resting intervals between each jump, were 
performed. Participants were asked to rate their perceived muscle soreness and perceived recovery status as 
per section 7.2.4.  
The participant’s first meal, consisting of a hemp protein shake and a pre-prepared carbohydrate and fat meal 
(See Section 7.2.8), was consumed before leaving the laboratory, along with two bottles of the appropriate 
supplement condition. A bag containing the participants’ meal plan and supplements for the subsequent 14 h 
was provided before departure, along with instructions for the timing of meals and supplement protocol.   
At 24 h POST and 48 h POST participants arrived to the laboratory after an overnight fast. A blood sample was 
taken prior to completion of the same warm-up and CMJ as Day 0. Soreness and perceived recovery were also 
recorded as described above.  
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7. 2. 7 Supplementation Protocol 
Each participant participated in three experimental trials separated by approximately 14 days. Each participant 
was randomly assigned to one of three groups in a cross-over design;  
 
• Bolus feeding (BOLUS), 3g free leucine every 4 hours for 14 hours 
• Pulse feeding (PULSE), 1.5g free leucine fed every 2 hours for 14 hours 
• Control group (CON), 3g maltodextrin fed every 2 hours for 14 hours 
Each supplement was provided as powder providing 1.5g of L-leucine (Sigma-Aldrich, Pharmagrade) or 
maltodextrin (Bulk Powders, UK) in an opaque 150ml bottle, to which plain water was added and the contents 
shook prior to ingestion. The flavour of the leucine and maltodextrin was masked with sucralose (0.04g per 
1.5g leucine/1.5g maltodextrin) to maintain the double-blind design of the study. Regardless of which 
condition the participant partook in, all participants consumed two bottles every two hours to maintain the 
double-blind design, as per figure 7.1. During the BOLUS condition, participants consumed 3g of leucine 
every 4 hours, and 3g of maltodextrin on the alternating four h period. During the PULSE condition, 
participants consumed 1.5g of leucine and 1.5g of maltodextrin every two hours. During the CON condition, 
participants consumed 3g of maltodextrin every two hours. Therefore, BOLUS and PULSE were isonitrogenous, 
and all three conditions were isocaloric. Participants were provided with pre-packaged bottles of supplements 
and instructed to consume each supplement at these specific times for the subsequent 14 h after completing 
the 10x10 leg press exercise protocol (See appendix 3 for participant instructions).  
7. 2. 8 Diet and Exercise Control  
The participants’ diets were controlled and standardised on Day 0 of the experimental trial i.e. during the 14 h 
recovery period, in which they followed a low leucine, but protein-rich meal plan for 14 h. Once the 10 x 10 
exercise protocol was completed, participants were provided their first meal of the plan in the laboratory. The 
remaining three meals were consumed at 4 h intervals throughout the day. Each meal plan was designed to 
provide the following – Protein 1.2g/kg (13% energy intake (EI)); Carbohydrate 5g/kg (53% EI); and Fat 
1.4g/kg (34% EI); and used low leucine plant-based foods such as hemp protein, cereal bars, nuts, isotonic 
sports drink, rice and oats (See appendix 4 for sample meal plan). Participants were asked not to partake in 
any form of organised exercise, foam rolling or mobilisation outside of the experimental trial for Day 0 and Day 
1 and were permitted to return to habitual exercise following the 48 h follow-up visit on Day 2.  
 
 
 133 
7. 2. 9 Data Analysis  
The concentration of creatine kinase (CK) and lactate dehydrogenase (LDH) in each blood samples was 
analysed as per section 3.4. We were unable to take blood samples from one participant, and another 
participant had CK values that were out of range for CK. CK and LDH are therefore representative of a n=11 
and 12, respectively. Jump height (by take-off velocity) and peak power was calculated from CMJ force plate 
data, as per Reiser, Rocheford and Armstrong (2006).   
7. 2. 10 Statistical Analysis 
Statistical analysis was performed using SPSS (IBM SPSS Statistics Version 23). In general, the distribution of 
the data approximated normality, or was transformed as appropriate to approximate normality. Two-way 
(condition x time) repeated measures ANOVAs was performed to determine changes, if any, in response to the 
exercise bout over time, and differences, if any, between supplement conditions at these time-points. When 
main or interaction effects were indicated, a repeated measures one-way ANOVA was used to determine 
differences between time-points within each supplement condition, using post-hoc pair-wise comparisons to 
PRE with Dunnet’s adjustment for multiple comparisons test. For all analyses, statistical significance was 
accepted at P<0.05. Independent of traditional null hypothesis statistical testing, standardised differences in 
the mean were used to assess magnitudes of effects for differences at 24 h and 48 h POST, compared to PRE. 
These effect sizes were calculated using Cohen’s d and interpreted using thresholds of 0.2, 0.5, and 0.8 for 
small, moderate, and large, respectively.  
 
 
 134 
 
Figure 7.1: Overview of study design.  
 
 
Figure 7.2: Overview of the supplement protocol in the 14-hour post-exercise period. LEU, leucine; 
MALTO, maltodextrin.  
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7. 3 Results  
7.3.1 Creatine Kinase and Lactate Dehydrogenase  
Figure 7.3A shows PRE CK values between each trial (u/L). Figure 7.4A represents percentage change from 
PRE for CK, at each time-point for each supplement condition (expressed as mean and SD). For CK, the two-way 
ANOVA revealed no main effect for condition (P=0.898), but a main effect for time (P=0.02). However, on 
further analysis, the post-hoc analysis revealed there was no difference in CK values between time-points 
(P>0.05 for all). Cohen’s d for differences in CK at POST, 24 h and 48 h compared to PRE were 1.66 (large), 
0.85 (large) and 0.57 (medium) for BOLUS respectively; 1.73 (large), 0.93 (large) and 0.39 (small), for PULSE 
respectively; and 1.90 (small), 1.00 (small) and 0.61 (medium), for CONTROL respectively.  
 
Figure 7.3B shows PRE LDH values between each trial (u/L). Figure 7.3B represents percentage change from 
PRE for LDH, at each time-point for each supplement condition (expressed as mean and SD). For LDH, the two-
way ANOVA revealed no main effect supplement condition (P=0.468), or for time-point (P=0.163). Cohen’s d 
for differences at POST, 24 h and 48 h compared to PRE were 1.35 (large), 0.78 (medium) and 0.67 (medium) 
for BOLUS respectively; 0.23 (small), -0.27 (small) and 0.08 (trivial), for PULSE respectively; and 0.07 (trivial), 
0.10 (trivial) and -0.11 (trivial), for CONTROL respectively. 
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Figure 7.3: Creatine kinase values (A) and lactate dehydrogenase (B) at PRE between each trial. Plotted as 
mean±SD (bars) and individual data points (lines and symbols). Expressed as units per per litre (u/L). n=11 for creatine 
kinase; n=12 for lactate dehydrogenase.  
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Figure 7.4: Percentage change in creatine kinase (A) and lactate dehydrogenase (B) expressed in units per 
litre (u/L), across each supplement condition, pre-exercise, immediately post-exercise, 24 hours and 48 
hours post-exercise.  Values are Mean±SD. A two-way repeated measures ANOVA was performed (Condition*Time-
point). When P<0.05, post-hoc one-way repeated measures ANOVA were used to determine where differences existed 
between time-points. Difference existing from PRE is indicated by *P<0.05.    
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7.3.2 Perceived Muscle Soreness and Recovery 
Figure 7.5A represents perceived muscle soreness, at each time-point for each supplement condition 
(expressed as mean and SD). For perceived muscle soreness, the two-way ANOVA revealed a main effect for 
time (P<0.001), but no main effect for condition (P=0.678). Perceived soreness experienced an increase in 
the immediate post-exercise period for each groups. Mean values increased from 1.2±1.0, 0.9±0.8 and 
1.0±1.1 at PRE, to 3.6±1.9, 3.8±2.2 and 3.2±2.1 at POST in BOLUS, PULSE and CONTROL, respectively 
(P<0.05 for all, Cohen’s d = 2.08 (large), 2.52 (large) and 1.86 (large), respectively). At 24 h POST, perceived 
soreness increased to 3.9±1.9, 4.2±1.7 and 4.6±2.5 in BOLUS, PULSE and CONTROL condition, (P<0.05 for 
all, Cohen’s d = 2.08 (large), 2.52 (large) and1.86 (large) respectively). At 48 h POST, perceived soreness 
remained elevated above PRE (3.5±2.2, 3.6±2.1 and 4.5±2.8 for BOLUS, PULSE and CONTROL, respectively) 
(P<0.05 for all, Cohen’s d = 1.36 (large), 1.74 (large) and 1.69 (large) respectively).  
 
Figure 7.5B represents perceived recovery at each time-point for each supplement condition (expressed as 
mean and SD). For perceived recovery, the two-way ANOVA revealed a main effect for time (P<0.001), but no 
main effect for condition (P=0.757). Perceived recovery decreased in the immediate post-exercise period for 
each group. Mean values decrease from 7.6±1.6, 8.1±1 and 7.9±1.1 at PRE, to 4.4±1.8, 4.1±2.1 and 
3.9±1.9 at POST, in BOLUS, PULSE and CONTROL, respectively (P<0.05 for all, Cohen’s d = -1.28 (large), -0.93 
(large) and -0.85 (large), respectively). At 24 h POST, perceived recovery decreased to 5.1±2.3, 5.1±2.4 and 
5.4±2.7 for BOLUS, PULSE and CONTROL, respectively (P<0.05 for all, Cohen’s d = -1.28 (large), -1.64 (large) 
and -1.22 (large), respectively). At 48 h POST, perceived recovery remained unchanged from PRE for all 
conditions 5.8±2.3, 6.4±2.4 and 6.3±2.5 for BOLUS, PULSE and CONTROL, respectively (P>0.2 for all, 
Cohen’s d =-0.86 (large), -0.93 (large) and -0.85 (large), respectively). 
7.3.3 Muscle Function   
Figure 7.6A represents jump height in centimetres, at each time-point for each supplement condition 
(expressed as mean and SD). For jump height, the two-way ANOVA revealed a main effect for time (P<0.001), 
but no main effect for condition (P=0.583). The post-hoc analysis revealed that jump height was lower 
immediately POST, in which it decreased from 35±6, 35±5 and 35±6 at PRE to 31±4, 30±5 and 31±5 for 
BOLUS, PULSE and CONTROL (P<0.05 for all, Cohen’s d = -0.83 (large), -0.93 (large) and -0.67 (medium), 
respectively). No further decrement in jump height was apparent at 24 h POST (P>0.99 for all). Jump height 
for BOLUS, PULSE and CONTROL at 24 h POST was 34±6, 34±7 and 35±5, respectively. Cohen’s d for jump 
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height at 24 h compared to PRE were -0.16 (trivial), -0.92 (large) and -0.02 (trivial), respectively. No further 
decrement in jump height was apparent 48 h POST (P>0.99 for all). Jump height for BOLUS, PULSE and 
CONTROL at 48 h POST was 35±5, 34±6 and 35±7, respectively. Cohen’s d for jump height at 48 h compared 
to PRE were -0.12 (trivial), -0.08 (trivial) and -0.01 (trivial), respectively.  
 
Figure 7.6B represents peak power in Watts, at each time-point for each supplement condition (expressed as 
mean and SD). For peak power, the two-way ANOVA revealed a main effect for time (P<0.001), but no main 
effect for condition (P=0.352). The post-hoc analysis revealed that peak power was lower immediately POST, in 
which it decreased from 4244±476, 4306±671 and 4280±684 at PRE to 3971±526, 3934±561 and 
4017±540 for BOLUS, PULSE and CONTROL (P<0.05 for all, Cohen’s d = -0.57 (medium), 0.60 (medium) and 
-0.43 (small) respectively). No further decrement in peak power was apparent at 24 h POST (P>0.99 for all). 
Jump height for BOLUS, PULSE and CONTROL at 24 h POST was 4223±662, 4209±656 and 4292±590, 
respectively. Cohen’s d for peak power at 24 h compared to PRE were -0.03 (trivial), -0.15 (trivial) and -0.02 
(trivial) respectively. No further decrement in peak power was apparent 48 h POST (P>0.99 for all). Peak power 
for BOLUS, PULSE and CONTROL at 48 h POST was 4247±709, 4196±633 and 4316±720, respectively. 
Cohen’s d for peak power at 48 h compared to PRE were 0.01 (trivial), 0.01 (trivial) and -0.17 (trivial), 
respectively.  
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Figure 7.5: Perceived soreness (A) and perceived recovery (B) using a 1-10 Likert visual analogous scale, 
across each supplement condition, pre-exercise, immediately post-exercise, 24 hours and 48 hours post-
exercise.  Values are Mean±SD. A two-way repeated measures ANOVA was performed (Condition*Time-point). When 
P<0.05, post-hoc one-way repeated measures ANOVA were used to determine where differences existed between time-
points. Difference existing from PRE is indicated by *P<0.05.    
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Figure 7.6: Jump height, expressed in centimetres (A) and peak power, expressed in Watts (B), across 
each supplement condition, pre-exercise, immediately post-exercise, 24 hours and 48 hours post-
exercise.  Values are Mean±SD. A two-way repeated measures ANOVA was performed (Condition*Time-point). When 
P<0.05, post-hoc one-way repeated measures ANOVA were used to determine where differences existed between time-
points. Difference existing from PRE is indicated by *P<0.05.    
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7.4 Discussion  
The aim of the current study was to investigate if 12g leucine, supplemented in the 14 h post-exercise period 
in either BOLUS or PULSE form, would ameliorate changes in blood markers of muscle damage, muscle 
function and perceived soreness and recovery, at 24 h and 48 h after an intense resistance exercise bout. Our 
results conclude that leucine supplementation of a protein-rich meal plan offers no enhancement in recovery 
from intense resistance exercise in the selected markers under investigation.  
Current literature suggests that the supplementation of AAs in the post-exercise period minimises the 
deleterious effects of intense resistance exercise. Greer et al., (2007) demonstrated that 2.5g BCAA pre-exercise 
and 60 min post-exercise, resulted in attenuated increase in CK, LDH and soreness following 90 min cycle at 
55% V02peak in untrained males. Waldron et al., (2017) demonstrated that ~8g BCAAs was superior to dextrose 
placebo in attenuating the decrease in CMJ performance and perceived soreness following an intense 
resistance exercise bout. Howatson et al. (2012) also concluded that 10g BCAAs x2 per day in the 4 days post-
exercise reduced the rise in CK concentrations and perceived soreness, compared to placebo, following 100 
drop jumps. Results from the present trial are in contrast with the aforementioned findings, in which no 
difference were apparent in CK, LDH, CMJ performance or perceived soreness, between leucine supplement 
groups, compared to a maltodextrin control. This is agreement with finding by Betts et al., (2009), in which 
21g protein was added to a carbohydrate drink, and fed in eight boluses every 30 min following 90 min 
intermittent shuttle runs. Authors found no difference in CK, LDH or soreness when protein was added to a 
carbohydrate drink. Similarly,   Ra et al., (2013) concluded that BCAA supplementation three times a day, for 2 
weeks prior and 3 days after intense resistance exercise had no added benefits on CK, LDH or perceived 
soreness, compared to control. The present findings suggest that 12g leucine ingested over the 14 hour post-
exercise period exhibits no further enhancement in recovery, when compared to a placebo, following intense 
resistance exercise. Importantly, we prescribed a meal plan for the day of the experimental protocol, which 
provided 1.2g/kg BM protein, with carbohydrate, fat and energy intake matched to the individuals BM and 
predicted energy requirements based on activity-adjusted metabolic rate. Of note, the dietary control of the 
trial was a strength of the study design, particularly as previous studies investigating the benefit of leucine 
supplementation on recovery from intense exercise allowed participant to follow their habitual diet (Kirby et 
al., 2012; Stock et al., 2010). The ad libitum dietary intake resulted in an intake of ~1g and ~1.4-1.9g/kg body 
mass protein respectively (Kirby et al., 2012; Stock et al., 2010). The higher intake of protein and particularly 
the lack of control over types of protein (i.e. the allowance of animal-based proteins), would result in a high 
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leucine intake post-exercise, and therefore potentially negate any benefit of additional supplementary leucine. 
In the present study it is possible that the meal plan provided sufficient nutrients to recover from intense 
exercise, and the additional leucine offered no further advantage on recovery. However, another explanation 
for the lack of differences, is that the markers of muscle damage and performance measures were not sensitive 
to the intense exercise bout, and therefore, any differences in measures as a result of the treatment group was 
unable to be detected.  
In relation to the latter point, our results suggest that 1) there is large inter-subject and intra-subject variability 
(See figure 7.3) in CK values following exercise; and 2) plasma CK is a poor marker of muscle damage in the 
conditions under study herein, both of which have been reported elsewhere (Waldron et al., 2017; Nosaka, 
Newton and Sacco, 2002; Malm et al., 2000). Moreover, the large variability at PRE due to our limited control 
of the participants’ own training outside the intervention may have contributed to variability in CK results in 
response to the intervention. Five participants showed particularly large variability in PRE CK values for the 
three trials (>380u/L between trials), which suggests that they were more/less rested for some exercise 
sessions than others (See figure 7.3). This highlights that asking participants to take 24 h rest from exercise 
before each exercise session was not sufficient time to facilitate full recovery from their own training, and 
emphasises the limitation of recruiting participants from different training backgrounds who are not 
participating in the same training programme (i.e. as part of the same sport/team). This is a plausible 
explanation for the large variation in CK concentrations in response to the exercise sessions (with some CK 
concentrations showing a decline 24 h and 48 h POST), as completing the trial with already elevated CK 
concentrations pre-intervention may have masked the exercise-induced increase in CK. In support, CK may 
recede to baseline values only 7 to 14 days following exercise cessation (Lieber and Friden, 2002), which 
would suggest that rest beyond the 24  h window  before commencing the exercise trial is warranted. LDH 
followed a similar pattern to CK, in that there was a high degree of inter-subject and intra-subject variability in 
results. There was no apparent difference in LDH for at any time-point or between conditions. This suggests 
that LDH is a poor marker of muscle damage or the outside training of participants interfered with LDH, as in 
the case of CK. 
Another explanation that should not be discounted is that the exercise protocol was unable to elicit sufficient 
muscle damage that could be detected in the blood markers chosen. The protocol was adapted from 
Macdonald et al., (2014) in which participants performed 10x10 in the back squat movement at 60% 1RM. This 
protocol resulted in deterioration in jump height performance, knee extension MVC and increase in perceived 
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muscle soreness in the 24-48 h post-exercise period. Furthermore, difference between treatment groups 
(presence or absence of foam rolling) for these parameters was also detected. While the protocol employed 
was similar to Macdonald et al., (2014), the leg press was used in place of a squat movement, as range of 
motion was easier to control with a leg press movement. The perceived soreness and recovery results suggest 
however that our modified exercise protocol was indeed successful in eliciting some degree of muscle 
damage. Perceived soreness increased at 24 h POST (240%-391% increase across conditions compared to PRE) 
and remained elevated at 48 h POST (200%-354% increase across conditions compared to PRE). This is 
consistent with finding by others assessing perceived soreness using a pain VAS at 24 and 48 h POST (Philpott 
et al., 2018; Macdonald et al., 2014; Cockburn et al., 2012; Howatson et al., 2012). Perceived recovery 
followed a similar trend, in which feelings of recovery decreased immediately post-exercise. A decrement in 
feeling of recovery and readiness to perform was apparent at 24 h; POST (33%-37% decrease across conditions) 
and remained apparent at 48 h POST (21%-24% decrease across conditions). It is partly for this reason that we 
speculate above that CK and LDH are not appropriate biomarkers of muscle damage in this study. In any case, 
there was no difference in perceived soreness or recovery between placebo and both leucine conditions, 
suggesting that supplementing with leucine in the 14 h post-exercise does not confer a benefit to alleviating 
sensations of DOMS. Similarly, Cockburn et al., (2012) demonstrated that the ingestion of 500ml and 1000ml 
milk post-exercise had no effect on change of perceived soreness, compared to when water was ingested 
following 6 sets of 10 repetitions knee flexion exercise. However, a positive attenuation of CK and recovery of 
knee flexion peak torque was apparent for the 1000ml milk group in the days following exercise. Etheridge, 
Philp and Watt, (2008) also demonstrated that the ingestion of 100g milk protein concentrate post-exercise 
had no effect on change of perceived soreness, compared to a placebo, following 30 min downhill running. 
However, a positive influence on recovery of MVC during an isometric knee extension, and 5 second peak 
power output (PPO) on a cycle ergometer, was apparent for the milk group. These results suggest that 
perceived soreness may be an insensitive measure of recovery, as the latter studies demonstrate that the 
treatment condition exhibited a positive effect on blood markers and performance measures, with no different 
for soreness measures.  
The use of a closed chain movement such as the leg press, as opposed to the open chain movement of the back 
squat, may not be appropriate for the current study to create sufficient muscle damage to elicit a robust decline 
in muscle function. While the premise for using large muscle groups to create muscle damage was to make the 
protocol specific to a real world setting in which complex movements are often performed in training (e.g. 
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deadlifts, squats, and bench press), an isolated movement (such as a leg extension or bicep curl) may have 
been more appropriate. A MVC assessment, in which muscle function in the movement used in the damaging 
protocol was assessed, may have given more of an insight into the extent of performance decrement in the 
exact muscle groups trained in the muscle-damaging protocol. While performance in CMJ showed a 
decrement immediately post-exercise, this decrement was not apparent 24 and 48 h POST for any condition. 
This in contrast with finding by Waldron et al., (2017) who found a decrement in CMJ performance at 24 h 
POST intense resistance training. Etheridge, Philp and Watt, (2008) also found a decrease in PPO at 24 h POST. 
However, in this study three maximal 5 second sprints on a cycle ergometer were used as an assessment of 
peak power. CMJ may potentially be an inappropriate measure of fatigue and recovery, and a MVC may have 
provided a better insight into fatigue and recovery status. Indeed, protocols in which an isolated movement 
was used to elicit muscle damage showed a marked decrease in MVC in the same movement 24 h and 48 h 
POST (Philpott et al., 2018; Howatson et al., 2012; Etheridge, Philp and Watt, 2008).  
The present study used a cross-over design, which while a strength in most study designs, is a potential caveat 
in the present study. The reason for using a cross-over design was that participants acted as their own control, 
which is particularly beneficial since participants were from different training backgrounds, a factor that may 
influence the severity of their response to the exercise bout. For instance, those individuals routinely exposed 
to a similar training stimulus to the movement and/or repetition range being used in the muscle-damaging 
protocol will have a blunted response in muscle damage to the protocol (McHugh, 2003). However, since we 
were attempting to investigate EIMD, a repeated bout effect may have interfered with the results, whereby the 
first trial created the most amount of muscle damage resulting in a substantial adaptation and rendering an 
attenuated response to subsequent trials (Howatson and Van Someren, 2008). To minimise the interference of 
the repeated bout effect with our results, we therefore adopted a randomised trial order for each participant. 
This method has been used elsewhere, however, exercise trials were separated by a 12-week interval to 
minimise the interference of a repeated bout effect (Shimomura et al., 2006). It remains a speculation as to 
what effect the cross-over design may have had on our results.  
In summary, it was difficult to interpret the true effect of leucine supplementation on recovery from EIMD due 
to multiple factors interfering with our outcome variables. Recommendations for future research in assessing 
the impact of a supplement strategy on ameliorating the negative implications of DOMS are as follows; Recruit 
participants from a team who are therefore partaking in a similar training program, thereby minimising the 
interference of different training programs with the response to the intense resistance exercise bout. Ask 
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participants to rest for 72 h before each exercise bout in order to ensure that they are rested from their own 
training and thereby establish a true baseline for ‘resting’ CK, or other biomarker, concentrations. If 
participants are recruited from a team in this way, opt for a parallel design, to minimise the interference of the 
repeated bout effect. Use an isolated movement such as a knee extension to elicit muscle damage, and use a 
MVC in the knee extension to assess muscle function at 24 h and 48 h POST.  
7.5 Conclusion  
Our results conclude that leucine supplementation offers no enhancement in recovery from EIMD.  
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Chapter 8 
8.0 The Effect of a Nutrition Intervention Targeting Leucine-Rich 
Meals on Changes in Calorie, Macronutrient and Micronutrient 
Intake, and Protein Distribution in Older Adults  
Background: Inadequate dietary protein intake is a key contributor to the decline in skeletal muscle mass and function 
with advancing age. Protein, and in particular the amino acid leucine, acts as an anabolic stimulus and stimulates skeletal 
muscle protein synthesis (MPS), and has therefore been emphasised in nutrition strategies targeting sarcopenia.  
Objective: The aim of the present study was to determine if instruction and support for a high protein diet, prescribing 
the equivalent of 3g of leucine per meal, eaten at breakfast, lunch and dinner, is efficacious in augmenting protein intake 
and protein distribution in older adults. 
Design: Participants aged ≥65 were recruited to participate in this study. Participants (n=56) were randomly assigned to 
one of the following three groups for 12 weeks, as part of a larger study that also included an exercise training 
intervention: nutrition and exercise group (NUTR+EX); non-exercise nutrition only group (NUTR) and exercise only group 
(EX). NUTR+EX and NUTR were provided with instructions and weekly support to follow a high protein diet that was rich in 
leucine. Meals equating to 3g of leucine were translated to user-friendly portion sizes and support was provided through 
weekly emails and fortnightly phone calls. EX were asked not to change their diet for the duration of the study. All 
participants completed a 3-day portion estimate food diary at week 0 (PRE), week 6 (MID) and week 12 (POST).  
Data Analysis: Food diaries were analysed using Nutritics Nutrition Analysis Software. Changes in calorie, macronutrient 
and micronutrient intake, and protein distribution over time and between groups was evaluated using a mixed ANOVA. 
Post-hoc analysis was performed using one-way ANOVA, repeated measured ANOVA, and pairwise comparisons with 
Bonferroni’s adjustment.  
Results: At MID, daily protein intake increased in NUTR+EX (65.8± 3.8 to 117.8±23.7g, P<0.01) and NUTR (73.4±25.7 
to 119.9±30.5g, P<0.01). At MID, Relative protein intake increased in NUTR+EX (0.90±0.20 vs. 1.57±0.49g/kg body 
mass, P<0.05) and NUTR (0.99±0.34 to 1.43±0.39 g/kg body mass, P<0.05). At MID and POST, average protein intakes 
for breakfast, lunch and dinner were ≥30g or ≥0.4g/kg protein, in both nutrition intervention groups. There was no 
difference between values at MID and POST in both nutrition intervention groups, whereas there was no change in any 
dietary parameter in EX from PRE to MID and POST. 
Conclusion: The nutrition intervention was efficacious in increasing protein intake and achieving a more even pattern of 
daily protein distribution. At MID and POST in both nutrition intervention groups, daily and per meal protein intake 
reflected an intake that is considered optimal for maximising MPS in older adults. Prescribing and providing support for a 
whole food-based diet, specifically targeting 3g leucine at breakfast, lunch and dinner, is an effective means of increasing 
protein intake and optimising daily protein distribution in older adults. 
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8.1 Introduction 
The age-related decline in skeletal muscle mass and function represents a fundamental threat to healthy 
ageing. This deterioration in muscle mass and function is associated with functional impairment, physical 
disability, increased frailty and a decrease in quality of life (Fielding et al., 2011; Janssen, 2010). This is a 
multifaceted issue and an effective prevention and treatment remains to be established (Janssen, 2010). 
Inadequate dietary intake, in particular protein, is a key contributor to this decline in muscle mass and function 
with advancing age (Phillips, 2015; Bauer et al., 2013; Malafarina et al., 2013). Protein and essential amino 
acid (EAA) supplementation, and/or exercise, which each act as an anabolic stimulus and stimulate MPS have 
been emphasised in preventing and treating age-related decline in muscle mass and function (Phillips, 2015; 
Bauer et al., 2013; Malafarina et al., 2013). 
Habitual protein intake tends to declines with advancing age. Fulgoni, (2008) reported total protein intake of 
91g/day/1.3g/kg in young adults aged 19-30 years, and 66g/day 1.0g/kg in older adults aged >71 years. In 
chapter 4, we showed that habitual dietary protein intake amongst Irish adults decreases from 1.3±0.4 g/kg/d 
in adults aged 18-35 years, to 1.1g±0.3 g/kg/d in adults aged >65 years. Furthermore, protein intake 
followed a skewed pattern, in which 15±10g, 30±15 and 44±17g was eaten and breakfast, lunch and dinner 
(See Chapter 4, Figure 4.1). This skewed pattern is considered to be suboptimal for maximising diurnal MPS 
rates (Paddon-Jones et al., 2015; Mamerow et al., 2014). In this instance, while protein intake at dinner is 
sufficient to elicit a robust postprandial anabolic response, low protein intake at breakfast and lunch represent 
a missed opportunity to maximise MPS for that mealtime. Distributing protein intake more equally throughout 
the day, in which each meal has a sufficient protein dose, has been shown to be most optimal to maximise 
MPS (Areta et al., 2013; Moore et al., 2012). Indeed, cross-sectional and epidemiological data demonstrate 
that a more even protein distribution throughout the day is related to a decrease in frailty (Bollwein et al., 
2013), and consuming 1-2 meals ≥30g protein per day is associated with greater lean mass and strength 
(Loenneke et al., 2016). Moreover, interventions to increase protein intake specifically at breakfast and lunch 
have resulted in positive changes in LBM in middle-aged adults (Norton et al., 2016; Bauer et al., 2015).  
While the current recommended daily intake of protein for all adults, regardless of age and sex, is 0.83g per kg 
body mass per day (g/kg/d) (European Food Safety Authority, 2012), older adults have a higher protein 
requirement than young (Nowson and O’Connell, 2015). There is a growing acceptance that older adults 
require >1.2g/kg/d protein to maintain muscle mass and function (Traylor, Gorissen and Phillips, 2018), with 
intakes up to 1.5g/kg/d required for those suffering from acute or chronic disease (Bauer et al., 2013). This 
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higher requirement for dietary protein is related to the dampened anabolic response to anabolic stimuli, such 
as exogenous essential amino acids (EAAs) and exercise, which is apparent in older adults and is termed 
‘anabolic resistance’ (Morton et al., 2018). However, this inferior anabolic response in older adults can be 
‘rescued’ by increasing the dose of EAA ingested (Paddon-Jones et al., 2004) and in particular the quantity of 
the AA leucine (Katsanos et al., 2006). Indeed, there is growing evidence to support the recommendation of 
protein on a ‘per meal’ basis. 0.40 g/kg per meal of a high-quality protein (Moore et al., 2015) or >20-30 g per 
meal, containing about 2.5 to 2.8g leucine (Layman et al., 2015; Bauer et al., 2013; Symons et al., 2009; 
Katsanos et al., 2006) represents the optimal per meal protein consumption to elicit a maximal anabolic 
response in elderly adults. Notably, leucine is well established as the key amino acid which triggers this 
postprandial anabolic response (Pasiakos, 2012; Atherton et al., 2010a). Despite the importance of leucine in 
the anabolic response, to date, the effect of specifically targeting an optimal dose of leucine on per meal basis, 
over an extended period, has not been explored for effects on muscle mass and function in older adults. 
However, prior to examining effects on functional outcomes, it is necessary to consider the effects of such a 
dietary strategy on changes in daily protein intake and distribution.  
The consumption of whole food meals, as opposed to the consumption of supplements via powder or capsule 
form, is representative of a normal diet (van Vliet et al., 2018). To date, much of the research aimed at 
increasing dietary protein intake in older adults has focus on the use of protein powders, such as whey and 
casein protein, and AA mixtures (Thomas et al., 2016; Norton et al., 2016; Bauer et al., 2015; Malafarina et al., 
2013) . While these studies show promise, there remains a significant gap in the literature for the use of a 
whole food-based nutrition intervention. Moreover, foods consumed in their whole-form, such as whole egg 
and whole-milk, when compared to egg white and skimmed milk, respectively, show superiority in stimulating 
postprandial anabolism (van Vliet et al., 2017; Elliot et al., 2006). Therefore, a whole-food intervention may 
offer an advantage to skeletal muscle accretion over time. Interventions targeting the consumption of beef 
twice daily (Daly et al., 2014), whole-milk twice daily (Tieland et al., 2012a) and a range of dairy products twice 
daily (Iuliano, Woods and Robbins, 2013), have proven efficacious in increasing dietary protein intake. 
However, a dietary strategy that does not rely on one food or food group for additional protein, and focuses on 
a mixture of protein sources, may represent a long-term, sustainable approach to increasing per meal protein 
intake in older adults. 
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The aim of the present study was to determine if instruction and support for a high protein diet, prescribing the 
equivalent of 3g of leucine per meal, eaten at breakfast, lunch and dinner, is efficacious in augmenting protein 
intake and protein distribution in older adults. 
8.2 Methods 
8.2.1 Study Design and Participants  
Participants were recruited primarily through a UCD Alumni newsletter seeking males and females aged ≥65 
years who were medically stable, and who were free-living, fully mobile and capable of completing the 
proposed intervention. Participants were excluded if they reported a history of myocardial infarction, cardiac 
illness, vascular disease, uncontrolled metabolic disease, stroke, or major systemic disease; or if already 
engaging in two or more structured exercise sessions per week. All participants gave informed written consent 
before participating in the study, which was approved by the Office of Research Ethics at University College 
Dublin in accordance with the Declaration of Helsinki. Upon entry to the study, which was part of a larger 
exercise training intervention study (chapter 9) participants were randomly assigned to one of the following 
three groups: nutrition and exercise group (NUTR+EX); exercise only (EX); non-exercise nutrition only group 
(NUTR). Five participants from NUTR were excluded from final analysis due to non-compliance and two 
participants dropped out of EX due to failure to commit to training frequency, leaving a final n size of 56 
(NUTR+EX, n=21; NUTR, n=16; EX, n=19). 
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Figure 8.1: Overview of study design.  
8.2.2 Nutrition Intervention   
All participants completed a Food Frequency Questionnaires before the intervention commenced, to capture 
habitual dietary intake. NUTR+EX and NUTR were instructed to follow a high protein diet, which focussed on 
the prescription of providing 3g leucine per meal, for the 12-week period (See appendix 5 for instructions on 
nutrition intervention). The nutrition strategy was designed using the USDA Food Composition Database, in 
which animal-based protein sources, equating to 3g of leucine, were translated to user-friendly portion sizes 
and meals. Participants from NUTR+EX and NUTR were brought into the laboratory in small groups of 4-6 and 
the nutrition strategy was explained in detail to the group. Participants were instructed to consume a leucine-
rich (≥3g) meal at breakfast, lunch and dinner, every day for the 12-week period. Participants were given a list 
of foods and the portion size of each food to choose from at each main meal. Participants were required to 
consume the specified portion in one sitting, and were asked not to split the portion over different eating 
occasions. No restriction was placed on energy intake. Participants were given a check-list diary to track their 
adherence daily (See appendix 6). A weekly newsletter was sent to both NUTR+EX and NUTR groups, 
detailing leucine-rich recipe ideas. Weekly contact was kept with NUTR+EX during supervised exercise 
sessions, while fortnightly phone call contact was kept with NUTR, in which continued support and advice was 
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provided to encourage participants to adhere to the intervention. EX were asked not to change their habitual 
dietary intake for the duration of the trial. All participants completed a 3-day portion estimate food diary at PRE, 
MID and POST. Participants were asked to estimate food-weight based on food packaging, and if this was not 
possible, to quantify and describe food size as accurately as possible. For mixed meals and recipes, participants 
were asked to record each meal component and/or ingredient separately (See appendix 7 for food diary 
instructions).  
8.2.3 Data Analysis 
Food diaries were analysed using Nutritics Nutrition Analysis Software (Version 5.029). The log of each meal 
was separated into eating occasions (EO), defined as any energy-containing food or fluid separated by more 
than 30 minutes. For intake and distribution, EO were assessed to determine the following:  
• Protein Distribution Score20(PDS20): The number of EO per day containing over 20g of protein, 
averaged across the 3 days.  
• Protein Distribution Score30(PDS30): The number of EO per day containing over 30g of protein, 
averaged across the 3 days.  
• Individual protein target (IPT): 0.4g x body mass (kg) per meal  
• Protein Distribution ScoreIPT(PDSIPT): The number of EO per day containing over the IPT, averaged over 
the 3 days.  
A score of 1 was given to each meal reaching the 20g protein, 30g protein and 0.4g/kg body mass protein 
threshold, for PDS20, PDS30 and PDSIPT, respectively. This scoring system is adapted from (MacKenzie et al., 
(2015) and based on the current recommendation of >20-30g protein and/or 0.4g/kg per meal in maximising 
MPS in older adults (Layman et al., 2015; Moore et al., 2015; Bauer et al., 2013; Symons et al., 2009).  
 8.2.4 Statistical Analysis 
 Statistical analysis was performed using SPSS (IBM SPSS Statistics Version 23). All data are presented as 
mean±SD. In general, the distribution of the data approximated normality, or was log transformed as 
appropriate to approximate normality, to allow detection of significant differences between and within groups. 
The difference from baseline over time within groups, and the difference between treatment groups at the 
same time-points, for all variables was analysed using a two-way (group x time) mixed ANOVA. When main or 
interaction effects were indicated, post-hoc analysis was performed using one-way ANOVA, repeated measured 
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ANOVA, and pairwise comparisons with Bonferroni’s adjustment for multiple comparisons. Statistical 
significance was accepted at P<0.05. 
8.3 Results  
8.3.2 Calorie and Macronutrient Intake  
Table 8.1 details energy and macronutrient intake in each group PRE, MID and POST. At PRE, EX group had a 
greater calorie intake compared to NUTR+EX (1823±344 vs. 1466±371 kcal, P<0.05, respectively). There was 
no change in dietary intake in EX throughout the intervention period, whereas the dietary intervention was 
successful in increasing daily protein intake, and consequently energy intake, in NUTR+EX and NUTR. At MID, 
protein intake increased in NUTR+EX (65.8±13.8g to 117.8±23.7g, P<0.001) and NUTR (73.4±25.7g to 
119.9±30.5g, P<0.001), compared to PRE, with no difference between values from MID to POST in both 
groups. Table 8.2 details calorie and macronutrient intake relative to body mass in each group at PRE, MID 
and POST. Relative protein intake increased in NUTR+EX (0.90±0.20 to 1.57±0.49g/kg, P<0.001) and NUTR 
(0.99±0.34 to 1.43±0.39 g/kg, P<0.001), between PRE and MID, with no change in EX. Fat intake increased 
at MID in NUTR+EX (56.2±19.7 to 73.4±22.7, P<0.05). Carbohydrate intake did not differ between groups 
and remained similar over time. 
 
Table 8.1: Calorie and macronutrient intakes at PRE (week 0), MID (week 6) and POST (week 12), in 
nutrition and exercise group (NUTR+EX), nutrition only group (NUTR) and exercise only group (EX). Data 
are mean±SD. CHO, carbohydrate. Statistical analysis was performed using two-way ANOVA. Post-hoc pairwise 
comparisons with Bonferroni’s adjustment were used to determine where differences existed within groups compared to 
PRE as indicated by *P<0.05, **P<0.01, ***P<0.001 for the annotated time-point. Differences between groups are 
indicated by # to denote differences from NUTR+EX group, and † to denote differences from NUTR group, for the time-
point (P<0.05).   
 Energy (kcal) Protein (g) CHO (g) Fat (g) Alcohol (g) 
NUTR+EX      
Pre 1466 ± 371 65.8 ± 13.8 152.0 ± 50.7 56.2 ± 19.7 13.4 ± 13.6 
Mid 1873 ± 449** 117.8 ± 23.7*** 151.6 ± 43.6 73.4 ± 22.7* 19.4 ± 20.3 
Post 1971 ±837** 117.1 ± 39.3*** 151.4 ± 51.2 70.6 ± 23.9 19.7 ± 18.0 
      
NUTR      
Pre 1648 ± 441 73.4 ± 25.7 173.6 ± 59.0 64.3 ± 22.3 12.7 ± 16.6 
Mid 1949 ± 428** 119.9 ± 30.5*** 154.6 ± 43.4 78.4 ± 23.9 20.3 ± 20.9 
Post 1989 ± 439** 113.1 ± 29.3*** 168.5 ±51.9 79.8 ± 27.1 20.2 ± 21.6 
      
EX      
Pre 1823 ± 344# 80.0 ± 18.1 188.0 ± 38.1 69.6 ± 18.1 17.1 ± 19.2 
Mid 1777 ± 437 77.4 ± 18.1#† 175.9 ± 53.4 67.6 ± 23.4 21.7 ± 22.7 
Post 1793 ± 421 75.6 ± 23.6#† 185.2 ± 63.7 66.6 ± 16.8 21.2 ± 20.7 
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Table 8.2: Relative macronutrient intakes at PRE (week 0), MID (week 6) and POST (week 12), in nutrition 
and exercise group (NUTR+EX), nutrition only group (NUTR) and exercise only group (EX). Data are 
mean±SD. CHO, carbohydrates; EI, energy intake. Statistical analysis was performed using two-way between-within 
ANOVA. Post-hoc pairwise comparisons with Bonferroni’s adjustment were used to determine where differences existed 
within groups compared to PRE as indicated by *P<0.05, **P<0.01 and ***P<0.001, for the annotated time-point. 
Differences between groups are indicated by # to denote differences from NUTR+EX group, and † to denote differences 
from NUTR group, for the time-point (P<0.05).   
 
8.3.3 Protein Distribution  
Table 8.3 presents PDS scores for meals reaching the 20g, 30g and 0.4g/kg protein target. At baseline PDS20 
was greater in EX compared to NUTR+EX (1.65±0.67 vs. 1.14±0.52, P=0.025). The nutrition intervention was 
successful in increasing PDS20 in NUTR+EX and NUTR. At MID, PDS20 increased in NUTR+EX (1.14±0.52 to 
2.68±0.41, P<0.001) and NUTR (1.50±0.54 to 2.69±0.48, P<0.001), with no difference between values 
from MID to POST in both groups.  PDS20 was greater in NUTR+EX and NUTR, compared to EX, at both MID and 
POST (P<0.001 for both). The nutrition intervention was successful in increasing PDS30 in NUTR+EX and NUTR. 
At MID, PDS30 increased in NUTR+EX (0.63±0.42 to 2.05±0.55, P<0.001) and NUTR (1.00±0.64 to 
2.17±0.69, P<0.001), with no difference between values from MID to POST in both groups. PDS30 was greater 
in NUTR+EX and NUTR, compared to EX, at both MID and POST (P<0.001 for both). There was no change in 
PDS20 or PDS30 in EX throughout the intervention period. 
The nutrition intervention was successful in increasing PDSIPT in NUTR+EX and NUTR. At MID, PDSIPT increased 
in NUTR+EX (0.68±0.4 to 2.00±0.63, P<0.001) and in NUTR (0.92±0.66 to 1.94±0.79, P<0.001), 
compared to PRE, with no difference between values from MID to POST in both groups.  PDSIPT was greater in 
  
Protein  
(g/kg) 
CHO 
(g/kg) 
Fats  
(g/kg) 
Alcohol  
(g/kg) 
Protein  
(% EI) 
CHO  
(% EI) 
Fat  
(% EI)  
Alcohol  
(% EI) 
NUTR 
+EX         
PRE 0.90±0.20 2.1±0.7 0.8±0.3 0.2±0.2 18.5±3.7 41.1±6.7 34.4±7.6 6.6±6.4 
MID 1.59±0.28*** 2.1±0.6 1.0±0.3 0.3±0.3 25.7±4.2*** 32.7±6.8*** 35.1±5.7 6.7±6.2 
POST 1.59±0.51*** 2.0±0.7 1.0±0.3 0.3±0.2 25.4±3.2*** 32.6±5.9*** 34.8±4.9 6.8±4.7 
         NUTR         
PRE 0.99±0.34 2.3±0.9 0.9±0.3 0.2±0.2 17.9±3.1 41.7±7.7 34.6±5.3 6.1±8.8 
MID 1.52±0.45*** 2.0±0.6 1.0±0.4 0.3±0.3 24.6±3.6*** 31.7±5.7*** 36.0±6.2 7.5±7.8 
POST 1.43±0.39** 2.1±0.8 1.0±0.4 0.3±0.3 22.9±4.4** 34.0±7.5** 35.6±6.6 7.4±8 
         EX         
PRE 1.14±0.35 2.6±0.7 1.0±0.4 0.2±0.3 17.8±3.7 41.7±7.2 34.2±6.5 6.0±6.5 
MID 1.10±0.30#† 2.5±0.8 1.0±0.4 0.3±0.3 18±4.1#† 40.0±9.2#† 33.9±5.5 7.9±8.5 
POST 1.05±0.28#† 2.6±0.8 0.9±0.3 0.3±0.3 16.9±3.6#† 41.0±7.8#† 33.9±6.4 8.0±7.8 
  
 
 155 
NUTR+EX and NUTR, compared to EX, at both MID and POST (P<0.001 for both). There was no change in 
PDSIPT in EX throughout the intervention period. 
 
Table 8.3: The average number of meals per day reaching ≥20g, ≥30g and 0.4g/kg (PDSIPT) protein, at 
PRE (week 0), MID (week 6) and POST (week 12), in nutrition and exercise group (NUTR+EX), nutrition 
only group (NUTR) and exercise only group (EX). Data are mean±SD. CHO, carbohydrates. Statistical analysis was 
performed using two-way ANOVA. Post-hoc pairwise comparisons with Bonferroni’s adjustment were used to determine 
where differences existed within groups compared to PRE as indicated by *P<0.05, **P<0.01 and ***P<0.001, for the 
annotated time-point. Differences between groups are indicated by # to denote differences from NUTR+EX group, and † to 
denote differences from NUTR group, for the time-point (P<0.05).   
 
Figure 8.2 represent total protein intake at each eating occasion, in each group at PRE, MID and POST. At PRE, 
there was no difference between groups for protein intake at any eating occasion. There was no change in 
protein intake for any eating occasion in EX over time. In NUTR+EX, protein intake at breakfast increased from 
12.4±4.9 to 33.1±10.2g at MID (P<0.001). A similar increase occurred in NUTR from PRE to MID (12.7±9.5 
to 32.7±13.9g, P<0.001). This increase in protein intake at breakfast was maintained at POST for NUTR+EX 
and NUTR and was not different to MID (32.0±12.9g, P<0.99; 32.1±13.4g, respectively, P<0.99 for both). AT 
MID, protein intake at lunch increased from 17.2±6.4 to 33.1±5.6g in NUTR+EX (P<0.001). A similar 
increase occurred in NUTR from PRE to MID (24.4±10 to 32.9±8.7g, P<0.018).  This increase in protein intake 
at lunch was maintained at POST for NUTR+EX and NUTR and was not different to MID (31.5±12g, P<0.99; 
34.9±9.3g, respectively, P<0.99 for both). AT MID, protein intake at dinner increased from 31.0±13.4 to 
44.5±15.4g in NUTR+EX (P=0.025). A similar increase occurred in NUTR from PRE to MID (35.9±12.8 to 
48.5±15.1g, P=0.045).  This increase in protein intake at dinner was maintained at POST for NUTR+EX and 
NUTR and was not different to MID (46.2±22.1g, P<0.99; 42.2±15.9g, P=0.25, respectively).  
  PDS 20 PDS 30 PDS IPT  
NUTR+EX    
PRE 1.14±0.52 0.63±0.42 0.68±0.40 
MID 2.68±0.41** 2.05±0.55*** 2.00±0.63*** 
POST 2.60±0.68*** 1.97±0.76*** 2.05±0.60*** 
 
 
  NUTR  
PRE 1.50±0.54 1.00±0.64 0.92±0.66 
MID 2.69±0.48*** 2.17±0.69*** 1.94±0.79*** 
POST 2.65±0.56*** 2.04±0.83*** 1.81±0.85*** 
 
 
  EX  
PRE 1.65±0.67# 0.84±0.41 1.05±0.67 
MID 1.58±0.60#† 0.77±0.27#† 0.91±0.54#† 
POST 1.49±0.61#† 0.70±0.41#† 0.81±0.39#† 
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Figure 8.2: Protein intake at breakfast lunch, dinner and snacks, at at PRE (week 0), MID (week 6) and 
POST (week 12), in nutrition and exercise group (A), nutrition only group (B) and exercise only group (C). 
Statistical analysis was performed using two-way between-within ANOVA. Post-hoc pairwise comparisons with Bonferroni’s 
adjustment were used to determine where differences existed within groups compared to PRE as indicated by *P<0.05, 
**P<0.01 and ***P<0.001. Differences between groups are indicated by # to denote differences from NUTR+EX group, 
and † to denote differences from Nutrition Only group, for the time-point (P<0.05).   
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Table 8.4 represents protein intake relative to body mass at breakfast, lunch and dinner in each group PRE, 
MID and POST. At PRE, there was no difference between groups in relative protein intake for breakfast, lunch 
and dinner. There was no change in relative protein intake for any eating occasion in EX over time. AT MID, 
relative protein intake at breakfast increased from 0.17±0.06 to 0.44±0.11g/kg, P<0.001. A similar increase 
occurred in NUTR from PRE to MID in NUTR+EX (0.16±0.13 to 0.42±0.2g/kg, P<0.001). AT MID, relative 
protein intake at lunch increased from 0.23±0.08 to 0.45±0.08g/kg in NUTR+EX (P<0.001). A similar 
increase occurred in NUTR from PRE to MID (0.32±0.14 to 0.42±0.14g, P=0.044). AT MID, relative protein 
intake at dinner increased from 0.41±0.17 to 0.60±0.22g/kg in NUTR+EX (P=0.016). Relative protein intake 
also increased in NUTR from PRE to MID (0.46±0.16 to 0.61±0.20g/kg, P=0.049).  
 
  
 
 
Breakfast 
 
Lunch 
 
Dinner  
Protein (g/kg) NUTR+EX          
 PRE 0.17 ± 0.06 0.23 ± 0.08 0.41 ± 0.17 
 MID 0.44 ± 0.11*** 0.45 ± 0.08*** 0.60 ± 0.22* 
 POST 0.41 ± 0.20*** 0.40 ± 0.23* 0.63 ± 0.31* 
           
 NUTR          
 PRE 0.16 ± 0.13 0.32 ± 0.14 0.46 ± 0.16 
 MID 0.42 ± 0.20*** 0.42 ± 0.14* 0.61 ± 0.20* 
 POST 0.41 ± 0.21** 0.44 ± 0.17* 0.59 ± 0.29 
           
 EX          
 PRE 0.23 ± 0.12 0.32 ± 0.14 0.49 ± 0.21 
 MID 0.23 ± 0.11#† 0.33 ± 0.17# 0.46 ± 0.21 
 POST 0.22 ± 0.12#† 0.24 ± 0.22† 0.55† ± 0.34 
Table 8.4: Body mass relative protein intake at breakfast, lunch and dinner at PRE (week 0), MID (week 6) 
and POST (week 12), in nutrition and exercise group (NUTR+EX), nutrition only group (NUTR) and exercise 
only group (EX). Data are mean±SD. Statistical analysis was performed using two-way ANOVA. Post-hoc pairwise 
comparisons with Bonferroni’s adjustment were used to determine where differences existed within groups compared to 
PRE as indicated by *P<0.05, **P<0.01 and ***P<0.001 for the annotated time-point. Differences between groups are 
indicated by # to denote differences from NUTR+EX group, and † to denote differences from NUTR group, for the time-
point (P<0.05).  
 
 
8.3.4 Dietary Components  
Table 8.5- 8.7 represent average dietary components in each group at PRE, MID and POST. In NUTR+EX, 
there was in an increase in lactose, saturated fat, monounsaturated fats, trans-fatty acids and cholesterol at MID 
and POST (P<0.05 for all). There was an increase across all B vitamins and vitamin D at MID and POST for 
NUTR+EX (P<0.05 for all). There was an increase in sodium, potassium, chloride, calcium, phosphorus, 
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magnesium, zinc, selenium and iodine intake at MID and POST for NUTR+EX (P<0.05 for all). In NUTR, 
cholesterol intake increased at MID and POST (P<0.05 for all) Lactose intake increase at POST in NUTR 
(P<0.05). Vitamin B2 and B12 intake increased at MID and POST in NUTR (P<0.05 for all). Vitamin B3, B5 and 
B7 increased at POST in NUTR (P<0.05 for all). There was an increase in selenium and iodine intake at MID and 
POST for NUTR (P<0.05 for all). There were no changes in micronutrient intakes in EX at any time-point.  
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 NUTR+EX NUTR EX 
 
PRE MID POST PRE MID POST PRE MID POST 
Starch (g) 90.1±35.0 83.0±35.5 87.4±30.2 101.5±31.2 81.3±30.2 85.8±32.9 108.3±23.9 98.9±23.5 109.9±44.4 
Oligosaccharide (g) 0.4±0.4 0.5±0.5 0.5±0.5 0.5±0.5 0.5±0.7 0.8±1.1 0.4±0.4 0.6±0.6 0.5±0.7 
Fibre (g) 14.3±3.8 15.4±3.7 15.6±4.0 17.4±5.9 15.3±6.1 15.0±5.1 20.9±7.5 19.4±7.8 19.8±7.9 
NSP (g) 10.9±3.3 11.6±3.2 11.6±3.2 13.2±4.5 12.0±4.8 11.5±4.2 16.6±6.8 15.4±7.1 15.7±6.8 
Sugars (g) 59.4±23.1 66.4±21.6 67.2±20.5 71.9±31.4 63.0±31.2 69.4±30.1 76.7±21.1 73.6±38.3 74.3±37.9 
Free Sugars (g) 19.1±12.3 19.6±10.7 16.9±10.1 29.0±18.8 19.9±10.3 24.7±13.8 22.2±12.9 20.6±13.8 26.3±16.5 
Glucose (g) 8.8±4.6 7.7±2.6 9.6±4.7 13.5±6.9 9.6±6.3 8.6±5.8 14.2±6.7 13.2±10.0 13.2±9.0 
Galactose (g) 0.7±1.3 0.1±0.1 0.1±0.3# 0.3±0.9 0.1±0.4 0.0±0.0# 0.2±0.5 0.3±0.8 0.4±0.6 
Fructose (g) 10.1±5.2 9.4±4.2 11.7±5.9 14.2±8.5 11.1±7.8 9.1±6.3 17.6±9.3 18.2±22.4 17.3±20.4 
Sucrose (g) 17.8±11.5 15.0±8.4 15.2±8.1 23.3±13.6 16.9±10.2 23.6±11.7 19.3±6.6 20.3±12.3 19.9±10.7 
Maltose (g) 2.7±1.3 2.4±1.5 2.7±1.5 4.6±2.7 2.7±1.2 3.6±2.1 5.0±3.6 4.7±3.6 5.7±4.4 
Lactose (g) 9.0±4.6 18.7±10.0*# 19.2±8.5*# 7.9±6.3 16.0±13.2 17.5±13.9*# 8.1±6.5 7.9±7.0 7.8±6.9 
Saturated Fat (g) 21.9±9.9 28.0±11.3* 29.0±8.0* 25.8±9.6 31.4±13.7 31.8±15.7 26.2±9.1 24.5±6.9 24.4±8.1 
MUFAS (g) 18.7±6.2 24.8±8.4* 26.1±6.8* 22.2±8.6 26.4±9.5 27.0±11.3 24.7±8.3 24.5±12.1 24.3±7.1 
PUFAS (g) 8.7±3.8 9.3±3.0 11.2±3.5 10.1±3.5 9.5±3.7 10.2±4.4 10.9±5.1 11.3±8.7 11.1±5.2 
Omega 3 (g) 1.2±0.8 1.4±1.1 2.1±1.5* 1.4±1.0 1.4±1.1 1.9±1.6 1.4±1.1 1.9±2.1 1.8±1.6 
Omega 6 (g) 4.8±3.2 4.6±2.0 5.3±1.7 4.9±2.8 5.2±2.6 5.4±2.8 5.1±3.8 5.2±5.9 5.0±3.5 
Trans-fatty acids (g) 0.7±0.5 1.2±0.6* 1.2±0.5* 0.9±0.4 1.2±0.7 1.3±0.8 1.0±0.6 0.9±0.5 0.9±0.5 
Cholesterol (mg) 246±79.7 447±149.9*# 464±152*# 293±175 497±221*# 475±216*# 261±106 269±95.8 253±115 
Table 8.5: Dietary nutrient intake at PRE (week 0), MID (week 6) and POST (week 12), in nutrition and exercise group (NUTR+EX), nutrition only group (NUTR) and exercise 
only group (EX). NSP, non-starch polysaccharides; MUFAs, monounsaturated fatty acids; PUFAs, poly-unsaturated fatty acids. Data are mean±SD. Statistical analysis was performed using two-way 
ANOVA. Post-hoc pairwise comparisons with Bonferroni’s adjustment were used to determine where differences existed within groups compared to PRE as indicated by *P<0.05. Differences between 
groups are indicated by # to denote differences from EX group for the time-point, #P<0.05.  
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 NUTR+EX NUTR EX 
 
PRE MID POST PRE MID POST PRE MID POST 
Vitamin A (µg) 743±559# 842±482 928±983 990±620 1077±623 768±420 1519±1294 759±447 794±442 
Vitamin C (mg) 55±33 81±43* 81±40 60±41 80±54 74±50 78±48 83±43 81±36 
Vitamin D (µg) 2.9±1.9 5.5±3.8* 8.2±5.4*# 4.6±2.8 5.8±4.2 7.0±5.1 3.7±3.1 4.0±2.5 4.3±3.3 
Vitamin E (mg) 6.4±3.9 7.5±3.1 7.8±3.0 7.7±2.9 7.2±3.1 7.1±2.9 7.7±3.8 7.7±5.3 7.6±3.5 
Vitamin K1 (µg) 11±8 35±34* 34±46 15±15 34±35 22±33 44±81 26±30 19±18 
Vitamin B1 (mg) 1.3±0.4 1.7±0.4* 1.7±0.6 1.4±0.6 1.7±0.7 1.8±0.7 1.5±0.4 1.5±0.5 1.6±0.8 
Vitamin B2 (mg) 1.2±0.4 2.2±0.5*# 2.4±0.6*# 1.3±0.5 2.2±1.0*# 2.3±1.1*# 1.6±0.7 1.5±0.5 1.5±0.6 
Vitamin B3 (mg) 29±9# 43±13* 50±17*# 34±10 46±15 46±18* 37±10 37±9 34±12 
Vitamin B5 (mg) 4.6±1.6 6.7±1.5*# 7.5±1.8*# 4.9±1.7 7.1±2.6# 7.2±2.7*# 5.3±1.3 5.2±1.3 4.9±1.3 
Vitamin B6 (mg) 1.5±0.5# 2.0±0.5* 2.3±0.8* 1.7±0.6 2.3±1.0 2.2±0.9 2.0±0.6 1.9±0.6 1.9±0.7 
Vitamin B7 (µg) 26±6# 44±13* 45±11*# 28±11# 43±17 43±18* 41±18 37±22 33±10 
Vitamin B9 (µg) 195±77 242±58* 263±84* 187±57# 238±102 226±92 250±81 251±82 237±97 
Vitamin B12 (µg) 4.4±1.6 8.8±3.1*# 11.3±4.9*# 5.3±2.8* 9.5±5.0*# 9.6±5.2# 6.7±6.4 5.3±2.7# 5.2±2.8# 
GL 88±34 83±28 89±27 100±31 81±28 90±31 103±22 96±29 106±34 
PRAL 14±12 31±12*# 34±16*# 13±13 33±14*# 33±19*# 9±14 7±19 6±16 
Table 8.6: Dietary vitamin, GL and PRAL intake, at PRE (week 0), MID (week 6) and POST (week 12), in nutrition and exercise group (NUTR+EX), nutrition only group (NUTR) 
and exercise only group (EX). GL, glycaemic load; PRAL, potential renal acid load. Data are mean±SD. Statistical analysis was performed using two-way ANOVA. Post-hoc pairwise comparisons with 
Bonferroni’s adjustment were used to determine where differences existed within groups compared to PRE as indicated by *P<0.05. Differences between groups are indicated by # to denote 
differences from EX group for the time-point, #P<0.05.  
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 NUTR+EX NUTR EX 
 
PRE MID POST PRE MID POST PRE MID POST 
Sodium (mg) 1491±542 2250±816*# 2184±809* 1825±785 2166±734 2397±1013 1790±502 1653±434 1776±502 
Potassium (mg) 2186±468# 3120±653* 3404±762* 2503±694 3164±1198 3084±1093 2885±773 2886±943 2919±980 
Chloride (mg) 2408±962 3527±1251* 3394±1021*# 2923±1146 3423±1120 3707±1484 3157±899 2806±744 2698±662 
Calcium (mg) 657±192# 1166±341* 1179±279* 805±297 1091±527 1140±600 902±270 882±479 889±433 
Phosphorus (mg) 1129±244# 1727±298*# 1872±451*# 1217±396 1732±630# 1746±680* 1365±269 1368±367 1354±438 
Magnesium (mg) 227±51# 325±118* 331±122* 243±72# 328±187 339±157 304±89 324±149 317±133 
Iron (mg) 8.9±2.6 10.3±2.3 12.0±3.7 9.3±2.7 10.8±3.5 10.6±4.0 12.5±5.2 16.4±24.6 16.9±22.2 
Zinc (mg) 7.1±2.2# 11.5±2.8* 12.0±4.3* 8.6±3.8 11.7±5.0 10.9±4.9 10.0±3.4 9.7±4.5 9.8±4.5 
Copper (mg) 0.8±0.2 1.1±0.3 1.1±0.5 1.0±0.3 1.0±0.4 1.0±0.4 1.5±1.0 1.3±0.9 1.3±0.7 
Manganese (mg) 3.0±1.2 2.9±1.1 2.8±1.0 3.0±1.1 2.7±1.0 2.7±1.2 3.8±1.4 4.0±2.2 4.0±2.2 
Selenium (µg) 45±16 70±27*# 77±29*# 48±19 77±27*# 76±36*# 53±22 52±18 48±18 
Iodine (µg) 141±68 250±92*# 268±89*# 117±66 250±144*# 224±132*# 138±70 121±53 127±101 
Table 8.7: Dietary mineral intake at PRE (week 0), MID (week 6) and POST (week 12), in nutrition and exercise group (NUTR+EX), nutrition only group (NUTR) and exercise 
only group (EX).  Data are mean±SD. Statistical analysis was performed using two-way ANOVA. Post-hoc pairwise comparisons with Bonferroni’s adjustment were used to determine where 
differences existed within groups compared to PRE as indicated by *P<0.05. Differences between groups are indicated by # to denote differences from EX group for the time-point, #P<0.05. 
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8.4 Discussion  
The current study demonstrates that intervention with a dietary strategy focussed on whole foods to provide a 
high protein intake, and specifically targeting 3g leucine at three meals per day, is efficacious in increasing 
protein intake and achieving a more even daily protein distribution in older adults. Since protein intake is a 
strong influence on skeletal muscle accretion (Norton et al., 2016; Daly et al., 2014), this nutrition intervention 
shows promise as a dietary strategy for targeting the age-related decline in muscle mass and function, either 
alone or in support of exercise training. The results of such an investigation are presented in chapter 9. 
Prior to the intervention, which represents the participants’ habitual dietary intake, daily protein intake was 
66±14g, 73±26g and 80±18g, for NUTR+EX, NUTR and EX, respectively, with no differences between 
groups. These are similar intakes to those in community-dwelling older adults in Ireland (Chapter 4) and 
elsewhere (Tieland et al., 2015). Relative to body mass, pre-intervention habitual protein intake was 
0.90±0.20 g/kg/d, 0.99±0.34 g/kg/d, 1.14±0.35 g/kg/d for NUTR+EX, NUTR and EX, respectively, with no 
differences between groups. While these habitual protein intakes exceed the current PRI for protein intake in 
adults, there is a growing consensus that this recommendation is outdated, and protein requirements for older 
adults are from 1.2 to 1.5g/kg/d (Bauer et al., 2013).  
The nutrition intervention was successful in increasing daily protein intake in NUTR+EX and NUTR. At MID, 
protein intake increased by 79% and 63% in NUTR+EX and NUTR, respectively. Relative protein intake 
increased from 0.90±0.20 to 1.57±0.49g/kg/d in NUTR+EX, and 0.99±0.34 to 1.43±0.39g/kg/d NUTR after 
6 weeks (MID). There were no differences between values from at MID and POST in both groups, suggesting 
that the participants successfully continued on the dietary strategy for the latter 6 weeks of the intervention. At 
MID, fat intake increased by 31% in NUTR+EX. This is likely due to the participants consuming foods which are 
higher in fat, such as eggs, dairy, oily fish and red meat, all of which were encouraged in the dietary strategy 
(See appendix 5 for instructions on nutrition intervention). In support, there was an increase in saturated fat, 
monounsaturated fat, omega 3 fatty acid intake and cholesterol in NUTR+EX, and lactose and cholesterol in 
NUTR, throughout the intervention. Carbohydrate intake did not differ between groups and remained the 
similar over time. Previous nutrition interventions, in which a protein enriched diet is derived from one food or 
a food group, have also been successful in increasing protein intake. For example, a food-based intervention 
targeting two servings of dairy protein per day resulted in a 25±12g increase in daily protein intake over 4 
weeks in ambulatory, aged care residents (Iuliano, Woods and Robbins, 2013). Total protein intake increased 
from 1.0g/kg/d to 1.3g/kg/d when 15g protein from whole milk were consumed directly after breakfast and 
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lunch (Tieland, et al., 2012a). 80g red meat consumed at lunch and dinner, 6 days a week for 16 weeks, 
caused dietary protein intake to increase from 73.4±23.2 to 88.3±17.5 g/d in older adults (Daly et al., 2014). 
Beelen, de Roos and de Groot, (2017) investigated the effect of protein enrichment of regular foods and drinks 
on protein intake in institutionalised older adults. To reflect a real world setting, alternative breads, fruit juices, 
soups and potatoes, which had been enriched with protein, were given as an option that participants could 
choose from.  The nutrition intervention was successful in increasing protein intake from 0.96 to 1.14 g/kg/d, 
which represented an extra 11.8g/d of protein. However, participants still fell below the recommendation of 
≥1.2g/kg/d to preserve LBM in older adults. Results from the present study show a greater increase in protein 
intake than this previous work and is analogous to that achieved by powdered protein supplementation in 
middle-aged to older adults (Norton et al., 2016). Similar to finding in the present study, a nutrition 
intervention which targeted breakfast and lunch enrichment with milk-based protein supplement, resulted an 
increase in total protein intake of 83±19 to 106±20g and 1.2±0.3 to 1.6±0.3g/kg/d over 24 weeks (Norton 
et al., 2016). A unique aspect to this present study was that participants were provided instruction and support 
for protein intakes that specifically translated to 3g leucine at three main meals. To attain 3g leucine per meal, 
≥30g high quality protein is often required; with a ‘high quality protein’, in this instance, referring to a protein 
that provides a large dose of EAAs, with animal-based proteins in particular considered to be of a higher quality 
protein when compared to a plant-based proteins (van Vliet, Burd and van Loon, 2015). Therefore, a plausible 
explanation for the greater changes seen during the present intervention is that participants were simply 
required to choose foods that were inherently higher in protein, resulting in a greater daily intake.  
Across all groups, pre-intervention protein intake followed a skewed pattern across meals, in which breakfast 
and lunch contained small amounts of protein, and the highest amount of protein is consumed at dinner. 
Breakfast, lunch and dinner accounted for 18%, 25%, 45% of protein intake in NUTR+EX; 16%, 31%, 46% in 
NUTR and 20%, 27%, 42% in EX, respectively. This skewed intake is reported elsewhere (Cardon-Thomas et al., 
2017; Tieland et al., 2015; Almoosawi et al., 2013; Bollwein et al., 2013; Ruiz Valenzuela et al., 2013), 
including Irish adults in Chapter 4.  Relative to body mass, prior to intervention, breakfast, lunch and dinner 
were 0.17, 0.23, 0.41g/kg of protein intake in NUTR+EX; 0.16, 0.32, 0.46g/kg in NUTR; and 0.23, 0.32 and 
0.49g/kg in EX, respectively. 0.4g/kg per meal is theorised as the required protein dose to maximise MPS in 
older adults (Moore et al., 2015), while in absolute values, >20-30g high quality protein is purported as the 
required protein dose to maximise postprandial MPS in older adults (Layman et al., 2015; Bauer et al., 2013; 
Symons et al., 2009). Therefore, prior to intervention, while dinner in NUTR+EX and NUTR reached this meal 
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threshold, breakfast and lunch failed to reach this threshold. The suboptimal protein consumed at these two 
meals represents a missed opportunity to initiate a robust postprandial anabolic response. At MID, daily 
protein intake was more evenly distributed between breakfast, lunch and dinner in NUTR+EX and NUTR. While 
distribution between these meals was skewed, in which dinner represented the greatest protein intake; 
protein intake across breakfast and lunch improved significantly in NUTR+EX and NUTR (See Table 8.4). At 
MID and POST, average intakes at each of the three main meals in both nutrition intervention groups were 
≥0.4g/kg and 30g. Since all food options suggested to participants as part of the dietary strategy were animal-
based and rich in leucine (eggs, poultry, beef, fish, yoghurt, milk, cheese, etc.), these foods were 
representative of a high quality protein sources. Similar to the present findings, Norton et al., (2016) achieved 
an increase from 0.23±0.1 to 0.4± 0.1g/kg for breakfast and from 0.31±0.2 to 0.47±2g/kg lunch with the 
enrichment of breakfast and lunch with 0.165g/kg of protein from powdered protein. These data suggest that 
the nutrition intervention successfully resulted in a protein intake and distribution pattern that is considered 
optimal for maximising cumulative daily MPS rates in older adults.  
Being cognisant of the 20 to 30g protein threshold per meal required to maximise postprandial anabolism, we 
sought to determine the number of meals reaching these two thresholds over each 3-day food diary period. 
The number of meals reaching ≥20g protein increased from ~1 per day, to >2.5 in both NUTR+EX and NUTR. 
This suggests that the nutrition intervention was successful in achieving a more optimal per meal protein 
intake. PDS30 increased in NUTR+EX, from ~0.6 to ~2 servings per day; and from ~1 to >2 servings per day 
in NUTR. This higher threshold is more stringent for assessing per meal protein intake, and shows that meals 
falling between the 20-30g threshold in NUTR+EX and NUTR account for this discrepancy. Although breakfast, 
lunch and dinner attained a mean group intake of 0.4g/kg per meal, the PDSIPT which counts the average 
number of meals per day which reached the 0.4g/kg threshold, revealed that on average, not all three the 
main meals reached this threshold. Nonetheless, there was an improvement in PDSIPT from PRE to MID in both 
nutrition intervention groups (An increase from ~0.7 to 2 in NUTR+EX, and an increase from ~0.9 to 2 
servings per day containing ≥0.4g/kg protein in NUTR).  
 
At the beginning of the study, the two nutrition intervention groups received the same instructions on the 
dietary intervention, and also received the same weekly newsletters detailing leucine-rich recipes and further 
support material. However, because NUTR+EX were also involved in the exercise intervention throughout, they 
potentially received additional support and counselling due to contact with the lead researcher during the 
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supervised exercise sessions (three times per week). Participants in NUTR instead received a fortnightly phone-
call from the lead researcher. Despite NUTR+EX and NUTR receiving different contact time and support, there 
was no difference in energy intake, protein intake, and protein distribution between groups. This suggests that 
an initial meeting in a small group, weekly newsletters and a fortnightly follow-up phone-calls are sufficient 
contact time for achieving adherence to the dietary intervention. This is in contrast to strategies used previously 
to achieve dietary adherence. In a 12-month weight-loss intervention, Gardner et al., (2018) used weekly face-
to-face counselling session in the initial 8 weeks to attain adherence to a low-carbohydrate or low-fat diet, in 
which no restriction was place on energy intake. Arguable, the use of a weekly newsletters and fortnightly 
phone-calls in the present study is less time-consuming and labour intensive when compared to strategies 
used by Gardner et al., (2018). However, the intervention by Gardner et al., (2018) was a over longer period, 
and also weight-loss focused, and additional support may be warranted for dietary interventions of this 
duration and type.  
A unique aspect to this study was that participants followed a whole food-based nutrition plan, for breakfast, 
lunch and dinner, rather than consuming powdered protein/AA supplements. Of note, there was an increase in 
micronutrient intake in NUTR+EX and NUTR, with no change in micronutrient intake in EX throughout the 
intervention period. This suggests that increasing protein intake through animal-based foods increases the 
micronutrient content of the diet, which is supported elsewhere (Phillips et al., 2015).   
As a consequence of increasing protein and fat intake, energy intake increase by 28% and 18% in NUTR+EX 
and NUTR, respectively. Energy intake was not restricted, and therefore intake was ad libitum. This is contrast 
with finding by Weigle et al., (2005) who provide high protein meals to participants, and placed no restriction 
on energy intake, over 12 weeks. Authors found a spontaneous decrease in energy intake due to an increase in 
satiety. The reason for an increase in calorie intake in the present study, is that instructions of protein intake 
was more regimented with participants required to consume ~30g protein from animal sources, with these 
sources often being high in fat, and therefore high in calories. We did not collect data on the ease or difficulty 
with which the participants followed the nutrition intervention. However, anecdotally, we noted that more than 
half of the participants in the study verbally reported struggling with consuming all three portions of protein 
per day at least one time throughout the intervention. Indeed, there were two dropouts in the NUTR group due 
to appetite difficulties. This is not surprising, as deterioration of appetite with age is well documented (Morley, 
2001), and protein is a satiating macronutrient (Astrup, 2005). Other contributors to inadequate intake of 
energy and protein in older adults include the cost of more nutrient-dense foods, difficulty chewing fibrous 
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foods and fear of eating too much fat and cholesterol in foods (Bauer et al., 2013; Malafarina et al., 2013; 
Chernoff 2004). While this nutrition intervention was successful in increasing protein intake, and achieving an 
average per meal protein threshold of ≥30g and/or 0.4g/kg, these aforementioned factors need considering 
when designing a long-term, sustainable dietary strategy that targets preservation of LBM in older adults. 
Furthermore, deriving this quantity of daily protein predominantly from animal sources may pose a threat to 
environmental sustainability (de Vries and de Boer, 2010). For these reason, there are merits in the use of 
supplementation with powdered protein and EAAs, or leucine-enrichment of low leucine foods, or a 
combination of whole food and supplementation in ameliorating the age-related decline in muscle mass and 
function.  
 
8.5 Conclusion  
A nutrition intervention targeting a high daily protein intake and 3g leucine at breakfast, lunch and dinner 
from whole foods is efficacious in increasing protein intake and achieving a more even distribution of protein 
intake in community-dwelling older adults. The nutrition intervention successfully resulted in participants 
consuming ≥30g and/or 0.4g/kg per meal of high quality protein at three main meals, which is purported to 
be optimal for maximising cumulative rates of MPS in older adults. A unique aspect of the current intervention 
was that participants consumed additional dietary protein at each meal from whole foods as opposed to 
powdered protein supplements. While there are benefits to using whole foods over supplements, such as 
increase in micronutrient intake, a well-established issue with advancing age is the deterioration of appetite. 
For that reason, protein supplementation, and particularly leucine-enrichment of lower leucine or plant-based 
foods, should not be discounted as a strategy for achieving recommended protein intake and distribution 
patterns in older adults. Indeed, a combination of both whole foods and leucine-enrichment, to achieve the 
desired 3g leucine per meal, may be the most feasible nutrition strategy in older adults. 
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Chapter 9  
9.0 The Effect of Concurrent Exercise Training and/or a Nutrition 
Intervention Targeting Leucine-Rich Meals on Body Composition 
and Physical Function in Older Adults 
 
Background: The age-related decline in muscle mass and function can contribute to an increased risk of morbidity and 
mortality, and a decrease in quality of life in older adults. A combination of exercise training and a high protein diet shows 
potential for prevention and treatment of this progressive deterioration. The majority of studies in older adults have 
employed powdered protein and oral nutrition solutions to increase protein intake, but recent evidence suggests whole 
food sources of protein may have added value for stimulating muscle protein synthesis and preventing the age related 
decline in muscle mass.  
Objective: The aim of the present study is to determine if a nutrition intervention, providing the equivalent of 3g of 
leucine per meal, eaten at breakfast, lunch and dinner, can augment exercise training-mediated effects on body 
composition and physical function in older adults.  
 
Design: Participants aged ≥65 years were recruited to participate in this study. Participants (n=56) were randomly 
assigned to one of the following three groups: nutrition and group (NUTR+EX); non-exercise nutrition only group (NUTR); 
and exercise only (EX). NUTR+EX and NUTR were provided with instructions and weekly support to follow a nutrition 
intervention targeting leucine-rich meals. Meals equating to 3g of leucine were translated to user-friendly portion sizes 
and support was provided through weekly emails and fortnightly phone calls. Exercise training consisted of 24 min of 
combined resistance and aerobic exercise performed three times per week for 12 weeks. Body composition, by DXA scan, 
and physical function outcomes were assessed at week 0 (PRE), week 6 (MID) and week 12 (POST).  
Data Analysis: A Two-way (group x time) mixed ANOVA was performed to determine changes in response to the 
intervention within each group, and differences between intervention groups at each time-point. When main or 
interaction effects were indicated, post-hoc pair-wise comparisons using Bonferroni’s adjustment was performed.   
Results: Protein intake increased by 79% and 63% in NUTR+EX and NUTR, respectively, and average protein intakes for 
breakfast, lunch and dinner were ≥30g or ≥0.4g/kg protein, in both groups. Lean body mass (LBM) increased in 
NUTR+EX only (1.1±1.7%; P<0.05) and fat mass increased in NUTR only (3.3±5.5%; P<0.05) at POST. 1RM leg press 
increased across both exercise groups, with the largest increase observed in NUTR+EX POST (33.4±37.7%), which was 
greater than EX at POST (12.8±16.6%, P<0.05). 1RM chest press increased in NUTR+EX (18.1±14.9%; P<0.05) and EX 
(19.2±14.5%; P<0.05) at POST, which were both greater than changes in NUTR (7.4±11.0%; P<0.05) (both P<0.05). 
Conclusion: Concurrent exercise training, combined with a leucine-rich nutrition intervention produces a gain in LBM 
and further augments improvements in lower limb strength, compared to exercise alone. The combination of exercise and 
nutrition should be strongly emphasised when targeting the prevention and/or treatment of age-related decline in 
muscle mass and function in older adults. 
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9.1 Introduction  
Ageing is associated with a progressive decline of muscle mass and muscle function, which are major 
contributors to decrease in quality of life, morbidity and mortality (Fielding et al., 2011; Janssen, 2010). 
Muscle mass experiences a modest 10% loss between the second and fifth decade of life, however, thereafter, 
this process is accelerated, in which a 30% loss typically occurs between the fifth and eight decade of life 
(Lexell, Taylor and Sjostrom 1988). Reduced physical activity with age is considered a strong contributor to the 
age-related decline of muscle mass, and the manifestation of a reduced sensitivity to the anabolic properties of 
exercise and exogenous protein, termed ‘anabolic resistance’, further exacerbates the matter (Burd, Gorissen 
and Van Loon, 2013; Malafarina et al., 2013; Thompson, 2007; Latham et al., 2004). Exercise and appropriate 
nutrition intervention remain two of the most modifiable and promising strategies in the prevention and 
treatment of age-related decline in muscle mass and function.  
 
Resistance exercise training (RET) is established as an effective approach to maintain or improve LBM and 
strength in older adults (Malafarina et al., 2013; Verdijk et al., 2009). Previous work from our laboratory has 
demonstrated the efficacy of concurrent exercise training (CET) (a combination of resistance and aerobic 
exercise) in improving a range of health-related parameters (Timmons et al., In Press). Indeed, concurrent 
training resulted in greater improvements in gait speed, lower limb strength and a reduction in trunk fat, 
when compared to aerobic exercise training alone or RET alone. However, in the absence of changes in LBM 
after 12 weeks of CET, an intervention which combines this training mode with a nutrition intervention that 
favour muscle accretion in older adults, is of interest in the present study.  
 
Age-related decline of muscle is related to the blunted response to anabolic stimuli (Katsanos et al., 2006; 
Katsanos et al., 2005; Cuthbertson, 2004), a phenomenon known as ‘anabolic resistance’. After protein 
ingestion, elderly show a decreased sensitivity to the anabolic stimulatory effects of EAAs. However, at a higher 
protein dose this deficit can be rectified and stimulation MPS above postabsorptive levels is apparent 
(Katsanos et al., 2006). Indeed, there is now a large body of evidence which supports the thesis that older 
adults have higher protein requirements when compared to young (Traylor, Gorissen and Phillips, 2018; 
Nowson and O’Connell, 2015; Bauer et al., 2013). Moreover, a higher quantity of leucine, the key AA in 
triggering MPS, is required to stimulate MPS above baseline in elderly populations (Katsanos et al., 2006; 
Katsanos et al., 2005). >20-30g of high quality protein, or that containing ~2.5 to 2.8g leucine per meal 
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(Layman et al., 2015; Bauer et al., 2013; Symons et al., 2009; Katsanos et al., 2006) is considered the 
requirement to elicit a near maximal anabolic response in older adults. 
 
Considering the anabolic properties of exercise training and appropriately timed protein/EAA ingestion, it 
would appear promising that combining both strategies has the potential to elicit greater improvement in 
muscle mass and function than exercise training alone. Furthermore, exercise increases the sensitivity of 
skeletal muscle to the anabolic stimulus of exogenous protein and EAA ingestion in young and old (Yang et al., 
2012a). While the combined effect of a protein and exercise interventions has shown positive changes on LBM 
in older adults (Finger et al., 2015), there are also inconsistent findings (Thomas, 2016; Verdijk et al., 2009; 
Leenders et al., 2013). Hence, there is still ambiguity as to the efficacy of protein ingestion alongside exercise 
training in older adults. At this time, an effective combined nutrition and exercise intervention that has the 
potential to ameliorate this decline in age-related muscle mass still remains unclear. The combined effect of a 
concurrent exercise and nutrition intervention, targeting an optimal leucine dose per meal in older adults, 
represents an obvious gap in the literature. The aim of the present study is to determine if a nutrition 
intervention, targeting the equivalent of 3g of leucine per meal, eaten at breakfast, lunch and dinner, can 
augment exercise training-mediated effects on lean body mass and physical function in older adults. 
9.2 Methods 
9.2.1 Study Design and Participants  
Participant recruitment and the broad study design are described in Chapter 8. 
9.2.2 Exercise Intervention  
NUTR+EX and EX performed three supervised exercise training sessions per week (Monday, Wednesday and 
Friday) for 12 weeks. This consisted of 12 min of resistance exercise training and 12 min of aerobic exercise 
training per session. All training sessions were supervised and performed on the Milon Circle (Milon, 
Germany), a smart card-enabled circuit featuring a combination of eight fully-automated strength (six); leg 
press, seated row, chest press, lat pulldown, leg extension and triceps dip; and aerobic (two) exercise 
machines; cross-trainer and cycle ergometer. The exercise session is described in figure 9.1. On week 1, 
resistance exercises were performed for 15 repetitions, for 1 minute, with 30 seconds rest between each 
station at ~60% 1RM. On week 4, resistance exercises were performed for 12 repetitions. On week 8 resistance 
exercises were performed for 12 repetitions. Resistance was increased weekly. Aerobic exercise was 
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maintained at an intensity of 80% predicted heart rate max, for 4 min on the cross-trainer and 4 min on the 
cycle ergometer. Heart rate was monitored continuously throughout each training session (Polar H7, Finland). 
NUTR were instructed not to change their habitual physical activity for the duration of the trial.  
 
Figure 9.1: Graphic representation of the Milon Circuit. Resistance exercise (blue) were performed for 1 minute, 
with each exercise performed twice (12 minutes). Cardiovascular exercise (red) were performed for 4 minutes, with 
participants completing 3 sets of cardiovascular stations (12 minutes). The total time of exercise was 24 minutes.  HR, 
heart rate.  
9.2.3 Nutrition Intervention   
NUTR+EX and NUTR were instructed to follow a high leucine nutrition intervention, as per chapter 8, for the 
12-week period (See Chapter 8, section 8.2.2 for details on nutrition intervention). EX were asked not to 
change their habitual dietary intake for the duration of the intervention.   
9.2.4 Physical Assessment  
The assessment procedure was identical to that carried out in (Timmons et al., In Press). This assessment, which 
took place over two consecutive days, was carried out at PRE (week 0), MID (week 6) and POST (week 12). On 
day 1, participants arrived to the lab after an overnight fast. Body mass (to the nearest 0.2 kg) using a 
calibrated digital scales (SECA, Germany), height (to the nearest 0.01 m) using a wall-mounted stadiometer 
(Holtain, UK), and body composition by dual-energy X-ray absorptiometry (DXA; Lunar iDXA, GE Healthcare, 
USA) were measured. Supine resting heart rate and blood pressure were then measured in duplicate using an 
automated blood pressure monitor (Omron, USA). Participants then consumed a small snack (a cereal bar and 
a banana) and were allowed water ad libitum. Handgrip strength of the dominant hand was then measured to 
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the nearest 0.5 kg using a hydraulic hand dynamometer (JAMAR, USA). Lower body physical function assessed 
using the 2.4m timed-up-and-go test (TUGT) and short physical performance battery (SPPB) consisting of 
habitual gait speed (3m), standing balance (non-tandem and tandem), and five repetition sit-to-stand. 
Cognitive function was then assessed using Montreal cognitive assessment test (MoCA). Lastly, aerobic fitness 
was assessed using the Chester step test. On day 2, participants reported to the exercise training facility (Medfit 
Proactive Healthcare) for the assessment of leg power by stair climbing test (SCT) and lower and upper limb 
strength by 1 repetition maximum (1RM) on leg press and chest press machines, respectively (Milon, 
Germany). Prior to the assessment at PRE, a first familiarisation session was performed wherein the correct 
lifting technique was demonstrated and practiced, after which maximum strength was estimated using the 
multiple repetitions testing procedure. This informed the assessment of 1RM, which was performed in a 
second session undertaken one week after the familiarisation session. 
9.2.5 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, Inc., USA), and are presented 
as mean±SD. Differences between groups at baseline (PRE) for all parameters were compared using a one-way 
ANOVA. A two-way (group x time) between-within ANOVA was performed to determine changes in response to 
the 12-week intervention within each group, and the differences between groups at each time-point. When 
main or interaction effects were indicated, post-hoc pair-wise comparisons using Bonferroni’s adjustment was 
performed.  Statistical significance was accepted at P<0.05.  
9.3 Results  
9.3.1 Attendance  
Attendance at the exercise training sessions averaged 87.4±7.9% throughout the 12-week intervention, and 
did not differ by training group at 86.3±10.2% and 88.7±4.1%, for NUTR+EX and EX, respectively.  
9.3.2 Anthropometric Measures 
Anthropometric measures at baseline in each group is presented in table 9.1. There were no differences in 
anthropometric measures between groups at baseline. Table 9.2 represents percentage change in 
anthropometric measures from baseline at MID and POST. Body mass increased by ~1% at post in both 
NUTR+EX and NUTR (both P<0.05) but this was in the form of LBM (1.1±1.7%; P<0.05) in NUTR+EX (See 
figure 9.2B), and fat mass (3.3±5.5%; P<0.05) in NUTR (See figure 9.2A). Trunk fat and trunk LBM were 
unchanged. Arm fat was unchanged in EX and NUTR+EX but increased at POST in NUTR (7.4±10.4%, P<0.05). 
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Arm LBM increased in EX and NUTR+EX at MID (3.0±4.9%; 3.0±3.9%; P<0.05) and POST (4.0±5.8%; 
3.4±5.5%; P<0.05) but was not statistically different in NUTR, as per figure 9.3A. Leg fat mass remained 
unchanged in NUTR+EX but decreased in EX at POST (-2.4±4.3%, P<0.05). However, leg fat mass significantly 
increased in NUTR compared to EX at MID (2.1±4.1%, P<0.05) and compared to both EX and NUTR+EX at 
POST (3.9±5.3%, P<0.05). Leg LBM remained statistically unchanged in all three groups, as per figure 9.3B. 
 
Table 9.1: Participant characteristics at baseline (PRE). 1RM, one-repetition maximum; BMI, body mass index; 
DBP, diastolic blood pressure; LBM, lean body mass; M/F, male/female; MoCA, Montreal cognitive assessment; RHR, 
resting heart rate; SBP, systolic blood pressure; SCT, stair climbing test; TUGT, timed up and go test. P values are reported 
from one-way ANOVA by group.  
  
 
NUTR+EX 
(n=21) 
 
 
NUTR 
(n=16) 
 
 
EX 
(n=19) 
 
 
ALL 
(n=56) 
 
P value 
 
Anthropometric 
Measures       
M/F (n/n)  11/10 8/8 9/10 28/28  
Age (y)  69.7±4.6 69.3±3.4 68.8±3.8 69.3±4.0 0.769 
Height (m)  168.5±8.5 168.7±9.7 167.6±10.4 168.2±9.4 0.933 
Body mass (kg)  75.1±13.0 79.0±8.8 72.5±11.6 75.3±11.5 0.255 
BMI (kg m-2)  26.3±3.0 28.0±4.4 25.8±3.6 26.6±3.7 0.197 
Body fat (%)  34.0±5.8 33.8±11.7 33.4±7.5 33.8±8.2 0.978 
Fat mass (kg)  24.47±5.83 26.36±11.13 23.28±6.5 24.61±7.84 0.519 
LBM (kg)  47.66±9.34 49.92±7.29 46.22±9.05 47.82±8.67 0.459 
Arm fat mass (kg)  2.50±0.53 2.59±1.01 2.51±0.75 2.53±0.75 0.923 
Arm LBM (kg)  5.38±1.58 5.42±1.27 5.32±1.73 5.37±1.53 0.983 
Leg fat mass (kg)  7.40±1.92 8.54±4.33 7.61±2.27 7.80±2.90 0.474 
Leg LBM (kg)  15.73±3.30 16.86±2.39 15.20±3.06 15.87±3.01 0.258 
Trunk fat mass (kg)  13.63±4.65 14.29±6.45 12.26±4.60 13.35±5.18 0.398 
Trunk LBM (kg)  23.13±4.28 24.28±3.73 22.40±4.02 23.21±4.04 0.497 
 
Muscle and Cognitive Function 
 
   
 
RHR (bpm) 63.2±10.2 62.3±8.0 62.4±9.7 62.7±9.3 0.939 
SBP (mmHg) 141.6±13.1 133.7±11.8 136.8±15.3 137.7±13.7 0.207 
DBP (mmHg) 85.7±10.1 79.4±7.4 81.3±7.1 82.4±8.7 0.069 
Hand-grip strength (kg) 31.7±9.1 31.9±11.9 32.3±11.7 32.0±10.6 0.984 
Gait speed (m s-1) 1.96±0.32 1.97±0.44 1.72±0.35 1.88±0.38 0.077 
Sit-to-stand (sec) 10.85±1.94 10.64±3.71 12.67±4.55 11.41±3.57 0.165 
TUGT (sec) 5.32±0.94 5.42±1.11 5.59±1.21 5.44±1.07 0.740 
SCT (W) 403.5±87.1 385.3±85.9 387.6±92.7 392.9±87.5 0.765 
1RM Leg press (kg) 125.9±39.9 129.9±32.5 129.6±56.1 128.3±43.6 0.951 
1RM chest press (kg) 41.9±16.0 40.8±16.8 39.4±15.4 40.7±15.8 0.887 
Chester step test (bpm) 124.4±11.3 121.4±9.7 125.3±11.3 123.8±10.8 0.548 
MoCA 27.0±2.5 26.2±2.3 26.6±1.6 26.7±2.2 0.497 
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Table 9.2: Changes in anthropometric measures in response to 12-week intervention for nutrition and 
exercise group (NUTR+EX), nutrition only group (NUTR) and exercise only group (EX). Post-hoc pairwise 
comparisons with Bonferroni’s adjustment were used to determine where differences existed within groups compared to 
PRE as indicated by *P<0.05, **P<0.01, ***P<0.001 for the annotated time-point and &P<0.05 vs. MID, and between 
groups at the respective time-point indicated by §P<0.05 vs. NUTR, #P<0.05 vs. EX, and ^P<0.05 vs. NUTR+EX. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NUTR+EX 
(n=21) 
 
 
NUTR 
(n=16) 
 
 
EX 
(n=19) 
 
Body mass    
%change from PRE to MID 0.3±1.3 1.1±1.8** -0.1±1.5 
%change from PRE to POST 0.7±1.5** 1.2±1.9** 0.1±1.7 
 
% body fat 
   
%change from PRE to MID -1.1±2.6 0.6±3.3 -0.2±3.1 
%change from PRE to POST -1.0±3.3 2.4±4.1**,#,^ -1.0±3.3 
 
Arm fat mass 
   
%change from PRE to MID 3.3±9.1 6.0±15.5 0.5±12.1 
%change from PRE to POST 1.0±9.6 7.4±10.4* 1.2±9.0 
 
Leg fat mass 
   
%change from PRE to MID 0.0±3.0 2.1±4.1# -1.7±3.5 
%change from PRE to POST -0.3±3.6 3.9±5.3***,#,^ -2.4±4.3* 
 
Trunk fat mass 
   
%change from PRE to MID -2.2±4.0 0.3±6.3 1.8±7.1 
%change from PRE to POST -0.4±5.3 3.4±8.8 1.1±10.7 
 
Trunk lean body mass 
   
%change from PRE to MID 0.5±2.0 0.0±3.4 0.6±3.2 
%change from PRE to POST 0.4±2.0 -0.2±3.7 -3.8±17.7 
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Table 9.3: Changes in muscle function and cognitive function in response to 12-week intervention for 
nutrition and exercise group (NUTR+EX), nutrition only group (NUTR) and exercise only group (EX). Post-
hoc pairwise comparisons with Bonferroni’s adjustment were used to determine where differences existed within groups 
compared to PRE as indicated by *P<0.05, **P<0.01, ***P<0.001 for the annotated time-point and &P<0.05 vs. MID, 
and between groups at the respective time-point indicated by §P<0.05 vs. NUTR, #P<0.05 vs. EX, and ^P<0.05 vs. 
NUTR+EX. 
 
      
 NUTR+EX 
      (n=21) 
 
 
NUTR 
(n=16) 
 
 
EX 
(n=19) 
 
RHR    
%change from PRE to MID -1.7±9.9 4.6±14.9 2.1±14.0 
%change from PRE to POST -1.6±11.2 -1.9±9.2 -5.3±7.3 
 
SBP 
   
%change from PRE to MID -5.3±9.9 1.5±13.6 -0.9±6.2 
%change from PRE to POST -3.6±11.1 0.6±12.5 -1.1±7.3 
 
DBP 
   
%change from PRE to MID -4.7±9.3 -0.5±11.3 -1.9±7.8 
%change from PRE to POST -4.2±9.0 -2.1±9.3 -3.3±5.1 
 
Hand-grip strength 
   
%change from PRE to MID 9.9±13.7*** 8.0±9.8* 7.5±9.5* 
%change from PRE to POST 10.4±13.2*** 13.6±13.7*** 10.8±10.1*** 
    
Sit-to-stand    
%change from PRE to MID -20.2±12.5*** -12.3±13.0*** -14.7±13.1*** 
%change from PRE to POST -26.3±9.8***,& -22.0±12.5***,& -26.2±14.1***,& 
 
TUGT 
   
%change from PRE to MID -9.0±8.5*** -7.8±9.1** -9.6±10.8*** 
%change from PRE to POST -13.6±8.9*** -12.7±10.8*** -10.4±14.5*** 
 
Gait speed 
   
%change from PRE to MID 1.0±9.7 -1.8±13.6 10.2±13.1** 
%change from PRE to POST 12.7±14.5***,& 9.3±16.3*,& 21.9±17.8***,& 
 
SCT 
   
%change from PRE to MID 4.0±10.1 4.5±6.2 1.3±6.9 
%change from PRE to POST 10.1±10.3***,& 14.2±12.5***,& 13.5±15.1***,& 
 
Chester step test 
   
%change from PRE to MID -9.6±5.8***,§ 0.3±7.9 -6.0±4.8***,§ 
%change from PRE to POST -10.1±6.5***,§ -5.0±6.8**,& -11.4±5.5***,&,§ 
 
MoCA 
   
%change from PRE to MID 3.4±10.0 3.5±8.6 2.0±8.0 
%change from PRE to POST 5.7±10.7** 6.2±8.1** 3.0±6.1 
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Figure 9.2: Changes in fat mass (A) LBM (B) assessed by DXA scan in response to 12 weeks of nutrition 
intervention with or without concurrent exercise training; (A) Fat mass; (B), Lean body mass (LBM). Data 
are mean±SD, representing %change from baseline (PRE) at 6 weeks (MID) and 12 weeks (POST). * symbols denote 
significant difference from PRE for the respective training group; *, P<0.05; **, P<0.01. # symbol denotes significant 
difference compared to EX at the respective time-point, P<0.05.; ^ symbol denotes significant difference compared to 
NUTR+EX at the respective time-point, P<0.05.  
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Figure 9.3: Changes in lean body mass of arms (A) and legs (B) assessed by DXA scan in response to 12 
weeks of nutrition intervention with or without concurrent exercise training; (A), Arm lean body mass 
(LBM); (B), Leg lean body mass. Data are mean±SD, representing %change from baseline (PRE) at 6 weeks (MID) and 
12 weeks (POST). * symbols denote significant difference from PRE for the respective training group; *, P<0.05; **, 
P<0.01.  
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9.3.3 Strength Outcomes 
There were no differences between groups at baseline for any strength parameter measured, as per table 9.1. 
Table 9.3 includes percentage change in strength outcomes from baseline at MID and POST. For upper limb 
strength, 1RM chest press was increased in NUTR+EX at both MID (9.2±12.3%; P<0.05) and POST 
(18.1±14.9%; P<0.05), and was increased at POST in both NUTR (7.4±11.0%; P<0.05) and EX (19.2±14.5%; 
P<0.05)(See figure 9.3A). These increases observed at POST in both exercise training groups were greater 
than NUTR (both P<0.05). For lower limb strength, 1RM leg press remained unchanged in NUTR but was 
increased in the two exercise training groups at POST (both P<0.05), with the largest increase observed at 
NUTR+EX POST (33.4±37.7%) being greater (both P<0.05) than NUTR+EX MID (13.5±20.8%) and EX POST 
(12.8±16.6%)(See figure 9.3B). Leg power was unchanged at MID but improved at POST in all groups (NUTR, 
EX and NUTR+EX as 14.2±12.5%, 13.5±15.1%, and 10.1±10.3%, respectively; all P<0.05).  
9.3.4 Physical Function  
Table 9.3 includes percentage change in physical outcome measures from baseline at MID and POST. 
Handgrip strength increased in all three groups by MID (8.0±9.8%, 7.5±9.5%, and 9.9±13.7% for NUTR, EX 
and NUTR+EX, respectively; all P<0.05), and POST (13.6±13.7%, 10.8±10.1%, and 10.4±13.2% for NUTR, 
EX and NUTR+EX respectively; all P<0.05). Performance in the sit-to-stand test was improved at MID (with 
completion times decreasing by -12.3±13.0%, -14.7±13.1%, and -20.2±12.5% for NUTR, EX and NUTR+EX, 
respectively; all P<0.05) and improved further at POST compared to MID (with completion times compared to 
PRE decreasing by -22.0±12.5%, -26.2±14.1%, and -26.3±9.8% for NUTR, EX and NUTR+EX, respectively; all 
P<0.05). Performance in the TUGT was improved at MID (with completion times decreasing by -7.8±9.1%, -
9.6±10.8%, and -9.0±8.5% for NUTR, EX and NUTR+EX, respectively; all P<0.05) and POST (with completion 
times decreasing by -12.7±10.8%, -10.4±14.5%, and -13.6±8.9% for NUTR, EX and NUTR+EX, respectively; 
all P<0.05). Gait speed was only increased in EX by MID (10.2±13.1%; P<0.05) but was increased for all three 
groups at POST compared to both PRE and MID (9.3±16.3%, 21.9±17.8%, and 12.7±14.5% vs. PRE for NUTR, 
EX and NUTR+EX, respectively; all P<0.05). 
9.3.5 Aerobic Fitness 
Table 9.3 includes percentage change in aerobic fitness from baseline at MID and POST. The changes in 
resting heart rate, systolic and diastolic blood pressure did not reach statistical significance in any group. 
Aerobic fitness improved at MID in EX and NUTR+EX compared to NUTR (with beats per minute decreasing by -
6.0±4.8%; -9.6±5.8%; P<0.05). At POST, aerobic fitness was significantly increased in NUTR compared to PRE 
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and MID (with beats per minute decreasing by -5.0±6.8% vs. PRE; P<0.05). However, increases in aerobic 
fitness in EX and NUTR+EX were significant at both MID and POST (with beats per minute at POST decreasing 
by -11.4±5.5% and -10.1±6.5% for EX and NUTR+EX respectively, both P<0.05), and both exercise training 
groups resulting in larger improvements in aerobic fitness compared to NUTR at both MID and POST (all 
P<0.05).  
9.3.6 Cognitive Function  
Table 9.3 includes percentage change in cognitive function from baseline at MID and POST. Cognitive 
function improved at POST in NUTR and NUTR+EX (6.2±8.1% and 5.7±10.7%; P<0.05), with EX remaining 
unchanged.  
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Figure 9.4: Changes in upper (A) and lower (B) limb muscle strength assessed by 1RM in response to 12 
weeks of nutrition supplementation with or without concurrent exercise training; (A), Chest press; (B), 
Leg press. Data are mean±SD, representing %change from baseline (PRE) at 6 weeks (MID) and 12 weeks (POST). * 
symbols denote significant difference from PRE for the respective training group; *, P<0.05; **, P<0.01; ***, P<0.001. 
§ symbol denotes significant difference compared to NUTR at the respective time-point, P<0.05.; # symbol denotes 
significant difference compared to EX at the respective time-point, P<0.05.  
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9.4 Discussion  
This present study confirms the efficacy of concurrent aerobic and resistance exercise training in improving a 
range of parameters related to body composition, physical and cognitive function in older adults. This is in 
agreement with previous findings from our laboratory (Timmons et al., In Press), which showed that concurrent 
aerobic and resistance exercise resulted in changes in physical and cognitive function over 12 weeks, and was 
superior to either aerobic or resistance exercise training alone across a range of parameters. Furthermore, co-
intervention with a high protein diet, targeting the equivalent of 3g of leucine per meal, eaten at breakfast, 
lunch and dinner, augmented some, but not all, training outcomes. Most notably, the nutrition intervention 
further improved training-mediated increases in LBM and lower limb strength. This same nutrition 
intervention, in the absence of exercise training, resulted in some improvements in physical function, but 
notably resulted in an increase in body fat mass with no changes in LBM.   
The effects of protein supplementation in combination with exercise, on changes in muscle mass and function, 
in older adults have been widely examined, with conflicting findings (Liao et al., 2017; Thomas et al., 2016; 
Finger et al., 2015; Cermak et al., 2012). Potential explanations for these discrepancies are divergent inclusion 
criteria for analyses, in particular, the inclusion of health and/or non-healthy, active and/or ambulatory 
individuals and different age cut-offs. The potential to benefit from a nutrition and exercise intervention is 
often greater for those who are unhealthy or have low habitual physical activity. Meanwhile, the inclusion of 
adults aged <65 years may be misrepresentative of an ‘elderly’ cohort who exhibit anabolic resistance (Morton 
and Phillips, 2018). The present study is novel in that the effect of a whole food-based nutrition intervention, 
targeting leucine-rich meals, with concurrent exercise training in older adults has not been previously 
explored. Both NUTR+EX and NUTR groups were instructed and supported in consuming a nutrition strategy, 
providing the equivalent of 3 g leucine at three main meals, with the aim of enhancing the exercise training-
mediated changes in LBM and physical function. This is consistent with guidelines which advocate consuming 
~3g leucine per meal to elicit a maximal anabolic response in older adults (Phillips, 2015; Katsanos et al., 
2006). The nutrition intervention resulted in an increase in daily protein intake of both nutrition groups from 
~1.0 g/kg/d to ~1.5 g/kg/d, and a more even distribution of protein intake across three meals, in which 
average protein intake at breakfast, lunch and dinner were ≥30g and/or ≥0.4g/kg per meal threshold to 
maximise postprandial MPS in older adults (Moore et al., 2015; Symons et al., 2009). Further details of the 
nutrition intervention and changes in dietary intakes are described in Chapter 8. 
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NUTR+EX produced a 0.53±0.86kg increase in LBM. This is in contrast to finding by Iglay et al., (2009), in 
which 12 weeks RET x3 days per week was combined with either a low (LP) or high protein (HP) diet consisting 
of eggs, meat and dairy, in older adults and no change in LBM occurred. Although the aim in the low protein 
and high protein group was to achieve 0.8g/kg/d and 1.6g/kg/d protein, respectively, the dietary protein 
intake achieved by the intervention was 0.9±0.1g/kg/d (LP) or 1.2±0.0g/kg/d (HP). Baseline protein intake 
across both groups was 1.1±0.1g/kg, therefore, it is likely that the modest ~0.1g/kg/d increase in protein 
intake in HP throughout the intervention was insufficient to elicit a greater increase in LBM. Our results are also 
in contrast with previous findings (Arnarson et al., 2013; Verdijk et al., 2009; Godard, Williamson and Trappe, 
2002), in which protein supplementation resulted in no further enhancements in LBM and muscle strength 
when combined with RET. However, a noticeable trend in the latter studies are the use of one single bolus 
supplement (Godard, Williamson and Trappe, 2002), or the administration of the supplement only on training 
days (Arnarson et al., 2013: Verdijk et al., 2009). Therefore, a plausible explanation for the positive outcomes 
on LBM and strength in the present study is that protein distribution was optimised, and all three main meals 
reached the meal threshold purported to maximise MPS (See Chapter 8), thereby resulting in muscle accretion 
over time. In support, Daly et al. (2014) reported similar improvements in LBM and strength when 45g protein 
from red meat was split between two daily meals, and combined with RET over 12 weeks.  Similarly, Tieland, et 
al., (2012a) reported positives changes in LBM when breakfast and lunch were enriched with 15g protein. 
Multiple adequate protein meals (4 x 20g) throughout the day can result in a greater cumulative anabolic 
response compared to smaller and frequent meals, or larger and less-frequent protein meals in young (Areta et 
al., 2013; Moore et al., 2012). Therefore, focusing on achieving >1 meal over the anabolic threshold may 
result in more beneficial outcomes for muscle hypertrophy and strength in older adults (Layman et al., 2015; 
Bauer et al., 2013).  
 
Concurrent exercise training has been established as an effective strategy to increase strength and function in 
older adults (Timmons et al., In Press; Holviala et al., 2010; Sillanpää et al., 2009; Wood et al., 2001). Indeed, 
both training groups (NUTR+EX and EX) experience improvements in strength (handgrip, upper and lower 
limb strength) and all functional parameters (sit-to-stand, timed-up-and-go test, stair climbing power test and 
gait speed) after 12 weeks. While there was a positive effect on handgrip strength, upper limb strength and 
physical function in NUTR alone and EX alone, the combination of both nutrition and training in NUTR+EX was 
more effective, particularly for lower limb strength. The considerable improvement in lower limb strength in 
NUTR+EX, compared to EX, which has been reported elsewhere (Daly et al., 2014; Chalé et al., 2013) and 
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supports the synergistic effect of exercise and nutrition in targeting the age-related decline in muscle strength.  
 
Participants in NUTR produced an increase in total fat mass (FM) (+0.71±1.15kg) with a negligible change in 
LBM (+0.03±1.30kg) from PRE to POST. These results are in contrast with Norton et al., (2016) who reported 
minimal change in FM and a positive change in LBM when breakfast and lunch were enriched with whey 
protein, in the absence of exercise. Similar to the present study, participants increased daily protein intake 
from 1.2g/kg/d to 1.6g/kg/d and the focus of the additional protein was to enrich breakfast and lunch, in which 
a protein intake of 0.4g/kg and 0.47g/kg was achieved. An increase of 0.24kg FM and 0.45g in LBM was 
apparent in the protein group, compared to an isocaloric maltodextrin control group, who produced a 0.06kg 
loss in FM and 0.16kg loss in LBM over the 24-week period. Participants in the protein supplement group 
reported a modest 5% increase in calorie intake. Meanwhile, in the present study, there was a 20.7% increase 
in energy intake in NUTR, with no changes in exercise habits, and therefore energy expenditure. These data 
suggest that in the absence of exercise, there was a propensity for the excess calories to be deposited as body 
fat. Excess adipose tissue, particularly in the abdominal area, is a major risk factor for morbidity and mortality 
during the ageing process (Kopelmam, 2000), therefore the present outcome of the ab libitum approach to 
energy intake, in the absence of exercise, warrants concern. The positive changes in LBM reported by Norton et 
al., (2016) may be explained by the age of the participants (50-70 years), which may not be entirely 
representative of an ‘elderly’ cohort, who exhibit anabolic resistance to dietary protein (Morton et al., 2018). In 
the absence of changes in LBM, the improvements in functional capacity apparent in NUTR may appear 
surprising. However, increases in muscle strength and function with protein supplementation, in the absence 
of exercise and measurable changes in lean mass is reported elsewhere (Kim and Lee, 2013; Tieland et al., 
2012b). Furthermore, a weak correlation exists between changes in muscle size and change in muscle strength 
following and training intervention is well-reported (Buckner et al., 2016). Nonetheless, these findings suggest 
that a potentially clinically significant improvement in physical function can be achieved without a need for a 
sizeable increase in LBM. 
 
The main limitation to the present study is the lack of a true (non-intervention) control group. The positive 
findings on functional outcomes in relation to NUTR cannot be entirely attributed to the daily consumption of 
added protein alone. There may be other mitigating factors regarding the physical and cognitive 
improvements, such as changes in physical activity. Of note, participants were recruited under the premise that 
they would be involved in a nutrition and/or training study. Due to their interest in participation, one would 
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assume that these individualised would be eager to introduce a change in both nutrition and exercise for the 
upcoming 12 weeks. It is possible that, although asked not to introduce any changes in physical activity, that 
individuals in the NUTR did indeed change their physical activity, thereby rendering improvements in physical 
and cognitive function.  
 
An even protein intake per meal is reported to increase daily MPS rates (Mamerow et al., 2014; Areta et al., 
2013), and has been proposed as a strategy that should be targeted to attenuate the age-related decline of 
LBM (Arentson-Lantz et al., 2015). This has been demonstrated in older adults with (Daly et al., 2014) and 
without exercise (Bauer et al., 2015). In NUTR+EX (and NUTR) there was a focus on achieving equal 
distribution of protein per meal, and reaching the ≥30g and/or ≥0.4g/kg per meal threshold. However, we 
cannot attribute the positive changes in LBM in NUTR+EX entirely to a more ‘even’ distribution of protein 
alone, as the 79% increase in daily protein intake very likely played a role in skeletal muscle accretion. 
Moreover, the role of equal distribution of protein across meals yields conflicting findings (Kim et al., 2015; 
Bouillanne et al., 2013; Arnal et al., 1999). It remains to be determined if the distribution of protein plays a 
large role in skeletal mass accretion and/or retention. Alternatively, it is possible that simply promoting an 
equal distribution of protein throughout the day inadvertently encourages an increase in protein intake at 
breakfast and lunch (two meals often low in protein, (Cardon-Thomas et al., 2017; Tieland et al., 2015), thereby 
increasing overall daily protein intake and resulting in positive changes in LBM. Nonetheless, promoting a 
greater protein intake at all three meals in the present study resulted in positive changes in LBM compared to 
either a nutrition or exercise control. While the mechanism (increase in total protein, a more even distribution 
of protein, or both?) is not fully understood, the results are promising and shed light on an effective nutrition 
and exercise strategy in promoting gains in skeletal muscle mass and physical function in older adults. 
9.5 Conclusion  
In summary, concurrent exercise training alone is efficacious in improving physical and cognitive function in 
older adults over 12 weeks. However, increasing daily protein consumption to 1.5g/kg body mass, and 
targeting the equivalent of 3g leucine per meal, is necessary to elicit gains in LBM and further augment 
improvements in lower limb strength. This study is unique in that participants followed a whole food nutrition 
strategy, as opposed to relying on powdered protein and oral nutrition solutions. Considering the positive 
outcomes achieved with the addition of the nutrition intervention to exercise, as well as some of the potentially 
deleterious outcomes when the same nutrition intervention is administered in the absence of exercise, the 
 
 
 184 
combination of exercise and nutrition should be strongly emphasised when targeting the age-related decline 
 in muscle mass and function in older adults.   
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Chapter 10 
10.0 General Discussion    
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10.1 Introduction  
The amino acid leucine is seen as a critical driver of the muscle protein synthetic response to a meal. Therefore, 
the use of free leucine as a supplement, and in particular, the enrichment of lower leucine foods, has received 
much interest in recent years. Indeed, leucine-enrichment, in which free leucine is added to a meal or food 
matrices, is emerging as a promising means of ‘rescuing’ the inferior anabolic response apparent after the 
ingestion of low leucine/plant-based protein sources and meals. Therefore, this thesis aimed to address several 
knowledge gaps around leucine supplementation and protein intakes in exercise, health and ageing contexts. 
Firstly, the postprandial leucinemia achieved following the ingestion of a free leucine with different dose and 
timing regimens, or in response to leucine-enriched meal was not previously established. Secondly, amino 
acid supplementation may play a role in exercise recovery by minimising the negative effects of exercise-
induced muscle damage after intense exercise, but the role of leucine in particular in these recovery processes 
was not well-investigated. Lastly, the prescription to consume leucine-rich foods may be efficacious in 
preventing or treating the decline in muscle mass and function apparent with advancing age, but a whole 
food-based dietary strategy, which specifically targets leucine-rich meals, in augmenting exercise training-
mediated changes in skeletal muscle mass and function, had not been previously investigated. 
 
Therefore, the aims of the present thesis were as follows;  
• To determine the current habitual dietary protein intake and protein distribution in Irish adults across 
the lifespan  
• To determine how different leucine supplementation strategies and leucine-enriched meals affect 
postprandial plasma leucinemia  
• To investigate the application of these supplementation strategies in recovery from intense exercise 
in young healthy males  
• To investigate if a high protein diet, targeting leucine-rich meals, augments exercise-mediated effects 
on LBM and function over a 12-week period in older adults 
 
10. 2 Plasma Kinetics Following Free Leucine and a Leucine-Enriched Mixed 
Meal  
Despite plasma leucine representing the most important amino acid for stimulating postprandial muscle 
protein synthesis, the plasma kinetics after the ingestion of leucine alone, and in combination with a meal, 
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were underexplored. The aim of chapter 5 was to determine the plasma leucine kinetics after the ingestion of 
free leucine in a 3g bolus, or two 1.5g boluses, separated by 2 hours, on plasma kinetics, compared to a 
maltodextrin control. In chapter 6, plasma leucine kinetics were determined after these same doses and timing 
strategies were co-ingested with a mixed meal.  The presence of macronutrients and fibre in the mixed meals 
in chapter 6 results in a delayed absorption of leucine into the circulation and attenuated the increase in 
leucinemia, compared to free leucine ingested in chapter 5. It appears that postprandial leucinemia is strongly 
compromised by the co-ingestion of a mixed meal. This is an important consideration when aiming to increase 
the anabolic potential of a meal through leucine-enrichment, since the purported ‘leucine threshold’ is seen as 
as a critical driver of the magnitude of postprandial MPS. Indeed, a higher dose of leucine may be required 
when enriching a mixed meal in order to create the desired leucine plasma kinetics associated with maximal 
postprandial MPS. While it is well supported that plasma leucinemia has an influence on the postprandial MPS 
response, the optimal plasma concentration and kinetics for maximising magnitude and duration of MPS 
remain to be determined. Future research that investigates the efficacy of leucine-enrichment on acute 
changes of MPS, and long-term changes in lean body mass (LBM), should investigate the postprandial plasma 
kinetics after the ingestion of the leucine-enriched meal, thereby offering more of an insight into the ideal 
plasma leucine kinetics for maximal stimulation of MPS. Noteworthy, the modulatory effect of plasma leucine 
kinetics has been contested in recent years. Indeed, plasma leucinemia is not the only factor that influences 
the anabolic effect of a meal and the potential relevance of factors such as the accompanying milieu of amino 
acids and the co-ingestion of macronutrients and micronutrients should not be discounted. Furthermore, 
although beyond the scope of the current thesis, factors such as muscle perfusion, intramuscular amino acid 
availability and amino acid sensing are important determinants of the muscle protein synthetic response. The 
relationship between these factors, the plasma leucine kinetics and the stimulation of MPS are all worthy of 
further study. 
 
10.3 The Role of Leucine in Ameliorating the Deleterious Effects of Intense 
Resistance Exercise   
The use of protein and amino acids in the post-exercise window is emerging as a potential strategy for 
ameliorating the deleterious effects of intense exercise in producing exercise-induced muscle damage and 
prolonged impairment of physical function. The aim of chapter 7 was to investigate the efficacy of 12g leucine, 
either bolus- or pulse-fed, in the 14 h post-exercise period, on recovery of muscle function, markers of muscle 
damage and perceived soreness following an intense resistance exercise bout. Our findings suggest that 
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leucine supplementation offered no benefit on recovery of muscle function, markers of muscle damage and 
perceived soreness following an intense resistance exercise bout. However, the study design and outcome 
measures used had several limitations, which may have increased the likelihood of a type 2 error i.e. false 
negative. In particular, the cross-over design used may have resulted in interference from the repeated bout 
effect, in which the first exercise trial created the most amount of muscle damage, thereby resulting in a 
substantial adaptation and rendering a dampened response to subsequent exercise trials. Furthermore, 
participants were perhaps not given adequate time to rest from their own training prior to each exercise trial, 
which meant that true ‘rested’ measures were not being established, particularly for blood markers of muscle 
damage. Another plausible explanation for the lack of benefit for leucine on exercise recovery is that that the 
meal plan provided sufficient protein to recover from intense exercise, and the additional leucine offered no 
further advantage on recovery. Future research should combine leucine supplement strategy with suboptimal 
protein intake from food, or less than that prescribed in the present study (1.2g/kg of protein). This may shed 
light on the true effect of leucine on ameliorating the negative effect of intense exercise.  
 
10.4 Protein and Healthy Ageing  
The age-related decline in skeletal muscle mass and function is a fundamental threat to ageing with 
independence and a good quality of life. Appropriate exercise and nutrition play a key role in the growth and 
maintenance of skeletal muscle. However, there remains debate about the efficacy of exercise and/or nutrition 
in ameliorating the age-related decline in muscle mass and function.  
 
Firstly, chapter 4 sought to determine the age and gender patterns for protein intake, protein distribution and 
protein source in Irish adults between 2008-2010, with the aim of identifying areas where nutrition may 
improve the outcome of those at risk of declining muscle mass with age. Through secondary analysis of the 
National Adult Nutrition Survey, a survey of 1500 adults aged 18 and upwards, we demonstrated that protein 
intake is greatest in young adults (aged 18-35 y), and is lower with increasing age, with the lowest protein 
intake occurring in adults aged ≥65 y. Furthermore, the purported ‘meal thresholds’ of protein required to 
elicit maximal postprandial MPS tends to be lower with increasing age, and lowest in adults aged ≥65 y. Of 
interest, breakfast was the lowest total protein- and animal protein-containing main meal across all age 
categories, and may represent an opportunity for improving overall protein intake, and protein distribution, 
particularly in older adults. Indeed, a high protein nutrition intervention targeting 0.4g/kg protein at breakfast 
and lunch has previously been shown to be effective in increasing LBM in middle aged adults over 24 weeks 
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(Norton et al., 2016). Therefore, targeting ‘per meal’ protein intake, particularly breakfast and lunch, which are 
often lower in protein intake compared to dinner, may be a promising strategy in combatting the age-related 
decline in muscle mass and function.  
 
Since dietary protein, and particularly leucine, play a key role in postprandial anabolism and these effects are 
enhanced by acute exercise, it follows that providing the equivalent of 3g leucine from whole food sources at 
three meals per day would positively influence exercise training-mediated changes in LBM. Chapter 8 sought 
to determine if a leucine-rich, whole food-based nutrition intervention was effective in increasing protein 
intake, and creating a daily protein distribution pattern that is considered most optimal for maximising daily 
rates of MPS. Our findings in chapter 8 suggest that a nutrition intervention, targeting 3g leucine per meal 
from whole foods, resulted in substantial increases in protein intake, energy intake, and a more even 
distribution of protein intake (≥0.4g/kg protein per meal).  
 
The aim of chapter 9 was to investigate if this same nutrition intervention, in the presence of exercise, could 
augment exercise training-mediated effects on body composition and physical function in older adults. In the 
presence of concurrent aerobic and resistance exercise training (three times per week), the nutrition co-
intervention resulted in positive changes in LBM and muscle function compared to exercise or nutrition alone. 
Of interest, in the absence of exercise, the nutrition intervention resulted in an increase in body fat mass, with 
no change in LBM, and an increase in some assessments of muscle function over 12 weeks. These results 
suggest that a high protein nutrition intervention, targeting leucine-rich meals, in combination with exercise 
training, is efficacious in increasing LBM and improving muscle function. However, in the absence of exercise, 
excess energy in the same nutrition intervention had a propensity to be deposited as body fat. The main 
limitation in the present study is the lack of a true (non-intervention) control group, which makes it difficult to 
attribute improvements in functional outcomes solely to the daily consumption of added protein alone. While 
the mechanism which underpins these improvements (increase in total protein, a more even distribution of 
protein, or a combination of both) is not fully understood, the results are promising and shed light on an 
effective nutrition and exercise strategy in promoting positive change in LBM and muscle function in older 
adults. Future research in this area should focus on intervention studies which determine the true impact of 
protein distribution on muscle accretion, possibly over longer time frames, in older adults. Furthermore, much 
of the research in older adults has focused on the use of powdered protein and oral nutrition solutions for 
additional protein, making chapter 8 and 9 novel, since the supplementary protein was derived solely from 
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whole foods. However, while this nutrition intervention was successful in increasing protein intake and 
improvement protein distribution, the deteriorating appetite in older adults is a factor which may impede the 
ability of older adults to stick to an entirely whole food-based high-protein diet, particularly those who are 
unwell, have swallowing difficulties, are malnourished, or confined to nursing homes and so on. This factor 
needs consideration when designing a long-term, sustainable nutrition strategy that targets preservation of 
LBM in older adults. For these reasons, there may be benefits to supplementation with powdered protein and 
EAAs, or leucine-enrichment of small meals in older adults. Future research should focus on the role of leucine-
enrichment of main meals in supporting exercise training-mediated changes in muscle mass and function, as 
this may offer a more pragmatic strategy for enhancing the anabolic potential of meals in older adults.   
 
10.5 Future Research  
In summary, there is a wealth of research to support the efficacy of leucine, administered within an amino acid 
mixtures and protein powders, in increasing postprandial leucinemia and muscle protein synthesis. However, 
the plasma leucinemia and the resultant muscle protein synthetic response, following leucine ingestion with a 
mixed meal (which is representative of leucine-enrichment in a real-world setting), remains underexplored 
and warrants further investigation. Furthermore, while the application of amino acids supplemented in the 
post-exercise period shows promise in accelerating recovery from exercise-induced muscle damage, the role of 
solely supplementary leucine and leucine-enrichment is a potential focus for future research. Finally, with the 
challenges faced by older adults in consuming adequate dietary protein and energy to maintain muscle mass 
and function, the investigation of leucine-enrichment of smaller meals in ameliorating the age-related decline 
in muscle mass represents an area for future research.   
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Appendix 1 – Chapter 7 –Pain Scale and Perceived Recovery Scale     
 
 
 
  
 
Appendix 2 – Chapter 7 –Position of participant on leg press, to control for movement range-of-
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Appendix 3 – Chapter 7 – Nutrition and supplement protocol instruction following the 14-hour  
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Appendix 4– Chapter 7 –Sample meal plan for male of body mass 75-80kg  
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Appendix 5 – Chapter 8&9 –Nutrition intervention instructions for participants in nutrition and 
exercise group    
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Appendix 6 – Chapter 8&9 – Dietary adherence sheet   
 
Weekly Protein Intake Checklist - Week Starting 3rd April 2017 
Please tick the TWO portions of protein that you have had at each meal. Remember, you will need to eat TWO of the 
following examples at three main meals: 
 
 
 
 
 
 
 Portion 1 Portion 2 
MONDAY 
Breakfast   
Lunch    
Dinner   
TUESDAY 
Breakfast   
Lunch    
Dinner   
WEDNESDAY 
Breakfast   
Lunch    
Dinner   
THURSDAY 
Breakfast   
Lunch    
Dinner   
FRIDAY 
Breakfast   
Lunch    
Dinner   
SATURDAY 
Breakfast   
Lunch    
Dinner   
SUNDAY 
Breakfast   
Lunch    
Dinner    
½ palm sized portion of chicken, steak, beef mince, 
turkey breast, turkey mince, fish 
150g pot low fat yoghurt  
 
Small tin of tuna/mackerel  ‘Deck of cards’ size of hard cheese  
3 piece of bacon/rashers 450ml milk  
2 pork/turkey sausages 2 medium eggs 
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Appendix 7 – Chapter 8&9 – 3-day food diary   
 
3-Day Food Diary 
 
 
Please keep a record of everything you eat and drink over the next 3 days 
 
Instructions: 
 
1. Every time you eat or drink something, write it down in the diary provided. 
 
2. For mixed meals, try to estimate the amount of each component of the meal.  
 
For example, if making a salad: 
 
If the bag of leaves says 70 g, and you use half the bag, then fill in diary as e.g. Rocket 
leaves 35 g 
 
If the container of tomatoes says 200 g, and you use a quarter of these, then fill in diary 
as e.g. Cherry tomatoes 50 g 
And so on through all components of a meal 
 
3. If this is not practical, then simply give an estimate of portion size e.g. a large 
handful of salad leaves, 8-10 cherry tomatoes 
 
4. Try to describe the food as accurately as possible, e.g. skimmed milk, multi-seed 
granary bread, milk chocolate-coated digestive biscuits as opposed to simply writing 
milk, bread and biscuits 
 
5. In the case of eating out, eating pre-packed meals/foods and similar, make an 
estimate of portion size. Note the brand and any other comments you want to add 
 
6. Where possible, always give estimates of the portion size: to do this you can use 
household measurements or write down the weight of the product from the packet 
where possible. 
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For example: 
 
• Large, medium or small banana  
• Three dessert spoons of peas  
• 200 g tin of baked beans 
• One large egg 
• Tayto, salt & vinegar, 40 g packet 
• One mug of instant coffee, black 
 
7. Where appropriate, be sure to note whether the food is cooked or uncooked. Try to 
describe the cooking method: 
 
For example: 
 
• 1 large egg, boiled, scrambled or fried in oil  
• Lamb chop, grilled 
• Frozen peas, boiled 
 
8. Don’t forget to include any sauces, condiments, or second helpings 
 
9. Remember to include all foods AND drinks AND supplements consumed at 
home and at other places such as restaurants and friend’s houses etc. 
 
10. Try to fill in the diary as you eat, instead of leaving it till the end of the day. This 
ensures that you won’t forget what you have eaten 
 
11. At all times, try to be as accurate and descriptive as possible 
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Appendix 8 – Chapter 5 – Participant Information Leaflet    
 
 
 
University College Dublin 
School of Public Health, Physiotherapy and Population Sciences 
Institute of Sport and Health 
Health Science Centre 
Belfield, Dublin 4, Ireland 
 
 
STUDY OF THE PLASMA KINETICS OF AN ORAL LEUCINE 
SUPPLEMENT DELIVERED BY A NOVEL MICROENCAPSULATION 
METHOD 
 
PARTICIPANT INFORMATION LEAFLET 
01/02/2015 
Thank you very much for your interest this research project. We are looking for volunteers to 
take part in a research study under the direction of Ms. Michelle Hone and Dr. Brendan Egan at 
the UCD Institute for Sport and Health, School of Public Health, Physiotherapy and Population 
Science. Please read the following paragraphs which should explain the research in greater 
detail. 
 
The aim of this study is to investigate the effect of delivering the nutrition supplement, leucine, in 
a novel form known as microencapsulation on the amount of leucine that is present in blood in 
the few hours after swallowing. Ms. Hone is funded by a postgraduate award known as the Irish 
Research Council Enterprise Partnership Scheme, in collaboration with AnaBio Technology. 
AnaBio are an Irish start-up who have developed this new technique for encapsulation of food 
ingredients to be used in this study. 
 
1. What is this research about? 
 
Leucine is an amino acid (a building block for protein) that is found naturally in certain foods. 
Unlike some other amino acids, the body cannot produce leucine itself, and it must be obtained 
from food sources. These sources include protein-containing foods such as meats and dairy 
products, as well as supplements such as whey protein and recovery shakes. 
 
Leucine plays an important role in recovery from exercise and in building muscle tissue. The 
process in which muscle tissue is created is referred to as muscle protein synthesis (MPS). It is 
possible that if the delivery of leucine is optimised, this process of creating muscle tissue may 
be maximised. Therefore, a novel encapsulation technique, which may enhance the delivery of 
leucine, is being tested in this study. 
 
2. Why are we doing this research? 
 
Research suggests that MPS has an upper limit in response to a quantity of leucine, meaning 
after a certain dose of leucine, the rate of MPS cannot be increased any further. However, when 
the level of leucine in the blood rises and falls intermittently, similar to what happens when we 
eat a meal, and then, eat another meal several hours later, the rate of muscle growth may be 
maximised. 
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To mimic this meal-to-meal scenario, and recreate this intermittent rising and falling of leucine in 
the blood, a novel microencapsulation technique has been developed which enables leucine to 
be released in intervals over several hours. Microencapsulation means that the individual 
leucine molecules are coated in a special protein that allows them to be put into a drink, and 
when the drink is consumed, this special protein coating is broken down at a slower rate than if 
leucine was consumed in its normal form. 
 
In addition, the use of encapsulated leucine may also improve solubility and the taste of leucine-
containing protein supplements used both in sport and in supplements that support healthy 
ageing.  
Thus, we are interested in the way that the delivery of this encapsulated leucine can influence 
the way in which leucine is digested and absorbed into the blood.  
 
3. How will the data be used? 
 
The results we obtain from your tests will be grouped together with those of others in the 
study. When the study is complete we would like to submit the grouped results to a 
scientific journal for publication. A report on the study will also be written.  
 
4. What will happen if I decide to take part in this research study? 
 
If you are happy to proceed, this research is due to commence in February 2015 and will 
run for about 5 months. However, your involvement will last only a few weeks, in which you 
will make five separate visits to the Human Performance Laboratory in the Institute for 
Sport and Health in UCD. Because the menstrual cycle affects metabolism of 
carbohydrate, fat and protein, this means that females would be required to visit once per 
month to complete visits, whereas males can visit once per week. For that reason and the 
time-constraints of the project, we are only recruiting males on this study. 
 
Before this, however, you will be asked to provide written consent to be a volunteer, and 
state that you have read this information sheet and understand the study protocol. Next 
you will come to UCD for your first visit. That visit and all subsequent visits will last 
approximately 5 hours. 
 
Each visit will be identical except for the varying the drink that you will drink, which will be 
in random order and you will not know which drink is which until after the study. This is 
known as “blinding”. For each visit, you will come to the Human Performance Laboratory in 
the Institute for Sport and Health at UCD (Newstead Block C) at between 8:00 and 9;00 
AM after an overnight fast. This means that you will come to the lab without eating your 
breakfast or consuming any drinks except water that morning. The testing session will 
consist as follows: 
 
• Blood collection: A small plastic needle known as a cannula will be placed in your arm vein 
to permit blood withdrawal. During the whole session, 11 blood samples will be collected 
each of about the size of a teaspoon, and this is a minimal quantity not able to alter any of 
your body’s normal functions. 
• Response to an oral leucine load: An initial resting blood sample will be taken before you 
have drunk any beverage. Next, you will be asked to consume one of five beverages (a 
drink containing encapsulated leucine, normal leucine in one dose, normal leucine in two 
doses a combination of normal leucine and encapsulated leucine, or a beverage containing 
no leucine). During the next four hours, while remaining in the lab, 10 blood samples will be 
collected at 15 minutes, 30 minutes, 45 minutes, a hour, and every half hour for the 
remaining 3 hours. 
 
After the collection of the last blood sample, you will be provided with a small meal 
consisting of a meat-based sandwich, a cereal bar and a piece of fruit. This will complete 
your commitment in the lab on that day. 
 
If you have any specific dietary requirements such as gluten intolerance or prefer a 
vegetarian option, you will have the opportunity to let us know prior to your first visit and 
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we can arrange for alternative foods..  
 
Once your first visit is complete, you will visit the lab again on four more occasions. 
Identical procedures will take place during these visits, except on each occasion, you will 
consume one of four other beverages.  
 
Prior to your first visit you will be asked to complete a two day food intake diary, a food 
frequency questionnaire and a habitual physical activity level questionnaire. These are 
standard research questionnaires and will take no longer than 25 minutes on total. During 
your first visit, you will also have your height and weight measured, and you will have your 
body composition (%fat and muscle) assessed using a dual energy x-ray body 
absorptiometry body scan also known as DXA. Wearing light, loose clothing, you will lay 
on a flat bed over which the scanner moves. A trained operator will position you correctly 
based on your size and stature, and you will lay still during the scan, which takes about 10 
minutes to complete. 
 
5. How will my privacy be protected? 
 
All study data will be stored securely in UCD. All study participants will be given a study 
code upon entering the study. Your name will appear beside this code on a master sheet 
that will be held in confidence by the lead investigator. This master sheet is the only link 
between your name and your study code. Your study code number will appear on all study 
documentation from there onwards. There will be no way in which you may be identified in 
the reported study findings. 
 
In addition, the master sheet containing your name and your assigned code will be 
destroyed after data collection is complete. After this point, it will no longer be possible to 
identify your data, in which case it will no longer be possible for you to withdraw the data 
from the study. However, this now anonymous data will be stored indefinitely and used in 
future research and scientific publications.  
 
6. What are the benefits of taking part in this research study? 
 
You will receive a comprehensive report of your current muscle and bone function, and 
physical activity level. You will receive a comprehensive report on the composition of your 
normal diet, and how to improve this, if necessary. These reports will be in the form of a 
Word document that will be emailed to you by Ms. Hone on the completion of analysis of 
your DXA scan and the questionnaires attached to the study. Within this report, we will 
provide a comparison of your data with other participants on the study as well as in 
comparison to international norms and health guidelines as appropriate. 
 
7. What are the risks of taking part in this research study? 
 
The risks associated with participation in the study are minimal. However, you should 
consider the following prior to giving consent to participate: 
 
There is a potential for a small amount of bruising to occur when a blood sample is drawn. 
To ensure this risk is kept to a minimum, a person trained specifically for this purpose will 
be employed to undertake this procedure. You may be assured that the procedures to be 
employed have been used extensively by the researchers conducting this study and are 
generally well-tolerated by participants. 
 
With respect to blood sampling, we will take all possible precautions to avoid infection 
during these procedures. These samples will be taken with sterile disposable needles, 
drapes and gauze; in fact, sterile (aseptic) techniques are used during all sampling 
procedures.  
 
You will undergo iDXA scanning once during the study. The iDXA scan for body 
composition works in a similar manner to an X-ray, but the radiation dose that you are 
subjected to is very much less than a standard X-ray (about 1/40th). At this level, the risk 
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to you, as described by the international authorities regulating the using of X-rays, is 
‘trivial’. 
 
After an overnight fast, there is a small change that your blood sugar levels may drop 
below normal levels, a situation known as fasting hypoglycemia. Symptoms include 
nausea, extreme hunger, feeling nervous or jittery, clammy, wet skin and/or excessive 
sweating not caused by exercise, rapid heartbeat, trembling. This is rare in young healthy 
men but if we observe, or you experience, any of these symptoms, we will measure blood 
sugar levels directly and provide a small snack consisting of a cereal bar and a sports 
drink as these provide a small amount of sugar to return you to normal levels.     
 
8. Can I change my mind at any stage and withdraw from the study? 
 
If at any time during the study you are uncomfortable with any of the testing or protocols, 
or if you can no longer commit to the study for whatever reason, you have the option to 
withdraw from the study up until the date of the final data collection. If you are a UCD 
student, withdrawal will not result in any penalty or affect your rights as a student of UCD, 
or your participant in recreational or competitive sport at UCD. 
 
9. How will I find out what happens with this project? 
 
You are free to contact any of the researchers involved in this study (contact details below) 
and ask additional information regarding your results, data etc. 
 
10. Contact details and further information:  
 
• Dr. Brendan Egan, PhD 
Email: brendan.egan@ucd.ie   
Phone: 01 716 3419 
Role: Principal investigator for this research and responsible for study design 
Responsible for medical assessment and support on the study 
 
 
• Michelle Hone, Postgraduate Research Student  
Email: michelle.hone@ucdconnect.ie  
Phone: 087 9342326 
Role: Responsible for coordination of all testing procedures 
 
 
We will be happy to answer any questions you may have. 
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Appendix 9 – Chapter 6 – Participant Information Leaflet    
 
 
 
Dublin City University 
School of Health and Human Performance 
 
 
STUDY OF THE PLASMA KINETICS OF LEUCINE WHEN 
COMBINED WITH A MIXED MEAL  
 
PARTICIPANT INFORMATION LEAFLET 
01/02/17 
Thank you very much for your interest this research project. We are looking for volunteers to 
take part in a research study under the direction of Ms. Michelle Hone and Dr. Brendan Egan at 
the DCU School of Health and Human Performance. Please read the following paragraphs, 
which should explain the research in greater detail. 
 
The aim of this study is to investigate the effect of delivering the nutrition supplement, leucine, 
on the amount of leucine that is present in blood in the few hours after swallowing. 
 
11. What is this research about? 
 
Leucine is an amino acid (a building block for protein) that is found naturally in certain foods. 
Unlike some other amino acids, the body cannot produce leucine itself, and it must be obtained 
from food sources. These sources include protein-containing foods such as meats and dairy 
products, as well as supplements such as whey protein and recovery shakes. 
 
Leucine plays an important role in recovery from exercise and in building muscle tissue. The 
process in which muscle tissue is created is referred to as muscle protein synthesis (MPS). It is 
possible that if the delivery of leucine is optimised, this process of creating muscle tissue may 
be maximised.  
 
12. Why are we doing this research? 
 
Research has shown that MPS is dictated by the concentration of leucine in the blood. A 
previous study in our labs investigated the concentrations of leucine in the blood after a leucine 
drink (leucine powder and water) was drank on its own. To mimic a real-life scenario, we want 
to investigate the concentrations of leucine in the blood after the same leucine drink has been 
drank, while a balanced meal of carbohydrates, fats and carbohydrates has been eaten with this 
drink.   
 
13. How will the data be used? 
 
The results we obtain from your tests will be grouped together with those of others in the 
study. When the study is complete we would like to submit the grouped results to a 
  
 
 228 
scientific journal for publication. A report on the study will also be written.  
 
 
 
14. What will happen if I decide to take part in this research study? 
 
If you are happy to proceed, this research is due to commence in February 2017 and will 
run for about 2 months. However, your involvement will last only a few weeks, in which you 
will make three separate visits to the Human Performance Laboratory in the School of 
Health and Human Performance in DCU. Because the menstrual cycle affects metabolism 
of carbohydrate, fat and protein, this means that females would be required to visit once 
per month to complete visits, whereas males can visit once per week. For that reason and 
the time-constraints of the project, we are only recruiting males on this study. 
 
Before this, however, you will be asked to provide written consent to be a volunteer, and 
state that you have read this information sheet and understand the study protocol. Next 
you will come to DCU for your first visit. That visit and all subsequent visits will last 
approximately 4.5 hours. 
 
Each visit will be identical except we will be varying the drink that you will drink, which will 
be in random order and you will not know which drink is which until after the study. This is 
known as “blinding”. For each visit, you will come to the Human Performance Laboratory in 
the School of Health and Human Performance in DCU at between 7:00 and 9;00 AM after 
an overnight fast. This means that you will come to the lab without eating your breakfast or 
consuming any drinks except water that morning. The testing session will consist as 
follows: 
 
• Blood collection: A small plastic needle known as a cannula will be placed in your arm vein 
to permit blood withdrawal. During the whole session, 11 blood samples will be collected 
each of about the size of a teaspoon, and this is a minimal quantity not able to alter any of 
your body’s normal functions. 
• Response to an oral leucine load and meal: An initial resting blood sample will be taken 
before you have eaten or drunk anything. Next, you will be asked to consume one of  three 
beverages (a drink containing leucine in one dose, a drink containing leucine in two doses, 
or a beverage containing no leucine). During the next four hours, while remaining in the lab, 
10 blood samples will be collected at 15 minutes, 30 minutes, 45 minutes, a hour, and every 
half hour for the remaining 3 hours. 
 
Once your first visit is complete, you will visit the lab again on two more occasions. 
Identical procedures will take place during these visits, except on each occasion, you will 
consume one of the other two beverages.  
 
 
15. How will my privacy be protected? 
 
All study data will be stored securely in DCU. All study participants will be given a study 
code upon entering the study. Your name will appear beside this code on a master sheet 
that will be held in confidence by the lead investigator. This master sheet is the only link 
between your name and your study code. Your study code number will appear on all study 
documentation from there onwards. There will be no way in which you may be identified in 
the reported study findings. 
 
In addition, the master sheet containing your name and your assigned code will be 
destroyed after data collection is complete. After this point, it will no longer be possible to 
identify your data, in which case it will no longer be possible for you to withdraw the data 
from the study. However, this now anonymous data will be stored indefinitely and used in 
future research and scientific publications.  
 
16. What are the risks of taking part in this research study? 
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The risks associated with participation in the study are minimal. However, you should 
consider the following prior to giving consent to participate: 
 
There is a potential for a small amount of bruising to occur when a blood sample is drawn. 
To ensure this risk is kept to a minimum, a person trained specifically for this purpose will 
be employed to undertake this procedure. You may be assured that the procedures to be 
employed have been used extensively by the researchers conducting this study and are 
generally well-tolerated by participants. 
 
With respect to blood sampling, we will take all possible precautions to avoid infection 
during these procedures. These samples will be taken with sterile disposable needles, 
drapes and gauze; in fact, sterile (aseptic) techniques are used during all sampling 
procedures.  
 
After an overnight fast, there is a small change that your blood sugar levels may drop 
below normal levels, a situation known as fasting hypoglycemia. Symptoms include 
nausea, extreme hunger, feeling nervous or jittery, clammy, wet skin and/or excessive 
sweating not caused by exercise, rapid heartbeat, trembling. This is rare in young healthy 
men but if we observe, or you experience, any of these symptoms, we will measure blood 
sugar levels directly and provide a small snack consisting of a cereal bar and a sports 
drink as these provide a small amount of sugar to return you to normal levels.     
 
17. Can I change my mind at any stage and withdraw from the study? 
 
If at any time during the study you are uncomfortable with any of the testing or protocols, 
or if you can no longer commit to the study for whatever reason, you have the option to 
withdraw from the study up until the date of the final data collection. If you are a DCU 
student, withdrawal will not result in any penalty or affect your rights as a student of UCD, 
or your participant in recreational or competitive sport at DCU. 
 
18. How will I find out what happens with this project? 
 
You are free to contact any of the researchers involved in this study (contact details below) 
and ask additional information regarding your results, data etc. 
 
19. Contact details and further information:  
 
• Dr. Brendan Egan, PhD 
Email: brendan.egan@dcu.ie   
Role: Principal investigator for this research and responsible for study design 
Responsible for medical assessment and support on the study 
 
 
• Michelle Hone, Postgraduate Research Student  
Email: michelle.hone2@mail.dcu.ie  
Phone: 087 9342326 
Role: Responsible for coordination of all testing procedures 
 
 
We will be happy to answer any questions you may have. 
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Appendix 10 – Chapter 7 – Participant Information Leaflet    
 
 
University College Dublin 
School of Public Health, Physiotherapy and Sports Science 
Institute of Sport and Health 
Health Science Centre 
Belfield, Dublin 4, Ireland 
 
 
EFFECT OF LEUCINE SUPPLEMENTATION ON MUSCLE 
SORENESS AND THE RECOVERY OF MUSCLE FUNCTION AFTER 
INTENSE EXERCISE 
	
PARTICIPANT INFORMATION LEAFLET 
01/02/2016 
 
Thank you very much for your interest in participating in this research project. We are looking 
for volunteers to take part in a research study for both a PhD study and final year research 
dissertation as part of the  BSc in Health and Performance Science. This research study will be 
carried out by Ms. Michelle Hone and colleagues under the supervision of Dr. Brendan Egan at 
the School of Public Health, Physiotherapy and Sports Science. Please read the following 
paragraphs, which will explain the research study in greater detail. 
 
The aim of this study is to investigate the delivery strategies of an amino acids, known as 
leucine, to optimise recovery in the 24 hours after intense weight lifting exercise.  
 
What is this research about? 
 
Most athletes are aware of a “post-exercise window of opportunity” existing during which it 
is recommended to consume nutrients as soon as possible during recovery from exercise. 
However, many previous studies have focused primarily on markers of muscle growth 
shortly after exercise, whereas we are interested in this phenomenon in team sport and 
strength/power athletes and their recovery over 24 hours in terms of strength and muscle 
soreness after a gym-type session.  
 
Why are we doing this research? 
 
This research aims to investigate if leucine supplementation can have a positive effect on 
recovery and muscle soreness in team sports athletes who have done an intense gym 
session. This research is important as it is still unknown whether leucine can impact 
recovery in team sports athletes, such as rugby, GAA, soccer, hockey, as well as 
strength/power athletes, despite the fact that leucine continue to soar in popularity 
amongst athletes.  
 
The post-exercise window of opportunity describes a period of time where repair and 
recovery processes are faster such as recovery of carbohydrates stores and repair of 
muscle. It is widely accepted that eating as soon as possible after exercise is best practice 
but many of the studies on which this advice is based were performed in 3 to 6 hour 
recovery windows, while complete recovery takes longer than this, likely up to 24 or 48 
hours. 
 
Leucine is an amino acid that has strong effects on muscle growth but less is known about 
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how the method of leucine delivery throughout a given day effects muscle soreness and 
recovery.  
 
We will investigate the influence of leucine supplementation during 24 hours of recovery on 
physical tests and blood-based markers of recovery as this has important implications for 
the type of nutrition advice given by nutritionists in team sport settings. 
 
How will the data be used? 
 
The results we obtain from your tests will be grouped together with those of others in the 
study. The data gathered from the study will be used to write up a final year dissertation for 
the BSc in Health and Performance Science at UCD, as well as Ms. Hone’s doctoral 
thesis. When the study is complete, we would like to submit the grouped results to a peer-
reviewed scientific journal for publication. 
 
What will happen if I decide to take part in this research study? 
 
If you are happy to proceed, this research is due to commence in late February 2016 and 
will run for about three months. However, your involvement will last only one month during 
which you will be required to report to the High Performance Unit at UCD Institute for Sport 
and Health on four separate occasions (on the same day of the week at the same time of 
day) over those four weeks. Before this however you will be asked to provide written 
consent to be a volunteer, and state that you have read this information sheet and 
understand the study protocol.  
 
During the first visit, your leg muscle strength will be assessed by means of three 
repetition maximum test also known as a 3RM test using a leg press machine. You must 
have at least one year worth of experience in gym training with this exercise before you 
can be allowed to participate in the study. Following a warm-up, you will begin to lift 
progressively heavier weights with two minutes rest between sets until you cannot lift any 
heavier. This will be your 3RM off which the rest of the study’s protocols will be based. We 
will also measure your height and weight and determine your quantities of muscle and fat 
using a DXA scan. This is a scan that measures your body composition (%fat and muscle). 
Wearing light, loose clothing, you will lay on a flat bed over which the scanner moves. A 
trained operator will position you correctly based on your size and stature, and you will lay 
still during the scan, which takes approximately 10 minutes to complete. Your total visit 
time will be approximately one hour. 
 
Over the next several weeks, you will then have three main “trials”. Each trial will be 
identical except for the different conditions for the recovery supplement explained below. 
Each main trial will proceed as follows: 
• Having not eaten anything since the night previous, and having not trained for 24 
hours previous, you will come to lab and undergo a battery of tests to measure 
your jumping ability and your leg and arm muscle strength. You will also provide a 
small blood sample from a vein in your arm. 
• Next, after a brief warm-up, you will perform an intense weightlifting session that 
involves 10 sets of 10 repetitions in the leg press exercise at 60% of the 1RM 
measured in the first visit, with two minutes rest between each set. Your form and 
timing of each repetition will be monitored throughout the session. 
• Fifteen minutes after the test, you will undergo the same battery of tests as earlier, 
to measure your jumping ability and your leg and arm muscle strength. You will 
also provide another small blood sample. Your total visit time will be approximately 
two hours.  
• Between the end of the exercise test and bedtime that night, you will be asked to 
drink 8 “shots” (about two mouthfuls) of the test nutrient dissolved in sweetened 
water. These will be taken at 2 hour intervals. You will also be not to do any 
training for the next 24 hours. You will be asked to follow a meal plan for the 
duration of the day, which consists of 4 main meals. Examples of what will be 
included on the meal plan are hemp protein (which will be provided by us), oats, 
banana, rice, avocado, nuts, etc. 
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• The next day, 24 hours after the end of the weightlifting session, you will come 
back again and undergo the same battery of tests to measure your jumping ability 
and your leg and arm muscle strength. You will also provide another small blood 
sample. This visit will last 30 minutes. 
• The following day, 48 hours after the end of the weightlifting session, you will come 
back again and undergo the same battery of tests to measure your jumping ability 
and your leg and arm muscle strength. You will also provide another small blood 
sample. This visit will last 30 minutes. 
 
You will repeat this whole pattern of a main trial three times over three weeks on the same 
day of the week, and this will complete your participation. 
 
The three trials reflect the fact that we are investigating three different drinks that will be 
provided to you in random order depending on the trial. These drinks are glucose (sugar), 
leucine delivered at four time points throughout and the day, and leucine delivered at eight 
time points throughout and the day.  
 
Why have I been invited to take part in this research? 
 
You have been asked to take part in this research because you are physically active and have a 
good history of training. Because we are interested in the response to individual exercise 
sessions and the effect of drinking different nutrients, having people who already are well-
trained will provide with the best insight into the responses that would occur if these sessions 
were undertaken as training. 
 
How will my privacy be protected? 
 
All study data will be stored securely in UCD. All study participants will be given a study 
code upon entering the study. Your name will appear beside this code on a master sheet 
that will be held in confidence by the project supervisor, Dr. Egan. This master sheet is the 
only link between your name and your study code. Your study code number will appear on 
all study documentation from there onwards. There will be no way in which you may be 
identified in the reported study findings. 
 
In addition, the master sheet containing your name and your assigned code will be 
destroyed after data collection is complete. After this point, it will no longer be possible to 
identify your data, in which case it will no longer be possible for you to withdraw the data 
from the study. However, this now anonymous data will be stored indefinitely and used in 
future research and scientific publications.  
 
What are the benefits of taking part in this research study? 
 
As each testing day is similar to an intense training session, by the end of this study, you 
may see an improvement in your overall strength and performance, which is likely to 
benefit you in your sport. As we also measure strength and body composition, we will be 
able to assess your fitness status relative to your peers and international norms. You will 
receive a comprehensive report of your current muscle and bone health (DXA scan) and 
information on the composition of your normal diet. 
 
What are the risks of taking part in this research study? 
 
The risks associated with participation in the study are minimal. However, you should 
consider the  
following prior to giving consent to participate: 
 
As with any exercise of high intensity and heavy lifting, there is a chance of muscle strain, 
but as these sessions are similar to those performed as part of your own sport and/or 
training, the risk is similar to that present in training. You will be taken through a gradual 
warm-up to reduce this risk. In general, there is little risk associated with these tests but 
the most likely event to occur immediately after or within the next few hours after the test is 
  
 
 233 
local muscle soreness in the legs, similar to the feeling of a hard training session in your 
respective sport. This will subside with after 36 hours. Should any emergency arise during 
the testing, the investigators are trained and certified in emergency first aid and CPR. 
 
When a blood sample is drawn, there may be a small amount of discomfort when the 
needle breaks the skin and potential for a small amount of bruising to occur. To ensure this 
risk is kept to a minimum, you may be assured that the procedure to be employed has 
been used extensively by the researchers conducting this study and is generally well-
tolerated by participants. The blood samples will be stored for up to 6 months at -20°C in a 
secure freezer at UCD Institute of Sport and Health to which only the project supervisor 
has access. Samples will be coded, so your name will not be associated with the samples, 
once the master coding sheet has been destroyed. The purpose of these samples are to 
analyze markers of inflammation and recovery in the blood. 
 
You will undergo DXA scanning on during the study. The iDXA scan for body composition 
works in a similar manner to an X-ray, but the radiation dose that you are subjected to is 
very much less than a standard X-ray (about 1/40th). At this level, the risk to you, as 
described by the international authorities regulating the using of X-rays, is ‘trivial’. 
 
All of the procedures described in section 4 above are standard procedures for the 
evaluation of strength, and nutrient supplementation effects. These procedures are 
currently the best methods for the questions being addressed. The project supervisor is 
experienced in the implementation of these techniques and the students are trained in the 
same. 
 
Can I change my mind at any stage and withdraw from the study? 
 
If at any time during the study you are uncomfortable with any of the testing or protocols, 
or if you can no longer commit to the study for whatever reason, you have the option to 
withdraw from the study up until the date of the final data collection. If you are a UCD 
student, withdrawal will not result in any penalty or affect your rights as a student of UCD, 
or your participant in recreational or competitive sport at UCD. 
 
How will I find out what happens with this project? 
 
You are free to contact any of the researchers involved in this study (contact details below) 
and ask additional information regarding your results, data etc. You will be provided written 
feedback on your results once the whole study is completed and the data are analyzed. 
 
Contact details and further information:  
 
Dr. Brendan Egan, PhD (Project supervisor for this research and responsible for study 
design) 
 
• brendan.egan@ucd.ie  
• 01 716 3419   
 
Michelle Hone (PhD student responsible for coordination of all testing procedures) 
 
• michelle.hone@ucdconnect.ie  
• 00353 87 934 2326 
 
We will be happy to answer any questions that you may have. 
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University College Dublin 
School of Public Health, Physiotherapy and Sports Sciences 
Institute for Sport and Health 
Health Science Centre 
Belfield, Dublin 4, Ireland 
 
 
EFFICACY OF NUTRITION GUIDELINES TO AUGMENT 
EXERCISE TRAINING EFFECTS IN SKELETAL MUSCLE MASS 
AND FUNCTION IN OLDER ADULTS 
PARTICIPANT INFORMATION LEAFLET 
27/03/17 
 
Thank you very much for taking time to consider participating in this research project. We are 
looking for volunteers to take part in a research study conducted by Mr. James Timmons and Ms. 
Michele Hone under the direction of Dr. Brendan Egan. Mr. Timmons is a post-graduate researcher at 
the UCD Institute for Sport and Health, School of Public Health, Physiotherapy and Sports Science. 
Ms. Hone is a post-graduate researcher in the School of Health and Human Performance, Dublin City 
University. Dr. Egan is a visiting associate professor in the School of Public Health, Physiotherapy and 
Sports Science, but whose primary role is as Senior Lecturer in Sports and Exercise Physiology at 
Dublin City University. Please read the following paragraphs, which should explain the research in 
greater detail. Mr. Timmons is funded by the Irish Research Council (IRC), an industry-academic 
collaboration supported by Medfit Proactive Healthcare, and Ms. Hone is also funded by the IRC. 
	
1. What is this research about? 
From approximately 50 years of age people begin to gradually lose muscle and strength. 
This is concerning because losses in muscle are associated with an increased risk of falls, fractures and 
physical disability. Therefore, it is important to identify nutrition strategies along with exercise 
interventions to slow muscle loss in older individuals. 
This study will examine how the body and mind adapt to 12 weeks of either exercise alone or 
exercise combined with food-based advice and substitutions to support exercise training in people 
over the age of 65 years. We think that providing a series of nutrition tips involving whole food 
substitutions will increase the benefits of exercise training and support healthy ageing. 
 
 
 
 
 
2. Why are we doing this research? 
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Having low muscle and strength is associated with increased risk of negative health 
conditions and reduced quality of life. This study will assess your muscle and strength. This study will 
test whether a series of nutrition tips, along with a supervised exercise training programme, will assist 
in the adaptation of the training programme in helping to preserve muscle and strength in older 
adults. This study will inform the development of an evidence-based lifestyle intervention for Irish 
older adults at risk for physical and mental decline, which may enable healthcare specialists to 
support healthy ageing. 
 
3. How will the data be used? 
The data gathered from the study will be used to write up part of a PhD thesis at University 
College Dublin (UCD) and Dublin City University (DCU), and may be used in the future for publication 
in a peer-reviewed scientific journal.  
	
4. What will happen if I decide to take part in this research study? 
If	you	decide	to	take	part	 in	this	research	and	fulfill	 the	 inclusion	criteria,	you	
will	be	required	to	participate	in	three	assessment	sessions:	at	baseline	(0	weeks),	mid-
point	(6	weeks)	and	after	completion	of	training	(12	weeks)	at	the	Human	Performance	
Laboratory	 at	 the	 UCD	 Institute	 for	 Sport	 and	 Health	 and	 in	 Medfit	 Proactive	
Healthcare,	 consisting	 of	 body	 composition,	 functional	 capacity,	 and	 cognitive	
performance	assessment.	
	
The	total	expected	time	per	visit/session	is	1	hour.	They	will	consist	as	follows:	
	
Test battery 1: @UCD Institute for Sport and Health 
 
You will arrive to the lab at UCD ISH after an overnight fast, i.e. you will not eat your breakfast that 
day, for the following assessments: 
Body Mass: Height and weight will be measured with a standard clinical scale and stadiometer 
 
DEXA (dual energy x-ray body absorptiometry) body scan: this is a scan that measures body 
composition (percentage of fat and muscle). Wearing light, loose clothing, you will lie on a flat bed 
over which the scanner moves. A trained operator will position the participant correctly based on your 
size and stature, and you will lie still during the scan, which takes about 10 minutes to complete. 
 
Blood Pressure: Immediately after your DXA while still lying down, blood pressure will be 
measured at the elbow using a standard blood pressure assessment  
 
Blood analysis: You will have a blood sample (about a tablespoon) taken by a trained technician 
from a vein in your arm, and this is a minimal quantity not able to alter any of your body’s normal 
functions. 
 
At this point, you will be provided with a small snack of a piece of fruit and cereal bar. You may drink 
water but you will still not be allowed to have tea or coffee 
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Handgrip strength: will next be measured with a device that will measure your ability ability to 
exert force in the handgrip. 
 
Timed Up and Go Test (TUGT):  In this test, you will stand up from a standard chair, walk a distance 
of 3m as fast as possible, turn, walk back to the chair, and sit again. 
 
Short Physical Performance Battery (SPPB): The SPPB is based on a timed short-distance walk, 
repeated chair stands, and balance test. Each of the performance measures is assigned a score 
ranging from 0 to 4, with 4 indicating the highest level of performance and 0 the inability to 
complete the test. Lower body function will be evaluated using tests of walking speed (3 m), standing 
balance, and the time which you need to rise from a chair five consecutive times as quickly as possible 
with the arms folded across their chest. 
 
Your mental function will be assessed using the Montreal Cognitive Assessment (MoCA), a 
brief measure of function that includes aspects of attention, language, verbal memory, and so on. The 
MoCA will be administered by trained personnel. 
 
The Chester Step Test will be used to estimate your aerobic fitness. During the test you will be 
asked to step on to and off a 15-cm step at a rate set by a beat on a computer. The initial step rate is 
15 steps per minute and every 2 minutes the tempo will be increased by 5 steps per minute. You will 
continue stepping until you reach 80% of your maximum predicted maximum heart rate, or rate the 
test as too hard, or reach the end of the 10-minutes 5-stage test. 
 
Test battery 2: @ Medfit Proactive Healthcare 
 
Stair Climbing Power Test (SCPT): This test requires you to climb a flight of stairs as quickly as 
possible but you are allowed to using a handrail for support if you wish. 
 
Upper/Lower Limb Strength Tests: Your upper and lower body strength will be measured using 
what is known as one repetition maximum (1RM), which means the most amount of weight that you 
can lift once. We will assess this on the chest press, a rowing exercise and a leg press. 
	
Exercise	training	programme	
This	will	take	in	Medfit	Proactive	Healthcare	(Blackrock	Business	Park,	Carysfort	
Avenue,	Blackrock,	Co.	Dublin).	All	training	sessions	will	be	supervised	and	performed	
in	a	group	setting,	three	days	per	week	(Mon,	Wed,	Fri)	for	twelve	weeks	(36	training	
sessions	in	total).	A	gradual	progression	will	be	built	into	the	training	programme	and	
the	programme	will	consist	of	aerobic-	and	strength-based	activities.	We	have	recently	
completed	 a	 study	 using	 an	 identical	 exercise	 training	 protocol	 that	 was	 very	 well	
received	 by	 the	 participants	 who	 were	 also	 over	 65	 years	 of	 age.	 You	 will	 be	
randomised	into	one	of	two	groups	as	follows:	
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Group 1: A group who trains as described above and will also be provided with nutrition guidelines to 
assist in the adaptation of the training programme. These guidelines will suggest food-based 
substitutions to consume both at breakfast and at lunch. 
Group 2: A group who trains as described above and does not change their habitual daily eating 
habits. 
 
5. How will we protect your privacy? 
 Your privacy will be protected in a number of ways. Your data will be stored on a password-
protected computer, which only the project supervisor will have access to. This data will be coded, so 
that you will be only potentially identifiable. Upon completion of the study, identifiable data will be 
destroyed, and only anonymous data will remain. 
 
6. What are the benefits of taking part in this research study? 
 Regular exercise has many positive effects on health and mood, and the proposed study will 
provide you with the recommended amount of weekly exercise for the twelve weeks of the training 
study The assessment of body composition by DXA, and the assessment of aerobic fitness, strength 
and cognitive ability are common measures of fitness, so we will be able to assess you relative to your 
peers and international norms. These results can be used to help plan your future exercise 
programme relative to current health and fitness. Additionally, based on your food diary, we will 
provide feedback on your dietary habits relative to your health status. During the testing period or at 
any time during the study, if we discover any medical issue that would warrant further investigation, 
we will inform you directly. The questionnaires completed and assessments performed in the study 
do not constitute a diagnosis and therefore will not be reported to your GP. However, when you 
receive your feedback pack after completion of the study, you are welcome to take your results to your 
GP for discussion if desired. 
It should be noted that there is a random allocation procedure within this study whereby you 
will randomly assigned to an intervention (exercise training & nutrition) or control group (exercise 
training only). If assigned to the control group, you will be asked to maintain your normal diet for the 
duration of the 12 week intervention period. You will still receive all of the same benefits of feedback 
on your current health and nutrition status. 
 
7. What are the risks of taking part in this research study? 
 In general, there is little risk associated with exercise training but the most likely event to 
occur immediately after or within the next few hours after training is, as with any exercise of 
moderate-to-high intensity, a chance of muscle strain and local muscle soreness. Any local muscle 
soreness will subside with after 24 hours. You will be taken through a gradual warm-up to reduce this 
risk. Should any emergency arise during the testing, the investigators are trained and certified in 
emergency first aid and CPR. 
When a blood sample is drawn, there may be a small amount of discomfort when the needle 
breaks the skin and potential for a small amount of bruising to occur. To ensure this risk is kept to a 
minimum, you may be assured that the procedure to be employed has been used extensively by the 
researchers conducting this study and is generally well tolerated by participants. We will take all 
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possible precautions to avoid infection during these procedures. These samples will be taken with 
sterile disposable needles, drapes and gauze; in fact, sterile (aseptic) techniques are used during all 
sampling procedures. These techniques will be performed by trained staff, and support staff within 
the Institute for Sport and Health are trained in first aid, and will be available throughout each trial if 
you require attention.  
You will undergo iDXA scanning once during the study. The iDXA scan for body composition 
works in a similar manner to an X-ray, but the radiation dose that you are subjected to is very much 
less than a standard X-ray (about 1/40th). At this level, the risk to you, as described by the 
international authorities regulating the using of X-rays, is ‘trivial’.   
 
8. Can I change my mind at any stage and withdraw from the study? 
If	 at	 any	 time	 during	 the	 study	 you	 are	 uncomfortable	 with	 any	 of	 the	
testing	 or	 protocols,	 or	 if	 you	 can	 no	 longer	 commit	 to	 the	 study	 for	 whatever	
reason,	you	have	 the	option	 to	withdraw	 from	the	study	up	until	 the	date	of	 the	
final	data	collection.		
 
9. How will I find out what happens with this project? 
 We will inform you of all outcomes and results when all data is collected and finalised. In the 
interim, we will provide feedback on your relative scores throughout the testing period 
 
10. Contact details and further information:  
If you have any further questions or queries please forward them to: 
 
• Dr.	Brendan	Egan,	PhD	
Email:	brendan.egan@ucd.ie	/	brendan.egan@dcu.ie	
Phone:	01	700	8803	
Role:	 Principal	 investigator	 for	 this	 research	 and	 responsible	 for	 study	
design	
	
• Mr.	James	Timmons,	Postgraduate	Research	Student		
Email:	james.timmons@ucdconnect.ie		
Role:	Responsible	for	coordination	of	all	testing	procedures	
	
• Ms.	Michele	Hone,	Postgraduate	Research	Student		
Email:	michelle.hone2@mail.dcu.ie	
Role:	Responsible	for	coordination	of	all	testing	procedures	
	
	
We	will	be	happy	to	answer	any	questions	you	may	have.	
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